0000010795-25-000022.txt : 20250206 0000010795-25-000022.hdr.sgml : 20250206 20250206170332 ACCESSION NUMBER: 0000010795-25-000022 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 73 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250206 DATE AS OF CHANGE: 20250206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BECTON DICKINSON & CO CENTRAL INDEX KEY: 0000010795 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 220760120 STATE OF INCORPORATION: NJ FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-04802 FILM NUMBER: 25598280 BUSINESS ADDRESS: STREET 1: ONE BECTON DR CITY: FRANKLIN LAKES STATE: NJ ZIP: 07417-1880 BUSINESS PHONE: 2018476800 MAIL ADDRESS: STREET 1: ONE BECTON DR CITY: FRANKLIN LAKE STATE: NJ ZIP: 07417 10-Q 1 bdx-20241231.htm 10-Q bdx-20241231
00000107959/302025Q1false459456xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:purebdx:claimbdx:lawsuitbdx:plaintiffbdx:segment00000107952024-10-012024-12-310000010795exch:XNYSus-gaap:CommonStockMember2024-10-012024-12-310000010795exch:XNYSbdx:Notes1.900dueDecember152026Member2024-10-012024-12-310000010795exch:XNYSbdx:Notes3.020dueMay242025Member2024-10-012024-12-310000010795exch:XNYSbdx:Notes1.208dueJune42026Member2024-10-012024-12-310000010795exch:XNYSbdx:Notes1213NotesDueFebruary122036Member2024-10-012024-12-310000010795exch:XNYSbdx:Notes0034DueAugust132025Member2024-10-012024-12-310000010795exch:XNYSbdx:Notes3.519DueFebruary82031Member2024-10-012024-12-310000010795exch:XNYSbdx:Notes3.828DueJune72032Member2024-10-012024-12-3100000107952024-12-3100000107952023-10-012023-12-3100000107952024-09-3000000107952023-09-3000000107952023-12-310000010795us-gaap:CommonStockMember2024-09-300000010795us-gaap:AdditionalPaidInCapitalMember2024-09-300000010795us-gaap:RetainedEarningsMember2024-09-300000010795us-gaap:DeferredCompensationShareBasedPaymentsMember2024-09-300000010795us-gaap:TreasuryStockCommonMember2024-09-300000010795us-gaap:RetainedEarningsMember2024-10-012024-12-310000010795us-gaap:AdditionalPaidInCapitalMember2024-10-012024-12-310000010795us-gaap:TreasuryStockCommonMember2024-10-012024-12-310000010795us-gaap:CommonStockMember2024-12-310000010795us-gaap:AdditionalPaidInCapitalMember2024-12-310000010795us-gaap:RetainedEarningsMember2024-12-310000010795us-gaap:DeferredCompensationShareBasedPaymentsMember2024-12-310000010795us-gaap:TreasuryStockCommonMember2024-12-310000010795us-gaap:CommonStockMember2023-09-300000010795us-gaap:AdditionalPaidInCapitalMember2023-09-300000010795us-gaap:RetainedEarningsMember2023-09-300000010795us-gaap:DeferredCompensationShareBasedPaymentsMember2023-09-300000010795us-gaap:TreasuryStockCommonMember2023-09-300000010795us-gaap:RetainedEarningsMember2023-10-012023-12-310000010795us-gaap:AdditionalPaidInCapitalMember2023-10-012023-12-310000010795us-gaap:TreasuryStockCommonMember2023-10-012023-12-310000010795us-gaap:CommonStockMember2023-12-310000010795us-gaap:AdditionalPaidInCapitalMember2023-12-310000010795us-gaap:RetainedEarningsMember2023-12-310000010795us-gaap:DeferredCompensationShareBasedPaymentsMember2023-12-310000010795us-gaap:TreasuryStockCommonMember2023-12-310000010795bdx:AcceleratedShareRepurchaseProgramMember2024-12-310000010795bdx:AcceleratedShareRepurchaseProgramMember2024-10-012024-12-310000010795bdx:AcceleratedShareRepurchaseProgramMemberus-gaap:SubsequentEventMember2025-01-012025-01-310000010795bdx:AcceleratedShareRepurchaseProgramMemberus-gaap:TreasuryStockCommonMemberus-gaap:SubsequentEventMember2025-01-012025-01-310000010795bdx:AcceleratedShareRepurchaseProgramMemberus-gaap:AdditionalPaidInCapitalMemberus-gaap:SubsequentEventMember2025-01-012025-01-310000010795bdx:AcceleratedShareRepurchaseProgramMember2023-10-012023-12-310000010795bdx:AcceleratedShareRepurchaseProgramMember2023-12-3100000107952021-11-030000010795us-gaap:SubsequentEventMember2025-01-280000010795us-gaap:AccumulatedTranslationAdjustmentMember2024-09-300000010795us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-09-300000010795us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-09-300000010795us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-09-300000010795us-gaap:AccumulatedTranslationAdjustmentMember2024-10-012024-12-310000010795us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-10-012024-12-310000010795us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-10-012024-12-310000010795us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-10-012024-12-310000010795us-gaap:AccumulatedTranslationAdjustmentMember2024-12-310000010795us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-12-310000010795us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-12-310000010795us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-12-310000010795us-gaap:AccumulatedTranslationAdjustmentMember2023-09-300000010795us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-09-300000010795us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-09-300000010795us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-09-300000010795us-gaap:AccumulatedTranslationAdjustmentMember2023-10-012023-12-310000010795us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-10-012023-12-310000010795us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-10-012023-12-310000010795us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-10-012023-12-310000010795us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000010795us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-310000010795us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310000010795us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-12-310000010795bdx:ShareBasedCompensationMember2024-10-012024-12-310000010795bdx:ShareBasedCompensationMember2023-10-012023-12-310000010795bdx:HerniaProductClaimsMember2024-12-310000010795bdx:HerniaProductClaimsMember2024-09-300000010795bdx:SECMatterMember2024-12-310000010795stpr:GAsrt:MaximumMember2024-10-012024-12-310000010795stpr:GA2024-10-012024-12-310000010795bdx:ItalianMedicalDevicePaybackLegislationMatterMember2024-12-310000010795bdx:PyxisMember2024-12-310000010795bdx:PyxisMember2024-10-012024-12-310000010795us-gaap:OtherOperatingIncomeExpenseMember2023-10-012023-12-310000010795bdx:ProductsWithinMassTortLitigationMember2024-12-310000010795bdx:ProductsWithinMassTortLitigationMember2024-09-3000000107952025-01-01bdx:ProductsandorServicesMember2024-12-3100000107952025-01-012024-12-3100000107952025-01-01bdx:ConsumablesMember2024-12-310000010795country:USus-gaap:OperatingSegmentsMemberbdx:MedicationDeliverySolutionsMemberbdx:MedicalMember2024-10-012024-12-310000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:MedicationDeliverySolutionsMemberbdx:MedicalMember2024-10-012024-12-310000010795us-gaap:OperatingSegmentsMemberbdx:MedicationDeliverySolutionsMemberbdx:MedicalMember2024-10-012024-12-310000010795country:USus-gaap:OperatingSegmentsMemberbdx:MedicationDeliverySolutionsMemberbdx:MedicalMember2023-10-012023-12-310000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:MedicationDeliverySolutionsMemberbdx:MedicalMember2023-10-012023-12-310000010795us-gaap:OperatingSegmentsMemberbdx:MedicationDeliverySolutionsMemberbdx:MedicalMember2023-10-012023-12-310000010795country:USus-gaap:OperatingSegmentsMemberbdx:MedicationManagementSolutionsMemberbdx:MedicalMember2024-10-012024-12-310000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:MedicationManagementSolutionsMemberbdx:MedicalMember2024-10-012024-12-310000010795us-gaap:OperatingSegmentsMemberbdx:MedicationManagementSolutionsMemberbdx:MedicalMember2024-10-012024-12-310000010795country:USus-gaap:OperatingSegmentsMemberbdx:MedicationManagementSolutionsMemberbdx:MedicalMember2023-10-012023-12-310000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:MedicationManagementSolutionsMemberbdx:MedicalMember2023-10-012023-12-310000010795us-gaap:OperatingSegmentsMemberbdx:MedicationManagementSolutionsMemberbdx:MedicalMember2023-10-012023-12-310000010795country:USus-gaap:OperatingSegmentsMemberbdx:PharmaceuticalSystemsMemberbdx:MedicalMember2024-10-012024-12-310000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:PharmaceuticalSystemsMemberbdx:MedicalMember2024-10-012024-12-310000010795us-gaap:OperatingSegmentsMemberbdx:PharmaceuticalSystemsMemberbdx:MedicalMember2024-10-012024-12-310000010795country:USus-gaap:OperatingSegmentsMemberbdx:PharmaceuticalSystemsMemberbdx:MedicalMember2023-10-012023-12-310000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:PharmaceuticalSystemsMemberbdx:MedicalMember2023-10-012023-12-310000010795us-gaap:OperatingSegmentsMemberbdx:PharmaceuticalSystemsMemberbdx:MedicalMember2023-10-012023-12-310000010795country:USus-gaap:OperatingSegmentsMemberbdx:AdvancedPatientMonitoringMemberbdx:MedicalMember2024-10-012024-12-310000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:AdvancedPatientMonitoringMemberbdx:MedicalMember2024-10-012024-12-310000010795us-gaap:OperatingSegmentsMemberbdx:AdvancedPatientMonitoringMemberbdx:MedicalMember2024-10-012024-12-310000010795country:USus-gaap:OperatingSegmentsMemberbdx:AdvancedPatientMonitoringMemberbdx:MedicalMember2023-10-012023-12-310000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:AdvancedPatientMonitoringMemberbdx:MedicalMember2023-10-012023-12-310000010795us-gaap:OperatingSegmentsMemberbdx:AdvancedPatientMonitoringMemberbdx:MedicalMember2023-10-012023-12-310000010795country:USus-gaap:OperatingSegmentsMemberbdx:MedicalMember2024-10-012024-12-310000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2024-10-012024-12-310000010795us-gaap:OperatingSegmentsMemberbdx:MedicalMember2024-10-012024-12-310000010795country:USus-gaap:OperatingSegmentsMemberbdx:MedicalMember2023-10-012023-12-310000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:MedicalMember2023-10-012023-12-310000010795us-gaap:OperatingSegmentsMemberbdx:MedicalMember2023-10-012023-12-310000010795country:USus-gaap:OperatingSegmentsMemberbdx:SpecimenManagementMemberbdx:LifeSciencesMember2024-10-012024-12-310000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:SpecimenManagementMemberbdx:LifeSciencesMember2024-10-012024-12-310000010795us-gaap:OperatingSegmentsMemberbdx:SpecimenManagementMemberbdx:LifeSciencesMember2024-10-012024-12-310000010795country:USus-gaap:OperatingSegmentsMemberbdx:SpecimenManagementMemberbdx:LifeSciencesMember2023-10-012023-12-310000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:SpecimenManagementMemberbdx:LifeSciencesMember2023-10-012023-12-310000010795us-gaap:OperatingSegmentsMemberbdx:SpecimenManagementMemberbdx:LifeSciencesMember2023-10-012023-12-310000010795country:USus-gaap:OperatingSegmentsMemberbdx:DiagnosticSolutionsMemberbdx:LifeSciencesMember2024-10-012024-12-310000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:DiagnosticSolutionsMemberbdx:LifeSciencesMember2024-10-012024-12-310000010795us-gaap:OperatingSegmentsMemberbdx:DiagnosticSolutionsMemberbdx:LifeSciencesMember2024-10-012024-12-310000010795country:USus-gaap:OperatingSegmentsMemberbdx:DiagnosticSolutionsMemberbdx:LifeSciencesMember2023-10-012023-12-310000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:DiagnosticSolutionsMemberbdx:LifeSciencesMember2023-10-012023-12-310000010795us-gaap:OperatingSegmentsMemberbdx:DiagnosticSolutionsMemberbdx:LifeSciencesMember2023-10-012023-12-310000010795country:USus-gaap:OperatingSegmentsMemberbdx:BiosciencesMemberbdx:LifeSciencesMember2024-10-012024-12-310000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:BiosciencesMemberbdx:LifeSciencesMember2024-10-012024-12-310000010795us-gaap:OperatingSegmentsMemberbdx:BiosciencesMemberbdx:LifeSciencesMember2024-10-012024-12-310000010795country:USus-gaap:OperatingSegmentsMemberbdx:BiosciencesMemberbdx:LifeSciencesMember2023-10-012023-12-310000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:BiosciencesMemberbdx:LifeSciencesMember2023-10-012023-12-310000010795us-gaap:OperatingSegmentsMemberbdx:BiosciencesMemberbdx:LifeSciencesMember2023-10-012023-12-310000010795country:USus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2024-10-012024-12-310000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2024-10-012024-12-310000010795us-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2024-10-012024-12-310000010795country:USus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2023-10-012023-12-310000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2023-10-012023-12-310000010795us-gaap:OperatingSegmentsMemberbdx:LifeSciencesMember2023-10-012023-12-310000010795country:USus-gaap:OperatingSegmentsMemberbdx:SurgeryMemberbdx:InterventionalMember2024-10-012024-12-310000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:SurgeryMemberbdx:InterventionalMember2024-10-012024-12-310000010795us-gaap:OperatingSegmentsMemberbdx:SurgeryMemberbdx:InterventionalMember2024-10-012024-12-310000010795country:USus-gaap:OperatingSegmentsMemberbdx:SurgeryMemberbdx:InterventionalMember2023-10-012023-12-310000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:SurgeryMemberbdx:InterventionalMember2023-10-012023-12-310000010795us-gaap:OperatingSegmentsMemberbdx:SurgeryMemberbdx:InterventionalMember2023-10-012023-12-310000010795country:USus-gaap:OperatingSegmentsMemberbdx:PeripheralInterventionMemberbdx:InterventionalMember2024-10-012024-12-310000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:PeripheralInterventionMemberbdx:InterventionalMember2024-10-012024-12-310000010795us-gaap:OperatingSegmentsMemberbdx:PeripheralInterventionMemberbdx:InterventionalMember2024-10-012024-12-310000010795country:USus-gaap:OperatingSegmentsMemberbdx:PeripheralInterventionMemberbdx:InterventionalMember2023-10-012023-12-310000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:PeripheralInterventionMemberbdx:InterventionalMember2023-10-012023-12-310000010795us-gaap:OperatingSegmentsMemberbdx:PeripheralInterventionMemberbdx:InterventionalMember2023-10-012023-12-310000010795country:USus-gaap:OperatingSegmentsMemberbdx:UrologyandCriticalCareMemberbdx:InterventionalMember2024-10-012024-12-310000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:UrologyandCriticalCareMemberbdx:InterventionalMember2024-10-012024-12-310000010795us-gaap:OperatingSegmentsMemberbdx:UrologyandCriticalCareMemberbdx:InterventionalMember2024-10-012024-12-310000010795country:USus-gaap:OperatingSegmentsMemberbdx:UrologyandCriticalCareMemberbdx:InterventionalMember2023-10-012023-12-310000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:UrologyandCriticalCareMemberbdx:InterventionalMember2023-10-012023-12-310000010795us-gaap:OperatingSegmentsMemberbdx:UrologyandCriticalCareMemberbdx:InterventionalMember2023-10-012023-12-310000010795country:USus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2024-10-012024-12-310000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2024-10-012024-12-310000010795us-gaap:OperatingSegmentsMemberbdx:InterventionalMember2024-10-012024-12-310000010795country:USus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2023-10-012023-12-310000010795us-gaap:NonUsMemberus-gaap:OperatingSegmentsMemberbdx:InterventionalMember2023-10-012023-12-310000010795us-gaap:OperatingSegmentsMemberbdx:InterventionalMember2023-10-012023-12-310000010795country:US2024-10-012024-12-310000010795us-gaap:NonUsMember2024-10-012024-12-310000010795country:US2023-10-012023-12-310000010795us-gaap:NonUsMember2023-10-012023-12-310000010795us-gaap:OperatingSegmentsMember2024-10-012024-12-310000010795us-gaap:OperatingSegmentsMember2023-10-012023-12-310000010795us-gaap:MaterialReconcilingItemsMember2024-10-012024-12-310000010795us-gaap:MaterialReconcilingItemsMember2023-10-012023-12-310000010795us-gaap:CorporateNonSegmentMember2024-10-012024-12-310000010795us-gaap:CorporateNonSegmentMember2023-10-012023-12-310000010795us-gaap:PensionPlansDefinedBenefitMember2024-10-012024-12-310000010795us-gaap:PensionPlansDefinedBenefitMember2023-10-012023-12-310000010795bdx:AdvancedPatientMonitoringMember2024-09-032024-09-030000010795bdx:AdvancedPatientMonitoringMemberus-gaap:DevelopedTechnologyRightsMember2024-12-310000010795bdx:AdvancedPatientMonitoringMemberus-gaap:CustomerRelationshipsMember2024-12-310000010795bdx:AdvancedPatientMonitoringMember2024-12-310000010795bdx:AdvancedPatientMonitoringMember2024-09-030000010795bdx:AdvancedPatientMonitoringMember2023-10-012023-12-310000010795us-gaap:EmployeeSeveranceMember2024-09-300000010795us-gaap:OtherRestructuringMember2024-09-300000010795us-gaap:EmployeeSeveranceMember2024-10-012024-12-310000010795us-gaap:OtherRestructuringMember2024-10-012024-12-310000010795us-gaap:EmployeeSeveranceMemberbdx:OtherInitiativesMember2024-10-012024-12-310000010795us-gaap:OtherRestructuringMemberbdx:OtherInitiativesMember2024-10-012024-12-310000010795bdx:OtherInitiativesMember2024-10-012024-12-310000010795us-gaap:EmployeeSeveranceMember2024-12-310000010795us-gaap:OtherRestructuringMember2024-12-310000010795us-gaap:DevelopedTechnologyRightsMember2024-12-310000010795us-gaap:DevelopedTechnologyRightsMember2024-09-300000010795us-gaap:CustomerRelationshipsMember2024-12-310000010795us-gaap:CustomerRelationshipsMember2024-09-300000010795us-gaap:IntellectualPropertyMember2024-12-310000010795us-gaap:IntellectualPropertyMember2024-09-300000010795us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember2024-12-310000010795us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember2024-09-300000010795us-gaap:TrademarksMember2024-12-310000010795us-gaap:TrademarksMember2024-09-300000010795bdx:MedicalMember2024-09-300000010795bdx:LifeSciencesMember2024-09-300000010795bdx:InterventionalMember2024-09-300000010795bdx:MedicalMember2024-10-012024-12-310000010795bdx:LifeSciencesMember2024-10-012024-12-310000010795bdx:InterventionalMember2024-10-012024-12-310000010795bdx:MedicalMember2024-12-310000010795bdx:LifeSciencesMember2024-12-310000010795bdx:InterventionalMember2024-12-310000010795us-gaap:ForeignExchangeContractMember2024-12-310000010795us-gaap:ForeignExchangeContractMember2024-09-300000010795us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2024-12-310000010795us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2024-09-300000010795us-gaap:DebtMemberus-gaap:NetInvestmentHedgingMember2024-12-310000010795us-gaap:DebtMemberus-gaap:NetInvestmentHedgingMember2024-09-300000010795us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2024-12-310000010795us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMember2024-09-300000010795us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMember2023-10-012023-12-310000010795bdx:ForeignCurrencyDenominatedDebtMember2024-10-012024-12-310000010795bdx:ForeignCurrencyDenominatedDebtMember2023-10-012023-12-310000010795us-gaap:CurrencySwapMember2024-10-012024-12-310000010795us-gaap:CurrencySwapMember2023-10-012023-12-310000010795bdx:TerminatedCurrencySwapMember2024-10-012024-12-310000010795bdx:FixedToFloatingMemberus-gaap:FairValueHedgingMember2024-12-310000010795bdx:FixedToFloatingMemberus-gaap:FairValueHedgingMember2024-09-300000010795srt:MinimumMember2024-10-012024-12-310000010795srt:MaximumMember2024-10-012024-12-310000010795bdx:IntegrationAndRestructuringExpenseMember2024-10-012024-12-310000010795srt:MinimumMember2024-12-310000010795srt:MaximumMember2024-12-310000010795bdx:RichardByrdMember2024-10-012024-12-310000010795bdx:RichardByrdTradingArrangementStockAppreciationRightsMemberbdx:RichardByrdMember2024-12-310000010795bdx:RichardByrdTradingArrangementCommonStockMemberbdx:RichardByrdMember2024-12-310000010795bdx:RichardByrdTradingArrangementCommonStockUponTheVestingOfTimeVestedUnitsMemberbdx:RichardByrdMember2024-12-310000010795bdx:RichardByrdTradingArrangementCommonStockUponTheVestingOfPerformanceUnitsMemberbdx:RichardByrdMember2024-12-310000010795bdx:AntoineEzellMember2024-10-012024-12-310000010795bdx:AntoineEzellTradingArrangementCommonStockMemberbdx:AntoineEzellMember2024-12-310000010795bdx:OfficerTradingArrangementMemberbdx:RichardByrdMember2024-10-012024-12-310000010795bdx:OfficerTradingArrangementMemberbdx:AntoineEzellMember2024-10-012024-12-31

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended December 31, 2024
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
Commission file number 001-4802
Becton, Dickinson and Company
(Exact name of registrant as specified in its charter)
New Jersey 22-0760120
(State or other jurisdiction of
incorporation or organization)		 (I.R.S. Employer
Identification No.)
1 Becton Drive,
Franklin Lakes,
New Jersey
07417-1880
(201)847-6800
(Address of principal executive offices) (Zip Code)(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading SymbolName of Each Exchange on Which Registered
Common stock, par value $1.00BDXNew York Stock Exchange
1.900% Notes due December 15, 2026BDX26New York Stock Exchange
3.020% Notes due May 24, 2025BDX25New York Stock Exchange
1.208% Notes due June 4, 2026BDX/26ANew York Stock Exchange
1.213% Notes due February 12, 2036BDX/36New York Stock Exchange
0.034% Notes due August 13, 2025BDX25ANew York Stock Exchange
3.519% Notes due February 8, 2031BDX31New York Stock Exchange
3.828% Notes due June 7, 2032BDX32ANew York Stock Exchange
    Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
    Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No   ☐
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer 
☒
  Accelerated filer ☐
Non-accelerated filer ☐Smaller reporting company ☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒
There were 287,135,421 shares of Common Stock, $1.00 par value, outstanding at December 31, 2024.

BECTON, DICKINSON AND COMPANY
FORM 10-Q
For the quarterly period ended December 31, 2024
TABLE OF CONTENTS
2

ITEM 1. FINANCIAL STATEMENTS
BECTON, DICKINSON AND COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
Millions of dollars, except per share data
(Unaudited)
 Three Months Ended
December 31,
 20242023
Revenues$5,168 $4,706 
Cost of products sold2,933 2,679 
Selling and administrative expense1,318 1,213 
Research and development expense343 290 
Integration, restructuring and transaction expense92 75 
Other operating expense, net28 11 
Total Operating Costs and Expenses4,715 4,267 
Operating Income453 439 
Interest expense(155)(111)
Interest income23 34 
Other expense, net(16)(4)
Income Before Income Taxes306 359 
Income tax provision3 77 
Net Income$303 $281 
Basic Earnings per Share$1.05 $0.97 
Diluted Earnings per Share$1.04 $0.96 
Dividends per Common Share$1.04 $0.95 
Amounts may not add due to rounding.
See notes to condensed consolidated financial statements
3

BECTON, DICKINSON AND COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Millions of dollars
(Unaudited)
 Three Months Ended
December 31,
 20242023
Net Income$303 $281 
Other Comprehensive Income (Loss), Net of Tax
Foreign currency translation adjustments46 40 
Defined benefit pension and postretirement plans8 12 
Cash flow hedges2 (18)
Other Comprehensive Income, Net of Tax56 33 
Comprehensive Income$359 $314 
Amounts may not add due to rounding.
See notes to condensed consolidated financial statements
4

BECTON, DICKINSON AND COMPANY
CONDENSED CONSOLIDATED BALANCE SHEETS
Millions of dollars, except per share amounts and numbers of shares

December 31,
2024		September 30,
2024
Assets(Unaudited)
Current Assets:
Cash and equivalents$711 $1,717 
Restricted cash102 139 
Short-term investments17 445 
Trade receivables, net2,638 3,033 
Inventories:
Materials904 803 
Work in process453 443 
Finished products2,502 2,597 
3,860 3,843 
Prepaid expenses and other1,331 1,292 
Total Current Assets8,659 10,468 
Property, Plant and Equipment14,156 14,378 
Less allowances for depreciation and amortization7,554 7,557 
Property, Plant and Equipment, Net6,602 6,821 
Goodwill26,329 26,465 
Developed Technology, Net7,439 7,733 
Customer Relationships, Net2,533 2,635 
Other Intangibles, Net517 549 
Other Assets2,586 2,615 
Total Assets$54,665 $57,286 
Liabilities and Shareholders’ Equity
Current Liabilities:
Current debt obligations$1,318 $2,170 
Payables, accrued expenses and other current liabilities6,347 6,786 
Total Current Liabilities7,664 8,956 
Long-Term Debt17,440 17,940 
Long-Term Employee Benefit Obligations939 942 
Deferred Income Taxes and Other Liabilities3,418 3,558 
Commitments and Contingencies (See Note 5)
Shareholders’ Equity
Common stock — $1 par value; authorized — 640,000,000 shares; issued — 370,594,401 shares in December 31, 2024 and September 30, 2024
371 371 
Capital in excess of par value19,768 19,893 
Retained earnings16,141 16,139 
Deferred compensation25 25 
Treasury stock(9,425)(8,807)
Accumulated other comprehensive loss(1,676)(1,732)
Total Shareholders’ Equity25,205 25,890 
Total Liabilities and Shareholders’ Equity$54,665 $57,286 

Amounts may not add due to rounding.
See notes to condensed consolidated financial statements
5

BECTON, DICKINSON AND COMPANY
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Millions of dollars
(Unaudited)
 Three Months Ended
December 31,
 20242023
Operating Activities
Net income $303 $281 
Adjustments to net income to derive net cash provided by continuing operating activities:
Depreciation and amortization607 561 
Share-based compensation90 83 
Deferred income taxes(151)(91)
Change in operating assets and liabilities(370)152 
Pension obligation(2)(129)
Other, net216 (2)
Net Cash Provided by Continuing Operating Activities693 855 
Investing Activities
Capital expenditures(105)(116)
Maturities and sales of investments411 — 
Acquisitions, net of cash acquired(8)— 
Other, net(94)(116)
Net Cash Provided by (Used for) Investing Activities204 (233)
Financing Activities
Change in short-term debt75 — 
Payments of debt(875)— 
Repurchases of common stock(750)(500)
Dividends paid(302)(275)
Other, net(76)(87)
Net Cash Used for Financing Activities(1,928)(862)
Discontinued Operations
Net cash used for operating activities of discontinued operations— (14)
Effect of exchange rate changes on cash and equivalents and restricted cash(12)7 
Net decrease in cash and equivalents and restricted cash(1,043)(247)
Opening Cash and Equivalents and Restricted Cash1,856 1,481 
Closing Cash and Equivalents and Restricted Cash$813 $1,234 
Amounts may not add due to rounding.
See notes to condensed consolidated financial statements
6

BECTON, DICKINSON AND COMPANY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
December 31, 2024
Note 1 – Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and, in the opinion of the management of Becton, Dickinson and Company (the "Company" or "BD"), include all adjustments which are of a normal recurring nature, necessary for a fair presentation of the financial position and the results of operations and cash flows for the periods presented. However, the financial statements do not include all information and accompanying notes required for a presentation in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s 2024 Annual Report on Form 10-K.
Within the financial statements and tables presented, certain columns and rows may not add due to the use of rounded numbers for disclosure purposes. Percentages and earnings per share amounts presented are calculated from the underlying amounts. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.
Note 2 – Accounting Changes
New Accounting Principles Not Yet Adopted
In November 2024, the Financial Accounting Standards Board (“FASB”) issued an accounting standard update that requires the Company to disclose more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in each relevant income statement expense caption. The update is effective for the Company beginning with its fiscal year 2028 reporting and for interim reporting beginning with its fiscal year 2029. Early adoption is permitted. The Company is currently evaluating the impact that this update will have on its disclosures.
In December 2023, the FASB issued an accounting standard update that requires more disaggregated information to be included in the income tax rate reconciliation and income taxes paid annual disclosures. This update is effective for the Company beginning in its fiscal year 2026 and the Company is currently evaluating the impact that this update will have on its disclosures.
In November 2023, the FASB issued a new accounting standard update that requires more disaggregated expense information about a public entity’s reportable segments. This update is effective for the Company beginning with its fiscal year 2025 reporting and for interim reporting beginning with its fiscal year 2026. The Company is currently evaluating the impact that this update will have on its disclosures.
Note 3 – Shareholders' Equity
Changes in certain components of shareholders' equity for the first quarters of fiscal years 2025 and 2024 were as follows:
 Common
Stock  Issued
at Par Value		Capital in
Excess of
Par Value		Retained
Earnings		Deferred
Compensation		Treasury Stock
(Millions of dollars)Shares (in
thousands)		Amount
Balance at September 30, 2024$371 $19,893 $16,139 $25 (81,493)$(8,807)
Net income— — 303 — — — 
Common dividends ($1.04 per share)
— — (302)— — — 
Issuance of shares under employee and other plans, net— (65)— — 679 (12)
Share-based compensation— 90 — — — — 
Common stock held in trusts, net (a)— — — — (8)— 
Repurchase of common stock— (150)— — (2,637)(606)
Balance at December 31, 2024$371 $19,768 $16,141 $25 (83,459)$(9,425)
7

 Common
Stock  Issued
at Par Value		Capital in
Excess of
Par Value		Retained
Earnings		Deferred
Compensation		Treasury Stock
(Millions of dollars)Shares (in
thousands)		Amount
Balance at September 30, 2023$371 $19,720 $15,535 $24 (80,203)$(8,305)
Net income— — 281 — — — 
Common dividends ($0.95 per share)
— — (275)— — — 
Issuance of shares under employee and other plans, net— (62)— — 647 (20)
Share-based compensation— 83 — — — — 
Common stock held in trusts, net (a)— — — — (19)— 
Repurchase of common stock— — — — (2,118)(503)
Balance at December 31, 2023$371 $19,741 $15,540 $24 (81,692)$(8,828)
(a)Common stock held in trusts consists of the Company’s shares held in rabbi trusts in connection with deferred compensation under the Company’s employee salary and bonus deferral plan and directors’ deferral plan.
Share Repurchases
In the first quarter of fiscal year 2025, the Company executed an accelerated share repurchase (“ASR”) agreement and accounted for the agreement as two transactions upon prepayment: (1) the initial delivery of shares was recorded as an increase to Common stock in treasury to recognize the acquisition of common stock acquired in a treasury stock transaction, and (2) the remaining amount of shares was recorded as a decrease to Capital in excess of par value to recognize a net share-settled forward sale contract indexed to the Company's own common stock. The impacts of these accelerated share repurchase transactions were as follows:
Execution DateSettlement DateAggregate Common Stock Repurchased (millions of dollars) (a)Initial Shares Delivered (in thousands)Additional Shares Delivered at Settlement (in thousands) (b)Total Shares Delivered (in thousands)
Q1 2025Q2 2025$750 2,637 619 3,256 
(a)    Excludes a 1% excise tax on share repurchases of $6 million.
(b)    Upon final settlement of the repurchase agreement and the forward sale contract, the Company’s receipt of additional shares was recorded as an increase to Common stock in treasury and an offsetting increase to Capital in excess of par value. The final settlement for the first quarter transaction amounted to $150 million.
In the first quarter of fiscal year 2024, the Company executed and settled ASR agreements for the repurchase of 2.118 million shares of its common stock for total consideration of $500 million, excluding a 1% excise tax on share repurchases of $3 million. The share repurchases were recorded as an increase to Treasury stock.
The share repurchases discussed above were made pursuant to the repurchase program authorized by the Board of Directors on November 3, 2021, for 10 million shares of BD common stock, for which there is no expiration date. As of December 31, 2024, 4 million shares remained unused under this program. On January 28, 2025, the Board of Directors authorized BD to repurchase up to an additional 10 million shares of BD common stock, for which there is no expiration date.
8

The components and changes of Accumulated other comprehensive income (loss) for the first quarters of fiscal years 2025 and 2024 were as follows:
(Millions of dollars)TotalForeign Currency
Translation		Benefit Plans
Cash Flow Hedges		Available-for-Sale Debt Securities
Balance at September 30, 2024$(1,732)$(1,244)$(557)$70 $(1)
Other comprehensive income before reclassifications, net of taxes49 46 — 3 — 
Amounts reclassified into income, net of taxes6 — 8 (2)— 
Balance at December 31, 2024$(1,676)$(1,199)$(549)$72 $(1)
(Millions of dollars)TotalForeign Currency
Translation		Benefit Plans
Cash Flow Hedges		Available-for-Sale Debt Securities
Balance at September 30, 2023$(1,548)$(1,078)$(571)$103 $— 
Other comprehensive income (loss) before reclassifications, net of taxes21 40 — (19)— 
Amounts reclassified into income, net of taxes12 — 12 1 — 
Balance at December 31, 2023$(1,515)$(1,038)$(559)$84 $— 
The amounts of foreign currency translation recognized in other comprehensive income during the three months ended December 31, 2024 and 2023 included net gains (losses) relating to net investment hedges. The amounts recognized in other comprehensive income relating to cash flow hedges primarily related to foreign exchange contracts during the three months ended December 31, 2024 and forward starting interest rate swaps during the three months ended December 31, 2023. Additional disclosures regarding the Company's derivatives are provided in Note 12.
The tax impacts for amounts recognized in other comprehensive income (loss) before reclassifications and for reclassifications out of Accumulated other comprehensive income (loss) relating to benefit plans and cash flow hedges during the three months ended December 31, 2024 and 2023 were immaterial to the Company's consolidated financial results.
Note 4 – Earnings per Share
The weighted average common shares used in the computations of basic and diluted earnings per share (shares in thousands) were as follows:
 Three Months Ended
December 31,
 20242023
Average common shares outstanding289,505 290,113 
Dilutive share equivalents from share-based plans884 1,285 
Average common and common equivalent shares outstanding – assuming dilution290,389 291,398 
Share equivalents excluded from the diluted shares outstanding calculation:
Share-based plans (a)2,758 552 
(a)Excluded from the diluted earnings per share calculation as the exercise prices of these awards were greater than the average market price of the Company’s common shares.
Note 5 – Contingencies
The Company is involved, both as a plaintiff and a defendant, in various legal proceedings that arise in the ordinary course of business, including, without limitation, product liability and environmental matters in certain U.S. and international locations. Given the uncertain nature of litigation generally, the Company is not able, in all cases, to reasonably estimate the amount or range of loss that could result from an unfavorable outcome of litigation in which the Company is a party. Even if the Company believes it has meritorious defenses, from time to time the Company engages in settlement discussions and mediations and considers settlements taking into account various factors including, among other things, developments in such legal proceedings
9

and the resulting risks and uncertainties. These activities have resulted in settlements for certain matters and going forward could result in further settlements, which may be confidential and could be significant and result in charges in excess of accruals.
In accordance with U.S. GAAP, the Company establishes accruals to the extent future losses are probable and reasonably estimable. With respect to putative class action lawsuits and certain tort actions in the United States and certain of the Canadian lawsuits described below or in its other SEC filings, the Company may not be able to determine if a probable loss exists or estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; (ii) the Company has not received and reviewed complete information regarding all or certain of the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, there is uncertainty as to the likelihood of a class being certified or the ultimate size of any class. With respect to certain of the civil investigative demands (“CIDs”) served by the Department of Justice which are discussed below, the Company may not be able to determine if a probable loss exists, unless otherwise noted, for the following reasons: (i) all or certain of the proceedings are in early stages; and/or (ii) there are significant factual and legal issues to be resolved.
Product Liability Matters
As of December 31, 2024, the Company is defending approximately 6,670 product liability claims involving the Company’s line of hernia repair devices (collectively, the “Hernia Product Claims”). The Company’s outstanding Hernia Product Claims as of September 30, 2024 were approximately 6,610, which reflected a settlement agreement that was consummated in the fourth quarter of fiscal year 2024 to resolve the vast majority of the Company’s existing hernia litigation. The majority of the claims are currently pending in a coordinated proceeding in Rhode Island State Court (“RI”) and in a federal multi-district litigation (“MDL”) established in the Southern District of Ohio, but claims are also pending in other state and/or federal court jurisdictions. In addition, outstanding claims include multiple putative class actions in Canada. Generally, the Hernia Product Claims seek damages for personal injury allegedly resulting from use of the products. The Company believes that it has meritorious defenses and is vigorously defending itself in these matters. There are no trials currently scheduled.
The Company also continues to be a defendant in certain other mass tort litigation. As of December 31, 2024, the Company is defending product liability claims involving the Company’s line of pelvic mesh products, the majority of which are pending in a coordinated proceeding in New Jersey Superior Court and in various federal court jurisdictions, the Company’s line of inferior vena cava (“IVC”) filter products, which are pending in various jurisdictions, and the Company’s line of implantable ports, the majority of which are pending in an MDL in the United States District Court for the District of Arizona. The Company believes that it has meritorious defenses and is vigorously defending itself in these matters.
In most product liability litigations like those described above, plaintiffs allege a wide variety of claims, ranging from allegations of serious injury caused by the products to efforts to obtain compensation notwithstanding the absence of any injury. In many of these cases, the Company has not yet received and reviewed complete information regarding the plaintiffs and their medical conditions and, consequently, is unable to fully evaluate the claims. The Company expects that it will receive and review additional information regarding any remaining unsettled product liability matters.
Other Matters
On November 2, 2020, a putative shareholder derivative action captioned Jankowski v. Forlenza, et al., Civ. No. 2:20-cv-15474, was filed in the U.S. District Court for the District of New Jersey by a shareholder, derivatively on behalf of the Company, against certain of the Company’s directors and officers. The complaint asserts claims for breach of fiduciary duty; violations of sections 10(b), 14(a) and 21D of the Exchange Act, and insider trading. The complaint principally alleges, that the Company made misleading statements regarding AlarisTM infusion pumps in a proxy statement and other SEC filings. A second federal derivative action was filed on January 24, 2021, and the two actions were consolidated and stayed. In March 2021, the Company received letters from two additional shareholders which, in general, mirrored the allegations in the derivative actions, and demanded, among other things, that the Board of Directors pursue claims against members of management for claimed breaches of fiduciary duties. Consistent with New Jersey law, the Board appointed a special committee to review the allegations and demands in the derivative actions and demand letters. Following an investigation, the special committee determined that no action was warranted, and rejected the shareholders’ demands, communicating its determination to counsel for the shareholders. On January 10, 2023, one of the two shareholders referenced above filed a separate derivative action that: (i) is generally consistent with the shareholder letter and the two prior actions; and (ii) purports to challenge the reasonableness of the special committee’s process and determination. That action was also stayed. Following entry of a stipulated scheduling order for an amended complaint and motion to dismiss the consolidated federal action, the case schedule was adjourned without date pending mediation. Mediation proceedings have taken place. On September 10, 2024, the Company received an additional substantially identical shareholder demand letter and on September 26, 2024, that shareholder filed a second substantially identical state court derivative action. In November 2024, the Company entered into an agreement in principle to resolve this matter for an amount that is not expected to be material to the Company’s consolidated financial results.
10

Beginning in February 2021, the Company received subpoenas from the Enforcement Division of the Securities and Exchange Commission (“SEC”) requesting information from the Company relating to, among other things, certain reporting issues involving BD AlarisTM infusion pumps included in SEC disclosures prior to 2021. In December 2024, the Company reached an agreement to resolve the matter with the SEC for its previously accrued amount of $175 million. In accordance with the terms of the settlement, the Company has engaged and is working with an independent compliance consultant to review practices and procedures relating to the evaluation of product recalls and remediation under U.S. GAAP and its disclosure controls and procedures, including but not limited to controls and procedures relating to collection and assessment of information concerning potential risks, contingencies, operating events, trends, and uncertainties.
In July 2017, C.R. Bard, which was acquired by the Company in December 2017, received a CID from the Department of Justice seeking documents and information relating to an investigation into possible violations of the False Claims Act in connection with the sales and marketing of FloChec® and QuantaFloTM devices. The Company has responded to these requests and met with the Department of Justice in February and July 2024; discussions are ongoing.
In April 2019, the Department of Justice served the Company and CareFusion with CIDs seeking information regarding certain of CareFusion’s contracts with the Department of Veteran’s Affairs, some dating back more than 10 years, for certain products, including AlarisTM and PyxisTM devices, in connection with a civil investigation of possible violations of the False Claims Act, and the government later expanded the investigation to include several additional contracts. The government has made several requests for documents and interviews or depositions of Company personnel and set forth a preliminary case assessment. The Company is cooperating with the government, responding to these requests and evaluating the assessment.
In September 2021, the Company received a CID related to an inquiry initiated by the Department of Justice in the Northern District of Georgia in 2018 concerning sales and marketing practices with respect to certain aspects of the Company’s urology business. After multiple document productions and interviews, the Company and the government mediated the case in an effort to resolve this dispute; an agreement was reached to resolve this matter for an adequately accrued amount that is not material to the Company’s consolidated financial results. This matter is now resolved.
In April 2023, the Department of Justice served the Company with a CID seeking information regarding the Company’s GenesisTM container products in connection with an investigation of possible violations of the False Claims Act. The government has requested documents and set forth a preliminary case assessment, and the Company is cooperating with the government, responding to its requests and evaluating the assessment.
The Company was sued in state and federal courts in Georgia by plaintiffs who work or reside near Company facilities in Covington, GA, where ethylene oxide (“EtO”) sterilization activities take place. The federal cases have been dismissed and refiled in state court. The plaintiffs in the cases seek compensatory and punitive damages. Pursuant to Georgia statute, punitive damages in these cases are generally capped at $250,000 per claimant, unless the plaintiff can prove that the Company acted, or failed to act, with a specific intent to cause harm, which the court to date has cast as a jury issue, meaning that the jury could negate the cap. The cases allege a variety of injuries, including but not limited to multiple types of cancer, allegedly attributable to exposure to EtO. As of December 31, 2024, the Company has approximately 360 of such suits involving approximately 375 plaintiffs asserting individual personal injury claims; approximately 50 of the cases also allege injury caused by exposure to a chemical of another defendant entirely unrelated to the Company. No cases have yet been tried although a trial date has been set for one such case scheduled for April 2025. The Company believes that it has meritorious defenses and is vigorously defending itself in these matters.
In 2015, legislation was enacted in Italy which requires medical technology companies to make payments to the Italian government if Italy’s medical device expenditures exceed annual regional expenditure ceilings. The amount of these payments is based on the amount by which the regional ceilings for the given year were exceeded. Considerable uncertainty has existed regarding the enforceability and implementation of this payback legislation since it was enacted and the Company, as well as other medical device companies, have filed appeals which challenge the enforceability of this legislation. In July 2024, the Italian Constitutional Court issued two judgments which concluded that the medical device payback legislation is constitutional; however, litigation proceedings before Italian Courts are still pending. While the Company recorded $62 million during its fiscal year 2024 as a preliminary estimate of the liability related to this matter, substantially all of which relates to periods prior to fiscal year 2024, ultimate resolution is unknown at this time, and it is possible that the amount of the Company’s liability could differ from the currently accrued amount.

In May 2024, CareFusion 303, Inc., the Company’s subsidiary that manufactures its BD PyxisTM dispensing equipment, received a Form 483 Notice following an inspection from the U.S. Food and Drug Administration (“FDA”) that contained observations of non-conformance with the FDA’s Quality System and Medical Device Reporting (“MDR”) regulations. In November 2024, the Company received a Warning Letter following the inspection of its Dispensing quality management system at its facility located in San Diego, California, citing certain alleged violations of the quality system regulations, MDR regulation, the corrections and removals reporting regulation and law. The Company’s liability recorded for estimated future
11

costs associated with certain actions required to respond to the Warning Letter and to address the non-conformities was $50 million as of December 31, 2024, which reflected a $22 million adjustment recorded to increase the liability during the first quarter of fiscal year 2025. The Company submitted a comprehensive response to address FDA’s feedback in the Warning Letter, which committed to implementing additional corrective actions; however, no assurances can be given regarding further action by the FDA as a result of the Warning Letter, or that corrective actions proposed and taken by CareFusion 303, Inc. will be adequate to address the Warning Letter. Any failure to adequately address this Warning Letter may result in regulatory actions initiated by the FDA without further notice, which may include, but are not limited to, seizure, injunction and civil monetary penalties. As a result, the ultimate resolution of this Warning Letter and its impact on the Company’s operations is unknown at this time, and it is possible that the amount of the Company’s liability could exceed its currently accrued amount.
The Company is also involved both as a plaintiff and a defendant in other legal proceedings and claims that arise in the ordinary course of business. The Company believes that it has meritorious defenses and is vigorously defending itself in each of these matters.
Except as otherwise noted, the Company cannot predict the outcome of the other legal matters discussed above, nor can it predict whether any outcome will have a material adverse effect on the Company’s consolidated results of operations and/or consolidated cash flows. Further, the Company may not be able to determine if a probable loss exists for certain of the other legal matters discussed above, and accordingly, the Company has recorded no provisions for such matters in its consolidated results of operations.
The Company is a potentially responsible party to a number of federal administrative proceedings in the United States brought under the Comprehensive Environment Response, Compensation and Liability Act, also known as “Superfund,” and similar state laws. The Company also is subject to administrative proceedings under environmental laws in jurisdictions outside the U.S. The affected sites are in varying stages of development. In some instances, the remedy has been completed, while in others, environmental studies are underway or commencing. For several sites, there are other potentially responsible parties that may be jointly or severally liable to pay all or part of cleanup costs. While it is not feasible to predict the outcome of these proceedings, based upon the Company’s experience, current information and applicable law, the Company does not expect these proceedings to have a material adverse effect on its consolidated results of operations and/or consolidated cash flows.
Litigation Accruals
The Company regularly monitors and evaluates the status of product liability and other litigated matters, and may, from time-to-time, engage in settlement discussions and mediations taking into consideration, among other things, developments in the litigation and the risks and uncertainties associated therewith. These activities have resulted in confidential settlements and going forward could result in further settlements, the terms of which may be confidential and could be significant and result in charges in excess of accruals. A determination of the accrual amounts for these contingencies is made after analysis of each litigation matter. When appropriate, the accrual is developed with the consultation of outside counsel and, in the case of certain mass tort litigation, actuarial specialists regarding the nature, timing, and extent of each matter.
During the first quarter of fiscal year 2024, the Company recorded a pre-tax benefit to Other operating expense, net, of approximately $36 million related to certain of the product liability matters discussed above under the heading “Product Liability Matters,” including the related legal defense costs. The benefit primarily reflected the favorable resolution of claims during the fiscal year.
The Company considers relevant information when estimating its product liability accruals, including, but not limited to: the nature, number, and quality of unfiled and filed claims; the rate of claims being filed; the status of settlement discussions with plaintiffs’ counsel; the allegations and documentation supporting or refuting such allegations; publicly available information regarding similar medical device mass tort settlements; historical information regarding other product liability settlements involving the Company; and the stage of litigation. Because currently available information regarding product liability matters is often limited, there is inherent uncertainty and volatility relating to the Company’s estimate of product liability. As additional information becomes available, the Company records adjustments to its product liability accruals as required.
Accruals for the Company's product liability claims which are discussed above, as well as the related legal defense costs, amounted to approximately $1.6 billion and $1.7 billion at December 31, 2024 and September 30, 2024, respectively. These accruals are recorded within Payables, accrued expenses and other current liabilities and Deferred Income Taxes and Other Liabilities on the Company's condensed consolidated balance sheets. The decrease in the Company’s product liability accrual as of December 31, 2024, as compared with September 30, 2024, largely reflected reductions due to the payment of settlements and legal fees. The increase in the number of outstanding hernia repair device claims discussed above did not materially impact the Company’s product liability accrual because the underlying estimate of the Company’s liability includes and already accounts for unfiled claims. Moreover, the accrual reflects the determination that the quality of new hernia report device claims has generally diminished over time. Amounts payable pursuant to the settlement agreement that was consummated in the fourth
12

quarter of fiscal year 2024 to resolve the vast majority of the Company’s hernia litigation are included within the Company's current product liability accrual and will be paid out over a multi-year period. Claim activity during the first quarter of fiscal year 2025 relating to the pelvic mesh device and IVC filter matters did not materially impact the Company’s product liability accrual as of December 31, 2024.
The particular outcome in any one product liability trial is typically not representative of potential outcomes of all cases or claims. Because the accrual already contemplates a wide range of possible outcomes, including those with a de minimis value, individual outcomes generally do not impact the value of other cases in the total case inventory or the overall product liability accrual.
In view of the uncertainties discussed above, the Company could incur charges in excess of any currently established accruals and, to the extent available, liability insurance. In the opinion of management, any such future charges, individually or in the aggregate, could have a material adverse effect on the Company’s consolidated results of operations, financial condition, and/or consolidated cash flows.
Note 6 – Revenues
The Company’s policies for recognizing sales have not changed from those described in the Company’s 2024 Annual Report on Form 10-K. The Company sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products which are distributed through independent distribution channels and directly by BD through sales representatives. End-users of the Company's products include healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. In the current and prior-year periods, the Company generated revenues attributable to licensing, which includes consideration received in exchange for the use of BD intellectual property by third parties.
Measurement of Revenues
The Company’s allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of its trade receivables. Such estimated credit losses are determined based on historical loss experiences, customer-specific credit risk, and reasonable and supportable forward-looking information, such as country or regional risks that are not captured in the historical loss information. The allowance for doubtful accounts for trade receivables is not material to the Company's consolidated financial results.
The Company's gross revenues are subject to a variety of deductions which are recorded in the same period that the underlying revenues are recognized. Such variable consideration includes rebates, sales discounts and sales returns. The Company’s rebate liabilities are classified as an offset to Trade receivables, net, or as Payables, accrued expenses and other current liabilities, depending on the form of settlement and were $813 million and $749 million at December 31, 2024 and September 30, 2024, respectively. The impact of other forms of variable consideration, including sales discounts and sales returns, is not material to the Company's revenues.
Effects of Revenue Arrangements on Condensed Consolidated Balance Sheets
Capitalized contract costs associated with the costs to fulfill contracts for certain products in the Medication Management Solutions organizational unit are immaterial to the Company's condensed consolidated balance sheets. Commissions relating to revenues recognized over a period longer than one year are recorded as assets which are amortized over the period over which the revenues underlying the commissions are recognized. Capitalized contract costs related to such commissions are immaterial to the Company's condensed consolidated balance sheets.
Contract liabilities for unearned revenue that is allocable to performance obligations, such as extended warranty and software maintenance contracts, which are performed over time, were approximately $502 million and $482 million as of December 31, 2024 and September 30, 2024, respectively, and are included in Payables, accrued expenses and other current liabilities on the Company’s condensed consolidated balance sheets. The Company's liability for product warranties provided under its agreements with customers is not material to its condensed consolidated balance sheets.
Remaining Performance Obligations
The Company's obligations relative to service contracts and pending installations of equipment, primarily in the Company's Medication Management Solutions unit, represent unsatisfied performance obligations of the Company. The revenues under existing contracts with original expected durations of more than one year, which are attributable to products and/or services that have not yet been installed or provided are estimated to be approximately $2.3 billion at December 31, 2024. The Company expects to recognize the majority of this revenue over the next three years.
13

Within the Company's Medication Management Solutions, Medication Delivery Solutions, Diagnostic Solutions, and Biosciences units, some contracts also contain minimum purchase commitments of reagents or other consumables, and the future sales of these consumables represent additional unsatisfied performance obligations of the Company. The revenue attributable to the unsatisfied minimum purchase commitment-related performance obligations, for contracts with original expected durations of more than one year, is estimated to be approximately $2.0 billion at December 31, 2024. This revenue will be recognized over the customer relationship periods.
Disaggregation of Revenues
A disaggregation of the Company's revenues by segment, organizational unit and geographic region is provided in Note 7.
Note 7 – Segment Data
The Company's organizational structure is based upon three worldwide business segments: BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional (“Interventional”). The Company's segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services. Segment disclosures are on a performance basis consistent with internal management reporting. The Company evaluates performance of its business segments and allocates resources to them primarily based upon segment operating income, which represents revenues reduced by product costs and operating expenses.
Revenues by segment, organizational unit and geographical areas for the three-month periods are detailed below. The Company has no material intersegment revenues.
Three Months Ended December 31,
(Millions of dollars)20242023
United StatesInternationalTotalUnited StatesInternationalTotal
Medical
Medication Delivery Solutions$694 $430 $1,124 $639 $413 $1,052 
Medication Management Solutions659 142 801 594 153 747 
Pharmaceutical Systems104 314 418 127 304 431 
Advanced Patient Monitoring159 113 271 — — — 
Total segment revenues$1,615 $999 $2,615 $1,360 $870 $2,230 
Life Sciences
Specimen Management (a)$238 $223 $462 $234 $213 $447 
Diagnostic Solutions (a)212 262 474 210 256 467 
Biosciences153 208 361 143 232 375 
Total segment revenues$603 $694 $1,297 $587 $701 $1,288 
Interventional
Surgery$303 $92 $395 $280 $88 $369 
Peripheral Intervention253 220 473 234 220 454 
Urology and Critical Care306 83 389 287 78 365 
Total segment revenues$861 $396 $1,257 $802 $386 $1,188 
Total Company revenues$3,080 $2,089 $5,168 $2,749 $1,957 $4,706 
(a)    During the first quarter of fiscal year 2025, Life Sciences split its former Integrated Diagnostic Solutions organizational unit into two units to better align BD resources with the distinct needs of each business.
14

Segment income for the three-month periods was as follows:
 Three Months Ended
December 31,
(Millions of dollars)20242023
Income Before Income Taxes
Medical$492 $535 
Life Sciences383 372 
Interventional387 291 
Total Segment Operating Income1,263 1,198 
Integration, restructuring and transaction expense(92)(75)
Net interest expense (132)(77)
Other unallocated items (a)(733)(688)
Total Income Before Income Taxes$306 $359 
(a)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense.
Note 8 – Benefit Plans
The Company has defined benefit pension plans covering certain employees in the United States and certain international locations. The measurement date used for these plans is September 30.
Net pension cost included the following components for the three-month periods:
 Three Months Ended
December 31,
(Millions of dollars)20242023
Service cost$12 $25 
Interest cost42 39 
Expected return on plan assets(56)(42)
Amortization of prior service credit— (1)
Amortization of loss10 16 
Net pension cost$8 $37 
The amounts provided above for amortization of prior service credit and amortization of loss represent the reclassifications of prior service credits and net actuarial losses that were recognized in Accumulated other comprehensive income (loss) in prior periods. All components of the Company’s net periodic pension and postretirement benefit costs, aside from service cost, are recorded to Other expense, net on its condensed consolidated statements of income.
15

Note 9 – Acquisition
Advanced Patient Monitoring
On September 3, 2024, the Company completed its acquisition of Edwards Lifesciences’ Critical Care product group (“Critical Care”), which was renamed as BD Advanced Patient Monitoring (“Advanced Patient Monitoring”). Since the acquisition date, financial results for Advanced Patient Monitoring’s product offerings are being reported as a separate organizational unit within the Medical segment. Advanced Patient Monitoring is a global leader in advanced monitoring solutions that expands the Company’s portfolio of smart connected care solutions with its growing set of leading monitoring technologies, advanced AI-enabled clinical decision tools and robust innovation pipeline that complement the Company's existing technologies serving operating rooms and intensive care units. The Company funded the transaction with cash on hand, using net proceeds raised through debt issuances in the third quarter of fiscal year 2024 and borrowings under its commercial paper program. The acquisition was accounted for under the acquisition method of accounting for business combinations.
The Company is in the process of finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed, related to assessing certain assumptions underlying the valuation of intangible assets. The preliminary allocations of the purchase price provide a reasonable basis for estimating the fair values of assets acquired and liabilities assumed. These provisional estimates may be adjusted upon the availability of further information regarding events or circumstances that existed at the acquisition date. Such adjustments may be significant. The fair value of consideration transferred in connection with the acquisition was $3.906 billion. As of December 31, 2024, the assets acquired and the liabilities assumed in this acquisition included developed technology intangible assets of $717 million, customer relationships intangible assets of $653 million and $713 million of other net assets, which are primarily inventory. The goodwill recorded from the excess of the purchase price over the fair value of the acquired net assets was $1.823 billion, which related to synergies expected to be gained from combining operations of the acquiree and acquirer, as well as revenue and cash flow projections associated with future innovative technologies expected to occur. The preliminary estimate of the goodwill that is expected to be deductible for tax purposes is approximately $1.1 billion.
The Company included Advanced Patient Monitoring in its consolidated results of operations beginning on September 3, 2024. The Company’s unaudited pro forma Revenues for the three months ended December 31, 2023, giving effect as if Advanced Patient Monitoring had been acquired as of October 1, 2022, were $4.957 billion. The calculation of pro forma Net Income for the three months ended December 31, 2023 is not practicable because of complexities associated with its hypothetical calculation.
Note 10 – Business Restructuring Charges
The Company incurred restructuring costs during the three months ended December 31, 2024, primarily in connection with the Company's simplification and other cost-saving initiatives, which were recorded within Integration, restructuring and transaction expense. These simplification and other cost-saving initiatives are focused on reducing complexity, optimizing the Company’s supply chain efficiency, streamlining its global manufacturing footprint, enhancing product quality, refining customer experience, and improving cost efficiency across all of the Company’s segments.
Restructuring liability activity for the three months ended December 31, 2024 was as follows:
(Millions of dollars)Employee
Termination
Other (a)
Total
Balance at September 30, 2024$58 $2 $60 
Charged to expense20 46 66 
Cash payments(29)(36)(65)
Non-cash settlements— (6)(6)
Other adjustments(2)— (2)
Balance at December 31, 2024$47 $6 $53 
(a)    Other non-employee-related expenses primarily relate to other costs associated with the execution of the Company’s cost efficiency and restructuring programs, such as incremental project management costs and facility exit costs.
16

Note 11 – Intangible Assets
Intangible assets consisted of:
 December 31, 2024September 30, 2024
(Millions of dollars)Gross
Carrying
Amount		Accumulated
Amortization		Net Carrying AmountGross
Carrying
Amount		Accumulated
Amortization		Net Carrying Amount
Amortized intangible assets
Developed technology$15,788 $(8,349)$7,439 $15,827 $(8,094)$7,733 
Customer relationships5,511 (2,978)2,533 5,513 (2,878)2,635 
Patents, trademarks and other1,188 (688)500 1,185 (682)503 
Amortized intangible assets$22,486 $(12,014)$10,472 $22,525 $(11,654)$10,871 
Unamortized intangible assets
Acquired in-process research and development$14 $44 
Trademarks2 2 
Unamortized intangible assets$16 $46 
Intangible amortization expense was $395 million and $365 million for the three months ended December 31, 2024 and 2023, respectively.
The following is a reconciliation of goodwill by business segment:
(Millions of dollars)Medical Life SciencesInterventional Total
Goodwill as of September 30, 2024$12,832 $904 $12,729 $26,465 
Purchase price allocation adjustments(12)— — (12)
Currency translation(51)(8)(66)(125)
Goodwill as of December 31, 2024$12,769 $896 $12,663 $26,329 
Note 12 – Derivative Instruments and Hedging Activities
The Company uses derivative instruments to mitigate certain exposures. The Company does not enter into derivative financial instruments for trading or speculative purposes. The effects these derivative instruments and hedged items had on the Company’s balance sheets and the fair values of the derivatives outstanding at December 31, 2024 and September 30, 2024 were not material. The effects on the Company’s financial performance and cash flows are provided below.
Foreign Currency Risks and Related Strategies
The Company has foreign currency exposures throughout Europe, Greater Asia, Canada and Latin America. Transactional currency exposures that arise from entering into transactions, generally on an intercompany basis, in non-hyperinflationary countries that are denominated in currencies other than the functional currency are mitigated primarily through the use of forward contracts.
In order to mitigate transactional foreign currency exposures resulting from anticipated intercompany purchases and sales denominated in a currency other than local functional currencies, the Company has hedged a portion of this currency risk with certain instruments such as foreign exchange forward and option contracts, which are designated as cash flow hedges.
In order to mitigate foreign currency exposure relating to its investments in certain foreign subsidiaries, the Company has hedged the currency risk associated with those investments with certain instruments, such as foreign currency-denominated debt and cross-currency swaps, which are designated as net investment hedges, as well as currency exchange contracts.
17

The notional amounts of the Company’s foreign currency-related derivative instruments as of December 31, 2024 and September 30, 2024 were as follows:
(Millions of dollars)Hedge DesignationDecember 31, 2024September 30, 2024
Foreign exchange contracts (a)Undesignated$2,366 $4,521 
Foreign exchange contracts (b)Cash flow hedges394 543 
Foreign currency-denominated debt (c)Net investment hedges2,874 3,065 
Cross-currency swaps (d)Net investment hedges1,022 1,366 
(a)Represents hedges of transactional foreign exchange exposures resulting primarily from intercompany payables and receivables. Gains and losses on these instruments are recognized immediately in income. These gains and losses are largely offset by gains and losses on the underlying hedged items, as well as the hedging costs associated with the derivative instruments. Net amounts recognized in Other expense, net, during the three months ended December 31, 2024 and 2023 were immaterial to the Company's consolidated financial results.
(b)Represents foreign exchange contracts related to anticipated intercompany purchases and sales, described above, which generally have durations of less than eighteen months.
(c)Represents foreign currency-denominated long-term notes outstanding which were effective as economic hedges of net investments in certain of the Company's foreign subsidiaries.
(d)Represents cross-currency swaps, which were effective as economic hedges of net investments in certain of the Company's foreign subsidiaries.
Net gains or losses resulting from the change in fair value of the foreign exchange contracts designated as cash flow hedges are initially recorded within Other comprehensive income (loss) and reclassified into earnings upon the occurrence of the related underlying third-party transaction. If foreign exchange contracts designated as cash flow hedges are terminated prematurely as a result of the hedged transaction being probable of not occurring, the balance in Accumulated other comprehensive income (loss) attributable to those derivatives is immediately reclassified into Revenues or Cost of products sold (depending on whether the hedged item is an intercompany sale or purchase). Net after tax losses recognized in Other comprehensive income (loss) as well as amounts reclassified from Accumulated other comprehensive income (loss) into earnings relating to these cash flow hedges during the three months ended December 31, 2024 were immaterial. No amounts relating to foreign exchange contracts designated as cash flow hedges were recognized in Other comprehensive income (loss) or reclassified from Accumulated other comprehensive income (loss) during three months ended December 31, 2023. The amounts expected to be reclassified from accumulated other comprehensive income into earnings within the next 12 months, are not material to the Company's consolidated financial results.
Net gains or losses relating to the net investment hedges, which are attributable to changes in the foreign currencies to U.S. dollar spot exchange rates, are recorded as foreign currency translation in Other comprehensive income (loss), net of tax. Upon the termination of a net investment hedge, any net gain or loss included in Accumulated other comprehensive income (loss) relative to the investment hedge remains until the foreign subsidiary investment is disposed of or is substantially liquidated.
Net gains (losses) recorded to Accumulated other comprehensive income (loss) relating to the Company's net investment hedges for the three-month periods were as follows:
 Three Months Ended
December 31,
(Millions of dollars)20242023
Foreign currency-denominated debt$145 $(29)
Cross-currency swaps (a)67 (55)
(a) The amount for the three months ended December 31, 2024 includes a loss, net of tax, of $18 million recognized on terminated cross-currency swaps.
Interest Rate Risks and Related Strategies
The Company uses a mix of fixed and variable rate debt to manage its interest rate exposure, and periodically uses interest rate swaps to manage such exposures. Under these interest rate swaps, the Company exchanges, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. These swaps are designated as either cash flow or fair value hedges.
18

Changes in the fair value of the interest rate swaps designated as cash flow hedges (i.e., hedging the exposure to variability in expected future cash flows that is attributable to a particular risk) are recorded in Other comprehensive income (loss), net of tax. If interest rate derivatives designated as cash flow hedges are terminated, the balance in Accumulated other comprehensive income (loss) attributable to those derivatives is reclassified into earnings, within Interest expense, over the remaining life of the hedged debt.
For interest rate swaps designated as fair value hedges (i.e., hedges against the exposure to changes in the fair value of an asset or a liability or an identified portion thereof that is attributable to a particular risk), changes in the fair value of the interest rate swaps offset changes in the fair value of the fixed rate debt due to changes in market interest rates. Amounts recorded during the three months ended December 31, 2024 and 2023 were immaterial to the Company's consolidated financial results.
The notional amounts of the Company’s interest rate-related derivative instruments as of December 31, 2024 and September 30, 2024 were as follows:
(Millions of dollars)Hedge DesignationDecember 31, 2024September 30, 2024
Interest rate swaps (a)Fair value hedges$700 $700 
(a)Represents fixed-to-floating interest rate swap agreements the Company entered into to convert the interest payments on certain long-term notes from the fixed rate to a floating interest rate based on secured overnight financing rates (“SOFR”).
Other Risk Exposures
The Company purchases resins, which are oil-based components used in the manufacture of certain products. Significant increases in world oil prices that lead to increases in resin purchase costs could impact future operating results. From time to time, the Company has managed price risks associated with these commodity purchases through commodity derivative forward contracts. The Company's commodity derivative forward contracts at December 31, 2024 and September 30, 2024 were immaterial to the Company's consolidated financial results.

Note 13 – Financial Instruments and Fair Value Measurements
The following reconciles cash and equivalents and restricted cash reported within the Company's condensed consolidated balance sheets at December 31, 2024 and September 30, 2024 to the total of these amounts shown on the Company's condensed consolidated statements of cash flows:
(Millions of dollars)December 31, 2024September 30, 2024
Cash and equivalents$711 $1,717 
Restricted cash102 139 
Cash and equivalents and restricted cash$813 $1,856 
Cash equivalents consist of all highly liquid investments with a maturity of three months or less at time of purchase. Restricted cash consists of cash restricted from withdrawal and usage except for certain product liability matters.
The fair values of the Company’s financial instruments are as follows:
(Millions of dollars)Basis of fair value measurementDecember 31, 2024September 30, 2024
Institutional money market accounts (a)Level 1$— $285 
Current portion of long-term debt (b)Level 2831 1,748 
Long-term debt (b)Level 216,337 17,199 
(a)These financial instruments are recorded within Cash and equivalents on the condensed consolidated balance sheets. The institutional money market accounts permit daily redemption. The fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions.
(b)Long-term debt is recorded at amortized cost. The fair value of long-term debt is measured based upon quoted prices in active markets for similar instruments.
Short-term investments are held to their maturities and are carried at cost, which approximates fair value. The short-term investments primarily consist of time deposits with maturities greater than three months and less than one year. All other
19

instruments measured by the Company at fair value, including derivatives, contingent consideration liabilities and available-for-sale debt securities, are immaterial to the Company's condensed consolidated balance sheets.
Nonrecurring Fair Value Measurements
In the first quarter of fiscal year 2025, the Company recorded a non-cash asset impairment charge of $30 million to Research and development expense to write down the carrying value of certain assets in the Life Sciences segment. The amount recognized was recorded to adjust the carrying amount of assets to the assets' fair values, which were estimated, based upon a market participant's perspective, using Level 3 measurements, including values estimated using the income approach.
Transfers of Trade Receivables
Over the normal course of its business activities, the Company transfers certain trade receivable assets to third parties under factoring agreements. Per the terms of these agreements, the Company surrenders control over its trade receivables upon transfer. Accordingly, the Company accounts for the transfers as sales of trade receivables by recognizing an increase to Cash and equivalents and a decrease to Trade receivables, net when proceeds from the transactions are received. The costs incurred by the Company in connection with factoring activities were not material to its consolidated financial results. The amounts transferred and yet to be remitted under factoring arrangements are provided below.
Three Months Ended December 31,
(Millions of dollars)20242023
Trade receivables transferred to third parties under factoring arrangements$360 $379 
December 31, 2024September 30, 2024
Amounts yet to be collected and remitted to the third parties$338 $254 
Supplier Finance Programs
The Company has agreements where participating suppliers are provided the ability to receive early payment of the Company’s obligations at a nominal discount through supplier finance programs entered into with third party financial institutions. The Company is not a party to these arrangements, and these programs do not impact the Company’s obligations or affect the Company’s payment terms, which generally range from 90 to 150 days. The agreements with the financial institutions do not require the Company to provide assets pledged as security or other forms of guarantees for the supplier finance programs. The Company had $118 million and $112 million of outstanding payables related to supplier finance programs as of December 31, 2024 and September 30, 2024, respectively, which were recorded within Payables, accrued expenses and other current liabilities on the Company's condensed consolidated balance sheets.

Note 14 – Income Taxes
Income Tax Expense
The Company’s effective income tax rates for the three months ended December 31, 2024 and 2023 were 0.9% and 21.6%, respectively. The decrease in the Company’s effective tax rate for the three months ended December 31, 2024 was largely due to the partial release of the valuation allowance established for a non-U.S. tax credit.

Note 15 – Subsequent Event
BD’s Intention to Separate Biosciences and Diagnostic Solutions
On February 5, 2025, the Company announced its intention to separate its Biosciences and Diagnostic Solutions business from the rest of the Company. The Company expects to announce more specifics on the separation plans by the end of fiscal year 2025 and intends to target completion of the transaction in fiscal year 2026. The completion of any separation transaction will be contingent upon various conditions and approvals, including approval of the Company’s board of directors, receipt of requisite regulatory clearances and compliance with applicable SEC requirements. No assurance can be given regarding the form that a separation transaction may take or the specific terms or timing, or that a separation will in fact occur.

20


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following commentary should be read in conjunction with the condensed consolidated financial statements and accompanying notes presented in this report. Within the tables presented throughout this discussion, certain columns may not add due to the use of rounded numbers for disclosure purposes. Percentages and earnings per share amounts presented are calculated from the underlying amounts. References to years throughout this discussion relate to our fiscal years, which end on September 30.
Company Overview
Becton, Dickinson and Company (“BD”) is a global medical technology company engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Company's organizational structure is based upon three principal business segments, BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional (“Interventional”).
BD’s products are manufactured and sold worldwide. Our products are marketed in the United States and internationally through independent distribution channels and directly to end-users by BD and independent sales representatives. We organize our operations outside the United States as follows: EMEA (which includes Europe, the Middle East and Africa); Greater Asia (which includes countries in Greater China, Japan, South Asia, Southeast Asia, Korea, Australia and New Zealand); Latin America (which includes Mexico, Central America, the Caribbean and South America); and Canada. We continue to pursue growth opportunities in emerging markets, which include the following geographic regions: Eastern Europe, the Middle East and Africa (collectively referred to below as “EMA”), as well as Latin America and certain countries within Greater Asia.
BD’s Intention to Separate Biosciences and Diagnostic Solutions
On February 5, 2025, we announced our intention to separate our Biosciences and Diagnostic Solutions business from the rest of BD. BD’s board of directors is committed to exploring all opportunities to execute the separation in a manner that maximizes shareholder value, including possible options such as a spin-off, sale, Reverse Morris Trust or other transaction. BD expects to announce more specifics on the separation plans by the end of fiscal year 2025 and intends to target completion of the transaction in fiscal year 2026.
Key Trends and Uncertainties Affecting Results of Operations
Our BD 2025 strategy for growth is anchored in three pillars: grow, simplify and empower. As we continue to execute this strategy, we have invested in research and development, strategic tuck-in acquisitions, geographic expansion, and new product programs to drive further revenue and profit growth. Our ability to sustain our long-term growth will depend on a number of factors, including our ability to expand our core business, and develop innovative new products, as well as continue to improve operating efficiency and organizational effectiveness. Our operations, supply chain, suppliers and customers are exposed to various global macroeconomic factors and other risks which we continually evaluate to assess their potential impact to our operations and financial results.
We have been experiencing, and may continue to experience, some adverse impact to our results of operations due to market dynamics in China, such as volume-based procurement programs (“VoBP”) and the government’s focus to improve compliance of healthcare practitioners. Also, reductions or delays in governmental research funding and/or higher interest rates could cause customers for our instruments and reagents to delay or forgo purchases of these products. The future demand for our products and services could also be impacted by deterioration in healthcare systems’ budgets and/or staffing levels.

Additionally, we have experienced, and may continue to experience, temporary shortages in supply of certain materials or components that are used in our products. The stable flow of global transport is critical to our operations and as such, events affecting the flow of logistics around the globe may adversely impact our supply chain and distribution channels. In general, major disruptions in the sourcing, manufacturing and distribution of our products could adversely impact our results of operations. Also, tariffs, sanctions or other trade barriers imposed by the United States, including those relating to China, Mexico or other countries and regions in which we do business, could adversely impact our supply chain costs and our results of operations. The ultimate impact of any new tariffs is subject to a number of factors including the effective date and duration of such tariffs, changes in the amount, scope and nature of the tariffs in the future, any countermeasures that the target countries may take and any mitigating actions that may become available.
For additional information on risk factors that may impact our business, results of operations, financial condition and cash flows, see Part II, Item 1A. Risk Factors of this Quarterly Report on Form 10-Q and Part I, Item 1A. Risk Factors of our 2024 Annual Report on Form 10-K (the “2024 Annual Report”).

21

Overview of Financial Results and Financial Condition
For the three months ended December 31, 2024, worldwide revenues of $5.168 billion increased 9.8% from the prior-year period. This increase reflected the following impacts:
Increase (decrease) in current-period revenues
Volume/other (a)3.5 %
Pricing0.4 %
Foreign currency impact0.2 %
Acquisition of Advanced Patient Monitoring5.7 %
Increase in revenues from the prior-year period
9.8 %
(a) Volume/other includes revenues attributable to products, services and licensing.
Cash flows from continuing operating activities were $693 million in the first three months of fiscal year 2025. At December 31, 2024, we had $830 million in cash and equivalents and short-term investments, including restricted cash. We continued to return value to our shareholders in the form of dividends. During the first three months of fiscal year 2025, we paid cash dividends to common shareholders of $302 million.
Each reporting period and given our worldwide operations, we face exposure to our results of operations from changes in foreign currencies. We calculate translational foreign currency impacts by converting our current-period local currency financial results using the prior-period foreign currency exchange rates and comparing these adjusted amounts to our current-period results, which allows us to compare results between periods as if exchange rates had remained constant period-over-period. The first quarter fiscal year 2025 impact of foreign currency on our revenues, which is primarily translational, is provided above. The translational impact on our earnings is provided further below. We evaluate our results of operations on both a reported and a foreign currency-neutral basis. As exchange rates are an important factor in understanding period-to-period comparisons, we believe the presentation of results on a foreign currency-neutral basis, excluding translational foreign currency impacts, in addition to reported results helps improve investors’ ability to understand our operating results and evaluate our performance in comparison to prior periods. We use results on a foreign currency-neutral basis as one measure to evaluate our performance. These results should be considered in addition to, not as a substitute for, results reported in accordance with U.S. generally accepted accounting principles ("GAAP"). Results on a foreign currency-neutral basis, as we present them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with U.S. GAAP.

Results of Operations
Medical Segment
The following summarizes first quarter Medical revenues by organizational unit:
 Three months ended December 31,
(Millions of dollars)20242023Total
Change		Estimated
FX
Impact		FXN Change
Medication Delivery Solutions$1,124 $1,052 6.9 %0.1 %6.8 %
Medication Management Solutions801 747 7.3 %0.2 %7.1 %
Pharmaceutical Systems418 431 (3.2)%— %(3.2)%
Advance Patient Monitoring271 — NMNMNM
Total Medical Revenues$2,615 $2,230 17.3 %0.2 %17.1 %
"NM" denotes that the percentage change is not meaningful.
The Medical segment’s revenue growth in the first quarter of 2025 primarily reflected the following:
•Volume growth and share gains attributable to the Medication Delivery Solutions unit’s Vascular Access Management portfolio, as well as strong sales of the unit’s hypodermic products.
•Growth in the Medication Management Solutions unit driven by double-digit growth in sales of infusion systems, partially offset by an unfavorable comparison to dispensing and pharmacy automation installations in the prior-year period.
22

•A decline in the Pharmaceutical Systems unit’s sales due to lower demand for prefillables syringes.
•Overall Medical segment revenue growth also reflected sales in the Advanced Patient Monitoring unit, which we acquired during the fourth quarter of fiscal year 2024.
Medical segment income for the three-month period is provided below.
Three months ended December 31,
(Millions of dollars)20242023
Medical segment income$492 $535 
Segment income as % of Medical revenues18.8 %24.0 %
The Medical segment's operating income as a percentage of revenues in the first quarter of 2025 compared with the first quarter of 2024 reflected the following:
•Lower gross profit margin in the first quarter of 2025 compared with the first quarter of 2024, which primarily reflected:
◦An unfavorable impact of $180 million due to a fair value step-up adjustment relating to Advanced Patient Monitoring's inventory on the acquisition date and higher amortization of intangible assets attributable to the Advanced Patient Monitoring unit, as well as a charge of $22 million to adjust future costs estimated for product remediation efforts; partially offset by
◦Lower manufacturing costs, which resulted from continuous improvement projects and other productivity initiatives and favorable product mix which was attributable to the Advanced Patient Monitoring unit’s products.
•Higher selling and administrative expense, as well as research and development expense, as percentages of revenues in the first quarter of 2025 compared with the first quarter of 2024 primarily reflected costs attributable to the Advanced Patient Monitoring unit.
Life Sciences Segment
The following summarizes first quarter Life Sciences revenues by organizational unit:
 Three months ended December 31,
(Millions of dollars)20242023Total
Change		Estimated
FX
Impact		FXN Change
Specimen Management (a)462 447 3.3 %— %3.3 %
Diagnostic Solutions (a)474 467 1.7 %0.2 %1.5 %
Biosciences361 375 (3.7)%0.4 %(4.1)%
Total Life Sciences Revenues$1,297 $1,288 0.7 %0.2 %0.5 %
(a)     During the first quarter of fiscal year 2025, Life Sciences split its former Integrated Diagnostic Solutions organizational unit into two units to better align BD resources with the distinct needs of each business.
The Life Sciences segment’s revenue growth in the first quarter of 2025 primarily reflected the following:
•Strong growth driven by sales of the Specimen Management unit’s BD VacutainerTM portfolio and customers’ upgrades to the unit’s higher value products.
•Strong growth in sales of the Diagnostic Solutions unit’s KiestraTM lab automation and MAXTM IVD platforms, partially offset by a delayed start to the current-year’s U.S. respiratory season.
•A decline in the Biosciences unit driven by anticipated lower demand for research instruments in the United States and China, partially offset by current-period licensing revenue.
23

Life Sciences segment income for the three-month period is provided below.
Three months ended December 31,
(Millions of dollars)20242023
Life Sciences segment income$383 $372 
Segment income as % of Life Sciences revenues29.6 %28.9 %

The Life Sciences segment's operating income as a percentage of revenues in the first quarter of 2025 compared with the first quarter of 2024 primarily reflected the following:
•Higher gross profit margin in the first quarter of 2025 compared with the first quarter of 2024 primarily reflected lower manufacturing costs resulting from continuous improvement projects and other productivity initiatives.
•Selling and administrative expense as a percentage of revenues in the first quarter of 2025 was higher compared with the first quarter of 2024 which primarily reflected higher administrative costs in the current-year period.
•Higher research and development expense as a percentage of revenues in the first quarter of 2025 compared with the first quarter of 2024 primarily reflected a $30 million write-down of certain assets.
Interventional Segment
The following summarizes first quarter Interventional revenues by organizational unit:
 Three months ended December 31,
(Millions of dollars)20242023Total
Change		Estimated
FX
Impact		FXN Change
Surgery$395 $369 7.0 %0.2 %6.8 %
Peripheral Intervention473 454 4.1 %0.3 %3.8 %
Urology and Critical Care389 365 6.6 %0.3 %6.3 %
Total Interventional Revenues$1,257 $1,188 5.8 %0.3 %5.5 %
The Interventional segment’s revenue growth in the first quarter of 2025 primarily reflected the following:
•Double-digit growth in the Surgery unit’s sales of infection prevention products, as well as strong growth in sales of hernia repair products, particularly the unit’s PhasixTM resorbable scaffold.
•Strong growth in sales of the Peripheral Intervention unit’s peripheral vascular disease and end-stage kidney disease platforms, partially offset by a decline in sales of our oncology products due to an expected VoBP impact in China.
•Continued double-digit growth in sales of the Urology and Critical Care unit’s PureWickTM offerings.
Interventional segment income for the three-month period is provided below.
Three months ended December 31,
(Millions of dollars)20242023
Interventional segment income$387 $291 
Segment income as % of Interventional revenues30.8 %24.5 %

The Interventional segment's operating income as a percentage of revenues in the first quarter of 2025 compared with the first quarter of 2024 reflected the following:
•Higher gross profit margin in the first quarter of 2025 compared with the first quarter of 2024, which primarily reflected favorable manufacturing variances and lower manufacturing costs, which resulted from continuous improvement projects and other productivity initiatives.
•Lower selling and administrative expense and research development expense as percentages of revenues in the first quarter of 2025 compared with the first quarter of 2024, which primarily reflected revenue growth that outpaced spending.
24

•Research and development expense as a percentage of revenues in the first quarter of 2025 was flat compared with the first quarter of 2024 which primarily reflected the timing of project spending.
Geographic Revenues
BD’s worldwide first quarter revenues by geography were as follows:
 Three months ended December 31,
(Millions of dollars)20242023Total
Change		Estimated
FX
Impact		FXN Change
United States$3,080 $2,749 12.0 %— %12.0 %
International2,089 1,957 6.7 %0.4 %6.3 %
Total Revenues$5,168 $4,706 9.8 %0.2 %9.6 %

U.S. revenue growth in the first quarter of 2025 reflected strong sales in the Medical segment’s Medication Delivery Solutions and Medication Management Solutions units, as well as solid growth across all of the Interventional segment’s units. Overall U.S. revenue growth also reflected the acquired Advanced Patient Monitoring unit’s sales. U.S. revenue growth in the first quarter of 2025 was partially offset by a decline in the Medical segment’s Pharmaceutical Systems unit, as further discussed above.
International revenue growth in the first quarter of 2025 was primarily driven by the Medical segment’s Medication Delivery Solutions unit. Overall international revenue growth in the first quarter of 2025 also reflected the acquired Advanced Patient Monitoring unit’s sales. International revenue growth in the first quarter of 2025 was partially offset by a decline in the Life Sciences segment’s Biosciences unit, as further discussed above. Current-period revenues in emerging markets primarily reflected strong sales in certain countries within Greater Asia, as well as in EMA, partially offset by a decline in China driven by unfavorable market dynamics, as further discussed above:
Three months ended December 31,
(Millions of dollars)20242023Total
Change		Estimated
FX
Impact		FXN Change
Emerging markets$729 $716 1.8 %(1.1)%2.9 %
Specified Items
Reflected in the financial results for the three-month periods of fiscal years 2025 and 2024 were the following specified items:
 Three months ended December 31,
(Millions of dollars)2024 2023
Restructuring costs (a)$66 $69 
Integration costs (a)24 5 
Transaction costs (b)3 — 
Separation-related items (c)— 2 
Purchase accounting adjustments (d)570 362 
European regulatory initiative-related costs (e)— 23 
Product, litigation, and other items (f)
102 14 
Total specified items764 475 
Less: tax impact of specified items and other tax related71 (24)
After-tax impact of specified items$693 $499 
(a)Represents amounts associated with restructuring and integration activities, which are recorded in Integration, restructuring and transaction expense and are further discussed below.
(b)Represents transaction costs, which are recorded in Integration, restructuring and transaction expense associated with the Advanced Patient Monitoring acquisition.
25

(c)Represents costs recorded to Other operating expense, net and incurred in connection with the separation of BD's former Diabetes Care business.
(d)Includes amortization and other adjustments related to the purchase accounting for acquisitions. BD’s amortization expense is recorded in Cost of products sold. The amount in the three-month period of 2025 includes $180 million due to a fair value step-up adjustment relating to Advanced Patient Monitoring's inventory on the acquisition date.
(e)Represents costs incurred to develop processes and systems to establish initial compliance with the European Union Medical Device Regulation and the European Union In Vitro Diagnostic Medical Device Regulation, which represent a significant, unusual change to the existing regulatory framework. We consider these costs to be duplicative of previously incurred costs and/or one-off costs, which are limited to a specific period of time. These expenses, which are recorded in Cost of products sold and Research and development expense, include the cost of labor, other services and consulting (in particular, research and development and clinical trials) and supplies, travel and other miscellaneous costs.
(f)Includes certain (income) expense items which are not part of ordinary operations and affect the comparability of the periods presented. Such items may include certain product remediation costs, certain legal matters, certain investment gains and losses, certain asset impairment charges, and certain pension settlement costs. The amount in the three-month period of 2025 included a charge within Cost of products sold of $22 million to adjust future costs estimated for product remediation efforts, as well as a non-cash $30 million charge recorded within Research and development expense to write down certain assets in the Life Sciences segment. The amount additionally included charges of approximately $29 million which were recorded to Other operating expense, net, and related to various legal matters. Additional disclosures regarding legislative and legal matters are provided in Note 5 in the Notes to Condensed Consolidated Financial Statements.

Gross Profit Margin
The comparison of gross profit margin for the three-month periods of fiscal years 2025 and 2024 reflected the following impacts:
 Three-month period
December 31, 2023 gross profit margin %
43.1 %
Impact of purchase accounting adjustments and other specified items(3.6)%
Operating performance3.5 %
Foreign currency impact0.3 %
December 31, 2024 gross profit margin %
43.3 %

The unfavorable impact on gross margin for the three-month period of 2025 from specified items reflects amortization of intangibles attributable to the Advanced Patient Monitoring acquisition and an impact of $180 million resulting from a fair value step-up adjustment relating to Advanced Patient Monitoring's inventory on the acquisition date. The impact from specified items in the current-year period also included a $22 million charge recorded in the Medical segment to adjust the estimate of future product remediation costs, as further discussed in Note 5 in the Notes to Condensed Consolidated Financial Statements.
Operating performance in the three-month period of 2025 compared with the prior-year period primarily reflected lower manufacturing costs resulting from our ongoing continuous improvement projects and other productivity initiatives, partially offset by higher labor costs.
26

Operating Expenses
A summary of operating expenses for the three-month period of fiscal years 2025 and 2024 is as follows:
 Three months ended December 31,Increase (decrease) in basis points
 20242023
(Millions of dollars)  
Selling and administrative expense$1,318 $1,213 
% of revenues25.5 %25.8 %(30)
Research and development expense$343 $290 
% of revenues6.6 %6.2 %40 
Integration, restructuring and transaction expense$92 $75 
Other operating expense, net$28 $11 
Selling and administrative expense
Selling and administrative expense as a percentage of revenues in the three-month period of 2025 was lower compared with the prior-year periods, which primarily reflected higher revenues, partially offset by higher selling costs in the current-year period.
Research and development expense
Higher research and development expense as a percentage of revenues in the three-month period of 2025 primarily reflected a $30 million write-down of certain assets in the Life Sciences segment and the timing of project spending.
Integration, restructuring and transaction expense
The amount in the three-month period of 2025 primarily included restructuring costs related to simplification and other cost-saving initiatives, as well as restructuring, integration and transaction costs relating to our acquisition of the Advanced Patient Monitoring unit. For further disclosures regarding restructuring costs, refer to Note 10 in the Notes to Condensed Consolidated Financial Statements.
Other operating expense, net
The amount in the three-month period of 2025 largely represented charges relating to legal matters. Additional disclosures regarding legislative and legal matters are provided in Note 5 in the Notes to Condensed Consolidated Financial Statements.
Nonoperating Income
Net interest expense
The components for the three-month periods of fiscal years 2025 and 2024 were as follows:
 Three months ended December 31,
(Millions of dollars)20242023
Interest expense$(155)$(111)
Interest income23 34 
Net interest expense$(132)$(77)
Higher interest expense for the three-month period of fiscal year 2025 compared with the prior-year period primarily reflected higher total debt outstanding at December 31, 2024 compared with December 31, 2023. The higher debt level in the current-year period reflected debt issued during fiscal year 2024 to fund the cash consideration payable upon our acquisition of Advanced Patient Monitoring.
27

Income Taxes
The income tax rates for the three-month periods of fiscal years 2025 and 2024 are provided below.
 Three months ended December 31,
20242023
Effective income tax rate0.9 %21.6 %
Impact, in basis points, from specified items(600)1,520 

The effective income tax rate for the three-month period of fiscal year 2025 compared with the prior-year period primarily reflected the impact of a favorable discrete item on the current-period rate as further discussed in Note 14 in the Notes to Condensed Consolidated Financial Statements.
Net Income and Diluted Earnings per Share
Net income and diluted earnings per share for the three-month periods of fiscal years 2025 and 2024 were as follows:
Three months ended December 31,
20242023
Net Income (Millions of dollars)$303 $281 
Diluted Earnings per Share$1.04 $0.96 
Unfavorable impact-specified items$(2.39)$(1.71)
Favorable impact-foreign currency translation$0.01 

Liquidity and Capital Resources
The following table summarizes our condensed consolidated statements of cash flows:
Three months ended December 31,
(Millions of dollars)20242023
Net cash provided by (used for):
Operating activities$693 $855 
Investing activities$204 $(233)
Financing activities$(1,928)$(862)

Net Cash Flows from Operating Activities
Cash flows from operating activities in the first three months of fiscal year 2025 was largely driven by our net income, adjusted by a change in operating assets and liabilities that was a net use of cash. This net use of cash primarily reflected higher levels of inventory and prepaid expenses, as well as lower levels of accounts payable and accrued expenses, partially offset by lower levels of trade receivables. The decrease in accounts payable and accrued expenses reflected our payment of $175 million relating to the SEC investigation as further discussed in Note 5 in the Notes to Condensed Consolidated Financial Statements.
Cash flows from operating activities in the first three months of fiscal year 2024 was largely driven by our net income, adjusted by a change in operating assets and liabilities that was a net source of cash. This net source of cash primarily reflected lower levels of trade receivables, partially offset by lower levels of accounts payable and accrued expenses. Cash flows from operating activities in 2024 additionally reflected a discretionary cash contribution of $150 million to fund our pension obligation.
Net Cash Flows from Investing Activities
Our investments in capital expenditures are focused on projects that enhance our cost structure and manufacturing capabilities, as well as support our BD 2025 strategy for growth and simplification. Net outflows from investing activities in the first three
28

months of fiscal year 2025 included capital expenditure-related outflows of $105 million, compared with $116 million in the prior-year period. Current-period cash flows from investing activities also included a $411 million inflow attributable to the maturity of time deposits.
Net Cash Flows from Financing Activities
Net cash flows from financing activities in the first three months of fiscal years 2025 and 2024 included the following significant cash flows:
Three months ended December 31,
(Millions of dollars)20242023
Cash inflow (outflow)
Change in short-term debt$75 $— 
Payments of debt$(875)$— 
Repurchases of common stock$(750)$(500)
Dividends paid$(302)$(275)

Certain measures relating to our total debt were as follows:
(Millions of dollars)December 31, 2024September 30, 2024
Total debt$18,758 $20,110 
Weighted average cost of total debt3.3 %3.4 %
Total debt as a percentage of total capital*42.0 %42.9 %
*    Represents shareholders’ equity, net non-current deferred income tax liabilities, and debt.
Cash and Short-Term Investments
At December 31, 2024, total worldwide cash and equivalents and short-term investments, including restricted cash, were approximately $830 million and were primarily held outside of the United States. We regularly review the amount of cash and short-term investments held outside of the United States and our historical foreign earnings are used to fund foreign investments or meet foreign working capital and property, plant and equipment expenditure needs. To fund cash needs in the United States, we rely on ongoing cash flow from U.S. operations, access to capital markets and remittances from foreign subsidiaries of earnings that are not considered to be permanently reinvested.
Financing Facilities
We have a senior unsecured revolving credit facility in place which will expire in September 2027. The credit facility provides borrowings of up to $2.750 billion, with separate sub-limits of $100 million and $194 million for letters of credit and swingline loans, respectively. The expiration date of the credit facility may be extended for up to one additional one-year period, subject to certain restrictions (including the consent of the lenders). The credit facility provides that we may, subject to additional commitments by lenders, request an additional $500 million of financing, for a maximum aggregate commitment under the credit facility of up to $3.250 billion. Proceeds from this facility may be used for general corporate purposes and Becton Dickinson Euro Finance S.à r.l., an indirect, wholly-owned finance subsidiary of BD, is authorized as an additional borrower under the credit facility. There were no borrowings outstanding under the revolving credit facility at December 31, 2024.
The agreement for our revolving credit facility contains the following financial covenants. We were in compliance with these covenants, as applicable, as of December 31, 2024.
•We are required to have a leverage coverage ratio of no more than:
◦4.25-to-1 as of the last day of each fiscal quarter following the closing of the credit facility; or
◦4.75-to-1 for the four full fiscal quarters following the consummation of a material acquisition.
We may access commercial paper programs over the normal course of our business activities. Our U.S. and multicurrency euro commercial paper programs provide for a maximum amount of unsecured borrowings under the two programs, in aggregate, of $2.750 billion. Proceeds from these programs may be used for working capital purposes and general corporate purposes, which may include acquisitions, share repurchases and repayments of debt. We had $475 million of commercial paper borrowings outstanding as of December 31, 2024. We have additional informal lines of credit outside the United States. Also, over the
29

normal course of our business activities, we transfer certain trade receivable assets to third parties under factoring agreements. Additional disclosures regarding sales of trade receivable assets are provided in Note 13 in the Notes to Condensed Consolidated Financial Statements.

Access to Capital and Credit Ratings
Our corporate credit ratings with Standard & Poor's Ratings Services (“S&P”), Moody’s Investors Service (“Moody’s) and Fitch Ratings (“Fitch”) at December 31, 2024 were unchanged compared with our ratings at September 30, 2024.
Lower corporate debt ratings and downgrades of our corporate credit ratings or other credit ratings may increase our cost of borrowing. We believe that given our debt ratings, our financial management policies, our ability to generate cash flow and the non-cyclical, geographically diversified nature of our businesses, we would have access to additional short-term and long-term capital should the need arise. A rating reflects only the view of a rating agency and is not a recommendation to buy, sell or hold securities. Ratings can be revised upward or downward at any time by a rating agency if such rating agency decides that circumstances warrant such a change.
Concentrations of Credit Risk
We continually evaluate our accounts receivables for potential credit losses, particularly those resulting from sales to government-owned or government-supported healthcare facilities in certain countries, as payment may be dependent upon the financial stability and creditworthiness of those countries’ national economies. In addition to continually evaluating all governmental receivables for potential credit losses based upon historical loss experiences, we also evaluate such receivables based upon the availability of government funding and reimbursement practices. We believe the current reserves related to all governmental receivables are adequate and that these receivables will not have a material adverse impact on our financial position or liquidity.
To date, we have not experienced a significant increased risk of credit losses in general as a result of current macroeconomic conditions. No assurances can be given that the risk of credit losses will not increase in the future given the uncertainty around the duration of the current macroeconomic challenges and pressures.
Other Matters
Critical Accounting Policies
There were no changes to our critical accounting policies from those disclosed in our 2024 Annual Report.
Regulatory Matters
Consent Decree with FDA
Our U.S. infusion pump organizational unit is operating under an amended consent decree originally entered into by Cardinal Health 303, Inc. with the FDA in 2007 related to its AlarisTM infusion pumps. In 2009, the decree was amended (the “Consent Decree”) to include all infusion pumps manufactured by or for CareFusion 303, Inc., which was acquired by BD in 2015. CareFusion 303, Inc. remains the manufacturer of BD AlarisTM infusion pumps. The Consent Decree does not apply to intravenous administration sets and accessories.  
Following an inspection that began in March 2020 of our Medication Management Systems’ Infusion quality management system operating out of the site in San Diego, California (CareFusion 303, Inc.), the FDA issued a Form 483 Notice (the “2020 Form 483 Notice”) that contained a number of observations regarding the quality system’s compliance with FDA’s Quality System, reporting of corrections and removals, and Medical Device Reporting (MDR) regulations. In December 2021, the FDA issued to CareFusion 303, Inc. a letter of non-compliance with respect to the Consent Decree (the “Non-Compliance Letter”) stating that, among other things, it had determined that certain of the corrective actions to address the 2020 Form 483 Notice appeared to be adequate, some were still in progress such that adequacy could not be determined yet, and certain others were not adequate (e.g., complaint handling and corrective and preventive actions, design verification and medical device reporting). Per the terms of the Non-Compliance Letter, CareFusion 303, Inc. provided the FDA with a proposed comprehensive corrective action plan (“CAP”) and has retained an independent expert to conduct periodic audits of the quality management system operating at the CareFusion 303, Inc. infusion pump facilities through 2025. CareFusion 303, Inc. has and will continue to update its CAP to address any observations that may arise during the course of these audits.
In addition, CareFusion 303, Inc. received an additional Form 483 Notice in May 2024 following an FDA inspection (“2024 Form 483 Notice”) that contained observations related to the site’s compliance with the FDA’s quality system regulations and MDR regulation related to its Infusion quality management system (covered by the Consent Decree) and separate Dispensing quality management system (which is not subject of the Consent Decree). On November 22, 2024, BD received a Warning
30

Letter from the FDA, which is limited to CareFusion 303, Inc.’s Dispensing quality management system and BD PyxisTM products (“Dispensing Warning Letter”). See “— FDA Warning Letters” below for further information.
The FDA’s review of our responses to the observations specific to the Infusion quality management system in the 2024 Form 483 Notice and the CAP is ongoing, and no assurances can be given regarding further action by the FDA as a result of the observations, including but not limited to action pursuant to the Consent Decree, or that corrective actions proposed by CareFusion 303, Inc. will be adequate to address these observations. Additionally, we cannot currently predict the amount of additional monetary investment that will be incurred to resolve this matter or the matter’s ultimate impact on our business.
The Consent Decree authorizes the FDA, in the event of any violations in the future, to order us to cease manufacturing and distributing infusion pumps, recall products and take other actions. We may be required to pay damages of $15,000 per day per violation if we fail to comply with any provision of the Consent Decree, up to $15 million per year.
We may be obligated to pay more costs in the future because, among other things, the FDA may determine that we are not fully compliant with the Consent Decree and Non-Compliance Letter and therefore impose penalties under the Consent Decree, and/or we may also be subject to future proceedings and litigation relating to the matters addressed in the Consent Decree, including, but not limited to, additional fines, penalties, other monetary remedies, and expansion of the terms of the Consent Decree. As of December 31, 2024, we do not believe that a loss is probable in connection with the Consent Decree, and accordingly, we have no accruals associated with compliance with the Consent Decree.
As previously disclosed, on July 21, 2023, BD received 510(k) clearance from the FDA for its updated BD Alaris™ Infusion System, which enables both remediation and a return to market for the BD Alaris™ Infusion System. This clearance covers updated hardware features for Point-of-Care Unit (PCU), large volume pumps, syringe pumps, patient-controlled analgesia (PCA) pumps, respiratory monitoring and auto-identification modules. It also covers a new BD Alaris™ Infusion System software version with enhanced cybersecurity, along with interoperability features that enable smart, connected care with electronic medical record systems. To address all open recalls and ensure all devices at customer sites are running the most recent version of the BD Alaris™ Infusion System Software, all of the current BD Alaris™ Infusion System devices in the U.S. market will be remediated or replaced with the updated 510(k) cleared version over the next several years.
FDA Warning Letters
On January 11, 2018, BD received a Warning Letter from the FDA with respect to our former BD Preanalytical Systems ("PAS") unit, citing certain alleged violations of quality system regulations and of law. BD has worked closely with the FDA and implemented corrective actions to address the quality management system concerns identified in the Warning Letter. In March 2020, the FDA conducted a subsequent inspection of PAS which it classified as Voluntary Action Indicated, which means the FDA will not take or recommend any administrative or regulatory action as a result of the unit’s response to the observations associated with the quality management concerns in the inspection. Additionally, in December 2022, the FDA conducted a subsequent inspection of PAS (now Specimen Management) with no observations. BD continues to work with the FDA to generate additional clinical evidence and file 510(k)s as remaining commitments associated with the Warning Letter. As of December 31, 2024, BD has received eight FDA clearances. The FDA review of these remaining commitments is ongoing, and no assurances can be given regarding further action by the FDA as a result of these commitments, including but not limited to action pursuant to the Warning Letter.
As noted above, on November 22, 2024, BD received the Dispensing Warning Letter following an inspection of its Dispensing quality management system at its facility located in San Diego, California, citing certain alleged violations of the quality system regulations, MDR regulation, the corrections and removals reporting regulation and law. BD submitted a comprehensive response to address FDA’s feedback in the Dispensing Warning Letter, which committed to implementing additional corrective actions; however, no assurances can be given regarding further action by the FDA as a result of FDA’s Dispensing Warning Letter, or that corrective actions proposed and taken by CareFusion 303, Inc. will be adequate to address the Dispensing Warning Letter. Any failure to adequately address the Dispensing Warning Letter may result in regulatory actions initiated by the FDA without further notice, which may include, but are not limited to, seizure, injunction and civil monetary penalties. As a result, the ultimate resolution of the Dispensing Warning Letter and its impact on the Company’s operations is unknown at this time. In connection with the Dispensing Warning Letter, the Company has accrued future costs estimated for product remediation efforts. See Note 5 in the Notes to Condensed Consolidated Financial Statements. It is possible that the amount of the Company’s liability could exceed its currently accrued amount.
Ethylene Oxide/Sterilization
There is increased focus on the use and emission of ethylene oxide by the U.S. Environmental Protection Agency (“EPA”) and state environmental regulatory agencies. Additional regulatory requirements associated with the use and emission of ethylene oxide may be imposed in the future, either domestically or outside the U.S. Ethylene oxide is the most frequently used sterilant
31

for medical devices and healthcare products in the U.S., and in certain cases is the only option to sterilize critical medical device products for the safe administration to patients. Any such increased regulation could require BD or sterilization service providers, including providers used by BD, to temporarily suspend operations to install additional emissions control technology, limit the use of ethylene oxide or take other actions, which would impact BD’s operations and further reduce the available capacity to sterilize medical devices and healthcare products, and could also result in additional costs. To this end, BD has proactively installed fugitive emissions controls at our facilities in East Columbus, NE and Sandy, UT. On April 5, 2024, the final National Emission Standards for Hazardous Air Pollutants (“NESHAP”): Ethylene Oxide Emissions Standards for Sterilization Facilities regulation issued by the EPA became effective. Companies generally have two years from the effective date to comply with the new requirements of the NESHAP. We are in the process of implementing certain changes to our facilities in accordance with NESHAP’s requirements, and such measures will require additional implementation and ongoing operational costs, including investments in certain new technologies.
In addition, on January 14, 2025, the EPA published a Notice of Availability for a Pesticide Registration Review; Interim Registration Review Decision for Ethylene Oxide (“ID”). The ID, which regulates the use of ethylene oxide as a sterilant and is intended to mitigate any human health and environmental risks associated with its use. We are assessing the impact of the ID on our sterilization facilities, on the third-party sterilization facilities that BD utilizes and on our operations more generally. Based on the Proposed interim Decision that EPA had published in 2023, we anticipate implementing certain changes at our facilities to comply with the ID’s requirements, and such measures will require additional implementation and ongoing operational costs, including investments in certain new technologies.
If any new or existing regulatory requirements or rulemaking result in the suspension, curtailment or interruption of sterilization operations at BD or at medical device sterilizers used by BD, or otherwise limit the availability of third-party sterilization capacity, this could interrupt or otherwise adversely impact production of certain of our products or lead to civil litigation or other claims against BD. BD has business continuity plans in place to mitigate the impact of any such disruptions, although these plans may not be able to fully offset such impact, for the reasons noted above.
For further discussion of risks relating to the regulations to which we are subject, see Part I, Item 1A, of our 2024 Annual Report.
Cautionary Statement Regarding Forward-Looking Statements
This report includes forward-looking statements within the meaning of the federal securities laws. BD and its representatives may also, from time to time, make certain forward-looking statements in publicly released materials, both written and oral, including statements contained in filings with the SEC, press releases, and our reports to shareholders. Forward-looking statements may be identified by the use of words such as “plan,” “expect,” “believe,” “intend,” “will,” “may,” “anticipate,” “estimate” and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance (including volume growth, pricing, sales and earnings per share growth, and cash flows) and statements regarding our strategy for growth, liquidity, future product development, regulatory approvals, competitive position and expenditures. This report also includes forward-looking statements regarding the proposed separation of BD’s Biosciences and Diagnostic Solutions business, including the anticipated benefits of the separation and the expected timing of completion of the separation. All statements that address our future operating performance or events or developments that we expect or anticipate will occur in the future are forward-looking statements.
Forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events, developments and operating performance, and speak only as of their dates. Investors should realize that if underlying assumptions prove inaccurate, or risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Investors are therefore cautioned not to place undue reliance on any forward-looking statements. Furthermore, we undertake no obligation to update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events and developments or otherwise, except as required by applicable law or regulations.
The following are some important factors that could cause our actual results to differ from our expectations in any forward-looking statements. For further discussion of certain of these factors, see Part II, Item 1A. Risk Factors of this Quarterly Report on Form 10-Q, Item 1A. Risk Factors in our 2024 Annual Report, and our subsequent Quarterly Reports on Form 10-Q.
•General global, regional or national economic downturns and macroeconomic trends, including heightened inflation, capital market volatility, interest rate and currency rate fluctuations, and economic slowdown or recession, that may result in unfavorable conditions that could negatively affect demand for our products and services, impact the prices we can charge for our products and services, disrupt our transportation networks or other aspects of our supply chain, impair our ability to produce our products, or increase borrowing costs.
•The impact of inflation and disruptions in our global supply chain on BD and our suppliers (particularly sole-source suppliers and providers of sterilization services), including fluctuations in the cost and availability of oil-based resins
32

and other raw materials, as well as certain components, used in the production or sterilization of our products, transportation constraints, disruptions and delays, product shortages, energy shortages or increased energy costs, labor shortages or disputes, and increased operating and labor costs.
•The risks associated with the proposed separation of our Biosciences and Diagnostic Solutions business, including risks related to the manner of the separation and factors that could delay, prevent or otherwise adversely affect the completion, timing or terms of the separation, or our ability to realize the expected benefits of the separation.
•Conditions in international markets, including social and political conditions, geopolitical developments such as the continuation and/or escalation of the evolving situations in Ukraine, the Middle East and Asia, civil unrest, political conflict, terrorist activity, governmental changes, restrictions on the ability to transfer capital across borders, economic sanctions, export controls, tariffs and other protectionist measures, barriers to market participation (such as local company and products preferences), difficulties in protecting and enforcing our intellectual property rights, and governmental expropriation of assets. Our international operations also increase our compliance risks, including risks under the Foreign Corrupt Practices Act and other anti-corruption and bribery laws, as well as regulatory and privacy laws.
•The impact of changes in U.S. federal or foreign laws and policies that could affect fiscal and tax policies, taxation (including tax reforms, such as the implementation of a global minimum tax, that could adversely impact multinational corporations), and international trade, including import and export licensing regulation and international trade agreements. In particular, tariffs, sanctions or other trade barriers imposed by the U.S. or other countries, including those relating to China, Mexico or other countries and regions in which we do business, could adversely impact our supply chain costs or otherwise adversely impact our results of operations. The ultimate impact of any new tariffs is subject to a number of factors including the effective date and duration of such tariffs, changes in the amount, scope and nature of the tariffs in the future, any countermeasures that the target countries may take and any mitigating actions that may become available.
•Cost-containment efforts in the U.S. or in other countries in which we do business, such as alternative payment reform, government-imposed pay back provisions, increased use of competitive bidding and tenders, including, without limitation, any expansion of the volume-based procurement process in China or the implementation of similar cost-containment efforts.
•Competitive factors that could adversely affect our operations, including new product introductions and technologies, including the use of artificial intelligence, by our current or future competitors, consolidation or strategic alliances among healthcare companies, distributors and/or payers of healthcare to improve their competitive position or develop new models for the delivery of healthcare, increased pricing pressure due to the impact of low-cost manufacturers, patents attained by competitors (particularly as patents on our products expire), new entrants into our markets and changes in the practice of medicine.
•Product efficacy or safety concerns or non-compliance with applicable regulatory requirements regarding our products (such as non-compliance of our products with registration requirements resulting from modifications to such products, or other factors, including, but not limited to, with respect to BD Alaris™ pumps and related sets and BD VacutainerTM) resulting in product recalls, lost revenue or other actions being taken with respect to products in the field or the ability to continue selling new products to customers (including restrictions on future product clearances and civil penalties), product liability or other claims and damage to our reputation. As a result of the CareFusion acquisition, our U.S. infusion pump business is operating under a Consent Decree with the FDA. The Consent Decree authorizes the FDA, in the event of any violations in the future, to order our U.S. infusion pump business to cease manufacturing and distributing products, recall products or take other actions, and order the payment of significant monetary damages if the business subject to the decree fails to comply with any provision of the Consent Decree. In accordance with our commitments to the FDA, the overall timing of replacement or remediation of the BD Alaris™ Infusion Systems and return to market in the U.S. may be impacted by, among other things, customer readiness, supply continuity and our continued engagement with the FDA.
•Deficit reduction efforts or other actions that reduce or freeze the availability of government funding for healthcare and research, which could weaken demand for our products and result in additional pricing pressures, as well as create potential collection risks associated with such sales.
•Fluctuations and pauses in university or U.S. and international governmental funding and policies for research.
•Changes in the way healthcare services are delivered, including transition of more care from acute to non-acute settings and increased focus on chronic disease management, which may affect the demand for our products and services. Additionally, budget constraints and staffing shortages, particularly shortages of nursing staff, may affect the prioritization of healthcare services, which could also impact the demand for certain of our products and services.
33

•Our ability to achieve our projected level or mix of product sales, as our earnings forecasts are based on projected sales volumes and pricing of many product types, some of which are more profitable than others.
•Changes in coverage policies or reimbursement levels, or adverse decisions relating to our products and services by governments or third-party payers, which could reduce demand for our products or the price we can charge for such products.
•Changes in the domestic and foreign healthcare industry, in medical practices or in patient preferences that result in a reduction in procedures using our products or increased pricing pressures, including cost-reduction measures instituted by and the continued consolidation among healthcare providers.
•The effects of regulatory or other events (such as public health crises) that adversely impact our supply chain, including our ability to manufacture (including sterilize) our products (particularly where production of a product line or sterilization operations are concentrated in one or a few plants), source materials or components or services from suppliers (including sole-source suppliers) that are needed for such manufacturing (including sterilization), or provide products to our customers, including events that impact key distributors. In particular, there has been increased regulatory focus on the use and emission of ethylene oxide in sterilization processes, and additional regulatory requirements may be imposed in the future that could adversely impact BD or our third-party sterilization providers.
•IT system disruptions, breaches or breakdowns, including through cyberattacks, ransom attacks or cyber-intrusion, which could impair our ability or that of our customers, suppliers and other business partners to conduct business, result in the loss of BD trade secrets or otherwise compromise sensitive information of BD or its customers, suppliers and other business partners, or of patients, including sensitive personal data, or result in efficacy or safety concerns for certain of our products, and result in investigations, legal proceedings, liability, expense or reputational damage or actions by regulatory bodies or civil litigation.
•Difficulties inherent in product development, including the potential inability to successfully continue technological innovation, successfully complete clinical trials, obtain and maintain regulatory approvals and registrations in the U.S. and abroad, obtain intellectual property protection for our products, obtain coverage and adequate reimbursement for new products, or gain and maintain market approval of products, as well as the possibility of infringement claims by competitors with respect to patents or other intellectual property rights, all of which could preclude or delay commercialization of a product. Delays in obtaining necessary approvals or clearances from the FDA or other regulatory agencies or changes in the regulatory process may also delay product launches and increase development costs.
•The impact of business combinations or divestitures, including any volatility in earnings relating to acquisition-related costs, and our ability to successfully integrate any business we may acquire.
•Risks relating to our overall level of indebtedness, including our ability to service our debt and refinance our indebtedness, which is dependent upon the capital markets and the overall macroeconomic environment and our financial condition at such time.
•Any impact that public health crises, such as pandemics and epidemics may have on our business, the global economy and the global healthcare system. This may include decreases in the demand for our products, disruptions to our operations or the operations of our suppliers and customers, disruptions to our supply chain, or increases in transportation costs.
•The risks associated with the qualification of the spin-off of our former Diabetes Care business as a tax-free transaction for U.S. federal income tax purposes.
•Our ability to penetrate or expand our operations in emerging markets, which depends on local economic and political conditions, and how well we are able to make necessary infrastructure enhancements to production facilities and distribution networks.
•Our ability to recruit and retain key employees and the impact of labor conditions which could increase employee turnover or increase our labor and operating costs and negatively affect our ability to efficiently operate our business.
•Fluctuations in the demand for products we sell to pharmaceutical companies that are used to manufacture, or are sold with, the products of such companies, as a result of funding constraints, consolidation or otherwise.
•The impact of climate change, or legal, regulatory or market measures to address climate change, such as regulation of greenhouse gas emissions, zero-carbon energy and sustainability mandates and related disclosure requirements, and additional taxes on fuel and energy, and changing customer and other stakeholder preferences and requirements, such as those regarding the use of materials of concern, increased demand for products with lower environmental footprints, and for companies to set and demonstrate progress against sustainability goals and greenhouse gas reduction targets.
34

•Natural disasters, including the impacts of hurricanes, tornadoes, windstorms, fires, earthquakes and floods and other extreme weather events, global health pandemics, war, terrorism, labor disruptions and international conflicts that could cause significant economic disruption and political and social instability, resulting in decreased demand for our products, adversely affect our manufacturing and distribution capabilities or cause interruptions in our supply chain.
•Pending and potential future litigation or other proceedings asserting, and/or investigations concerning and/or subpoenas and requests seeking information with respect to, alleged violations of law (including in connection with federal and/or state healthcare programs (such as Medicare or Medicaid), government contracts and/or sales and marketing practices (such as investigative subpoenas and the civil investigative demands received by BD)), potential anti-corruption and related internal control violations under the Foreign Corrupt Practices Act, antitrust claims, securities law claims, environmental and product liability matters (including pending claims relating to ethylene oxide, our hernia repair implant products, surgical continence and pelvic organ prolapse products for women, vena cava filter products and implantable ports, which involve, or could involve in the future, lawsuits seeking class action status or seeking to establish multi-district or other consolidated proceedings), data privacy breaches and patent infringement, and the availability or collectability of insurance relating to any such claims.
•New or changing laws and regulations affecting our domestic and foreign operations, or changes in enforcement practices, including, without limitation, laws relating to sales practices, environmental protection and reporting, price controls, privacy, data protection, cybersecurity, artificial intelligence, employment, labor, and licensing and regulatory requirements for new products and products in the post-marketing phase. In particular, the U.S. and other countries may impose new requirements regarding registration, labeling or prohibited materials that may require us to re-register products already on the market or otherwise impact our ability to market our products. Environmental laws, particularly with respect to the emission of greenhouse gases, are also becoming more stringent throughout the world, which may increase our costs of operations or necessitate changes in our manufacturing plants or processes or those of our suppliers, or result in liability to BD.
•The effect of adverse media exposure or other publicity regarding BD’s business or operations, including the effect on BD’s reputation or demand for its products.
•The effect of market fluctuations on the value of assets in BD’s pension plans and on actuarial interest rate and asset return assumptions, which could require BD to make additional contributions to the plans or increase our pension plan expense.
•Our ability to obtain the anticipated benefits of restructuring programs, if any, that we may undertake.
The foregoing list sets forth many, but not all, of the factors that could impact our ability to achieve results described in any forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider this list to be a complete statement of all potential risks and uncertainties.
35


Item 3.    Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes in information reported since the end of the fiscal year ended September 30, 2024.
Item 4.    Controls and Procedures
An evaluation was carried out by BD’s management, with the participation of BD’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of BD’s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934) as of December 31, 2024. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the design and operation of these disclosure controls and procedures were, as of the end of the period covered by this report, effective and designed to ensure that material information relating to BD and its consolidated subsidiaries would be made known to them by others within these entities.
There were no changes in our internal control over financial reporting during the fiscal quarter ended December 31, 2024 identified in connection with the above-referenced evaluation that have materially affected, or are reasonably likely to materially affect, BD’s internal control over financial reporting. On September 3, 2024, BD completed the acquisition of Edwards Lifesciences’ Critical Care product group (“Critical Care”), which was renamed as BD Advanced Patient Monitoring (“Advanced Patient Monitoring”). In our 2024 Annual Report on Form 10-K, we excluded Advanced Patient Monitoring from our evaluation of internal control over financial reporting. This exclusion was in accordance with the U.S. Securities and Exchange Commission's general guidance that a recently acquired business may be omitted from the assessment scope for up to one year from the date of acquisition. BD has extended its oversight and monitoring processes that support our internal control over financial reporting, as well as our disclosure controls and procedures, to the acquired operations of Advanced Patient Monitoring. We will incorporate Advanced Patient Monitoring into our annual assessment of internal control over financial reporting for our fiscal year ending September 30, 2025.


36

PART II - OTHER INFORMATION
Item 1.    Legal Proceedings
We are involved, both as a plaintiff and a defendant, in various legal proceedings, including product liability and environmental matters as set forth in our 2024 Annual Report, and in Note 5 of the Notes to Condensed Consolidated Financial Statements in this report, which is incorporated herein by reference.


37

Item 1A.     Risk Factors

There have been no material changes to the risk factors previously disclosed in Part I, Item 1A, of our 2024 Annual Report, except as follows.
Risks Relating to the Proposed Separation of the Biosciences and Diagnostic Solutions Business
On February 5, 2025, BD announced its intention to separate its Biosciences and Diagnostic Solutions business from the rest of BD. BD’s board of directors has not yet determined the manner in which to execute the separation, which may include possible options such as a spin-off, sale, Reverse Morris Trust or other transaction. BD expects to announce more specifics on the separation plans by the end of fiscal year 2025 and intends to target completion of the transaction in fiscal year 2026. There are many factors that could impact the structure or timing of, or BD’s determination to proceed with, the proposed separation, including market conditions, material adverse changes in business or industry conditions, unanticipated costs, potential problems or delays in obtaining various regulatory and tax approvals or clearances and changes in the regulatory or legal environment.
The proposed separation, if consummated, involves risks, including potential difficulties associated with the separation of operations, services and personnel, potential disruption in BD’s operations or businesses, the potential loss of, or inability to recruit, key employees and potential adverse effects on relationships with key customers and other business counterparties. In addition, BD may incur significant expenses in connection with pursuing the proposed separation. Pursuing the proposed separation will require significant time and attention from BD’s senior management and employees, which could disrupt BD’s ongoing business and adversely affect financial results and results of operations. If BD does not successfully manage these risks, BD’s business, financial condition and results of operations could be adversely affected.
The completion of any separation transaction will be contingent upon various conditions and approvals, including approval of BD’s board of directors, receipt of requisite regulatory clearances and compliance with applicable SEC requirements. No assurance can be given regarding the form that a separation transaction may take or the specific terms or timing, or that a separation will in fact occur. In addition, if the proposed separation is completed, BD may not be able to achieve the full strategic and financial benefits that are expected to result from the separation. Delays or failure to consummate the proposed separation could negatively affect BD’s business, financial condition and results of operations.
Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds
The table below sets forth certain information regarding our purchases of common stock of BD during the quarter ended December 31, 2024.
Issuer Purchases of Equity Securities
For the three months ended December 31, 2024Total Number of
Shares Purchased (1)		Average Price
Paid per
Share		Total Number of
Shares Purchased
as Part of
Publicly
Announced Plans
or Programs 		Maximum Number
of Shares that May
Yet Be Purchased
Under the Plans or
Programs (2)
October 1 - 31, 20241,110 $240.01 — 6,681,777 
November 1 – 30, 2024257 236.47 — 6,681,777 
December 1 – 31, 2024 (3)
2,636,667 230.36 2,636,667 4,045,110 
Total2,638,034 $230.37 2,636,667 4,045,110 
(1)Includes 1,367 shares purchased during the quarter in open market transactions by the trust relating to BD’s Deferred Compensation and Retirement Benefit Restoration Plan and 1996 Directors’ Deferral Plan.
(2)Represents shares available under a repurchase program authorized by the Board of Directors on November 3, 2021, for 10 million shares, for which there is no expiration date.
(3)Shares purchased includes an initial delivery of 2,636,667 shares of our common stock received upon payment of $750 million under an accelerated share repurchase (“ASR”) agreement, which was executed in December 2024. An additional 619,071 shares were delivered in January 2025 based upon final settlement of the ASR agreement. The total average price paid per share in the table above reflects the volume weighted average price of BD's shares over the term
38

of the ASR agreement. Additional disclosures regarding this transaction are provided in Note 3 of the Notes to Condensed Consolidated Financial Statements in this report.
On January 28, 2025, the Board of Directors authorized BD to repurchase up to an additional 10 million shares of BD common stock, for which there is no expiration date.
39

Item 3.    Defaults Upon Senior Securities
Not applicable.
Item 4.    Mine Safety Disclosures
Not applicable.
Item 5.    Other Information
Rule 10b5-1 and Non-Rule 10b5-1 Trading Arrangements
During the three months ended December 31, 2024, certain of our officers adopted “Rule 10b5-1 trading arrangements,” as defined in Item 408(a) of Regulation S-K of the Exchange Act, as follows.
On December 11, 2024, Richard Byrd, Executive Vice President and President, Interventional Segment of BD, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Byrd’s plan is for (i) the exercise of up to 15,061 stock appreciation rights (“SARs”) at various exercise prices, net of shares withheld to satisfy applicable taxes, (ii) the sale of up to 2,399 shares of BD’s common stock, (iii) the sale of up to 1,123 shares of BD’s common stock upon the vesting of time vested units (“TVUs”), net of shares withheld to satisfy applicable taxes, and (iv) the sale of up to 1,590 shares of BD’s common stock upon the vesting of performance units, subject to the final payout factor and net of shares withheld to satisfy applicable taxes. The foregoing exercises or sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and March 15, 2026.
On December 16, 2024, Antoine Ezell, Executive Vice President, President of the Americas and Chief Marketing Officer of BD, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Ezell’s plan is for the sale of up to 3,900 shares of BD’s common stock. The sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and March 17, 2026.
During the three months ended December 31, 2024, none of our officers or directors adopted, terminated or modified any “non-Rule 10b5-1 trading arrangement,” as defined in Item 408(a) of Regulation S-K of the Exchange Act.
Item 6.    Exhibits
Subsidiary Issuer of Guaranteed Securities.
  Certifications of Chief Executive Officer and Chief Financial Officer, pursuant to SEC Rule 13a - 14(a).
  Certifications of Chief Executive Officer and Chief Financial Officer, pursuant to Rule 13a - 14(b) and Section 1350 of Chapter 63 of Title 18 of the U.S. Code.
101  The following materials from this report, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Income, (iii) the Condensed Consolidated Statements of Comprehensive Income, (iv) the Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements.
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).


40

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Becton, Dickinson and Company
(Registrant)
Dated: February 6, 2025
/s/ Christopher J. DelOrefice
Christopher J. DelOrefice
Executive Vice President and Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)
41
 EX-22 2 ex2212312024.htm EX-22 Document

Exhibit 22
Subsidiary Issuers of Guaranteed Securities
As of December 31, 2024, Becton, Dickinson and Company (“BD”) is the guarantor of the senior unsecured registered notes listed below issued by Becton Dickinson Euro Finance S.à r.l. (“BD Finance”). BD owns, directly or indirectly, 100% of BD Finance.
Becton Dickinson Euro Finance S.à r.l.
1.208% Notes due June 4, 2026
0.334% Notes due August 13, 2028
3.553% Notes due September 13, 2029
1.213% Notes due February 12, 2036
4.029% Notes due June 7, 2036
1.336% Notes due August 13, 2041







 EX-31 3 ex3112312024.htm EX-31 Document

Exhibit 31
CERTIFICATION
I, Thomas E. Polen, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Becton, Dickinson and Company;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: February 6, 2025
/s/ Thomas E. Polen
Thomas E. Polen
Chairman, Chief Executive Officer and President



CERTIFICATION
I, Christopher J. DelOrefice, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Becton, Dickinson and Company;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: February 6, 2025
/s/ Christopher J. DelOrefice
Christopher J. DelOrefice
Executive Vice President and Chief Financial Officer

EX-32 4 ex3212312024.htm EX-32 Document

Exhibit 32
CERTIFICATION
The certification set forth below is being submitted in connection with the Quarterly Report on Form 10-Q of Becton, Dickinson and Company for the quarter ended December 31, 2024 (the “Report”) for the purpose of complying with Rule 13a – 14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code.
I, Thomas E. Polen, the Chief Executive Officer of Becton, Dickinson and Company, certify that:
1.such Report fully complies with the requirements of Section 13(a) of the Exchange Act; and
2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Becton, Dickinson and Company.
Date: February 6, 2025
/s/ Thomas E. Polen
Name: Thomas E. Polen
Chief Executive Officer



CERTIFICATION

The certification set forth below is being submitted in connection with the Quarterly Report on Form 10-Q of Becton, Dickinson and Company for the quarter ended December 31, 2024 (the “Report”) for the purpose of complying with Rule 13a – 14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code.
I, Christopher J. DelOrefice, the Chief Financial Officer of Becton, Dickinson and Company, certify that:
1.such Report fully complies with the requirements of Section 13(a) of the Exchange Act; and
2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Becton, Dickinson and Company.
Date: February 6, 2025
/s/ Christopher J. DelOrefice
Name: Christopher J. DelOrefice
Chief Financial Officer

 EX-101.SCH 5 bdx-20241231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - Condensed Consolidated Statements of Income link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - Condensed Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 9952156 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - Accounting Changes link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Earnings per Share link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Contingencies link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Revenues link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Segment Data link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Benefit Plans link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Acquisition link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Business Restructuring Charges link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Derivative Instruments and Hedging Activities link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - Financial Instruments and Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 9955511 - Disclosure - Accounting Changes (Policies) link:presentationLink link:calculationLink link:definitionLink 9955512 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 9955513 - Disclosure - Earnings per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9955514 - Disclosure - Segment Data (Tables) link:presentationLink link:calculationLink link:definitionLink 9955515 - Disclosure - Benefit Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 9955516 - Disclosure - Business Restructuring Charges (Tables) link:presentationLink link:calculationLink link:definitionLink 9955517 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9955518 - Disclosure - Derivative Instruments and Hedging Activities (Tables) link:presentationLink link:calculationLink link:definitionLink 9955519 - Disclosure - Financial Instruments and Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9955520 - Disclosure - Shareholders' Equity - Changes in Certain Components of Shareholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 9955521 - Disclosure - Shareholders' Equity - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955522 - Disclosure - Shareholders' Equity - Accumulated Other Comprehensive Income (Loss) - Components and Changes of Accumulated Other Comprehensive Income (Loss) (Detail) link:presentationLink link:calculationLink link:definitionLink 9955523 - Disclosure - Shareholders' Equity - Accelerated Share Repurchases (Details) link:presentationLink link:calculationLink link:definitionLink 9955524 - Disclosure - Earnings per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 9955525 - Disclosure - Contingencies (Detail) link:presentationLink link:calculationLink link:definitionLink 9955526 - Disclosure - Revenues (Details) link:presentationLink link:calculationLink link:definitionLink 9955526 - Disclosure - Revenues (Details) link:presentationLink link:calculationLink link:definitionLink 9955527 - Disclosure - Segment Data - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9955528 - Disclosure - Segment Data - Revenues by Geographic Areas (Detail) link:presentationLink link:calculationLink link:definitionLink 9955529 - Disclosure - Segment Data - Financial Information for Company's Segments (Detail) link:presentationLink link:calculationLink link:definitionLink 9955530 - Disclosure - Benefit Plans (Detail) link:presentationLink link:calculationLink link:definitionLink 9955531 - Disclosure - Acquisition (Details) link:presentationLink link:calculationLink link:definitionLink 9955532 - Disclosure - Business Restructuring Charges (Detail) link:presentationLink link:calculationLink link:definitionLink 9955533 - Disclosure - Intangible Assets - Components of Intangible Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 9955534 - Disclosure - Intangible Assets - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9955535 - Disclosure - Intangible Assets - Reconciliation of Goodwill by Business Segment (Detail) link:presentationLink link:calculationLink link:definitionLink 9955536 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Notional Amounts of Outstanding Derivative Positions (Detail) link:presentationLink link:calculationLink link:definitionLink 9955537 - Disclosure - Derivative Instruments and Hedging Activities - Gains (Losses) on Net Investment Hedges (Details) link:presentationLink link:calculationLink link:definitionLink 9955538 - Disclosure - Derivative Instruments and Hedging Activities - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9955539 - Disclosure - Financial Instruments and Fair Value Measurements - Cash and Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 9955540 - Disclosure - Financial Instruments and Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9955541 - Disclosure - Financial Instruments and Fair Value Measurements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9955542 - Disclosure - Financial Instruments and Fair Value Measurements - Transfer of Financial Assets Accounted for as Sales (Details) link:presentationLink link:calculationLink link:definitionLink 9955543 - Disclosure - Income Taxes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 bdx-20241231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 bdx-20241231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 bdx-20241231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Adjustments to net income to derive net cash provided by continuing operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Statistical Measurement [Domain] Statistical Measurement [Domain] Payments of debt Repayments of Long-Term Debt Pharmaceutical Systems Pharmaceutical Systems [Member] Pharmaceutical Systems [Member] Cover [Abstract] Cover [Abstract] Net decrease in cash and equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Diagnostic Solutions Diagnostic Solutions [Member] Diagnostic Solutions Schedule of Notional Amounts of Outstanding Derivative Positions Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] Trading Symbol Trading Symbol Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Fair value hedges Fair Value Hedging [Member] All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Specimen Management Specimen Management [Member] Specimen Management Accelerated Share Repurchases Accelerated Share Repurchases [Table Text Block] NEW YORK STOCK EXCHANGE, INC. NEW YORK STOCK EXCHANGE, INC. [Member] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Transfer of Financial Assets Accounted for as Sales Transfer of Financial Assets Accounted for as Sales [Table Text Block] Dividends per Common Share (USD per share) Common Stock, Dividends, Per Share, Declared Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Purchase price allocation adjustments Goodwill, Measurement Period Adjustment Accelerated Share Repurchases [Table] Accelerated Share Repurchases [Table] Total shares to be delivered under accelerated share repurchase program Total Shares to be Delivered Under Accelerated Share Repurchase Program Total Shares to be Delivered Under Accelerated Share Repurchase Program Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Currency Swap Currency Swap [Member] Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Hedging Relationship [Domain] Hedging Relationship [Domain] Financial Instruments and Fair Value Measurements Fair Value Disclosures [Text Block] Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Award Timing Disclosures [Line Items] Net investment hedges Net Investment Hedging [Member] Other Performance Measure, Amount Other Performance Measure, Amount Notes 1.900% due December 15, 2026 Notes 1.900% due December 15, 2026 [Member] Notes 1.900% due December 15, 2026 [Member] Goodwill [Line Items] Goodwill [Line Items] Net interest expense Interest Income (Expense), Operating Pending claims Loss Contingency, Pending Claims, Number Cash flow hedges Cash Flow Hedging [Member] Financing Activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Notes 3.828% due June 7, 2032 Notes 3.828% due June 7, 2032 [Member] Notes 3.828% due June 7, 2032 United States UNITED STATES Inventories: Inventory, Net [Abstract] Consumables Consumables [Member] Consumables [Member] Service cost Defined Benefit Plan, Service Cost Advanced Patient Monitoring Advanced Patient Monitoring [Member] Advanced Patient Monitoring Dilutive share equivalents from share-based plans (shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Surgery Surgery [Member] Surgery [Member] Other Assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Gross Carrying Amount Finite-Lived Intangible Assets, Gross Repurchase of common stock (in shares) Repurchase of common stock (in shares) Treasury Stock, Shares, Acquired Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Retirement Plan Type [Axis] Retirement Plan Type [Axis] Operating Segments Operating Segments [Member] Rebate liability Contract With Customer, Rebate Liability Contract With Customer, Rebate Liability Medication Delivery Solutions Medication Delivery Solutions [Member] Medication Delivery Solutions [Member] Treasury Stock Treasury Stock, Common [Member] Finite And Indefinite Lived Intangible Assets [Line Items] Finite And Indefinite Lived Intangible Assets [Line Items] Finite And Indefinite Lived Intangible Assets [Line Items] Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Share Based Compensation Share Based Compensation [Member] Share Based Compensation [Member] Equity Components [Axis] Equity Components [Axis] Prepaid expenses and other Other Assets, Current Award Timing Method Award Timing Method [Text Block] Net pension cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Restructuring Type [Axis] Restructuring Type [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Foreign currency-denominated debt Foreign Currency-Denominated Debt [Member] Foreign-Currency Denominated Debt [Member] Insider Trading Policies and Procedures [Line Items] Total Operating Costs and Expenses Costs and Expenses Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Adjustment to Compensation, Amount Adjustment to Compensation Amount Deferred compensation Common Stock, Shares Held in Employee Trust1 Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees. Capital in excess of par value Additional Paid in Capital, Common Stock Compensation Amount Outstanding Recovery Compensation Amount Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Developed technology Developed Technology Rights [Member] Company Selected Measure Amount Company Selected Measure Amount Geographical [Axis] Geographical [Axis] Antoine Ezell [Member] Antoine Ezell Tabular List, Table Tabular List [Table Text Block] Other adjustments Restructuring Reserve, Accrual Adjustment Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Loss contingency accrual Loss Contingency Accrual Share equivalents excluded from the diluted shares outstanding calculation (shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Cash payments Payments for Restructuring Opening Cash and Equivalents and Restricted Cash Closing Cash and Equivalents and Restricted Cash Cash and equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Common stock held in trusts, net (in shares) Common Stock Held In Trusts Net Shares Number of common stock shares held in trust. Customer Relationships, Net Finite Lived Customer Relationships Net Net carrying amount as of the balance sheet date of an asset acquired in a business combination representing a favorable existing relationship with customers having a finite beneficial life. Current Assets: Assets, Current [Abstract] Goodwill Goodwill, beginning balance Goodwill, ending balance Goodwill Consolidation Items [Axis] Consolidation Items [Axis] Organizational Unit [Domain] Organizational Unit [Domain] [Domain] for Organizational Unit [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Other Comprehensive Income (Loss), Net of Tax Other Comprehensive Income (Loss), Net of Tax [Abstract] Stock repurchase program, authorized amount Share Repurchase Program, Authorized, Amount Beginning balance (shares) Ending balance (shares) Treasury Stock, Common, Shares Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service [Domain] Product and Service [Domain] Entity Information [Line Items] Entity Information [Line Items] Employee Stock Option Share-Based Payment Arrangement, Option [Member] Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Goodwill [Roll Forward] Goodwill [Roll Forward] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Other, net Proceeds from (Payments for) Other Financing Activities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Comprehensive Income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Pension Plans Pension Plan [Member] Products and/or Services Products and/or Services [Member] Products and/or Services [Member] Security Exchange Name Security Exchange Name Products Within Mass Tort Litigation Products Within Mass Tort Litigation [Member] Products Within Mass Tort Litigation Medical Medical [Member] Medical. Award Type Award Type [Axis] Currency translation Goodwill, Foreign Currency Translation Gain (Loss) Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Richard Byrd, Trading Arrangement, Stock Appreciation Rights [Member] Richard Byrd, Trading Arrangement, Stock Appreciation Rights Property, Plant and Equipment, Net Property, Plant and Equipment, Net Work in process Inventory, Work in Process, Net of Reserves Schedule of Cash and Cash Equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Notes 1.208% due June 4, 2026 Notes 1.208% due June 4, 2026 [Member] Notes 1.208% due June 4, 2026 [Member] Common stock, par value (USD per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Research and development expense Research and Development Expense Expiration Date Trading Arrangement Expiration Date Number of EtO lawsuits filed Number Of EtO Sterilization Lawsuits Filed Number Of EtO Sterilization Lawsuits Filed Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Net Cash Provided by Continuing Operating Activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations Total Shareholder Return Amount Total Shareholder Return Amount Common stock, shares issued (shares) Common Stock, Shares, Issued Short-term investments Other Short-Term Investments Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Other Initiatives Other Initiatives [Member] Other Initiatives [Member] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Less allowances for depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, Plant and Equipment Property, Plant and Equipment, Gross Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Common stock, shares authorized (shares) Common Stock, Shares Authorized Acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Average common and common equivalent shares outstanding - assuming dilution (shares) Weighted Average Number of Shares Outstanding, Diluted MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Total Shareholders’ Equity Beginning balance Ending balance Equity, Attributable to Parent Treasury stock Treasury Stock, Value Amortization of loss Defined Benefit Plan, Amortization of Gain (Loss) Business Combinations [Abstract] Business Combinations [Abstract] Investing Activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Stock Repurchase Program, Excise Tax Stock Repurchase Program, Excise Tax Stock Repurchase Program, Excise Tax Interest expense Interest Expense, Nonoperating Reconciliation of Goodwill by Business Segment Schedule of Goodwill [Table Text Block] Selling and administrative expense Selling, General and Administrative Expense Richard Byrd, Trading Arrangement, Common Stock Upon The Vesting Of Performance Units [Member] Richard Byrd, Trading Arrangement, Common Stock Upon The Vesting Of Performance Units Current debt obligations Debt, Current Trade receivables, net Accounts Receivable, after Allowance for Credit Loss, Current Asset impairment charges Asset Impairment Charges Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus Exchange [Domain] Exchange [Domain] All Executive Categories All Executive Categories [Member] Summary of Restructuring Accrual Activity Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Available-for-Sale Debt Securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Business Acquisition, Goodwill, Expected Tax Deductible Amount Business Acquisition, Goodwill, Expected Tax Deductible Amount Assets Assets [Abstract] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Other Comprehensive Income, Net of Tax Other Comprehensive Income (Loss), Net of Tax Document Type Document Type Derivative Contract [Domain] Derivative Contract [Domain] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Financial Information for Company's Segments Schedule of Segment Reporting Information, by Segment [Table Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan [Table] Accelerated Share Repurchase Program Accelerated Share Repurchase Program [Member] Accelerated Share Repurchase Program Unamortized intangible assets Indefinite-Lived Intangible Assets (Excluding Goodwill) Maximum Maximum [Member] Intangible amortization expense Amortization of Intangible Assets Contract with customer, liability Contract with Customer, Liability Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Payment terms of supplier finance programs (in days) Supplier Finance Program, Payment Timing, Period Net Carrying Amount Finite-Lived Intangible Assets, Net Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Net Assets Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Net Assets Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Net Assets Acquired in-process research and development Unclassified Indefinite-Lived Intangible Assets [Member] International Non-US [Member] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Contingencies Commitments and Contingencies, Policy [Policy Text Block] Financial Instruments and Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Richard Byrd, Trading Arrangement, Common Stock Upon The Vesting Of Time Vested Units [Member] Richard Byrd, Trading Arrangement, Common Stock Upon The Vesting Of Time Vested Units Acquisition Business Combination Disclosure [Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Supplier finance program, obligation Supplier Finance Program, Obligation Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income Before Income Taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount All Award Types Award Type [Domain] Name Outstanding Recovery, Individual Name Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Common stock issued for share-based compensation and other plans, net (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Components of Intangible Assets Schedule of Intangible Assets and Goodwill [Table Text Block] Long-Term Employee Benefit Obligations Liability, Defined Benefit Plan, Noncurrent Non-PEO NEO Non-PEO NEO [Member] Capital in Excess of Par Value Additional Paid-in Capital [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] Hernia Product Claims HerniaProductClaims [Member] HerniaProductClaims [Member] Percentage of excise tax excluded Stock Repurchase Program, Excise Tax, Percentage Stock Repurchase Program, Excise Tax, Percentage Italian Medical Device Payback Legislation Matter Italian Medical Device Payback Legislation Matter [Member] Italian Medical Device Payback Legislation Matter Award Timing Predetermined Award Timing Predetermined [Flag] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Benefit Plans Retirement Benefits [Text Block] Class of Stock [Line Items] Class of Stock [Line Items] Customer relationships Customer Relationships [Member] Entity Listings, Exchange [Axis] Entity Listings, Exchange [Axis] New Accounting Principle Adopted and New Accounting Principles Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Amortization of prior service credit Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Diluted Earnings per Share (USD per share) Earnings Per Share, Diluted Class of Stock [Axis] Class of Stock [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Weighted Average Common Shares Used in Computations of Basic and Diluted Earnings Per Share Schedule of Weighted Average Number of Shares [Table Text Block] Revenues Revenue from Contract with Customer [Policy Text Block] Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Type of Restructuring [Domain] Type of Restructuring [Domain] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Number of principal business segments (segment) Number of Operating Segments Retirement Benefits [Abstract] Retirement Benefits [Abstract] Share Repurchase Program, Remaining Authorized, Number of Shares Share Repurchase Program, Remaining Authorized, Number of Shares Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Employee Termination Employee Severance [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Business Restructuring Charges Restructuring and Related Activities Disclosure [Text Block] Share-based compensation Share-Based Payment Arrangement, Noncash Expense Benefit Plans Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Income tax provision Income Tax Expense (Benefit) Interest cost Defined Benefit Plan, Interest Cost Notional amount of derivative Derivative, Notional Amount Corporate, Non-Segment Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] Pyxis Pyxis [Member] Pyxis Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Effective income tax rate reconciliation, percent Effective Income Tax Rate Reconciliation, Percent Net Cash Provided by (Used for) Investing Activities Net Cash Provided by (Used in) Investing Activities Operating Income Operating Income (Loss) Business Acquisition [Line Items] Business Acquisition [Line Items] Total Liabilities and Shareholders’ Equity Liabilities and Equity Other, net Other Operating Activities, Cash Flow Statement Subsequent Events Subsequent Events [Text Block] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Interventional Interventional Interventional [Member] Interventional [Member] Other Intangibles, Net Other Intangible Assets, Net Derivative Instruments and Hedging Activities Derivative Instruments and Hedging Activities Disclosure [Text Block] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Charged to expense Restructuring Charges Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Dividends paid Payments of Dividends Interest income Investment Income, Interest Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Individual: Individual [Axis] Revenue, remaining performance obligation, expected timing of satisfaction (in years) Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Cash Flow Hedges Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Inventories Inventory, Net Product and Service [Axis] Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Statement [Line Items] Statement [Line Items] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Urology and Critical Care Urology and Critical Care [Member] Urology and Critical Care [Member] Schedule of Shareholders Equity Schedule of Stockholders Equity [Table Text Block] Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Business Combination, Consideration Transferred Business Combination, Consideration Transferred Liabilities and Shareholders’ Equity Liabilities and Equity [Abstract] Net Pension and Postretirement Cost Schedule of Net Benefit Costs [Table Text Block] Derivative Instruments and Hedging Activities Derivatives, Policy [Policy Text Block] Foreign Currency-Denominated Debt Debt [Member] Loss contingency, number of plaintiffs Loss Contingency, Number of Plaintiffs Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Foreign Currency Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net Foreign Currency Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Other Operating Income (Expense) Other Operating Income (Expense) [Member] Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Business Acquisition, Pro Forma Revenue Business Acquisition, Pro Forma Revenue Derivative Instrument [Axis] Derivative Instrument [Axis] Exercise Price Award Exercise Price Earnings per Share Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Subsequent Event Subsequent Event [Member] Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Shareholders’ Equity Equity, Attributable to Parent [Abstract] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Restructuring Plan [Axis] Restructuring Plan [Axis] Segments [Domain] Segments [Domain] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Share repurchase program, excise tax Share Repurchase Program, Excise Tax Notes 1.213% Notes due February 12, 2036 Notes 1.213% Notes due February 12, 2036 [Member] Notes 1.213% Notes due February 12, 2036 All Individuals All Individuals [Member] Number of EtO sterilization lawsuits, allege injury from unrelated defendants Number of EtO Sterilization Lawsuits, Allege Injury From Unrelated Defendants Number of EtO Sterilization Lawsuits, Allege Injury From Unrelated Defendants PEO PEO [Member] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Entities [Table] Entities [Table] Interest Rate Swaps Fixed To Floating [Member] Fixed To Floating [Member] Name Trading Arrangement, Individual Name Other expense, net Other Nonoperating Income (Expense) Long-term debt Loans Payable, Fair Value Disclosure Non-cash settlements Restructuring Reserve, Settled without Cash Total Segment Operating Income Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Organizational Unit [Axis] Organizational Unit [Axis] Organizational Unit [Axis] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Institutional money market accounts Cash and Cash Equivalents, Fair Value Disclosure Payables, accrued expenses and other current liabilities Accounts Payable and Accrued Liabilities, Current Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Local Phone Number Local Phone Number Share Repurchase Program, Authorized, Number of Shares Share Repurchase Program, Authorized, Number of Shares Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Other Other Restructuring [Member] PEO Total Compensation Amount PEO Total Compensation Amount Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Defined benefit pension and postretirement plans Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Contingencies Commitments and Contingencies Disclosure [Text Block] Common Stock Common Stock  Issued at Par Value Common Stock [Member] Measure: Measure [Axis] Issuance of shares under employee and other plans, net Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Trade receivables transferred to third parties under factoring arrangements Transfers of financial assets during the period. Transfers of financial assets during the period. Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Amounts yet to be collected and remitted to the third parties Transfer of Financial Assets Accounted for as Sales, Amount Derecognized Medication Management Solutions Medication Management Solutions [Member] Medication Management Solutions [Member] Entity Emerging Growth Company Entity Emerging Growth Company Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Segment Reporting [Abstract] Segment Reporting [Abstract] Restricted cash Restricted cash Restricted Cash and Investments, Current Entity Central Index Key Entity Central Index Key Loss contingency, damages sought, value Loss Contingency, Damages Sought, Value Terminated Currency Swap Terminated Currency Swap [Member] Terminated Currency Swap Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Foreign Currency Translation Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Product liability accrual, pre-tax credit Product Liability Accrual, Period Expense Shareholders' Equity Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Segment Data Segment Reporting Disclosure [Text Block] Net cash used for operating activities of discontinued operations Cash Provided by (Used in) Operating Activities, Discontinued Operations Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Amounts reclassified into income, net of taxes Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Accounting Changes Accounting Standards Update and Change in Accounting Principle [Text Block] Entity Shell Company Entity Shell Company Number of additional shares authorized to be repurchased (in shares) Stock Repurchase Program, Number of Additional Shares Authorized to be Repurchased Stock Repurchase Program, Number of Additional Shares Authorized to be Repurchased Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Loss contingency, loss in period Loss Contingency, Loss in Period Title Trading Arrangement, Individual Title Deferred Compensation Deferred Compensation, Share-Based Payments [Member] Statement [Table] Statement [Table] Consolidation Items [Domain] Consolidation Items [Domain] City Area Code City Area Code Current Liabilities: Liabilities, Current [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Foreign currency translation adjustments Net gains (losses) recorded to Accumulated other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Total Current Assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] GEORGIA GEORGIA Repurchases of common stock Payments for Repurchase of Common Stock Change in operating assets and liabilities Increase (Decrease) in Operating Capital Long-Term Debt Long-Term Debt, Excluding Current Maturities Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Income Taxes Income Tax Disclosure [Text Block] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Equity [Abstract] Materials Inventory, Raw Materials, Net of Reserves Retained earnings Retained Earnings (Accumulated Deficit) Class of Stock [Domain] Class of Stock [Domain] Deferred income taxes Deferred Income Taxes and Tax Credits Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Change in short-term debt Proceeds from (Repayments of) Short-Term Debt Net Cash Used for Financing Activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Accounting Changes and Error Corrections [Abstract] Accounting Changes and Error Corrections [Abstract] Common dividends Dividends, Common Stock, Cash Amendment Flag Amendment Flag Richard Byrd, Trading Arrangement, Common Stock [Member] Richard Byrd, Trading Arrangement, Common Stock Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Entity Registrant Name Entity Registrant Name Operating Activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Depreciation and amortization Depreciation, Depletion and Amortization Fair Value as of Grant Date Award Grant Date Fair Value Subsequent Events [Abstract] Subsequent Events [Abstract] Current portion of long-term debt Fair Value Of Debt Classified From Long Term To Short Term Fair Value Of Debt Classified From Long Term To Short Term Antoine Ezell, Trading Arrangement, Common Stock [Member] Antoine Ezell, Trading Arrangement, Common Stock Other comprehensive income before reclassifications, net of taxes Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Geographical [Domain] Geographical [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Schedule of Restructuring and Related Costs [Table] Restructuring Cost [Table] Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Common stock — $1 par value; authorized — 640,000,000 shares; issued — 370,594,401 shares in December 31, 2024 and September 30, 2024 Common Stock, Value, Issued Cash and equivalents Cash and equivalents Cash and Cash Equivalents, at Carrying Value Other, net Payments for (Proceeds from) Other Investing Activities Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Pension obligation Increase (Decrease) in Pension Benefit Obligation Amount of increase (decrease) in obligation for pension benefits. Notes 0.034% due August 13, 2025 Notes 0.034% due August 13, 2025 [Member] Notes 0.034% due August 13, 2025 Maturities and sales of investments Proceeds from Sale, Maturity and Collection of Investments Basic Earnings per Share (USD per share) Earnings Per Share, Basic Loss contingency accrual, product liability, net Loss Contingency Accrual, Product Liability, Net Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Trademarks Trademarks [Member] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Schedule of Goodwill [Table] Goodwill [Table] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Total Current Liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Total Assets Assets Cost of products sold Cost of Goods and Services Sold Capital expenditures Payments to Acquire Property, Plant, and Equipment Deferred Income Taxes and Other Liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Derivative Instruments and Hedging Activities Disclosures [Table] Derivative Instruments and Hedging Activities Disclosures [Table] Commitments and Contingencies (See Note 5) Commitments and Contingencies Integration, restructuring and transaction expense Integration, restructuring and transaction expense Integration, Restructuring and Transaction Expense Expenses associated with exit or disposal activities pursuant to an authorized plan. Also includes acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; business integration costs, systems integration and conversion costs, and severance and other employee-related costs; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. Excludes expenses related to a discontinued operation or an asset retirement obligation. Termination Date Trading Arrangement Termination Date Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Accelerated Share Repurchases [Line Items] Accelerated Share Repurchases [Line Items] Revenues Revenues Revenue from External Customers by Geographic Area Revenue from External Customers by Geographic Areas [Table Text Block] Entity Address, City or Town Entity Address, City or Town Debt Instrument [Axis] Debt Instrument [Axis] Net Income Net Income Net income Net Income (Loss) Attributable to Parent Other operating expense, net Other Operating Income (Expense), Net Trading Arrangement: Trading Arrangement [Axis] Finite And Indefinite Lived Intangible Assets [Table] Finite And Indefinite Lived Intangible Assets [Table] Finite And Indefinite Lived Intangible Assets [Table] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Loss Contingencies [Table] Loss Contingencies [Table] Business Acquisition [Axis] Business Acquisition [Axis] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Integration and Restructuring Expense Integration and Restructuring Expense [Member] Integration and Restructuring Expense Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Peripheral Intervention Peripheral Intervention [Member] Peripheral Intervention [Member] Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Revenues Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Repurchase of common stock Repurchase of common stock Treasury Stock, Value, Acquired, Cost Method Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Effect of exchange rate changes on cash and equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Restructuring Plan [Domain] Restructuring Plan [Domain] Name Forgone Recovery, Individual Name Document Period End Date Document Period End Date Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Maturity period of short-term investments at the time of purchase Maturity Period Of Short Term Investment The maturity period of time deposits classified as short-term investments in the consolidated balance sheet. Finished products Inventory, Finished Goods, Net of Reserves Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Life Sciences Life Sciences Life Sciences [Member] Life Sciences [Member] Notes 3.020% due May 24, 2025 Notes 3.020% due May 24, 2025 [Member] Notes 3.020% due May 24, 2025 [Member] Richard Byrd [Member] Richard Byrd Insider Trading Arrangements [Line Items] Developed Technology, Net Core And Developed Technology Net Intangible assets arising from acquisitions. These assets represent acquired intellectual property that is already technologically feasible upon the acquisition date. Segment Reconciling Items Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Patents, trademarks and other Intellectual Property [Member] Adjustment to Compensation: Adjustment to Compensation [Axis] Foreign Exchange Contracts Foreign Exchange Contract [Member] Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Notes 3.519% due February 8, 2031 Notes 3.519% due February 8, 2031 [Member] Notes 3.519% due February 8, 2031 Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Accumulated other comprehensive loss Beginning balance Ending balance Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Biosciences Biosciences [Member] Biosciences [Member] Retained Earnings Retained Earnings [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] SEC Matter SEC Matter [Member] SEC Matter Average common shares outstanding (shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Officer Trading Arrangement [Member] Officer Trading Arrangement Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Entity Filer Category Entity Filer Category Beginning Balance Ending Balance Restructuring Reserve Revenue, remaining performance obligation, amount Revenue, Remaining Performance Obligation, Amount Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Company Selected Measure Name Company Selected Measure Name EX-101.PRE 9 bdx-20241231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.25.0.1
Cover Page
 3 Months Ended
Dec. 31, 2024
shares
Entity Information [Line Items]  
Document Type 10-Q
Document Quarterly Report true
Document Period End Date Dec. 31, 2024
Document Transition Report false
Entity File Number 001-4802
Entity Registrant Name Becton, Dickinson and Company
Entity Incorporation, State or Country Code NJ
Entity Tax Identification Number 22-0760120
Entity Address, Address Line One 1 Becton Drive,
Entity Address, City or Town Franklin Lakes,
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07417-1880
City Area Code (201)
Local Phone Number 847-6800
Entity Current Reporting Status Yes
Entity Interactive Data Current Yes
Entity Filer Category Large Accelerated Filer
Entity Small Business false
Entity Emerging Growth Company false
Entity Shell Company false
Entity Common Stock, Shares Outstanding 287,135,421
Entity Central Index Key 0000010795
Current Fiscal Year End Date --09-30
Document Fiscal Year Focus 2025
Document Fiscal Period Focus Q1
Amendment Flag false
Common Stock | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security Common stock, par value $1.00
Trading Symbol BDX
Security Exchange Name NYSE
Notes 1.900% due December 15, 2026 | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security 1.900% Notes due December 15, 2026
Trading Symbol BDX26
Security Exchange Name NYSE
Notes 3.020% due May 24, 2025 | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security 3.020% Notes due May 24, 2025
Trading Symbol BDX25
Security Exchange Name NYSE
Notes 1.208% due June 4, 2026 | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security 1.208% Notes due June 4, 2026
Trading Symbol BDX/26A
Security Exchange Name NYSE
Notes 1.213% Notes due February 12, 2036 | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security 1.213% Notes due February 12, 2036
Trading Symbol BDX/36
Security Exchange Name NYSE
Notes 0.034% due August 13, 2025 | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security 0.034% Notes due August 13, 2025
Trading Symbol BDX25A
Security Exchange Name NYSE
Notes 3.519% due February 8, 2031 | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security 3.519% Notes due February 8, 2031
Trading Symbol BDX31
Security Exchange Name NYSE
Notes 3.828% due June 7, 2032 | NEW YORK STOCK EXCHANGE, INC.  
Entity Information [Line Items]  
Title of 12(b) Security 3.828% Notes due June 7, 2032
Trading Symbol BDX32A
Security Exchange Name NYSE
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.25.0.1
Condensed Consolidated Statements of Income - USD ($)
$ in Millions
 3 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Statement [Abstract]    
Revenues $ 5,168 $ 4,706
Cost of products sold 2,933 2,679
Selling and administrative expense 1,318 1,213
Research and development expense 343 290
Integration, restructuring and transaction expense 92 75
Other operating expense, net 28 11
Total Operating Costs and Expenses 4,715 4,267
Operating Income 453 439
Interest expense 155 111
Interest income 23 34
Other expense, net (16) (4)
Income Before Income Taxes 306 359
Income tax provision 3 77
Net Income $ 303 $ 281
Basic Earnings per Share (USD per share) $ 1.05 $ 0.97
Diluted Earnings per Share (USD per share) 1.04 0.96
Dividends per Common Share (USD per share) $ 1.04 $ 0.95
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.25.0.1
Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
 3 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Statement of Comprehensive Income [Abstract]    
Net Income $ 303 $ 281
Other Comprehensive Income (Loss), Net of Tax    
Foreign currency translation adjustments 46 40
Defined benefit pension and postretirement plans 8 12
Cash flow hedges 2 (18)
Other Comprehensive Income, Net of Tax 56 33
Comprehensive Income $ 359 $ 314
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.25.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2024
Sep. 30, 2024
Current Assets:    
Cash and equivalents $ 711 $ 1,717
Restricted cash 102 139
Short-term investments 17 445
Trade receivables, net 2,638 3,033
Inventories:    
Materials 904 803
Work in process 453 443
Finished products 2,502 2,597
Inventories 3,860 3,843
Prepaid expenses and other 1,331 1,292
Total Current Assets 8,659 10,468
Property, Plant and Equipment 14,156 14,378
Less allowances for depreciation and amortization 7,554 7,557
Property, Plant and Equipment, Net 6,602 6,821
Goodwill 26,329 26,465
Developed Technology, Net 7,439 7,733
Customer Relationships, Net 2,533 2,635
Other Intangibles, Net 517 549
Other Assets 2,586 2,615
Total Assets 54,665 57,286
Current Liabilities:    
Current debt obligations 1,318 2,170
Payables, accrued expenses and other current liabilities 6,347 6,786
Total Current Liabilities 7,664 8,956
Long-Term Debt 17,440 17,940
Long-Term Employee Benefit Obligations 939 942
Deferred Income Taxes and Other Liabilities 3,418 3,558
Commitments and Contingencies (See Note 5)
Shareholders’ Equity    
Common stock — $1 par value; authorized — 640,000,000 shares; issued — 370,594,401 shares in December 31, 2024 and September 30, 2024 371 371
Capital in excess of par value 19,768 19,893
Retained earnings 16,141 16,139
Deferred compensation 25 25
Treasury stock (9,425) (8,807)
Accumulated other comprehensive loss (1,676) (1,732)
Total Shareholders’ Equity 25,205 25,890
Total Liabilities and Shareholders’ Equity $ 54,665 $ 57,286
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.25.0.1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2024
Sep. 30, 2024
Statement of Financial Position [Abstract]    
Common stock, par value (USD per share) $ 1 $ 1
Common stock, shares authorized (shares) 640,000,000 640,000,000
Common stock, shares issued (shares) 370,594,401 370,594,401
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.25.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 3 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Operating Activities    
Net Income $ 303 $ 281
Adjustments to net income to derive net cash provided by continuing operating activities:    
Depreciation and amortization 607 561
Share-based compensation 90 83
Deferred income taxes (151) (91)
Change in operating assets and liabilities (370) 152
Pension obligation (2) (129)
Other, net 216 (2)
Net Cash Provided by Continuing Operating Activities 693 855
Investing Activities    
Capital expenditures (105) (116)
Maturities and sales of investments 411 0
Acquisitions, net of cash acquired (8) 0
Other, net (94) (116)
Net Cash Provided by (Used for) Investing Activities 204 (233)
Financing Activities    
Change in short-term debt 75 0
Payments of debt (875) 0
Repurchases of common stock (750) (500)
Dividends paid (302) (275)
Other, net (76) (87)
Net Cash Used for Financing Activities (1,928) (862)
Net cash used for operating activities of discontinued operations 0 (14)
Effect of exchange rate changes on cash and equivalents and restricted cash (12) 7
Net decrease in cash and equivalents and restricted cash (1,043) (247)
Opening Cash and Equivalents and Restricted Cash 1,856 1,481
Closing Cash and Equivalents and Restricted Cash $ 813 $ 1,234
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.25.0.1
Basis of Presentation
 3 Months Ended
Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and, in the opinion of the management of Becton, Dickinson and Company (the "Company" or "BD"), include all adjustments which are of a normal recurring nature, necessary for a fair presentation of the financial position and the results of operations and cash flows for the periods presented. However, the financial statements do not include all information and accompanying notes required for a presentation in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s 2024 Annual Report on Form 10-K.
Within the financial statements and tables presented, certain columns and rows may not add due to the use of rounded numbers for disclosure purposes. Percentages and earnings per share amounts presented are calculated from the underlying amounts. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.25.0.1
Accounting Changes
 3 Months Ended
Dec. 31, 2024
Accounting Changes and Error Corrections [Abstract]  
Accounting Changes Accounting Changes
New Accounting Principles Not Yet Adopted
In November 2024, the Financial Accounting Standards Board (“FASB”) issued an accounting standard update that requires the Company to disclose more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in each relevant income statement expense caption. The update is effective for the Company beginning with its fiscal year 2028 reporting and for interim reporting beginning with its fiscal year 2029. Early adoption is permitted. The Company is currently evaluating the impact that this update will have on its disclosures.
In December 2023, the FASB issued an accounting standard update that requires more disaggregated information to be included in the income tax rate reconciliation and income taxes paid annual disclosures. This update is effective for the Company beginning in its fiscal year 2026 and the Company is currently evaluating the impact that this update will have on its disclosures.
In November 2023, the FASB issued a new accounting standard update that requires more disaggregated expense information about a public entity’s reportable segments. This update is effective for the Company beginning with its fiscal year 2025 reporting and for interim reporting beginning with its fiscal year 2026. The Company is currently evaluating the impact that this update will have on its disclosures.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.25.0.1
Shareholders' Equity
 3 Months Ended
Dec. 31, 2024
Stockholders' Equity Note [Abstract]  
Shareholders' Equity Shareholders' Equity
Changes in certain components of shareholders' equity for the first quarters of fiscal years 2025 and 2024 were as follows:
 Common
Stock  Issued
at Par Value		Capital in
Excess of
Par Value		Retained
Earnings		Deferred
Compensation		Treasury Stock
(Millions of dollars)Shares (in
thousands)		Amount
Balance at September 30, 2024$371 $19,893 $16,139 $25 (81,493)$(8,807)
Net income— — 303 — — — 
Common dividends ($1.04 per share)
— — (302)— — — 
Issuance of shares under employee and other plans, net— (65)— — 679 (12)
Share-based compensation— 90 — — — — 
Common stock held in trusts, net (a)— — — — (8)— 
Repurchase of common stock— (150)— — (2,637)(606)
Balance at December 31, 2024$371 $19,768 $16,141 $25 (83,459)$(9,425)
 Common
Stock  Issued
at Par Value		Capital in
Excess of
Par Value		Retained
Earnings		Deferred
Compensation		Treasury Stock
(Millions of dollars)Shares (in
thousands)		Amount
Balance at September 30, 2023$371 $19,720 $15,535 $24 (80,203)$(8,305)
Net income— — 281 — — — 
Common dividends ($0.95 per share)
— — (275)— — — 
Issuance of shares under employee and other plans, net— (62)— — 647 (20)
Share-based compensation— 83 — — — — 
Common stock held in trusts, net (a)— — — — (19)— 
Repurchase of common stock— — — — (2,118)(503)
Balance at December 31, 2023$371 $19,741 $15,540 $24 (81,692)$(8,828)
(a)Common stock held in trusts consists of the Company’s shares held in rabbi trusts in connection with deferred compensation under the Company’s employee salary and bonus deferral plan and directors’ deferral plan.
Share Repurchases
In the first quarter of fiscal year 2025, the Company executed an accelerated share repurchase (“ASR”) agreement and accounted for the agreement as two transactions upon prepayment: (1) the initial delivery of shares was recorded as an increase to Common stock in treasury to recognize the acquisition of common stock acquired in a treasury stock transaction, and (2) the remaining amount of shares was recorded as a decrease to Capital in excess of par value to recognize a net share-settled forward sale contract indexed to the Company's own common stock. The impacts of these accelerated share repurchase transactions were as follows:
Execution DateSettlement DateAggregate Common Stock Repurchased (millions of dollars) (a)Initial Shares Delivered (in thousands)Additional Shares Delivered at Settlement (in thousands) (b)Total Shares Delivered (in thousands)
Q1 2025Q2 2025$750 2,637 619 3,256 
(a)    Excludes a 1% excise tax on share repurchases of $6 million.
(b)    Upon final settlement of the repurchase agreement and the forward sale contract, the Company’s receipt of additional shares was recorded as an increase to Common stock in treasury and an offsetting increase to Capital in excess of par value. The final settlement for the first quarter transaction amounted to $150 million.
In the first quarter of fiscal year 2024, the Company executed and settled ASR agreements for the repurchase of 2.118 million shares of its common stock for total consideration of $500 million, excluding a 1% excise tax on share repurchases of $3 million. The share repurchases were recorded as an increase to Treasury stock.
The share repurchases discussed above were made pursuant to the repurchase program authorized by the Board of Directors on November 3, 2021, for 10 million shares of BD common stock, for which there is no expiration date. As of December 31, 2024, 4 million shares remained unused under this program. On January 28, 2025, the Board of Directors authorized BD to repurchase up to an additional 10 million shares of BD common stock, for which there is no expiration date.
The components and changes of Accumulated other comprehensive income (loss) for the first quarters of fiscal years 2025 and 2024 were as follows:
(Millions of dollars)TotalForeign Currency
Translation		Benefit Plans
Cash Flow Hedges		Available-for-Sale Debt Securities
Balance at September 30, 2024$(1,732)$(1,244)$(557)$70 $(1)
Other comprehensive income before reclassifications, net of taxes49 46 — 3 — 
Amounts reclassified into income, net of taxes6 — 8 (2)— 
Balance at December 31, 2024$(1,676)$(1,199)$(549)$72 $(1)
(Millions of dollars)TotalForeign Currency
Translation		Benefit Plans
Cash Flow Hedges		Available-for-Sale Debt Securities
Balance at September 30, 2023$(1,548)$(1,078)$(571)$103 $— 
Other comprehensive income (loss) before reclassifications, net of taxes21 40 — (19)— 
Amounts reclassified into income, net of taxes12 — 12 1 — 
Balance at December 31, 2023$(1,515)$(1,038)$(559)$84 $— 
The amounts of foreign currency translation recognized in other comprehensive income during the three months ended December 31, 2024 and 2023 included net gains (losses) relating to net investment hedges. The amounts recognized in other comprehensive income relating to cash flow hedges primarily related to foreign exchange contracts during the three months ended December 31, 2024 and forward starting interest rate swaps during the three months ended December 31, 2023. Additional disclosures regarding the Company's derivatives are provided in Note 12.
The tax impacts for amounts recognized in other comprehensive income (loss) before reclassifications and for reclassifications out of Accumulated other comprehensive income (loss) relating to benefit plans and cash flow hedges during the three months ended December 31, 2024 and 2023 were immaterial to the Company's consolidated financial results.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.25.0.1
Earnings per Share
 3 Months Ended
Dec. 31, 2024
Earnings Per Share [Abstract]  
Earnings per Share Earnings per Share
The weighted average common shares used in the computations of basic and diluted earnings per share (shares in thousands) were as follows:
 Three Months Ended
December 31,
 20242023
Average common shares outstanding289,505 290,113 
Dilutive share equivalents from share-based plans884 1,285 
Average common and common equivalent shares outstanding – assuming dilution290,389 291,398 
Share equivalents excluded from the diluted shares outstanding calculation:
Share-based plans (a)2,758 552 
(a)Excluded from the diluted earnings per share calculation as the exercise prices of these awards were greater than the average market price of the Company’s common shares.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.25.0.1
Contingencies
 3 Months Ended
Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Contingencies Contingencies
The Company is involved, both as a plaintiff and a defendant, in various legal proceedings that arise in the ordinary course of business, including, without limitation, product liability and environmental matters in certain U.S. and international locations. Given the uncertain nature of litigation generally, the Company is not able, in all cases, to reasonably estimate the amount or range of loss that could result from an unfavorable outcome of litigation in which the Company is a party. Even if the Company believes it has meritorious defenses, from time to time the Company engages in settlement discussions and mediations and considers settlements taking into account various factors including, among other things, developments in such legal proceedings
and the resulting risks and uncertainties. These activities have resulted in settlements for certain matters and going forward could result in further settlements, which may be confidential and could be significant and result in charges in excess of accruals.
In accordance with U.S. GAAP, the Company establishes accruals to the extent future losses are probable and reasonably estimable. With respect to putative class action lawsuits and certain tort actions in the United States and certain of the Canadian lawsuits described below or in its other SEC filings, the Company may not be able to determine if a probable loss exists or estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; (ii) the Company has not received and reviewed complete information regarding all or certain of the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, there is uncertainty as to the likelihood of a class being certified or the ultimate size of any class. With respect to certain of the civil investigative demands (“CIDs”) served by the Department of Justice which are discussed below, the Company may not be able to determine if a probable loss exists, unless otherwise noted, for the following reasons: (i) all or certain of the proceedings are in early stages; and/or (ii) there are significant factual and legal issues to be resolved.
Product Liability Matters
As of December 31, 2024, the Company is defending approximately 6,670 product liability claims involving the Company’s line of hernia repair devices (collectively, the “Hernia Product Claims”). The Company’s outstanding Hernia Product Claims as of September 30, 2024 were approximately 6,610, which reflected a settlement agreement that was consummated in the fourth quarter of fiscal year 2024 to resolve the vast majority of the Company’s existing hernia litigation. The majority of the claims are currently pending in a coordinated proceeding in Rhode Island State Court (“RI”) and in a federal multi-district litigation (“MDL”) established in the Southern District of Ohio, but claims are also pending in other state and/or federal court jurisdictions. In addition, outstanding claims include multiple putative class actions in Canada. Generally, the Hernia Product Claims seek damages for personal injury allegedly resulting from use of the products. The Company believes that it has meritorious defenses and is vigorously defending itself in these matters. There are no trials currently scheduled.
The Company also continues to be a defendant in certain other mass tort litigation. As of December 31, 2024, the Company is defending product liability claims involving the Company’s line of pelvic mesh products, the majority of which are pending in a coordinated proceeding in New Jersey Superior Court and in various federal court jurisdictions, the Company’s line of inferior vena cava (“IVC”) filter products, which are pending in various jurisdictions, and the Company’s line of implantable ports, the majority of which are pending in an MDL in the United States District Court for the District of Arizona. The Company believes that it has meritorious defenses and is vigorously defending itself in these matters.
In most product liability litigations like those described above, plaintiffs allege a wide variety of claims, ranging from allegations of serious injury caused by the products to efforts to obtain compensation notwithstanding the absence of any injury. In many of these cases, the Company has not yet received and reviewed complete information regarding the plaintiffs and their medical conditions and, consequently, is unable to fully evaluate the claims. The Company expects that it will receive and review additional information regarding any remaining unsettled product liability matters.
Other Matters
On November 2, 2020, a putative shareholder derivative action captioned Jankowski v. Forlenza, et al., Civ. No. 2:20-cv-15474, was filed in the U.S. District Court for the District of New Jersey by a shareholder, derivatively on behalf of the Company, against certain of the Company’s directors and officers. The complaint asserts claims for breach of fiduciary duty; violations of sections 10(b), 14(a) and 21D of the Exchange Act, and insider trading. The complaint principally alleges, that the Company made misleading statements regarding AlarisTM infusion pumps in a proxy statement and other SEC filings. A second federal derivative action was filed on January 24, 2021, and the two actions were consolidated and stayed. In March 2021, the Company received letters from two additional shareholders which, in general, mirrored the allegations in the derivative actions, and demanded, among other things, that the Board of Directors pursue claims against members of management for claimed breaches of fiduciary duties. Consistent with New Jersey law, the Board appointed a special committee to review the allegations and demands in the derivative actions and demand letters. Following an investigation, the special committee determined that no action was warranted, and rejected the shareholders’ demands, communicating its determination to counsel for the shareholders. On January 10, 2023, one of the two shareholders referenced above filed a separate derivative action that: (i) is generally consistent with the shareholder letter and the two prior actions; and (ii) purports to challenge the reasonableness of the special committee’s process and determination. That action was also stayed. Following entry of a stipulated scheduling order for an amended complaint and motion to dismiss the consolidated federal action, the case schedule was adjourned without date pending mediation. Mediation proceedings have taken place. On September 10, 2024, the Company received an additional substantially identical shareholder demand letter and on September 26, 2024, that shareholder filed a second substantially identical state court derivative action. In November 2024, the Company entered into an agreement in principle to resolve this matter for an amount that is not expected to be material to the Company’s consolidated financial results.
Beginning in February 2021, the Company received subpoenas from the Enforcement Division of the Securities and Exchange Commission (“SEC”) requesting information from the Company relating to, among other things, certain reporting issues involving BD AlarisTM infusion pumps included in SEC disclosures prior to 2021. In December 2024, the Company reached an agreement to resolve the matter with the SEC for its previously accrued amount of $175 million. In accordance with the terms of the settlement, the Company has engaged and is working with an independent compliance consultant to review practices and procedures relating to the evaluation of product recalls and remediation under U.S. GAAP and its disclosure controls and procedures, including but not limited to controls and procedures relating to collection and assessment of information concerning potential risks, contingencies, operating events, trends, and uncertainties.
In July 2017, C.R. Bard, which was acquired by the Company in December 2017, received a CID from the Department of Justice seeking documents and information relating to an investigation into possible violations of the False Claims Act in connection with the sales and marketing of FloChec® and QuantaFloTM devices. The Company has responded to these requests and met with the Department of Justice in February and July 2024; discussions are ongoing.
In April 2019, the Department of Justice served the Company and CareFusion with CIDs seeking information regarding certain of CareFusion’s contracts with the Department of Veteran’s Affairs, some dating back more than 10 years, for certain products, including AlarisTM and PyxisTM devices, in connection with a civil investigation of possible violations of the False Claims Act, and the government later expanded the investigation to include several additional contracts. The government has made several requests for documents and interviews or depositions of Company personnel and set forth a preliminary case assessment. The Company is cooperating with the government, responding to these requests and evaluating the assessment.
In September 2021, the Company received a CID related to an inquiry initiated by the Department of Justice in the Northern District of Georgia in 2018 concerning sales and marketing practices with respect to certain aspects of the Company’s urology business. After multiple document productions and interviews, the Company and the government mediated the case in an effort to resolve this dispute; an agreement was reached to resolve this matter for an adequately accrued amount that is not material to the Company’s consolidated financial results. This matter is now resolved.
In April 2023, the Department of Justice served the Company with a CID seeking information regarding the Company’s GenesisTM container products in connection with an investigation of possible violations of the False Claims Act. The government has requested documents and set forth a preliminary case assessment, and the Company is cooperating with the government, responding to its requests and evaluating the assessment.
The Company was sued in state and federal courts in Georgia by plaintiffs who work or reside near Company facilities in Covington, GA, where ethylene oxide (“EtO”) sterilization activities take place. The federal cases have been dismissed and refiled in state court. The plaintiffs in the cases seek compensatory and punitive damages. Pursuant to Georgia statute, punitive damages in these cases are generally capped at $250,000 per claimant, unless the plaintiff can prove that the Company acted, or failed to act, with a specific intent to cause harm, which the court to date has cast as a jury issue, meaning that the jury could negate the cap. The cases allege a variety of injuries, including but not limited to multiple types of cancer, allegedly attributable to exposure to EtO. As of December 31, 2024, the Company has approximately 360 of such suits involving approximately 375 plaintiffs asserting individual personal injury claims; approximately 50 of the cases also allege injury caused by exposure to a chemical of another defendant entirely unrelated to the Company. No cases have yet been tried although a trial date has been set for one such case scheduled for April 2025. The Company believes that it has meritorious defenses and is vigorously defending itself in these matters.
In 2015, legislation was enacted in Italy which requires medical technology companies to make payments to the Italian government if Italy’s medical device expenditures exceed annual regional expenditure ceilings. The amount of these payments is based on the amount by which the regional ceilings for the given year were exceeded. Considerable uncertainty has existed regarding the enforceability and implementation of this payback legislation since it was enacted and the Company, as well as other medical device companies, have filed appeals which challenge the enforceability of this legislation. In July 2024, the Italian Constitutional Court issued two judgments which concluded that the medical device payback legislation is constitutional; however, litigation proceedings before Italian Courts are still pending. While the Company recorded $62 million during its fiscal year 2024 as a preliminary estimate of the liability related to this matter, substantially all of which relates to periods prior to fiscal year 2024, ultimate resolution is unknown at this time, and it is possible that the amount of the Company’s liability could differ from the currently accrued amount.

In May 2024, CareFusion 303, Inc., the Company’s subsidiary that manufactures its BD PyxisTM dispensing equipment, received a Form 483 Notice following an inspection from the U.S. Food and Drug Administration (“FDA”) that contained observations of non-conformance with the FDA’s Quality System and Medical Device Reporting (“MDR”) regulations. In November 2024, the Company received a Warning Letter following the inspection of its Dispensing quality management system at its facility located in San Diego, California, citing certain alleged violations of the quality system regulations, MDR regulation, the corrections and removals reporting regulation and law. The Company’s liability recorded for estimated future
costs associated with certain actions required to respond to the Warning Letter and to address the non-conformities was $50 million as of December 31, 2024, which reflected a $22 million adjustment recorded to increase the liability during the first quarter of fiscal year 2025. The Company submitted a comprehensive response to address FDA’s feedback in the Warning Letter, which committed to implementing additional corrective actions; however, no assurances can be given regarding further action by the FDA as a result of the Warning Letter, or that corrective actions proposed and taken by CareFusion 303, Inc. will be adequate to address the Warning Letter. Any failure to adequately address this Warning Letter may result in regulatory actions initiated by the FDA without further notice, which may include, but are not limited to, seizure, injunction and civil monetary penalties. As a result, the ultimate resolution of this Warning Letter and its impact on the Company’s operations is unknown at this time, and it is possible that the amount of the Company’s liability could exceed its currently accrued amount.
The Company is also involved both as a plaintiff and a defendant in other legal proceedings and claims that arise in the ordinary course of business. The Company believes that it has meritorious defenses and is vigorously defending itself in each of these matters.
Except as otherwise noted, the Company cannot predict the outcome of the other legal matters discussed above, nor can it predict whether any outcome will have a material adverse effect on the Company’s consolidated results of operations and/or consolidated cash flows. Further, the Company may not be able to determine if a probable loss exists for certain of the other legal matters discussed above, and accordingly, the Company has recorded no provisions for such matters in its consolidated results of operations.
The Company is a potentially responsible party to a number of federal administrative proceedings in the United States brought under the Comprehensive Environment Response, Compensation and Liability Act, also known as “Superfund,” and similar state laws. The Company also is subject to administrative proceedings under environmental laws in jurisdictions outside the U.S. The affected sites are in varying stages of development. In some instances, the remedy has been completed, while in others, environmental studies are underway or commencing. For several sites, there are other potentially responsible parties that may be jointly or severally liable to pay all or part of cleanup costs. While it is not feasible to predict the outcome of these proceedings, based upon the Company’s experience, current information and applicable law, the Company does not expect these proceedings to have a material adverse effect on its consolidated results of operations and/or consolidated cash flows.
Litigation Accruals
The Company regularly monitors and evaluates the status of product liability and other litigated matters, and may, from time-to-time, engage in settlement discussions and mediations taking into consideration, among other things, developments in the litigation and the risks and uncertainties associated therewith. These activities have resulted in confidential settlements and going forward could result in further settlements, the terms of which may be confidential and could be significant and result in charges in excess of accruals. A determination of the accrual amounts for these contingencies is made after analysis of each litigation matter. When appropriate, the accrual is developed with the consultation of outside counsel and, in the case of certain mass tort litigation, actuarial specialists regarding the nature, timing, and extent of each matter.
During the first quarter of fiscal year 2024, the Company recorded a pre-tax benefit to Other operating expense, net, of approximately $36 million related to certain of the product liability matters discussed above under the heading “Product Liability Matters,” including the related legal defense costs. The benefit primarily reflected the favorable resolution of claims during the fiscal year.
The Company considers relevant information when estimating its product liability accruals, including, but not limited to: the nature, number, and quality of unfiled and filed claims; the rate of claims being filed; the status of settlement discussions with plaintiffs’ counsel; the allegations and documentation supporting or refuting such allegations; publicly available information regarding similar medical device mass tort settlements; historical information regarding other product liability settlements involving the Company; and the stage of litigation. Because currently available information regarding product liability matters is often limited, there is inherent uncertainty and volatility relating to the Company’s estimate of product liability. As additional information becomes available, the Company records adjustments to its product liability accruals as required.
Accruals for the Company's product liability claims which are discussed above, as well as the related legal defense costs, amounted to approximately $1.6 billion and $1.7 billion at December 31, 2024 and September 30, 2024, respectively. These accruals are recorded within Payables, accrued expenses and other current liabilities and Deferred Income Taxes and Other Liabilities on the Company's condensed consolidated balance sheets. The decrease in the Company’s product liability accrual as of December 31, 2024, as compared with September 30, 2024, largely reflected reductions due to the payment of settlements and legal fees. The increase in the number of outstanding hernia repair device claims discussed above did not materially impact the Company’s product liability accrual because the underlying estimate of the Company’s liability includes and already accounts for unfiled claims. Moreover, the accrual reflects the determination that the quality of new hernia report device claims has generally diminished over time. Amounts payable pursuant to the settlement agreement that was consummated in the fourth
quarter of fiscal year 2024 to resolve the vast majority of the Company’s hernia litigation are included within the Company's current product liability accrual and will be paid out over a multi-year period. Claim activity during the first quarter of fiscal year 2025 relating to the pelvic mesh device and IVC filter matters did not materially impact the Company’s product liability accrual as of December 31, 2024.
The particular outcome in any one product liability trial is typically not representative of potential outcomes of all cases or claims. Because the accrual already contemplates a wide range of possible outcomes, including those with a de minimis value, individual outcomes generally do not impact the value of other cases in the total case inventory or the overall product liability accrual.
In view of the uncertainties discussed above, the Company could incur charges in excess of any currently established accruals and, to the extent available, liability insurance. In the opinion of management, any such future charges, individually or in the aggregate, could have a material adverse effect on the Company’s consolidated results of operations, financial condition, and/or consolidated cash flows.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenues
 3 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
Revenues Revenues
The Company’s policies for recognizing sales have not changed from those described in the Company’s 2024 Annual Report on Form 10-K. The Company sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products which are distributed through independent distribution channels and directly by BD through sales representatives. End-users of the Company's products include healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. In the current and prior-year periods, the Company generated revenues attributable to licensing, which includes consideration received in exchange for the use of BD intellectual property by third parties.
Measurement of Revenues
The Company’s allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of its trade receivables. Such estimated credit losses are determined based on historical loss experiences, customer-specific credit risk, and reasonable and supportable forward-looking information, such as country or regional risks that are not captured in the historical loss information. The allowance for doubtful accounts for trade receivables is not material to the Company's consolidated financial results.
The Company's gross revenues are subject to a variety of deductions which are recorded in the same period that the underlying revenues are recognized. Such variable consideration includes rebates, sales discounts and sales returns. The Company’s rebate liabilities are classified as an offset to Trade receivables, net, or as Payables, accrued expenses and other current liabilities, depending on the form of settlement and were $813 million and $749 million at December 31, 2024 and September 30, 2024, respectively. The impact of other forms of variable consideration, including sales discounts and sales returns, is not material to the Company's revenues.
Effects of Revenue Arrangements on Condensed Consolidated Balance Sheets
Capitalized contract costs associated with the costs to fulfill contracts for certain products in the Medication Management Solutions organizational unit are immaterial to the Company's condensed consolidated balance sheets. Commissions relating to revenues recognized over a period longer than one year are recorded as assets which are amortized over the period over which the revenues underlying the commissions are recognized. Capitalized contract costs related to such commissions are immaterial to the Company's condensed consolidated balance sheets.
Contract liabilities for unearned revenue that is allocable to performance obligations, such as extended warranty and software maintenance contracts, which are performed over time, were approximately $502 million and $482 million as of December 31, 2024 and September 30, 2024, respectively, and are included in Payables, accrued expenses and other current liabilities on the Company’s condensed consolidated balance sheets. The Company's liability for product warranties provided under its agreements with customers is not material to its condensed consolidated balance sheets.
Remaining Performance Obligations
The Company's obligations relative to service contracts and pending installations of equipment, primarily in the Company's Medication Management Solutions unit, represent unsatisfied performance obligations of the Company. The revenues under existing contracts with original expected durations of more than one year, which are attributable to products and/or services that have not yet been installed or provided are estimated to be approximately $2.3 billion at December 31, 2024. The Company expects to recognize the majority of this revenue over the next three years.
Within the Company's Medication Management Solutions, Medication Delivery Solutions, Diagnostic Solutions, and Biosciences units, some contracts also contain minimum purchase commitments of reagents or other consumables, and the future sales of these consumables represent additional unsatisfied performance obligations of the Company. The revenue attributable to the unsatisfied minimum purchase commitment-related performance obligations, for contracts with original expected durations of more than one year, is estimated to be approximately $2.0 billion at December 31, 2024. This revenue will be recognized over the customer relationship periods.
Disaggregation of Revenues
A disaggregation of the Company's revenues by segment, organizational unit and geographic region is provided in Note 7.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Data
 3 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Segment Data Segment Data
The Company's organizational structure is based upon three worldwide business segments: BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional (“Interventional”). The Company's segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services. Segment disclosures are on a performance basis consistent with internal management reporting. The Company evaluates performance of its business segments and allocates resources to them primarily based upon segment operating income, which represents revenues reduced by product costs and operating expenses.
Revenues by segment, organizational unit and geographical areas for the three-month periods are detailed below. The Company has no material intersegment revenues.
Three Months Ended December 31,
(Millions of dollars)20242023
United StatesInternationalTotalUnited StatesInternationalTotal
Medical
Medication Delivery Solutions$694 $430 $1,124 $639 $413 $1,052 
Medication Management Solutions659 142 801 594 153 747 
Pharmaceutical Systems104 314 418 127 304 431 
Advanced Patient Monitoring159 113 271 — — — 
Total segment revenues$1,615 $999 $2,615 $1,360 $870 $2,230 
Life Sciences
Specimen Management (a)$238 $223 $462 $234 $213 $447 
Diagnostic Solutions (a)212 262 474 210 256 467 
Biosciences153 208 361 143 232 375 
Total segment revenues$603 $694 $1,297 $587 $701 $1,288 
Interventional
Surgery$303 $92 $395 $280 $88 $369 
Peripheral Intervention253 220 473 234 220 454 
Urology and Critical Care306 83 389 287 78 365 
Total segment revenues$861 $396 $1,257 $802 $386 $1,188 
Total Company revenues$3,080 $2,089 $5,168 $2,749 $1,957 $4,706 
(a)    During the first quarter of fiscal year 2025, Life Sciences split its former Integrated Diagnostic Solutions organizational unit into two units to better align BD resources with the distinct needs of each business.
Segment income for the three-month periods was as follows:
 Three Months Ended
December 31,
(Millions of dollars)20242023
Income Before Income Taxes
Medical$492 $535 
Life Sciences383 372 
Interventional387 291 
Total Segment Operating Income1,263 1,198 
Integration, restructuring and transaction expense(92)(75)
Net interest expense (132)(77)
Other unallocated items (a)(733)(688)
Total Income Before Income Taxes$306 $359 
(a)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.25.0.1
Benefit Plans
 3 Months Ended
Dec. 31, 2024
Retirement Benefits [Abstract]  
Benefit Plans Benefit Plans
The Company has defined benefit pension plans covering certain employees in the United States and certain international locations. The measurement date used for these plans is September 30.
Net pension cost included the following components for the three-month periods:
 Three Months Ended
December 31,
(Millions of dollars)20242023
Service cost$12 $25 
Interest cost42 39 
Expected return on plan assets(56)(42)
Amortization of prior service credit— (1)
Amortization of loss10 16 
Net pension cost$8 $37 
The amounts provided above for amortization of prior service credit and amortization of loss represent the reclassifications of prior service credits and net actuarial losses that were recognized in Accumulated other comprehensive income (loss) in prior periods. All components of the Company’s net periodic pension and postretirement benefit costs, aside from service cost, are recorded to Other expense, net on its condensed consolidated statements of income.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.25.0.1
Acquisition
 3 Months Ended
Dec. 31, 2024
Business Combinations [Abstract]  
Acquisition Acquisition
Advanced Patient Monitoring
On September 3, 2024, the Company completed its acquisition of Edwards Lifesciences’ Critical Care product group (“Critical Care”), which was renamed as BD Advanced Patient Monitoring (“Advanced Patient Monitoring”). Since the acquisition date, financial results for Advanced Patient Monitoring’s product offerings are being reported as a separate organizational unit within the Medical segment. Advanced Patient Monitoring is a global leader in advanced monitoring solutions that expands the Company’s portfolio of smart connected care solutions with its growing set of leading monitoring technologies, advanced AI-enabled clinical decision tools and robust innovation pipeline that complement the Company's existing technologies serving operating rooms and intensive care units. The Company funded the transaction with cash on hand, using net proceeds raised through debt issuances in the third quarter of fiscal year 2024 and borrowings under its commercial paper program. The acquisition was accounted for under the acquisition method of accounting for business combinations.
The Company is in the process of finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed, related to assessing certain assumptions underlying the valuation of intangible assets. The preliminary allocations of the purchase price provide a reasonable basis for estimating the fair values of assets acquired and liabilities assumed. These provisional estimates may be adjusted upon the availability of further information regarding events or circumstances that existed at the acquisition date. Such adjustments may be significant. The fair value of consideration transferred in connection with the acquisition was $3.906 billion. As of December 31, 2024, the assets acquired and the liabilities assumed in this acquisition included developed technology intangible assets of $717 million, customer relationships intangible assets of $653 million and $713 million of other net assets, which are primarily inventory. The goodwill recorded from the excess of the purchase price over the fair value of the acquired net assets was $1.823 billion, which related to synergies expected to be gained from combining operations of the acquiree and acquirer, as well as revenue and cash flow projections associated with future innovative technologies expected to occur. The preliminary estimate of the goodwill that is expected to be deductible for tax purposes is approximately $1.1 billion.
The Company included Advanced Patient Monitoring in its consolidated results of operations beginning on September 3, 2024. The Company’s unaudited pro forma Revenues for the three months ended December 31, 2023, giving effect as if Advanced Patient Monitoring had been acquired as of October 1, 2022, were $4.957 billion. The calculation of pro forma Net Income for the three months ended December 31, 2023 is not practicable because of complexities associated with its hypothetical calculation.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.25.0.1
Business Restructuring Charges
 3 Months Ended
Dec. 31, 2024
Restructuring and Related Activities [Abstract]  
Business Restructuring Charges Business Restructuring Charges
The Company incurred restructuring costs during the three months ended December 31, 2024, primarily in connection with the Company's simplification and other cost-saving initiatives, which were recorded within Integration, restructuring and transaction expense. These simplification and other cost-saving initiatives are focused on reducing complexity, optimizing the Company’s supply chain efficiency, streamlining its global manufacturing footprint, enhancing product quality, refining customer experience, and improving cost efficiency across all of the Company’s segments.
Restructuring liability activity for the three months ended December 31, 2024 was as follows:
(Millions of dollars)Employee
Termination
Other (a)
Total
Balance at September 30, 2024$58 $2 $60 
Charged to expense20 46 66 
Cash payments(29)(36)(65)
Non-cash settlements— (6)(6)
Other adjustments(2)— (2)
Balance at December 31, 2024$47 $6 $53 
(a)    Other non-employee-related expenses primarily relate to other costs associated with the execution of the Company’s cost efficiency and restructuring programs, such as incremental project management costs and facility exit costs.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.25.0.1
Intangible Assets
 3 Months Ended
Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets Intangible Assets
Intangible assets consisted of:
 December 31, 2024September 30, 2024
(Millions of dollars)Gross
Carrying
Amount		Accumulated
Amortization		Net Carrying AmountGross
Carrying
Amount		Accumulated
Amortization		Net Carrying Amount
Amortized intangible assets
Developed technology$15,788 $(8,349)$7,439 $15,827 $(8,094)$7,733 
Customer relationships5,511 (2,978)2,533 5,513 (2,878)2,635 
Patents, trademarks and other1,188 (688)500 1,185 (682)503 
Amortized intangible assets$22,486 $(12,014)$10,472 $22,525 $(11,654)$10,871 
Unamortized intangible assets
Acquired in-process research and development$14 $44 
Trademarks2 2 
Unamortized intangible assets$16 $46 
Intangible amortization expense was $395 million and $365 million for the three months ended December 31, 2024 and 2023, respectively.
The following is a reconciliation of goodwill by business segment:
(Millions of dollars)Medical Life SciencesInterventional Total
Goodwill as of September 30, 2024$12,832 $904 $12,729 $26,465 
Purchase price allocation adjustments(12)— — (12)
Currency translation(51)(8)(66)(125)
Goodwill as of December 31, 2024$12,769 $896 $12,663 $26,329 
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.25.0.1
Derivative Instruments and Hedging Activities
 3 Months Ended
Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Instruments and Hedging Activities Derivative Instruments and Hedging Activities
The Company uses derivative instruments to mitigate certain exposures. The Company does not enter into derivative financial instruments for trading or speculative purposes. The effects these derivative instruments and hedged items had on the Company’s balance sheets and the fair values of the derivatives outstanding at December 31, 2024 and September 30, 2024 were not material. The effects on the Company’s financial performance and cash flows are provided below.
Foreign Currency Risks and Related Strategies
The Company has foreign currency exposures throughout Europe, Greater Asia, Canada and Latin America. Transactional currency exposures that arise from entering into transactions, generally on an intercompany basis, in non-hyperinflationary countries that are denominated in currencies other than the functional currency are mitigated primarily through the use of forward contracts.
In order to mitigate transactional foreign currency exposures resulting from anticipated intercompany purchases and sales denominated in a currency other than local functional currencies, the Company has hedged a portion of this currency risk with certain instruments such as foreign exchange forward and option contracts, which are designated as cash flow hedges.
In order to mitigate foreign currency exposure relating to its investments in certain foreign subsidiaries, the Company has hedged the currency risk associated with those investments with certain instruments, such as foreign currency-denominated debt and cross-currency swaps, which are designated as net investment hedges, as well as currency exchange contracts.
The notional amounts of the Company’s foreign currency-related derivative instruments as of December 31, 2024 and September 30, 2024 were as follows:
(Millions of dollars)Hedge DesignationDecember 31, 2024September 30, 2024
Foreign exchange contracts (a)Undesignated$2,366 $4,521 
Foreign exchange contracts (b)Cash flow hedges394 543 
Foreign currency-denominated debt (c)Net investment hedges2,874 3,065 
Cross-currency swaps (d)Net investment hedges1,022 1,366 
(a)Represents hedges of transactional foreign exchange exposures resulting primarily from intercompany payables and receivables. Gains and losses on these instruments are recognized immediately in income. These gains and losses are largely offset by gains and losses on the underlying hedged items, as well as the hedging costs associated with the derivative instruments. Net amounts recognized in Other expense, net, during the three months ended December 31, 2024 and 2023 were immaterial to the Company's consolidated financial results.
(b)Represents foreign exchange contracts related to anticipated intercompany purchases and sales, described above, which generally have durations of less than eighteen months.
(c)Represents foreign currency-denominated long-term notes outstanding which were effective as economic hedges of net investments in certain of the Company's foreign subsidiaries.
(d)Represents cross-currency swaps, which were effective as economic hedges of net investments in certain of the Company's foreign subsidiaries.
Net gains or losses resulting from the change in fair value of the foreign exchange contracts designated as cash flow hedges are initially recorded within Other comprehensive income (loss) and reclassified into earnings upon the occurrence of the related underlying third-party transaction. If foreign exchange contracts designated as cash flow hedges are terminated prematurely as a result of the hedged transaction being probable of not occurring, the balance in Accumulated other comprehensive income (loss) attributable to those derivatives is immediately reclassified into Revenues or Cost of products sold (depending on whether the hedged item is an intercompany sale or purchase). Net after tax losses recognized in Other comprehensive income (loss) as well as amounts reclassified from Accumulated other comprehensive income (loss) into earnings relating to these cash flow hedges during the three months ended December 31, 2024 were immaterial. No amounts relating to foreign exchange contracts designated as cash flow hedges were recognized in Other comprehensive income (loss) or reclassified from Accumulated other comprehensive income (loss) during three months ended December 31, 2023. The amounts expected to be reclassified from accumulated other comprehensive income into earnings within the next 12 months, are not material to the Company's consolidated financial results.
Net gains or losses relating to the net investment hedges, which are attributable to changes in the foreign currencies to U.S. dollar spot exchange rates, are recorded as foreign currency translation in Other comprehensive income (loss), net of tax. Upon the termination of a net investment hedge, any net gain or loss included in Accumulated other comprehensive income (loss) relative to the investment hedge remains until the foreign subsidiary investment is disposed of or is substantially liquidated.
Net gains (losses) recorded to Accumulated other comprehensive income (loss) relating to the Company's net investment hedges for the three-month periods were as follows:
 Three Months Ended
December 31,
(Millions of dollars)20242023
Foreign currency-denominated debt$145 $(29)
Cross-currency swaps (a)67 (55)
(a) The amount for the three months ended December 31, 2024 includes a loss, net of tax, of $18 million recognized on terminated cross-currency swaps.
Interest Rate Risks and Related Strategies
The Company uses a mix of fixed and variable rate debt to manage its interest rate exposure, and periodically uses interest rate swaps to manage such exposures. Under these interest rate swaps, the Company exchanges, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. These swaps are designated as either cash flow or fair value hedges.
Changes in the fair value of the interest rate swaps designated as cash flow hedges (i.e., hedging the exposure to variability in expected future cash flows that is attributable to a particular risk) are recorded in Other comprehensive income (loss), net of tax. If interest rate derivatives designated as cash flow hedges are terminated, the balance in Accumulated other comprehensive income (loss) attributable to those derivatives is reclassified into earnings, within Interest expense, over the remaining life of the hedged debt.
For interest rate swaps designated as fair value hedges (i.e., hedges against the exposure to changes in the fair value of an asset or a liability or an identified portion thereof that is attributable to a particular risk), changes in the fair value of the interest rate swaps offset changes in the fair value of the fixed rate debt due to changes in market interest rates. Amounts recorded during the three months ended December 31, 2024 and 2023 were immaterial to the Company's consolidated financial results.
The notional amounts of the Company’s interest rate-related derivative instruments as of December 31, 2024 and September 30, 2024 were as follows:
(Millions of dollars)Hedge DesignationDecember 31, 2024September 30, 2024
Interest rate swaps (a)Fair value hedges$700 $700 
(a)Represents fixed-to-floating interest rate swap agreements the Company entered into to convert the interest payments on certain long-term notes from the fixed rate to a floating interest rate based on secured overnight financing rates (“SOFR”).
Other Risk Exposures
The Company purchases resins, which are oil-based components used in the manufacture of certain products. Significant increases in world oil prices that lead to increases in resin purchase costs could impact future operating results. From time to time, the Company has managed price risks associated with these commodity purchases through commodity derivative forward contracts. The Company's commodity derivative forward contracts at December 31, 2024 and September 30, 2024 were immaterial to the Company's consolidated financial results.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments and Fair Value Measurements
 3 Months Ended
Dec. 31, 2024
Fair Value Disclosures [Abstract]  
Financial Instruments and Fair Value Measurements Financial Instruments and Fair Value Measurements
The following reconciles cash and equivalents and restricted cash reported within the Company's condensed consolidated balance sheets at December 31, 2024 and September 30, 2024 to the total of these amounts shown on the Company's condensed consolidated statements of cash flows:
(Millions of dollars)December 31, 2024September 30, 2024
Cash and equivalents$711 $1,717 
Restricted cash102 139 
Cash and equivalents and restricted cash$813 $1,856 
Cash equivalents consist of all highly liquid investments with a maturity of three months or less at time of purchase. Restricted cash consists of cash restricted from withdrawal and usage except for certain product liability matters.
The fair values of the Company’s financial instruments are as follows:
(Millions of dollars)Basis of fair value measurementDecember 31, 2024September 30, 2024
Institutional money market accounts (a)Level 1$— $285 
Current portion of long-term debt (b)Level 2831 1,748 
Long-term debt (b)Level 216,337 17,199 
(a)These financial instruments are recorded within Cash and equivalents on the condensed consolidated balance sheets. The institutional money market accounts permit daily redemption. The fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions.
(b)Long-term debt is recorded at amortized cost. The fair value of long-term debt is measured based upon quoted prices in active markets for similar instruments.
Short-term investments are held to their maturities and are carried at cost, which approximates fair value. The short-term investments primarily consist of time deposits with maturities greater than three months and less than one year. All other
instruments measured by the Company at fair value, including derivatives, contingent consideration liabilities and available-for-sale debt securities, are immaterial to the Company's condensed consolidated balance sheets.
Nonrecurring Fair Value Measurements
In the first quarter of fiscal year 2025, the Company recorded a non-cash asset impairment charge of $30 million to Research and development expense to write down the carrying value of certain assets in the Life Sciences segment. The amount recognized was recorded to adjust the carrying amount of assets to the assets' fair values, which were estimated, based upon a market participant's perspective, using Level 3 measurements, including values estimated using the income approach.
Transfers of Trade Receivables
Over the normal course of its business activities, the Company transfers certain trade receivable assets to third parties under factoring agreements. Per the terms of these agreements, the Company surrenders control over its trade receivables upon transfer. Accordingly, the Company accounts for the transfers as sales of trade receivables by recognizing an increase to Cash and equivalents and a decrease to Trade receivables, net when proceeds from the transactions are received. The costs incurred by the Company in connection with factoring activities were not material to its consolidated financial results. The amounts transferred and yet to be remitted under factoring arrangements are provided below.
Three Months Ended December 31,
(Millions of dollars)20242023
Trade receivables transferred to third parties under factoring arrangements$360 $379 
December 31, 2024September 30, 2024
Amounts yet to be collected and remitted to the third parties$338 $254 
Supplier Finance Programs
The Company has agreements where participating suppliers are provided the ability to receive early payment of the Company’s obligations at a nominal discount through supplier finance programs entered into with third party financial institutions. The Company is not a party to these arrangements, and these programs do not impact the Company’s obligations or affect the Company’s payment terms, which generally range from 90 to 150 days. The agreements with the financial institutions do not require the Company to provide assets pledged as security or other forms of guarantees for the supplier finance programs. The Company had $118 million and $112 million of outstanding payables related to supplier finance programs as of December 31, 2024 and September 30, 2024, respectively, which were recorded within Payables, accrued expenses and other current liabilities on the Company's condensed consolidated balance sheets.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.25.0.1
Income Taxes
 3 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
Income Tax Expense
The Company’s effective income tax rates for the three months ended December 31, 2024 and 2023 were 0.9% and 21.6%, respectively. The decrease in the Company’s effective tax rate for the three months ended December 31, 2024 was largely due to the partial release of the valuation allowance established for a non-U.S. tax credit.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.25.0.1
Subsequent Events
 3 Months Ended
Dec. 31, 2024
Subsequent Events [Abstract]  
Subsequent Events Subsequent Event
BD’s Intention to Separate Biosciences and Diagnostic Solutions
On February 5, 2025, the Company announced its intention to separate its Biosciences and Diagnostic Solutions business from the rest of the Company. The Company expects to announce more specifics on the separation plans by the end of fiscal year 2025 and intends to target completion of the transaction in fiscal year 2026. The completion of any separation transaction will be contingent upon various conditions and approvals, including approval of the Company’s board of directors, receipt of requisite regulatory clearances and compliance with applicable SEC requirements. No assurance can be given regarding the form that a separation transaction may take or the specific terms or timing, or that a separation will in fact occur.
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.25.0.1
Pay vs Performance Disclosure - USD ($)
$ in Millions
 3 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Pay vs Performance Disclosure    
Net Income $ 303 $ 281
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.25.0.1
Insider Trading Arrangements
 3 Months Ended
Dec. 31, 2024
shares
Trading Arrangements, by Individual  
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
Richard Byrd [Member]  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement
On December 11, 2024, Richard Byrd, Executive Vice President and President, Interventional Segment of BD, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Byrd’s plan is for (i) the exercise of up to 15,061 stock appreciation rights (“SARs”) at various exercise prices, net of shares withheld to satisfy applicable taxes, (ii) the sale of up to 2,399 shares of BD’s common stock, (iii) the sale of up to 1,123 shares of BD’s common stock upon the vesting of time vested units (“TVUs”), net of shares withheld to satisfy applicable taxes, and (iv) the sale of up to 1,590 shares of BD’s common stock upon the vesting of performance units, subject to the final payout factor and net of shares withheld to satisfy applicable taxes. The foregoing exercises or sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and March 15, 2026.
Name Richard Byrd
Title Executive Vice President and President, Interventional Segment of BD
Rule 10b5-1 Arrangement Adopted true
Adoption Date December 11, 2024
Expiration Date March 15, 2026
Antoine Ezell [Member]  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement
On December 16, 2024, Antoine Ezell, Executive Vice President, President of the Americas and Chief Marketing Officer of BD, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Ezell’s plan is for the sale of up to 3,900 shares of BD’s common stock. The sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and March 17, 2026.
Name Antoine Ezell
Title Executive Vice President, President of the Americas and Chief Marketing Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date December 16, 2024
Expiration Date March 17, 2026
Richard Byrd, Trading Arrangement, Stock Appreciation Rights [Member] | Richard Byrd [Member]  
Trading Arrangements, by Individual  
Aggregate Available 15,061
Richard Byrd, Trading Arrangement, Common Stock [Member] | Richard Byrd [Member]  
Trading Arrangements, by Individual  
Aggregate Available 2,399
Richard Byrd, Trading Arrangement, Common Stock Upon The Vesting Of Time Vested Units [Member] | Richard Byrd [Member]  
Trading Arrangements, by Individual  
Aggregate Available 1,123
Richard Byrd, Trading Arrangement, Common Stock Upon The Vesting Of Performance Units [Member] | Richard Byrd [Member]  
Trading Arrangements, by Individual  
Aggregate Available 1,590
Antoine Ezell, Trading Arrangement, Common Stock [Member] | Antoine Ezell [Member]  
Trading Arrangements, by Individual  
Aggregate Available 3,900
Officer Trading Arrangement [Member] | Richard Byrd [Member]  
Trading Arrangements, by Individual  
Arrangement Duration 459 days
Officer Trading Arrangement [Member] | Antoine Ezell [Member]  
Trading Arrangements, by Individual  
Arrangement Duration 456 days
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.25.0.1
Accounting Changes (Policies)
 3 Months Ended
Dec. 31, 2024
Accounting Changes and Error Corrections [Abstract]  
New Accounting Principle Adopted and New Accounting Principles Not Yet Adopted
New Accounting Principles Not Yet Adopted
In November 2024, the Financial Accounting Standards Board (“FASB”) issued an accounting standard update that requires the Company to disclose more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in each relevant income statement expense caption. The update is effective for the Company beginning with its fiscal year 2028 reporting and for interim reporting beginning with its fiscal year 2029. Early adoption is permitted. The Company is currently evaluating the impact that this update will have on its disclosures.
In December 2023, the FASB issued an accounting standard update that requires more disaggregated information to be included in the income tax rate reconciliation and income taxes paid annual disclosures. This update is effective for the Company beginning in its fiscal year 2026 and the Company is currently evaluating the impact that this update will have on its disclosures.
In November 2023, the FASB issued a new accounting standard update that requires more disaggregated expense information about a public entity’s reportable segments. This update is effective for the Company beginning with its fiscal year 2025 reporting and for interim reporting beginning with its fiscal year 2026. The Company is currently evaluating the impact that this update will have on its disclosures.
Contingencies
The Company is involved, both as a plaintiff and a defendant, in various legal proceedings that arise in the ordinary course of business, including, without limitation, product liability and environmental matters in certain U.S. and international locations. Given the uncertain nature of litigation generally, the Company is not able, in all cases, to reasonably estimate the amount or range of loss that could result from an unfavorable outcome of litigation in which the Company is a party. Even if the Company believes it has meritorious defenses, from time to time the Company engages in settlement discussions and mediations and considers settlements taking into account various factors including, among other things, developments in such legal proceedings
and the resulting risks and uncertainties. These activities have resulted in settlements for certain matters and going forward could result in further settlements, which may be confidential and could be significant and result in charges in excess of accruals.
In accordance with U.S. GAAP, the Company establishes accruals to the extent future losses are probable and reasonably estimable. With respect to putative class action lawsuits and certain tort actions in the United States and certain of the Canadian lawsuits described below or in its other SEC filings, the Company may not be able to determine if a probable loss exists or estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; (ii) the Company has not received and reviewed complete information regarding all or certain of the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, there is uncertainty as to the likelihood of a class being certified or the ultimate size of any class. With respect to certain of the civil investigative demands (“CIDs”) served by the Department of Justice which are discussed below, the Company may not be able to determine if a probable loss exists, unless otherwise noted, for the following reasons: (i) all or certain of the proceedings are in early stages; and/or (ii) there are significant factual and legal issues to be resolved.
In view of the uncertainties discussed above, the Company could incur charges in excess of any currently established accruals and, to the extent available, liability insurance. In the opinion of management, any such future charges, individually or in the aggregate, could have a material adverse effect on the Company’s consolidated results of operations, financial condition, and/or consolidated cash flows.
Revenues
Measurement of Revenues
The Company’s allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of its trade receivables. Such estimated credit losses are determined based on historical loss experiences, customer-specific credit risk, and reasonable and supportable forward-looking information, such as country or regional risks that are not captured in the historical loss information. The allowance for doubtful accounts for trade receivables is not material to the Company's consolidated financial results.
The Company's gross revenues are subject to a variety of deductions which are recorded in the same period that the underlying revenues are recognized. Such variable consideration includes rebates, sales discounts and sales returns.
Derivative Instruments and Hedging Activities The Company uses derivative instruments to mitigate certain exposures. The Company does not enter into derivative financial instruments for trading or speculative purposes.
The Company uses a mix of fixed and variable rate debt to manage its interest rate exposure, and periodically uses interest rate swaps to manage such exposures. Under these interest rate swaps, the Company exchanges, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. These swaps are designated as either cash flow or fair value hedges.
Changes in the fair value of the interest rate swaps designated as cash flow hedges (i.e., hedging the exposure to variability in expected future cash flows that is attributable to a particular risk) are recorded in Other comprehensive income (loss), net of tax. If interest rate derivatives designated as cash flow hedges are terminated, the balance in Accumulated other comprehensive income (loss) attributable to those derivatives is reclassified into earnings, within Interest expense, over the remaining life of the hedged debt.
For interest rate swaps designated as fair value hedges (i.e., hedges against the exposure to changes in the fair value of an asset or a liability or an identified portion thereof that is attributable to a particular risk), changes in the fair value of the interest rate swaps offset changes in the fair value of the fixed rate debt due to changes in market interest rates.
Cash Equivalents Cash equivalents consist of all highly liquid investments with a maturity of three months or less at time of purchase.
Restricted Cash Restricted cash consists of cash restricted from withdrawal and usage except for certain product liability matters.
Financial Instruments and Fair Value Measurements The fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions.Long-term debt is recorded at amortized cost. The fair value of long-term debt is measured based upon quoted prices in active markets for similar instruments.Short-term investments are held to their maturities and are carried at cost, which approximates fair value. The short-term investments primarily consist of time deposits with maturities greater than three months and less than one year.
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.25.0.1
Shareholders' Equity (Tables)
 3 Months Ended
Dec. 31, 2024
Stockholders' Equity Note [Abstract]  
Schedule of Shareholders Equity
Changes in certain components of shareholders' equity for the first quarters of fiscal years 2025 and 2024 were as follows:
 Common
Stock  Issued
at Par Value		Capital in
Excess of
Par Value		Retained
Earnings		Deferred
Compensation		Treasury Stock
(Millions of dollars)Shares (in
thousands)		Amount
Balance at September 30, 2024$371 $19,893 $16,139 $25 (81,493)$(8,807)
Net income— — 303 — — — 
Common dividends ($1.04 per share)
— — (302)— — — 
Issuance of shares under employee and other plans, net— (65)— — 679 (12)
Share-based compensation— 90 — — — — 
Common stock held in trusts, net (a)— — — — (8)— 
Repurchase of common stock— (150)— — (2,637)(606)
Balance at December 31, 2024$371 $19,768 $16,141 $25 (83,459)$(9,425)
 Common
Stock  Issued
at Par Value		Capital in
Excess of
Par Value		Retained
Earnings		Deferred
Compensation		Treasury Stock
(Millions of dollars)Shares (in
thousands)		Amount
Balance at September 30, 2023$371 $19,720 $15,535 $24 (80,203)$(8,305)
Net income— — 281 — — — 
Common dividends ($0.95 per share)
— — (275)— — — 
Issuance of shares under employee and other plans, net— (62)— — 647 (20)
Share-based compensation— 83 — — — — 
Common stock held in trusts, net (a)— — — — (19)— 
Repurchase of common stock— — — — (2,118)(503)
Balance at December 31, 2023$371 $19,741 $15,540 $24 (81,692)$(8,828)
(a)Common stock held in trusts consists of the Company’s shares held in rabbi trusts in connection with deferred compensation under the Company’s employee salary and bonus deferral plan and directors’ deferral plan.
Accelerated Share Repurchases The impacts of these accelerated share repurchase transactions were as follows:
Execution DateSettlement DateAggregate Common Stock Repurchased (millions of dollars) (a)Initial Shares Delivered (in thousands)Additional Shares Delivered at Settlement (in thousands) (b)Total Shares Delivered (in thousands)
Q1 2025Q2 2025$750 2,637 619 3,256 
(a)    Excludes a 1% excise tax on share repurchases of $6 million.
(b)    Upon final settlement of the repurchase agreement and the forward sale contract, the Company’s receipt of additional shares was recorded as an increase to Common stock in treasury and an offsetting increase to Capital in excess of par value. The final settlement for the first quarter transaction amounted to $150 million.
Schedule of Accumulated Other Comprehensive Income (Loss)
The components and changes of Accumulated other comprehensive income (loss) for the first quarters of fiscal years 2025 and 2024 were as follows:
(Millions of dollars)TotalForeign Currency
Translation		Benefit Plans
Cash Flow Hedges		Available-for-Sale Debt Securities
Balance at September 30, 2024$(1,732)$(1,244)$(557)$70 $(1)
Other comprehensive income before reclassifications, net of taxes49 46 — 3 — 
Amounts reclassified into income, net of taxes6 — 8 (2)— 
Balance at December 31, 2024$(1,676)$(1,199)$(549)$72 $(1)
(Millions of dollars)TotalForeign Currency
Translation		Benefit Plans
Cash Flow Hedges		Available-for-Sale Debt Securities
Balance at September 30, 2023$(1,548)$(1,078)$(571)$103 $— 
Other comprehensive income (loss) before reclassifications, net of taxes21 40 — (19)— 
Amounts reclassified into income, net of taxes12 — 12 1 — 
Balance at December 31, 2023$(1,515)$(1,038)$(559)$84 $— 
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.25.0.1
Earnings per Share (Tables)
 3 Months Ended
Dec. 31, 2024
Earnings Per Share [Abstract]  
Weighted Average Common Shares Used in Computations of Basic and Diluted Earnings Per Share
The weighted average common shares used in the computations of basic and diluted earnings per share (shares in thousands) were as follows:
 Three Months Ended
December 31,
 20242023
Average common shares outstanding289,505 290,113 
Dilutive share equivalents from share-based plans884 1,285 
Average common and common equivalent shares outstanding – assuming dilution290,389 291,398 
Share equivalents excluded from the diluted shares outstanding calculation:
Share-based plans (a)2,758 552 
(a)Excluded from the diluted earnings per share calculation as the exercise prices of these awards were greater than the average market price of the Company’s common shares.
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Data (Tables)
 3 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Revenue from External Customers by Geographic Area
Revenues by segment, organizational unit and geographical areas for the three-month periods are detailed below. The Company has no material intersegment revenues.
Three Months Ended December 31,
(Millions of dollars)20242023
United StatesInternationalTotalUnited StatesInternationalTotal
Medical
Medication Delivery Solutions$694 $430 $1,124 $639 $413 $1,052 
Medication Management Solutions659 142 801 594 153 747 
Pharmaceutical Systems104 314 418 127 304 431 
Advanced Patient Monitoring159 113 271 — — — 
Total segment revenues$1,615 $999 $2,615 $1,360 $870 $2,230 
Life Sciences
Specimen Management (a)$238 $223 $462 $234 $213 $447 
Diagnostic Solutions (a)212 262 474 210 256 467 
Biosciences153 208 361 143 232 375 
Total segment revenues$603 $694 $1,297 $587 $701 $1,288 
Interventional
Surgery$303 $92 $395 $280 $88 $369 
Peripheral Intervention253 220 473 234 220 454 
Urology and Critical Care306 83 389 287 78 365 
Total segment revenues$861 $396 $1,257 $802 $386 $1,188 
Total Company revenues$3,080 $2,089 $5,168 $2,749 $1,957 $4,706 
(a)    During the first quarter of fiscal year 2025, Life Sciences split its former Integrated Diagnostic Solutions organizational unit into two units to better align BD resources with the distinct needs of each business.
Financial Information for Company's Segments
Segment income for the three-month periods was as follows:
 Three Months Ended
December 31,
(Millions of dollars)20242023
Income Before Income Taxes
Medical$492 $535 
Life Sciences383 372 
Interventional387 291 
Total Segment Operating Income1,263 1,198 
Integration, restructuring and transaction expense(92)(75)
Net interest expense (132)(77)
Other unallocated items (a)(733)(688)
Total Income Before Income Taxes$306 $359 
(a)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense.
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.25.0.1
Benefit Plans (Tables)
 3 Months Ended
Dec. 31, 2024
Retirement Benefits [Abstract]  
Net Pension and Postretirement Cost
Net pension cost included the following components for the three-month periods:
 Three Months Ended
December 31,
(Millions of dollars)20242023
Service cost$12 $25 
Interest cost42 39 
Expected return on plan assets(56)(42)
Amortization of prior service credit— (1)
Amortization of loss10 16 
Net pension cost$8 $37 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.25.0.1
Business Restructuring Charges (Tables)
 3 Months Ended
Dec. 31, 2024
Restructuring and Related Activities [Abstract]  
Summary of Restructuring Accrual Activity
Restructuring liability activity for the three months ended December 31, 2024 was as follows:
(Millions of dollars)Employee
Termination
Other (a)
Total
Balance at September 30, 2024$58 $2 $60 
Charged to expense20 46 66 
Cash payments(29)(36)(65)
Non-cash settlements— (6)(6)
Other adjustments(2)— (2)
Balance at December 31, 2024$47 $6 $53 
(a)    Other non-employee-related expenses primarily relate to other costs associated with the execution of the Company’s cost efficiency and restructuring programs, such as incremental project management costs and facility exit costs.
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.25.0.1
Intangible Assets (Tables)
 3 Months Ended
Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Components of Intangible Assets
Intangible assets consisted of:
 December 31, 2024September 30, 2024
(Millions of dollars)Gross
Carrying
Amount		Accumulated
Amortization		Net Carrying AmountGross
Carrying
Amount		Accumulated
Amortization		Net Carrying Amount
Amortized intangible assets
Developed technology$15,788 $(8,349)$7,439 $15,827 $(8,094)$7,733 
Customer relationships5,511 (2,978)2,533 5,513 (2,878)2,635 
Patents, trademarks and other1,188 (688)500 1,185 (682)503 
Amortized intangible assets$22,486 $(12,014)$10,472 $22,525 $(11,654)$10,871 
Unamortized intangible assets
Acquired in-process research and development$14 $44 
Trademarks2 2 
Unamortized intangible assets$16 $46 
Reconciliation of Goodwill by Business Segment
The following is a reconciliation of goodwill by business segment:
(Millions of dollars)Medical Life SciencesInterventional Total
Goodwill as of September 30, 2024$12,832 $904 $12,729 $26,465 
Purchase price allocation adjustments(12)— — (12)
Currency translation(51)(8)(66)(125)
Goodwill as of December 31, 2024$12,769 $896 $12,663 $26,329 
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.25.0.1
Derivative Instruments and Hedging Activities (Tables)
 3 Months Ended
Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Notional Amounts of Outstanding Derivative Positions
The notional amounts of the Company’s foreign currency-related derivative instruments as of December 31, 2024 and September 30, 2024 were as follows:
(Millions of dollars)Hedge DesignationDecember 31, 2024September 30, 2024
Foreign exchange contracts (a)Undesignated$2,366 $4,521 
Foreign exchange contracts (b)Cash flow hedges394 543 
Foreign currency-denominated debt (c)Net investment hedges2,874 3,065 
Cross-currency swaps (d)Net investment hedges1,022 1,366 
(a)Represents hedges of transactional foreign exchange exposures resulting primarily from intercompany payables and receivables. Gains and losses on these instruments are recognized immediately in income. These gains and losses are largely offset by gains and losses on the underlying hedged items, as well as the hedging costs associated with the derivative instruments. Net amounts recognized in Other expense, net, during the three months ended December 31, 2024 and 2023 were immaterial to the Company's consolidated financial results.
(b)Represents foreign exchange contracts related to anticipated intercompany purchases and sales, described above, which generally have durations of less than eighteen months.
(c)Represents foreign currency-denominated long-term notes outstanding which were effective as economic hedges of net investments in certain of the Company's foreign subsidiaries.
(d)Represents cross-currency swaps, which were effective as economic hedges of net investments in certain of the Company's foreign subsidiaries.
The notional amounts of the Company’s interest rate-related derivative instruments as of December 31, 2024 and September 30, 2024 were as follows:
(Millions of dollars)Hedge DesignationDecember 31, 2024September 30, 2024
Interest rate swaps (a)Fair value hedges$700 $700 
(a)Represents fixed-to-floating interest rate swap agreements the Company entered into to convert the interest payments on certain long-term notes from the fixed rate to a floating interest rate based on secured overnight financing rates (“SOFR”).
Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss)
Net gains (losses) recorded to Accumulated other comprehensive income (loss) relating to the Company's net investment hedges for the three-month periods were as follows:
 Three Months Ended
December 31,
(Millions of dollars)20242023
Foreign currency-denominated debt$145 $(29)
Cross-currency swaps (a)67 (55)
(a) The amount for the three months ended December 31, 2024 includes a loss, net of tax, of $18 million recognized on terminated cross-currency swaps.
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments and Fair Value Measurements (Tables)
 3 Months Ended
Dec. 31, 2024
Fair Value Disclosures [Abstract]  
Schedule of Cash and Cash Equivalents
The following reconciles cash and equivalents and restricted cash reported within the Company's condensed consolidated balance sheets at December 31, 2024 and September 30, 2024 to the total of these amounts shown on the Company's condensed consolidated statements of cash flows:
(Millions of dollars)December 31, 2024September 30, 2024
Cash and equivalents$711 $1,717 
Restricted cash102 139 
Cash and equivalents and restricted cash$813 $1,856 
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
The fair values of the Company’s financial instruments are as follows:
(Millions of dollars)Basis of fair value measurementDecember 31, 2024September 30, 2024
Institutional money market accounts (a)Level 1$— $285 
Current portion of long-term debt (b)Level 2831 1,748 
Long-term debt (b)Level 216,337 17,199 
(a)These financial instruments are recorded within Cash and equivalents on the condensed consolidated balance sheets. The institutional money market accounts permit daily redemption. The fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions.
(b)Long-term debt is recorded at amortized cost. The fair value of long-term debt is measured based upon quoted prices in active markets for similar instruments.
Transfer of Financial Assets Accounted for as Sales The amounts transferred and yet to be remitted under factoring arrangements are provided below.
Three Months Ended December 31,
(Millions of dollars)20242023
Trade receivables transferred to third parties under factoring arrangements$360 $379 
December 31, 2024September 30, 2024
Amounts yet to be collected and remitted to the third parties$338 $254 
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.25.0.1
Shareholders' Equity - Changes in Certain Components of Shareholders' Equity (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 3 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Beginning balance $ 25,890  
Net income 303 $ 281
Ending balance $ 25,205  
Dividends per Common Share (USD per share) $ 1.04 $ 0.95
Common Stock  Issued at Par Value    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Beginning balance $ 371 $ 371
Ending balance 371 371
Capital in Excess of Par Value    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Beginning balance 19,893 19,720
Issuance of shares under employee and other plans, net (65) (62)
Share-based compensation 90 83
Repurchase of common stock (150)  
Ending balance 19,768 19,741
Retained Earnings    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Beginning balance 16,139 15,535
Net income 303 281
Common dividends (302) (275)
Ending balance 16,141 15,540
Deferred Compensation    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Beginning balance 25 24
Ending balance 25 24
Treasury Stock    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Beginning balance $ (8,807) $ (8,305)
Beginning balance (shares) (81,493) (80,203)
Issuance of shares under employee and other plans, net $ (12) $ (20)
Common stock issued for share-based compensation and other plans, net (in shares) 679 647
Common stock held in trusts, net (in shares) (8) (19)
Repurchase of common stock (in shares) (2,637) (2,118)
Repurchase of common stock $ (606) $ (503)
Ending balance $ (9,425) $ (8,828)
Ending balance (shares) (83,459) (81,692)
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.25.0.1
Shareholders' Equity - Additional Information (Details) - USD ($)
shares in Thousands, $ in Millions
 1 Months Ended 3 Months Ended
Jan. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Jan. 28, 2025
Nov. 03, 2021
Class of Stock [Line Items]          
Share Repurchase Program, Authorized, Number of Shares         10,000
Share Repurchase Program, Remaining Authorized, Number of Shares   4,000      
Subsequent Event          
Class of Stock [Line Items]          
Number of additional shares authorized to be repurchased (in shares)       10,000  
Accelerated Share Repurchase Program          
Class of Stock [Line Items]          
Repurchase of common stock (in shares)   2,637 2,118    
Stock repurchase program, authorized amount   $ 750 $ 500    
Percentage of excise tax excluded   1.00% 1.00%    
Stock Repurchase Program, Excise Tax     $ 3    
Accelerated Share Repurchase Program | Subsequent Event          
Class of Stock [Line Items]          
Repurchase of common stock (in shares) 619        
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.25.0.1
Shareholders' Equity - Accumulated Other Comprehensive Income (Loss) - Components and Changes of Accumulated Other Comprehensive Income (Loss) (Detail) - USD ($)
$ in Millions
 3 Months Ended
Dec. 31, 2024
Dec. 31, 2023
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance $ (1,732) $ (1,548)
Other comprehensive income before reclassifications, net of taxes 49 21
Amounts reclassified into income, net of taxes 6 12
Ending balance (1,676) (1,515)
Foreign Currency Translation    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (1,244) (1,078)
Other comprehensive income before reclassifications, net of taxes 46 40
Amounts reclassified into income, net of taxes 0 0
Ending balance (1,199) (1,038)
Benefit Plans    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (557) (571)
Other comprehensive income before reclassifications, net of taxes 0 0
Amounts reclassified into income, net of taxes 8 12
Ending balance (549) (559)
Cash Flow Hedges    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance 70 103
Other comprehensive income before reclassifications, net of taxes 3 (19)
Amounts reclassified into income, net of taxes (2) 1
Ending balance 72 84
Available-for-Sale Debt Securities    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (1) 0
Other comprehensive income before reclassifications, net of taxes 0 0
Amounts reclassified into income, net of taxes 0 0
Ending balance $ (1) $ 0
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.25.0.1
Shareholders' Equity - Accelerated Share Repurchases (Details) - USD ($)
shares in Thousands, $ in Millions
 1 Months Ended 3 Months Ended
Jan. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Treasury Stock      
Accelerated Share Repurchases [Line Items]      
Repurchase of common stock (in shares)   2,637 2,118
Repurchase of common stock   $ 606 $ 503
Capital in Excess of Par Value      
Accelerated Share Repurchases [Line Items]      
Repurchase of common stock   150  
Accelerated Share Repurchase Program      
Accelerated Share Repurchases [Line Items]      
Stock repurchase program, authorized amount   $ 750 $ 500
Repurchase of common stock (in shares)   2,637 2,118
Total shares to be delivered under accelerated share repurchase program   3,256  
Percentage of excise tax excluded   1.00% 1.00%
Share repurchase program, excise tax   $ 6  
Accelerated Share Repurchase Program | Subsequent Event      
Accelerated Share Repurchases [Line Items]      
Repurchase of common stock (in shares) 619    
Accelerated Share Repurchase Program | Subsequent Event | Treasury Stock      
Accelerated Share Repurchases [Line Items]      
Repurchase of common stock $ 150    
Accelerated Share Repurchase Program | Subsequent Event | Capital in Excess of Par Value      
Accelerated Share Repurchases [Line Items]      
Repurchase of common stock $ 150    
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.25.0.1
Earnings per Share (Detail) - shares
shares in Thousands
 3 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Earnings Per Share [Abstract]    
Average common shares outstanding (shares) 289,505 290,113
Dilutive share equivalents from share-based plans (shares) 884 1,285
Average common and common equivalent shares outstanding - assuming dilution (shares) 290,389 291,398
Share Based Compensation    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Share equivalents excluded from the diluted shares outstanding calculation (shares) 2,758 552
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.25.0.1
Contingencies (Detail)
$ in Thousands
 3 Months Ended
Dec. 31, 2024
USD ($)
claim
lawsuit
plaintiff
Dec. 31, 2023
USD ($)
Sep. 30, 2024
USD ($)
claim
Other Operating Income (Expense)      
Loss Contingencies [Line Items]      
Product liability accrual, pre-tax credit   $ 36,000  
Pyxis      
Loss Contingencies [Line Items]      
Loss contingency, loss in period $ 22,000    
Loss contingency accrual, product liability, net 50,000    
Products Within Mass Tort Litigation      
Loss Contingencies [Line Items]      
Loss contingency accrual, product liability, net $ 1,600,000   $ 1,700,000
GEORGIA      
Loss Contingencies [Line Items]      
Number of EtO lawsuits filed | lawsuit 360    
Loss contingency, number of plaintiffs | plaintiff 375    
Number of EtO sterilization lawsuits, allege injury from unrelated defendants | lawsuit 50    
GEORGIA | Maximum      
Loss Contingencies [Line Items]      
Loss contingency, damages sought, value $ 250    
Hernia Product Claims      
Loss Contingencies [Line Items]      
Pending claims | claim 6,670   6,610
SEC Matter      
Loss Contingencies [Line Items]      
Loss contingency accrual $ 175,000    
Italian Medical Device Payback Legislation Matter      
Loss Contingencies [Line Items]      
Loss contingency accrual $ 62,000    
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenues (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Sep. 30, 2024
Disaggregation of Revenue [Line Items]    
Rebate liability $ 813 $ 749
Contract with customer, liability $ 502 $ 482
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01    
Disaggregation of Revenue [Line Items]    
Revenue, remaining performance obligation, expected timing of satisfaction (in years) 3 years  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 | Products and/or Services    
Disaggregation of Revenue [Line Items]    
Revenue, remaining performance obligation, amount $ 2,300  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 | Consumables    
Disaggregation of Revenue [Line Items]    
Revenue, remaining performance obligation, amount $ 2,000  
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Data - Additional Information (Detail)
 3 Months Ended
Dec. 31, 2024
segment
Segment Reporting [Abstract]  
Number of principal business segments (segment) 3
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Data - Revenues by Geographic Areas (Detail) - USD ($)
$ in Millions
 3 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Segment Reporting Information [Line Items]    
Revenues $ 5,168 $ 4,706
Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Revenues 2,615 2,230
Operating Segments | Life Sciences    
Segment Reporting Information [Line Items]    
Revenues 1,297 1,288
Operating Segments | Interventional    
Segment Reporting Information [Line Items]    
Revenues 1,257 1,188
United States    
Segment Reporting Information [Line Items]    
Revenues 3,080 2,749
United States | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Revenues 1,615 1,360
United States | Operating Segments | Life Sciences    
Segment Reporting Information [Line Items]    
Revenues 603 587
United States | Operating Segments | Interventional    
Segment Reporting Information [Line Items]    
Revenues 861 802
International    
Segment Reporting Information [Line Items]    
Revenues 2,089 1,957
International | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Revenues 999 870
International | Operating Segments | Life Sciences    
Segment Reporting Information [Line Items]    
Revenues 694 701
International | Operating Segments | Interventional    
Segment Reporting Information [Line Items]    
Revenues 396 386
Medication Delivery Solutions | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Revenues 1,124 1,052
Medication Delivery Solutions | United States | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Revenues 694 639
Medication Delivery Solutions | International | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Revenues 430 413
Medication Management Solutions | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Revenues 801 747
Medication Management Solutions | United States | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Revenues 659 594
Medication Management Solutions | International | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Revenues 142 153
Pharmaceutical Systems | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Revenues 418 431
Pharmaceutical Systems | United States | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Revenues 104 127
Pharmaceutical Systems | International | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Revenues 314 304
Advanced Patient Monitoring | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Revenues 271 0
Advanced Patient Monitoring | United States | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Revenues 159 0
Advanced Patient Monitoring | International | Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Revenues 113 0
Specimen Management | Operating Segments | Life Sciences    
Segment Reporting Information [Line Items]    
Revenues 462 447
Specimen Management | United States | Operating Segments | Life Sciences    
Segment Reporting Information [Line Items]    
Revenues 238 234
Specimen Management | International | Operating Segments | Life Sciences    
Segment Reporting Information [Line Items]    
Revenues 223 213
Diagnostic Solutions | Operating Segments | Life Sciences    
Segment Reporting Information [Line Items]    
Revenues 474 467
Diagnostic Solutions | United States | Operating Segments | Life Sciences    
Segment Reporting Information [Line Items]    
Revenues 212 210
Diagnostic Solutions | International | Operating Segments | Life Sciences    
Segment Reporting Information [Line Items]    
Revenues 262 256
Biosciences | Operating Segments | Life Sciences    
Segment Reporting Information [Line Items]    
Revenues 361 375
Biosciences | United States | Operating Segments | Life Sciences    
Segment Reporting Information [Line Items]    
Revenues 153 143
Biosciences | International | Operating Segments | Life Sciences    
Segment Reporting Information [Line Items]    
Revenues 208 232
Surgery | Operating Segments | Interventional    
Segment Reporting Information [Line Items]    
Revenues 395 369
Surgery | United States | Operating Segments | Interventional    
Segment Reporting Information [Line Items]    
Revenues 303 280
Surgery | International | Operating Segments | Interventional    
Segment Reporting Information [Line Items]    
Revenues 92 88
Peripheral Intervention | Operating Segments | Interventional    
Segment Reporting Information [Line Items]    
Revenues 473 454
Peripheral Intervention | United States | Operating Segments | Interventional    
Segment Reporting Information [Line Items]    
Revenues 253 234
Peripheral Intervention | International | Operating Segments | Interventional    
Segment Reporting Information [Line Items]    
Revenues 220 220
Urology and Critical Care | Operating Segments | Interventional    
Segment Reporting Information [Line Items]    
Revenues 389 365
Urology and Critical Care | United States | Operating Segments | Interventional    
Segment Reporting Information [Line Items]    
Revenues 306 287
Urology and Critical Care | International | Operating Segments | Interventional    
Segment Reporting Information [Line Items]    
Revenues $ 83 $ 78
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Data - Financial Information for Company's Segments (Detail) - USD ($)
$ in Millions
 3 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Segment Reporting Information [Line Items]    
Integration, restructuring and transaction expense $ (92) $ (75)
Income Before Income Taxes 306 359
Operating Segments    
Segment Reporting Information [Line Items]    
Total Segment Operating Income 1,263 1,198
Operating Segments | Medical    
Segment Reporting Information [Line Items]    
Total Segment Operating Income 492 535
Operating Segments | Life Sciences    
Segment Reporting Information [Line Items]    
Total Segment Operating Income 383 372
Operating Segments | Interventional    
Segment Reporting Information [Line Items]    
Total Segment Operating Income 387 291
Segment Reconciling Items    
Segment Reporting Information [Line Items]    
Integration, restructuring and transaction expense (92) (75)
Net interest expense (132) (77)
Corporate, Non-Segment    
Segment Reporting Information [Line Items]    
Total Segment Operating Income $ (733) $ (688)
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.25.0.1
Benefit Plans (Detail) - Pension Plans - USD ($)
$ in Millions
 3 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Defined Benefit Plan Disclosure [Line Items]    
Service cost $ 12 $ 25
Interest cost 42 39
Expected return on plan assets (56) (42)
Amortization of prior service credit 0 (1)
Amortization of loss 10 16
Net pension cost $ 8 $ 37
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.25.0.1
Acquisition (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 03, 2024
Dec. 31, 2023
Dec. 31, 2024
Sep. 30, 2024
Business Acquisition [Line Items]        
Goodwill     $ 26,329 $ 26,465
Advanced Patient Monitoring        
Business Acquisition [Line Items]        
Business Combination, Consideration Transferred $ 3,906      
Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Net Assets     713  
Goodwill $ 1,823      
Business Acquisition, Goodwill, Expected Tax Deductible Amount     1,100  
Business Acquisition, Pro Forma Revenue   $ 4,957    
Advanced Patient Monitoring | Developed technology        
Business Acquisition [Line Items]        
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles     717  
Advanced Patient Monitoring | Customer relationships        
Business Acquisition [Line Items]        
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles     $ 653  
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.25.0.1
Business Restructuring Charges (Detail)
$ in Millions
 3 Months Ended
Dec. 31, 2024
USD ($)
Restructuring Reserve [Roll Forward]  
Beginning Balance $ 60
Charged to expense 66
Cash payments (65)
Ending Balance 53
Other Initiatives  
Restructuring Reserve [Roll Forward]  
Non-cash settlements (6)
Other adjustments (2)
Employee Termination  
Restructuring Reserve [Roll Forward]  
Beginning Balance 58
Charged to expense 20
Cash payments (29)
Ending Balance 47
Employee Termination | Other Initiatives  
Restructuring Reserve [Roll Forward]  
Non-cash settlements 0
Other adjustments (2)
Other  
Restructuring Reserve [Roll Forward]  
Beginning Balance 2
Charged to expense 46
Cash payments (36)
Ending Balance 6
Other | Other Initiatives  
Restructuring Reserve [Roll Forward]  
Non-cash settlements (6)
Other adjustments $ 0
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.25.0.1
Intangible Assets - Components of Intangible Assets (Detail) - USD ($)
$ in Millions
Dec. 31, 2024
Sep. 30, 2024
Finite And Indefinite Lived Intangible Assets [Line Items]    
Gross Carrying Amount $ 22,486 $ 22,525
Accumulated Amortization (12,014) (11,654)
Net Carrying Amount 10,472 10,871
Unamortized intangible assets 16 46
Acquired in-process research and development    
Finite And Indefinite Lived Intangible Assets [Line Items]    
Unamortized intangible assets 14 44
Trademarks    
Finite And Indefinite Lived Intangible Assets [Line Items]    
Unamortized intangible assets 2 2
Developed technology    
Finite And Indefinite Lived Intangible Assets [Line Items]    
Gross Carrying Amount 15,788 15,827
Accumulated Amortization (8,349) (8,094)
Net Carrying Amount 7,439 7,733
Customer relationships    
Finite And Indefinite Lived Intangible Assets [Line Items]    
Gross Carrying Amount 5,511 5,513
Accumulated Amortization (2,978) (2,878)
Net Carrying Amount 2,533 2,635
Patents, trademarks and other    
Finite And Indefinite Lived Intangible Assets [Line Items]    
Gross Carrying Amount 1,188 1,185
Accumulated Amortization (688) (682)
Net Carrying Amount $ 500 $ 503
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.25.0.1
Intangible Assets - Additional Information (Detail) - USD ($)
$ in Millions
 3 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]    
Intangible amortization expense $ 395 $ 365
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.25.0.1
Intangible Assets - Reconciliation of Goodwill by Business Segment (Detail)
$ in Millions
 3 Months Ended
Dec. 31, 2024
USD ($)
Goodwill [Roll Forward]  
Goodwill, beginning balance $ 26,465
Purchase price allocation adjustments (12)
Currency translation (125)
Goodwill, ending balance 26,329
Medical  
Goodwill [Roll Forward]  
Goodwill, beginning balance 12,832
Purchase price allocation adjustments (12)
Currency translation (51)
Goodwill, ending balance 12,769
Life Sciences  
Goodwill [Roll Forward]  
Goodwill, beginning balance 904
Purchase price allocation adjustments 0
Currency translation (8)
Goodwill, ending balance 896
Interventional  
Goodwill [Roll Forward]  
Goodwill, beginning balance 12,729
Purchase price allocation adjustments 0
Currency translation (66)
Goodwill, ending balance $ 12,663
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.25.0.1
Derivative Instruments and Hedging Activities - Schedule of Notional Amounts of Outstanding Derivative Positions (Detail) - USD ($)
$ in Millions
Dec. 31, 2024
Sep. 30, 2024
Foreign Exchange Contracts    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Notional amount of derivative $ 2,366 $ 4,521
Foreign Exchange Contracts | Cash flow hedges    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Notional amount of derivative 394 543
Currency Swap | Net investment hedges    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Notional amount of derivative 1,022 1,366
Interest Rate Swaps | Fair value hedges    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Notional amount of derivative 700 700
Foreign Currency-Denominated Debt | Net investment hedges    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Notional amount of derivative $ 2,874 $ 3,065
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.25.0.1
Derivative Instruments and Hedging Activities - Gains (Losses) on Net Investment Hedges (Details) - USD ($)
$ in Millions
 3 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Derivative Instruments, Gain (Loss) [Line Items]    
Net gains (losses) recorded to Accumulated other comprehensive income (loss), net of tax $ 46 $ 40
Foreign currency-denominated debt    
Derivative Instruments, Gain (Loss) [Line Items]    
Net gains (losses) recorded to Accumulated other comprehensive income (loss), net of tax 145 (29)
Currency Swap    
Derivative Instruments, Gain (Loss) [Line Items]    
Net gains (losses) recorded to Accumulated other comprehensive income (loss), net of tax 67 $ (55)
Terminated Currency Swap    
Derivative Instruments, Gain (Loss) [Line Items]    
Net gains (losses) recorded to Accumulated other comprehensive income (loss), net of tax $ (18)  
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.25.0.1
Derivative Instruments and Hedging Activities - Additional Information (Detail) - Foreign Exchange Contracts - Cash flow hedges
$ in Millions
 3 Months Ended
Dec. 31, 2023
USD ($)
Derivative Instruments and Hedging Activities Disclosures [Line Items]  
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax $ 0
Foreign Currency Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net $ 0
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments and Fair Value Measurements - Cash and Equivalents and Restricted Cash (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Sep. 30, 2024
Dec. 31, 2023
Sep. 30, 2023
Fair Value Disclosures [Abstract]        
Cash and equivalents $ 711 $ 1,717    
Restricted cash 102 139    
Cash and equivalents and restricted cash $ 813 $ 1,856 $ 1,234 $ 1,481
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments and Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Sep. 30, 2024
Fair Value Disclosures [Abstract]    
Institutional money market accounts $ 0 $ 285
Current portion of long-term debt 831 1,748
Long-term debt $ 16,337 $ 17,199
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments and Fair Value Measurements - Additional Information (Detail) - USD ($)
$ in Millions
 3 Months Ended
Dec. 31, 2024
Sep. 30, 2024
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Supplier finance program, obligation $ 118 $ 112
Integration and Restructuring Expense    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Asset impairment charges $ 30  
Minimum    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Maturity period of short-term investments at the time of purchase 3 months  
Payment terms of supplier finance programs (in days) 90 days  
Maximum    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Maturity period of short-term investments at the time of purchase 1 year  
Payment terms of supplier finance programs (in days) 150 days  
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.25.0.1
Financial Instruments and Fair Value Measurements - Transfer of Financial Assets Accounted for as Sales (Details) - USD ($)
$ in Millions
 3 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Sep. 30, 2024
Fair Value Disclosures [Abstract]      
Trade receivables transferred to third parties under factoring arrangements $ 360 $ 379  
Amounts yet to be collected and remitted to the third parties $ 338   $ 254
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.25.0.1
Income Taxes - Additional Information (Details)
 3 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Tax Disclosure [Abstract]    
Effective income tax rate reconciliation, percent 0.90% 21.60%
EXCEL 67 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 68 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 69 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 71 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.0.1 html 243 232 1 false 79 0 false 8 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.bd.com/role/CoverPage Cover Page Cover 1 false false R2.htm 9952151 - Statement - Condensed Consolidated Statements of Income Sheet http://www.bd.com/role/CondensedConsolidatedStatementsofIncome Condensed Consolidated Statements of Income Statements 2 false false R3.htm 9952152 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.bd.com/role/CondensedConsolidatedStatementsofComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 3 false false R4.htm 9952153 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.bd.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 4 false false R5.htm 9952154 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.bd.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 9952155 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 9952156 - Disclosure - Basis of Presentation Sheet http://www.bd.com/role/BasisofPresentation Basis of Presentation Notes 7 false false R8.htm 9952157 - Disclosure - Accounting Changes Sheet http://www.bd.com/role/AccountingChanges Accounting Changes Notes 8 false false R9.htm 9952158 - Disclosure - Shareholders' Equity Sheet http://www.bd.com/role/ShareholdersEquity Shareholders' Equity Notes 9 false false R10.htm 9952159 - Disclosure - Earnings per Share Sheet http://www.bd.com/role/EarningsperShare Earnings per Share Notes 10 false false R11.htm 9952160 - Disclosure - Contingencies Sheet http://www.bd.com/role/Contingencies Contingencies Notes 11 false false R12.htm 9952161 - Disclosure - Revenues Sheet http://www.bd.com/role/Revenues Revenues Notes 12 false false R13.htm 9952162 - Disclosure - Segment Data Sheet http://www.bd.com/role/SegmentData Segment Data Notes 13 false false R14.htm 9952163 - Disclosure - Benefit Plans Sheet http://www.bd.com/role/BenefitPlans Benefit Plans Notes 14 false false R15.htm 9952164 - Disclosure - Acquisition Sheet http://www.bd.com/role/Acquisition Acquisition Notes 15 false false R16.htm 9952165 - Disclosure - Business Restructuring Charges Sheet http://www.bd.com/role/BusinessRestructuringCharges Business Restructuring Charges Notes 16 false false R17.htm 9952166 - Disclosure - Intangible Assets Sheet http://www.bd.com/role/IntangibleAssets Intangible Assets Notes 17 false false R18.htm 9952167 - Disclosure - Derivative Instruments and Hedging Activities Sheet http://www.bd.com/role/DerivativeInstrumentsandHedgingActivities Derivative Instruments and Hedging Activities Notes 18 false false R19.htm 9952168 - Disclosure - Financial Instruments and Fair Value Measurements Sheet http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurements Financial Instruments and Fair Value Measurements Notes 19 false false R20.htm 9952169 - Disclosure - Income Taxes Sheet http://www.bd.com/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 9952170 - Disclosure - Subsequent Events Sheet http://www.bd.com/role/SubsequentEvents Subsequent Events Notes 21 false false R22.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 22 false false R23.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 23 false false R24.htm 9955511 - Disclosure - Accounting Changes (Policies) Sheet http://www.bd.com/role/AccountingChangesPolicies Accounting Changes (Policies) Policies http://www.bd.com/role/AccountingChanges 24 false false R25.htm 9955512 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.bd.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.bd.com/role/ShareholdersEquity 25 false false R26.htm 9955513 - Disclosure - Earnings per Share (Tables) Sheet http://www.bd.com/role/EarningsperShareTables Earnings per Share (Tables) Tables http://www.bd.com/role/EarningsperShare 26 false false R27.htm 9955514 - Disclosure - Segment Data (Tables) Sheet http://www.bd.com/role/SegmentDataTables Segment Data (Tables) Tables http://www.bd.com/role/SegmentData 27 false false R28.htm 9955515 - Disclosure - Benefit Plans (Tables) Sheet http://www.bd.com/role/BenefitPlansTables Benefit Plans (Tables) Tables http://www.bd.com/role/BenefitPlans 28 false false R29.htm 9955516 - Disclosure - Business Restructuring Charges (Tables) Sheet http://www.bd.com/role/BusinessRestructuringChargesTables Business Restructuring Charges (Tables) Tables http://www.bd.com/role/BusinessRestructuringCharges 29 false false R30.htm 9955517 - Disclosure - Intangible Assets (Tables) Sheet http://www.bd.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://www.bd.com/role/IntangibleAssets 30 false false R31.htm 9955518 - Disclosure - Derivative Instruments and Hedging Activities (Tables) Sheet http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesTables Derivative Instruments and Hedging Activities (Tables) Tables http://www.bd.com/role/DerivativeInstrumentsandHedgingActivities 31 false false R32.htm 9955519 - Disclosure - Financial Instruments and Fair Value Measurements (Tables) Sheet http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsTables Financial Instruments and Fair Value Measurements (Tables) Tables http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurements 32 false false R33.htm 9955520 - Disclosure - Shareholders' Equity - Changes in Certain Components of Shareholders' Equity (Details) Sheet http://www.bd.com/role/ShareholdersEquityChangesinCertainComponentsofShareholdersEquityDetails Shareholders' Equity - Changes in Certain Components of Shareholders' Equity (Details) Details 33 false false R34.htm 9955521 - Disclosure - Shareholders' Equity - Additional Information (Details) Sheet http://www.bd.com/role/ShareholdersEquityAdditionalInformationDetails Shareholders' Equity - Additional Information (Details) Details 34 false false R35.htm 9955522 - Disclosure - Shareholders' Equity - Accumulated Other Comprehensive Income (Loss) - Components and Changes of Accumulated Other Comprehensive Income (Loss) (Detail) Sheet http://www.bd.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossComponentsandChangesofAccumulatedOtherComprehensiveIncomeLossDetail Shareholders' Equity - Accumulated Other Comprehensive Income (Loss) - Components and Changes of Accumulated Other Comprehensive Income (Loss) (Detail) Details 35 false false R36.htm 9955523 - Disclosure - Shareholders' Equity - Accelerated Share Repurchases (Details) Sheet http://www.bd.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails Shareholders' Equity - Accelerated Share Repurchases (Details) Details 36 false false R37.htm 9955524 - Disclosure - Earnings per Share (Detail) Sheet http://www.bd.com/role/EarningsperShareDetail Earnings per Share (Detail) Details http://www.bd.com/role/EarningsperShareTables 37 false false R38.htm 9955525 - Disclosure - Contingencies (Detail) Sheet http://www.bd.com/role/ContingenciesDetail Contingencies (Detail) Details http://www.bd.com/role/Contingencies 38 false false R39.htm 9955526 - Disclosure - Revenues (Details) Sheet http://www.bd.com/role/RevenuesDetails Revenues (Details) Details http://www.bd.com/role/Revenues 39 false false R40.htm 9955527 - Disclosure - Segment Data - Additional Information (Detail) Sheet http://www.bd.com/role/SegmentDataAdditionalInformationDetail Segment Data - Additional Information (Detail) Details 40 false false R41.htm 9955528 - Disclosure - Segment Data - Revenues by Geographic Areas (Detail) Sheet http://www.bd.com/role/SegmentDataRevenuesbyGeographicAreasDetail Segment Data - Revenues by Geographic Areas (Detail) Details 41 false false R42.htm 9955529 - Disclosure - Segment Data - Financial Information for Company's Segments (Detail) Sheet http://www.bd.com/role/SegmentDataFinancialInformationforCompanysSegmentsDetail Segment Data - Financial Information for Company's Segments (Detail) Details 42 false false R43.htm 9955530 - Disclosure - Benefit Plans (Detail) Sheet http://www.bd.com/role/BenefitPlansDetail Benefit Plans (Detail) Details http://www.bd.com/role/BenefitPlansTables 43 false false R44.htm 9955531 - Disclosure - Acquisition (Details) Sheet http://www.bd.com/role/AcquisitionDetails Acquisition (Details) Details http://www.bd.com/role/Acquisition 44 false false R45.htm 9955532 - Disclosure - Business Restructuring Charges (Detail) Sheet http://www.bd.com/role/BusinessRestructuringChargesDetail Business Restructuring Charges (Detail) Details http://www.bd.com/role/BusinessRestructuringChargesTables 45 false false R46.htm 9955533 - Disclosure - Intangible Assets - Components of Intangible Assets (Detail) Sheet http://www.bd.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetail Intangible Assets - Components of Intangible Assets (Detail) Details 46 false false R47.htm 9955534 - Disclosure - Intangible Assets - Additional Information (Detail) Sheet http://www.bd.com/role/IntangibleAssetsAdditionalInformationDetail Intangible Assets - Additional Information (Detail) Details 47 false false R48.htm 9955535 - Disclosure - Intangible Assets - Reconciliation of Goodwill by Business Segment (Detail) Sheet http://www.bd.com/role/IntangibleAssetsReconciliationofGoodwillbyBusinessSegmentDetail Intangible Assets - Reconciliation of Goodwill by Business Segment (Detail) Details 48 false false R49.htm 9955536 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Notional Amounts of Outstanding Derivative Positions (Detail) Sheet http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetail Derivative Instruments and Hedging Activities - Schedule of Notional Amounts of Outstanding Derivative Positions (Detail) Details 49 false false R50.htm 9955537 - Disclosure - Derivative Instruments and Hedging Activities - Gains (Losses) on Net Investment Hedges (Details) Sheet http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesGainsLossesonNetInvestmentHedgesDetails Derivative Instruments and Hedging Activities - Gains (Losses) on Net Investment Hedges (Details) Details http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesTables 50 false false R51.htm 9955538 - Disclosure - Derivative Instruments and Hedging Activities - Additional Information (Detail) Sheet http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesAdditionalInformationDetail Derivative Instruments and Hedging Activities - Additional Information (Detail) Details 51 false false R52.htm 9955539 - Disclosure - Financial Instruments and Fair Value Measurements - Cash and Equivalents and Restricted Cash (Details) Sheet http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsCashandEquivalentsandRestrictedCashDetails Financial Instruments and Fair Value Measurements - Cash and Equivalents and Restricted Cash (Details) Details 52 false false R53.htm 9955540 - Disclosure - Financial Instruments and Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) Sheet http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails Financial Instruments and Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) Details 53 false false R54.htm 9955541 - Disclosure - Financial Instruments and Fair Value Measurements - Additional Information (Detail) Sheet http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsAdditionalInformationDetail Financial Instruments and Fair Value Measurements - Additional Information (Detail) Details 54 false false R55.htm 9955542 - Disclosure - Financial Instruments and Fair Value Measurements - Transfer of Financial Assets Accounted for as Sales (Details) Sheet http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsTransferofFinancialAssetsAccountedforasSalesDetails Financial Instruments and Fair Value Measurements - Transfer of Financial Assets Accounted for as Sales (Details) Details 55 false false R56.htm 9955543 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://www.bd.com/role/IncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 56 false false All Reports Book All Reports bdx-20241231.htm bdx-20241231.xsd bdx-20241231_cal.xml bdx-20241231_def.xml bdx-20241231_lab.xml bdx-20241231_pre.xml http://fasb.org/srt/2024 http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 74 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "bdx-20241231.htm": { "nsprefix": "bdx", "nsuri": "http://www.bd.com/20241231", "dts": { "inline": { "local": [ "bdx-20241231.htm" ] }, "schema": { "local": [ "bdx-20241231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "bdx-20241231_cal.xml" ] }, "definitionLink": { "local": [ "bdx-20241231_def.xml" ] }, "labelLink": { "local": [ "bdx-20241231_lab.xml" ] }, "presentationLink": { "local": [ "bdx-20241231_pre.xml" ] } }, "keyStandard": 215, "keyCustom": 17, "axisStandard": 25, "axisCustom": 1, "memberStandard": 35, "memberCustom": 42, "hidden": { "total": 7, "http://xbrl.sec.gov/ecd/2024": 2, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 243, "entityCount": 1, "segmentCount": 79, "elementCount": 522, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 528, "http://xbrl.sec.gov/dei/2024": 50, "http://xbrl.sec.gov/ecd/2024": 22, "http://fasb.org/srt/2024": 3 }, "report": { "R1": { "role": "http://www.bd.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome", "longName": "9952151 - Statement - Condensed Consolidated Statements of Income", "shortName": "Condensed Consolidated Statements of Income", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "unique": true } }, "R3": { "role": "http://www.bd.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "longName": "9952152 - Statement - Condensed Consolidated Statements of Comprehensive Income", "shortName": "Condensed Consolidated Statements of Comprehensive Income", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "unique": true } }, "R4": { "role": "http://www.bd.com/role/CondensedConsolidatedBalanceSheets", "longName": "9952153 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:OtherShortTermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "unique": true } }, "R5": { "role": "http://www.bd.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "9952154 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows", "longName": "9952155 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "unique": true } }, "R7": { "role": "http://www.bd.com/role/BasisofPresentation", "longName": "9952156 - Disclosure - Basis of Presentation", "shortName": "Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.bd.com/role/AccountingChanges", "longName": "9952157 - Disclosure - Accounting Changes", "shortName": "Accounting Changes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.bd.com/role/ShareholdersEquity", "longName": "9952158 - Disclosure - Shareholders' Equity", "shortName": "Shareholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.bd.com/role/EarningsperShare", "longName": "9952159 - Disclosure - Earnings per Share", "shortName": "Earnings per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.bd.com/role/Contingencies", "longName": "9952160 - Disclosure - Contingencies", "shortName": "Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.bd.com/role/Revenues", "longName": "9952161 - Disclosure - Revenues", "shortName": "Revenues", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.bd.com/role/SegmentData", "longName": "9952162 - Disclosure - Segment Data", "shortName": "Segment Data", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.bd.com/role/BenefitPlans", "longName": "9952163 - Disclosure - Benefit Plans", "shortName": "Benefit Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.bd.com/role/Acquisition", "longName": "9952164 - Disclosure - Acquisition", "shortName": "Acquisition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.bd.com/role/BusinessRestructuringCharges", "longName": "9952165 - Disclosure - Business Restructuring Charges", "shortName": "Business Restructuring Charges", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.bd.com/role/IntangibleAssets", "longName": "9952166 - Disclosure - Intangible Assets", "shortName": "Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivities", "longName": "9952167 - Disclosure - Derivative Instruments and Hedging Activities", "shortName": "Derivative Instruments and Hedging Activities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurements", "longName": "9952168 - Disclosure - Financial Instruments and Fair Value Measurements", "shortName": "Financial Instruments and Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.bd.com/role/IncomeTaxes", "longName": "9952169 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.bd.com/role/SubsequentEvents", "longName": "9952170 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true }, "uniqueAnchor": null }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.bd.com/role/AccountingChangesPolicies", "longName": "9955511 - Disclosure - Accounting Changes (Policies)", "shortName": "Accounting Changes (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.bd.com/role/ShareholdersEquityTables", "longName": "9955512 - Disclosure - Shareholders' Equity (Tables)", "shortName": "Shareholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.bd.com/role/EarningsperShareTables", "longName": "9955513 - Disclosure - Earnings per Share (Tables)", "shortName": "Earnings per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.bd.com/role/SegmentDataTables", "longName": "9955514 - Disclosure - Segment Data (Tables)", "shortName": "Segment Data (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.bd.com/role/BenefitPlansTables", "longName": "9955515 - Disclosure - Benefit Plans (Tables)", "shortName": "Benefit Plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.bd.com/role/BusinessRestructuringChargesTables", "longName": "9955516 - Disclosure - Business Restructuring Charges (Tables)", "shortName": "Business Restructuring Charges (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.bd.com/role/IntangibleAssetsTables", "longName": "9955517 - Disclosure - Intangible Assets (Tables)", "shortName": "Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesTables", "longName": "9955518 - Disclosure - Derivative Instruments and Hedging Activities (Tables)", "shortName": "Derivative Instruments and Hedging Activities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsTables", "longName": "9955519 - Disclosure - Financial Instruments and Fair Value Measurements (Tables)", "shortName": "Financial Instruments and Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.bd.com/role/ShareholdersEquityChangesinCertainComponentsofShareholdersEquityDetails", "longName": "9955520 - Disclosure - Shareholders' Equity - Changes in Certain Components of Shareholders' Equity (Details)", "shortName": "Shareholders' Equity - Changes in Certain Components of Shareholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-15", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "unique": true } }, "R34": { "role": "http://www.bd.com/role/ShareholdersEquityAdditionalInformationDetails", "longName": "9955521 - Disclosure - Shareholders' Equity - Additional Information (Details)", "shortName": "Shareholders' Equity - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-48", "name": "srt:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-48", "name": "srt:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.bd.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossComponentsandChangesofAccumulatedOtherComprehensiveIncomeLossDetail", "longName": "9955522 - Disclosure - Shareholders' Equity - Accumulated Other Comprehensive Income (Loss) - Components and Changes of Accumulated Other Comprehensive Income (Loss) (Detail)", "shortName": "Shareholders' Equity - Accumulated Other Comprehensive Income (Loss) - Components and Changes of Accumulated Other Comprehensive Income (Loss) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-13", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "unique": true } }, "R36": { "role": "http://www.bd.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails", "longName": "9955523 - Disclosure - Shareholders' Equity - Accelerated Share Repurchases (Details)", "shortName": "Shareholders' Equity - Accelerated Share Repurchases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-22", "name": "us-gaap:TreasuryStockSharesAcquired", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-42", "name": "bdx:TotalSharesToBeDeliveredUnderAcceleratedShareRepurchaseProgram", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "unique": true } }, "R37": { "role": "http://www.bd.com/role/EarningsperShareDetail", "longName": "9955524 - Disclosure - Earnings per Share (Detail)", "shortName": "Earnings per Share (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.bd.com/role/ContingenciesDetail", "longName": "9955525 - Disclosure - Contingencies (Detail)", "shortName": "Contingencies (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-84", "name": "us-gaap:ProductLiabilityAccrualPeriodExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-84", "name": "us-gaap:ProductLiabilityAccrualPeriodExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.bd.com/role/RevenuesDetails", "longName": "9955526 - Disclosure - Revenues (Details)", "shortName": "Revenues (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-10", "name": "bdx:ContractWithCustomerRebateLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "bdx:ContractWithCustomerRebateLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.bd.com/role/SegmentDataAdditionalInformationDetail", "longName": "9955527 - Disclosure - Segment Data - Additional Information (Detail)", "shortName": "Segment Data - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.bd.com/role/SegmentDataRevenuesbyGeographicAreasDetail", "longName": "9955528 - Disclosure - Segment Data - Revenues by Geographic Areas (Detail)", "shortName": "Segment Data - Revenues by Geographic Areas (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-116", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "unique": true } }, "R42": { "role": "http://www.bd.com/role/SegmentDataFinancialInformationforCompanysSegmentsDetail", "longName": "9955529 - Disclosure - Segment Data - Financial Information for Company's Segments (Detail)", "shortName": "Segment Data - Financial Information for Company's Segments (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "bdx:IntegrationRestructuringAndTransactionExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-172", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "unique": true } }, "R43": { "role": "http://www.bd.com/role/BenefitPlansDetail", "longName": "9955530 - Disclosure - Benefit Plans (Detail)", "shortName": "Benefit Plans (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-178", "name": "us-gaap:DefinedBenefitPlanServiceCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-178", "name": "us-gaap:DefinedBenefitPlanServiceCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.bd.com/role/AcquisitionDetails", "longName": "9955531 - Disclosure - Acquisition (Details)", "shortName": "Acquisition (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-180", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "unique": true } }, "R45": { "role": "http://www.bd.com/role/BusinessRestructuringChargesDetail", "longName": "9955532 - Disclosure - Business Restructuring Charges (Detail)", "shortName": "Business Restructuring Charges (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-12", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.bd.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetail", "longName": "9955533 - Disclosure - Intangible Assets - Components of Intangible Assets (Detail)", "shortName": "Intangible Assets - Components of Intangible Assets (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.bd.com/role/IntangibleAssetsAdditionalInformationDetail", "longName": "9955534 - Disclosure - Intangible Assets - Additional Information (Detail)", "shortName": "Intangible Assets - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.bd.com/role/IntangibleAssetsReconciliationofGoodwillbyBusinessSegmentDetail", "longName": "9955535 - Disclosure - Intangible Assets - Reconciliation of Goodwill by Business Segment (Detail)", "shortName": "Intangible Assets - Reconciliation of Goodwill by Business Segment (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillPurchaseAccountingAdjustments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "unique": true } }, "R49": { "role": "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetail", "longName": "9955536 - Disclosure - Derivative Instruments and Hedging Activities - Schedule of Notional Amounts of Outstanding Derivative Positions (Detail)", "shortName": "Derivative Instruments and Hedging Activities - Schedule of Notional Amounts of Outstanding Derivative Positions (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-214", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-214", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesGainsLossesonNetInvestmentHedgesDetails", "longName": "9955537 - Disclosure - Derivative Instruments and Hedging Activities - Gains (Losses) on Net Investment Hedges (Details)", "shortName": "Derivative Instruments and Hedging Activities - Gains (Losses) on Net Investment Hedges (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-223", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "unique": true } }, "R51": { "role": "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesAdditionalInformationDetail", "longName": "9955538 - Disclosure - Derivative Instruments and Hedging Activities - Additional Information (Detail)", "shortName": "Derivative Instruments and Hedging Activities - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-222", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "us-gaap:ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-222", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "us-gaap:ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsCashandEquivalentsandRestrictedCashDetails", "longName": "9955539 - Disclosure - Financial Instruments and Fair Value Measurements - Cash and Equivalents and Restricted Cash (Details)", "shortName": "Financial Instruments and Fair Value Measurements - Cash and Equivalents and Restricted Cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true }, "uniqueAnchor": null }, "R53": { "role": "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "longName": "9955540 - Disclosure - Financial Instruments and Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)", "shortName": "Financial Instruments and Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsAdditionalInformationDetail", "longName": "9955541 - Disclosure - Financial Instruments and Fair Value Measurements - Additional Information (Detail)", "shortName": "Financial Instruments and Fair Value Measurements - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:SupplierFinanceProgramObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:SupplierFinanceProgramObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsTransferofFinancialAssetsAccountedforasSalesDetails", "longName": "9955542 - Disclosure - Financial Instruments and Fair Value Measurements - Transfer of Financial Assets Accounted for as Sales (Details)", "shortName": "Financial Instruments and Fair Value Measurements - Transfer of Financial Assets Accounted for as Sales (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-1", "name": "bdx:TransfersOfFinancialAssetsDuringThePeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "bdx:TransfersOfFinancialAssetsDuringThePeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.bd.com/role/IncomeTaxesAdditionalInformationDetails", "longName": "9955543 - Disclosure - Income Taxes - Additional Information (Details)", "shortName": "Income Taxes - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bdx-20241231.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AOCIAttributableToParentNetOfTaxRollForward", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossComponentsandChangesofAccumulatedOtherComprehensiveIncomeLossDetail" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "bdx_AcceleratedShareRepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "AcceleratedShareRepurchaseProgramMember", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails", "http://www.bd.com/role/ShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accelerated Share Repurchase Program", "label": "Accelerated Share Repurchase Program [Member]", "documentation": "Accelerated Share Repurchase Program" } } }, "auth_ref": [] }, "us-gaap_AcceleratedShareRepurchasesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcceleratedShareRepurchasesLineItems", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accelerated Share Repurchases [Line Items]", "label": "Accelerated Share Repurchases [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AcceleratedShareRepurchasesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcceleratedShareRepurchasesTable", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accelerated Share Repurchases [Table]", "label": "Accelerated Share Repurchases [Table]", "documentation": "Disclosure of information about accelerated share repurchase (ASR) program." } } }, "auth_ref": [ "r114" ] }, "us-gaap_AcceleratedShareRepurchasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcceleratedShareRepurchasesTextBlock", "presentation": [ "http://www.bd.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Accelerated Share Repurchases", "label": "Accelerated Share Repurchases [Table Text Block]", "documentation": "Tabular disclosure of accelerated share repurchase (ASR) programs. An ASR is a combination of transactions that permits an entity to purchase a targeted number of shares immediately with the final purchase price of those shares determined by an average market price over a fixed period of time. An accelerated share repurchase program is intended to combine the immediate share retirement benefits of a tender offer with the market impact and pricing benefits of a disciplined daily open market stock repurchase program. ASRs can be disclosed as part of stockholders' equity." } } }, "auth_ref": [ "r114" ] }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingChangesAndErrorCorrectionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Changes and Error Corrections [Abstract]", "label": "Accounting Changes and Error Corrections [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Payables, accrued expenses and other current liabilities", "label": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r74", "r75" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r1033" ] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossComponentsandChangesofAccumulatedOtherComprehensiveIncomeLossDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Benefit\u00a0Plans", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": [ "r5", "r6", "r12", "r22", "r88", "r1009", "r1010", "r1011" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Less allowances for depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r34", "r188", "r670" ] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossComponentsandChangesofAccumulatedOtherComprehensiveIncomeLossDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Flow Hedges", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r207", "r214", "r215", "r561", "r834", "r1009" ] }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossComponentsandChangesofAccumulatedOtherComprehensiveIncomeLossDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-Sale Debt Securities", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]", "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": [ "r203", "r204", "r205", "r207", "r214", "r215", "r1009" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossComponentsandChangesofAccumulatedOtherComprehensiveIncomeLossDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r213", "r214", "r597", "r599", "r600", "r601", "r602", "r603" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets", "http://www.bd.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossComponentsandChangesofAccumulatedOtherComprehensiveIncomeLossDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r21", "r22", "r89", "r198", "r667", "r706", "r709" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossComponentsandChangesofAccumulatedOtherComprehensiveIncomeLossDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r213", "r214", "r597", "r599", "r600", "r601", "r602", "r603" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossComponentsandChangesofAccumulatedOtherComprehensiveIncomeLossDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r4", "r12", "r22", "r86", "r87", "r214", "r215", "r599", "r600", "r601", "r602", "r603", "r1009" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r950" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Capital in excess of par value", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r81" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails", "http://www.bd.com/role/ShareholdersEquityChangesinCertainComponentsofShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital in Excess\u00a0of Par\u00a0Value", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r720", "r1020", "r1021", "r1022", "r1023", "r1079", "r1137" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r963" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r963" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r963" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r963" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.bd.com/role/ShareholdersEquityChangesinCertainComponentsofShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r50", "r51", "r502" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to net income to derive net cash provided by continuing operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "bdx_AdvancedPatientMonitoringMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "AdvancedPatientMonitoringMember", "presentation": [ "http://www.bd.com/role/AcquisitionDetails", "http://www.bd.com/role/SegmentDataRevenuesbyGeographicAreasDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Advanced Patient Monitoring", "label": "Advanced Patient Monitoring [Member]", "documentation": "Advanced Patient Monitoring" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r996" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r922", "r932", "r942", "r974" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r925", "r935", "r945", "r977" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r997" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r963" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r970" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r926", "r936", "r946", "r970", "r978", "r982", "r990" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r988" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.bd.com/role/IntangibleAssetsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible amortization expense", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r8", "r319", "r326", "r848" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.bd.com/role/EarningsperShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share equivalents excluded from the diluted shares outstanding calculation (shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r256" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.bd.com/role/EarningsperShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r29" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.bd.com/role/EarningsperShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.bd.com/role/EarningsperShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r29" ] }, "bdx_AntoineEzellMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "AntoineEzellMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Antoine Ezell [Member]", "documentation": "Antoine Ezell" } } }, "auth_ref": [] }, "bdx_AntoineEzellTradingArrangementCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "AntoineEzellTradingArrangementCommonStockMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Antoine Ezell, Trading Arrangement, Common Stock [Member]", "documentation": "Antoine Ezell, Trading Arrangement, Common Stock" } } }, "auth_ref": [] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit", "presentation": [ "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Asset impairment charges", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r8", "r33" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r123", "r134", "r192", "r223", "r260", "r268", "r286", "r290", "r300", "r362", "r363", "r365", "r366", "r367", "r368", "r369", "r371", "r372", "r559", "r562", "r595", "r664", "r757", "r841", "r842", "r888", "r913", "r1070", "r1071", "r1097" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r184", "r201", "r223", "r300", "r362", "r363", "r365", "r366", "r367", "r368", "r369", "r371", "r372", "r559", "r562", "r595", "r888", "r1070", "r1071", "r1097" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current Assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r985" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r986" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r981" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r981" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r981" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r981" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r981" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r981" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r984" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r983" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r982" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r982" ] }, "bdx_BiosciencesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "BiosciencesMember", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesbyGeographicAreasDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Biosciences", "label": "Biosciences [Member]", "documentation": "Biosciences [Member]" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.bd.com/role/AcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r320", "r321", "r322", "r323", "r324", "r555", "r871", "r874" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.bd.com/role/AcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r52", "r53", "r320", "r321", "r322", "r323", "r324", "r555", "r871", "r874" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.bd.com/role/AcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r555" ] }, "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount", "crdr": "debit", "presentation": [ "http://www.bd.com/role/AcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Goodwill, Expected Tax Deductible Amount", "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount", "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes." } } }, "auth_ref": [ "r58" ] }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionsProFormaRevenue", "crdr": "credit", "presentation": [ "http://www.bd.com/role/AcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Pro Forma Revenue", "label": "Business Acquisition, Pro Forma Revenue", "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period." } } }, "auth_ref": [ "r553", "r554" ] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://www.bd.com/role/AcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Consideration Transferred", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r1", "r2", "r11" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.bd.com/role/Acquisition" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisition", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r116", "r556" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "presentation": [ "http://www.bd.com/role/AcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": [ "r54", "r55" ] }, "bdx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNetAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bd.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNetAssets", "crdr": "debit", "presentation": [ "http://www.bd.com/role/AcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Net Assets", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Net Assets", "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Net Assets" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Business Combinations [Abstract]", "label": "Business Combinations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsCashandEquivalentsandRestrictedCashDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets", "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsCashandEquivalentsandRestrictedCashDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and equivalents", "verboseLabel": "Cash and equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r26", "r186", "r828" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Institutional money market accounts", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1080", "r1081" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.bd.com/role/AccountingChangesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r27" ] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://www.bd.com/role/AccountingChangesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Cash", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": [ "r27", "r122" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsCashandEquivalentsandRestrictedCashDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsCashandEquivalentsandRestrictedCashDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Opening Cash and Equivalents and Restricted Cash", "periodEndLabel": "Closing Cash and Equivalents and Restricted Cash", "totalLabel": "Cash and equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r26", "r100", "r221" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net decrease in cash and equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r3", "r100" ] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowHedgingMember", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesAdditionalInformationDetail", "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flow hedges", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r63" ] }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Net cash used for operating activities of discontinued operations", "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations", "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r73", "r100" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r961" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r958" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r956" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://www.bd.com/role/CoverPage", "http://www.bd.com/role/ShareholdersEquityChangesinCertainComponentsofShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r141", "r195", "r196", "r197", "r223", "r250", "r251", "r253", "r255", "r262", "r263", "r300", "r362", "r365", "r366", "r367", "r371", "r372", "r390", "r391", "r394", "r397", "r404", "r595", "r714", "r715", "r716", "r717", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r745", "r766", "r784", "r802", "r803", "r804", "r805", "r806", "r1000", "r1017", "r1024" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r195", "r196", "r197", "r262", "r390", "r391", "r392", "r394", "r397", "r402", "r404", "r714", "r715", "r716", "r717", "r860", "r1000", "r1017" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r962" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r962" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies (See Note 5)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r78", "r126", "r665", "r744" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.bd.com/role/Contingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r108", "r353", "r354", "r811", "r1058", "r1064" ] }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesPolicyTextBlock", "presentation": [ "http://www.bd.com/role/AccountingChangesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Contingencies", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies." } } }, "auth_ref": [ "r36", "r812" ] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareDeclared", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome", "http://www.bd.com/role/ShareholdersEquityChangesinCertainComponentsofShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends per Common Share (USD per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r113" ] }, "bdx_CommonStockHeldInTrustsNetShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.bd.com/20241231", "localname": "CommonStockHeldInTrustsNetShares", "presentation": [ "http://www.bd.com/role/ShareholdersEquityChangesinCertainComponentsofShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock held in trusts, net (in shares)", "label": "Common Stock Held In Trusts Net Shares", "documentation": "Number of common stock shares held in trust." } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.bd.com/role/CoverPage", "http://www.bd.com/role/ShareholdersEquityChangesinCertainComponentsofShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Common Stock", "terseLabel": "Common Stock\u00a0 Issued at\u00a0Par\u00a0Value", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r904", "r905", "r906", "r908", "r909", "r910", "r911", "r1020", "r1021", "r1023", "r1079", "r1136", "r1137" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (USD per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r80" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r80", "r745" ] }, "bdx_CommonStockSharesHeldInEmployeeTrust1": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bd.com/20241231", "localname": "CommonStockSharesHeldInEmployeeTrust1", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred compensation", "label": "Common Stock, Shares Held in Employee Trust1", "documentation": "Value of common stock issued to a trust (for example, but not limited to, rabbi trust) set up specifically to accumulate stock for the sole purpose of distribution to participating employees." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r80" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock \u2014 $1 par value; authorized \u2014 640,000,000 shares; issued \u2014 370,594,401 shares in December\u00a031, 2024 and September\u00a030, 2024", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r80", "r666", "r888" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r967" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r966" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r968" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r965" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Retirement Benefits [Abstract]", "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive Income", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r23", "r210", "r212", "r218", "r658", "r675", "r676" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.bd.com/role/SegmentDataFinancialInformationforCompanysSegmentsDetail", "http://www.bd.com/role/SegmentDataRevenuesbyGeographicAreasDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]", "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": [ "r132", "r142", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r226", "r260", "r270", "r284", "r285", "r286", "r287", "r288", "r290", "r291", "r292", "r362", "r363", "r364", "r365", "r367", "r368", "r369", "r370", "r371", "r841", "r842", "r1004", "r1005", "r1070", "r1071" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.bd.com/role/SegmentDataFinancialInformationforCompanysSegmentsDetail", "http://www.bd.com/role/SegmentDataRevenuesbyGeographicAreasDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]", "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": [ "r132", "r142", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r226", "r260", "r270", "r284", "r285", "r286", "r287", "r288", "r290", "r291", "r292", "r362", "r363", "r364", "r365", "r367", "r368", "r369", "r370", "r371", "r841", "r842", "r1004", "r1005", "r1070", "r1071" ] }, "bdx_ConsumablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "ConsumablesMember", "presentation": [ "http://www.bd.com/role/RevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consumables", "label": "Consumables [Member]", "documentation": "Consumables [Member]" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.bd.com/role/RevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract with customer, liability", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r406", "r407", "r425" ] }, "bdx_ContractWithCustomerRebateLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bd.com/20241231", "localname": "ContractWithCustomerRebateLiability", "crdr": "credit", "presentation": [ "http://www.bd.com/role/RevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rebate liability", "label": "Contract With Customer, Rebate Liability", "documentation": "Contract With Customer, Rebate Liability" } } }, "auth_ref": [] }, "bdx_CoreAndDevelopedTechnologyNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bd.com/20241231", "localname": "CoreAndDevelopedTechnologyNet", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Developed Technology, Net", "label": "Core And Developed Technology Net", "documentation": "Intangible assets arising from acquisitions. These assets represent acquired intellectual property that is already technologically feasible upon the acquisition date." } } }, "auth_ref": [] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateNonSegmentMember", "presentation": [ "http://www.bd.com/role/SegmentDataFinancialInformationforCompanysSegmentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate, Non-Segment", "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": [ "r15", "r285", "r286", "r287", "r288", "r291", "r1029" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of products sold", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r91", "r92", "r618" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Total Operating Costs and Expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r96" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CurrencySwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrencySwapMember", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesGainsLossesonNetInvestmentHedgesDetails", "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Currency Swap", "label": "Currency Swap [Member]", "documentation": "Swap involving the exchange of principal and interest in one currency for another currency." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRelationshipsMember", "presentation": [ "http://www.bd.com/role/AcquisitionDetails", "http://www.bd.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r57", "r1048", "r1049", "r1050", "r1051", "r1053", "r1054", "r1056", "r1057" ] }, "us-gaap_DebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtCurrent", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current debt obligations", "label": "Debt, Current", "documentation": "Amount of debt and lease obligation, classified as current." } } }, "auth_ref": [ "r193" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r20", "r74", "r75", "r124", "r125", "r226", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r855", "r856", "r857", "r858", "r859", "r887", "r1018", "r1059", "r1060", "r1061", "r1095", "r1096" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r20", "r226", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r855", "r856", "r857", "r858", "r859", "r887", "r1018", "r1059", "r1060", "r1061", "r1095", "r1096" ] }, "us-gaap_DebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtMember", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency-Denominated Debt", "label": "Debt [Member]", "documentation": "Contractual obligation to pay money on demand or on fixed or determinable dates." } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationShareBasedPaymentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationShareBasedPaymentsMember", "presentation": [ "http://www.bd.com/role/ShareholdersEquityChangesinCertainComponentsofShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Compensation", "label": "Deferred Compensation, Share-Based Payments [Member]", "documentation": "Deferred compensation arrangements (such as stock or unit options and share or unit awards) that are equity-based payments with individual employees. The arrangements are generally based on employment contracts between the entity and one or more selected officers or key employees, and contain a promise by the employer to pay certain amounts or benefits at designated future dates, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Other \"sub-members\" can be added as necessary." } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxesAndTaxCredits", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Taxes and Tax Credits", "documentation": "Amount of deferred income tax expense (benefit) and income tax credits." } } }, "auth_ref": [ "r102" ] }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "crdr": "credit", "calculation": { "http://www.bd.com/role/BenefitPlansDetail": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.bd.com/role/BenefitPlansDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Amortization of loss", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan." } } }, "auth_ref": [ "r430", "r468", "r489", "r869", "r870" ] }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "crdr": "debit", "calculation": { "http://www.bd.com/role/BenefitPlansDetail": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bd.com/role/BenefitPlansDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of prior service credit", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan." } } }, "auth_ref": [ "r430", "r469", "r490", "r869", "r870" ] }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanDisclosureLineItems", "presentation": [ "http://www.bd.com/role/BenefitPlansDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan Disclosure [Line Items]", "label": "Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "crdr": "credit", "calculation": { "http://www.bd.com/role/BenefitPlansDetail": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bd.com/role/BenefitPlansDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Expected return on plan assets", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan." } } }, "auth_ref": [ "r430", "r467", "r488", "r869", "r870" ] }, "us-gaap_DefinedBenefitPlanInterestCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanInterestCost", "crdr": "debit", "calculation": { "http://www.bd.com/role/BenefitPlansDetail": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bd.com/role/BenefitPlansDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Interest cost", "label": "Defined Benefit Plan, Interest Cost", "documentation": "Amount of cost recognized for passage of time related to defined benefit plan." } } }, "auth_ref": [ "r430", "r434", "r466", "r487", "r869", "r870" ] }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "crdr": "debit", "calculation": { "http://www.bd.com/role/BenefitPlansDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bd.com/role/BenefitPlansDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Net pension cost", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan." } } }, "auth_ref": [ "r464", "r485", "r869", "r870" ] }, "us-gaap_DefinedBenefitPlanServiceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanServiceCost", "crdr": "debit", "calculation": { "http://www.bd.com/role/BenefitPlansDetail": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bd.com/role/BenefitPlansDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Service cost", "label": "Defined Benefit Plan, Service Cost", "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": [ "r432", "r465", "r486", "r869", "r870" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r8", "r260", "r273", "r290", "r841", "r842" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesAdditionalInformationDetail", "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesGainsLossesonNetInvestmentHedgesDetails", "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r735", "r737", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r758", "r759", "r760", "r761", "r772", "r773", "r774", "r775", "r778", "r779", "r780", "r781", "r796", "r797", "r798", "r799", "r904", "r906", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1090", "r1091" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesAdditionalInformationDetail", "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesGainsLossesonNetInvestmentHedgesDetails", "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r66", "r67", "r68", "r120", "r735", "r737", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r758", "r759", "r760", "r761", "r772", "r773", "r774", "r775", "r778", "r779", "r780", "r781", "r796", "r797", "r798", "r799", "r833", "r904", "r906", "r1083", "r1084", "r1085", "r1086", "r1087", "r1088", "r1090", "r1091" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivities" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r119", "r565", "r573" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesAdditionalInformationDetail", "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesAdditionalInformationDetail", "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]", "label": "Derivative Instruments and Hedging Activities Disclosures [Table]", "documentation": "Disclosure of information about derivatives and hedging activities." } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesAdditionalInformationDetail", "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r14", "r66", "r67" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesGainsLossesonNetInvestmentHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Table]", "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r14", "r66", "r67", "r68", "r70", "r71", "r564" ] }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesGainsLossesonNetInvestmentHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r564" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount of derivative", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r1076", "r1077" ] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://www.bd.com/role/AccountingChangesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r14", "r59", "r60", "r65", "r69", "r225", "r244" ] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DevelopedTechnologyRightsMember", "presentation": [ "http://www.bd.com/role/AcquisitionDetails", "http://www.bd.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Developed technology", "label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": [ "r117", "r1048", "r1049", "r1050", "r1051", "r1053", "r1054", "r1056", "r1057" ] }, "bdx_DiagnosticSolutionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "DiagnosticSolutionsMember", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesbyGeographicAreasDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Diagnostic Solutions", "label": "Diagnostic Solutions [Member]", "documentation": "Diagnostic Solutions" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.bd.com/role/RevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r424", "r861", "r862", "r863", "r864", "r865", "r866", "r867" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.bd.com/role/RevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r424", "r861", "r862", "r863", "r864", "r865", "r866", "r867" ] }, "us-gaap_DividendsCommonStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": [ "http://www.bd.com/role/ShareholdersEquityChangesinCertainComponentsofShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Common dividends", "label": "Dividends, Common Stock, Cash", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash." } } }, "auth_ref": [ "r113" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r917" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r949" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": [ "r960" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Basic Earnings per Share (USD per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r219", "r236", "r237", "r238", "r239", "r240", "r241", "r248", "r250", "r253", "r254", "r255", "r259", "r551", "r558", "r577", "r578", "r659", "r677", "r835" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted Earnings per Share (USD per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r219", "r236", "r237", "r238", "r239", "r240", "r241", "r250", "r253", "r254", "r255", "r259", "r551", "r558", "r577", "r578", "r659", "r677", "r835" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.bd.com/role/EarningsperShare" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r247", "r256", "r257", "r258" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash and equivalents and restricted cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r596" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.bd.com/role/IncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate reconciliation, percent", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r533", "r878" ] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeSeveranceMember", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Termination", "label": "Employee Severance [Member]", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitiesTable", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entities [Table]", "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r915" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r915" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r915" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInformationLineItems", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Information [Line Items]", "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r999" ] }, "dei_EntityListingsExchangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsExchangeAxis", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Listings, Exchange [Axis]", "label": "Entity Listings, Exchange [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r915" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r915" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r915" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r915" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r954" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": [ "r995" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": [ "r995" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r995" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails", "http://www.bd.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossComponentsandChangesofAccumulatedOtherComprehensiveIncomeLossDetail", "http://www.bd.com/role/ShareholdersEquityChangesinCertainComponentsofShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r13", "r180", "r213", "r214", "r215", "r227", "r228", "r229", "r233", "r240", "r242", "r244", "r261", "r301", "r304", "r331", "r405", "r539", "r540", "r546", "r547", "r548", "r552", "r557", "r558", "r566", "r567", "r568", "r569", "r570", "r572", "r576", "r597", "r599", "r600", "r601", "r602", "r603", "r605", "r606", "r609", "r674", "r702", "r703", "r704", "r720", "r784" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r964" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r922", "r932", "r942", "r974" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r919", "r929", "r939", "r971" ] }, "dei_ExchangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ExchangeDomain", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange [Domain]", "label": "Exchange [Domain]", "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r970" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r579", "r580", "r588", "r880" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r579", "r580", "r588", "r880" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments and Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r583", "r585", "r586", "r587", "r590", "r591", "r592", "r593", "r594", "r654", "r880", "r884" ] }, "us-gaap_FairValueHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueHedgingMember", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value hedges", "label": "Fair Value Hedging [Member]", "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk." } } }, "auth_ref": [ "r62" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.bd.com/role/AccountingChangesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments and Fair Value Measurements", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "bdx_FairValueOfDebtClassifiedFromLongTermToShortTerm": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bd.com/20241231", "localname": "FairValueOfDebtClassifiedFromLongTermToShortTerm", "crdr": "credit", "presentation": [ "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of long-term debt", "label": "Fair Value Of Debt Classified From Long Term To Short Term", "documentation": "Fair Value Of Debt Classified From Long Term To Short Term" } } }, "auth_ref": [] }, "bdx_FiniteAndIndefiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.bd.com/20241231", "localname": "FiniteAndIndefiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.bd.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Finite And Indefinite Lived Intangible Assets [Line Items]", "label": "Finite And Indefinite Lived Intangible Assets [Line Items]", "documentation": "Finite And Indefinite Lived Intangible Assets [Line Items]" } } }, "auth_ref": [] }, "bdx_FiniteAndIndefiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.bd.com/20241231", "localname": "FiniteAndIndefiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.bd.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Finite And Indefinite Lived Intangible Assets [Table]", "label": "Finite And Indefinite Lived Intangible Assets [Table]", "documentation": "Finite And Indefinite Lived Intangible Assets [Table]" } } }, "auth_ref": [] }, "bdx_FiniteLivedCustomerRelationshipsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bd.com/20241231", "localname": "FiniteLivedCustomerRelationshipsNet", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Relationships, Net", "label": "Finite Lived Customer Relationships Net", "documentation": "Net carrying amount as of the balance sheet date of an asset acquired in a business combination representing a favorable existing relationship with customers having a finite beneficial life." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.bd.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetail": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bd.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r190", "r305", "r325", "r848" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.bd.com/role/AcquisitionDetails", "http://www.bd.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r318", "r320", "r321", "r322", "r324", "r325", "r328", "r329", "r619", "r623", "r824" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.bd.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetail": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bd.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Carrying Amount", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r305", "r325", "r623", "r848" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.bd.com/role/AcquisitionDetails", "http://www.bd.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r318", "r320", "r321", "r322", "r324", "r325", "r328", "r329", "r824" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.bd.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bd.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Net Carrying Amount", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r619", "r1054" ] }, "bdx_FixedToFloatingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "FixedToFloatingMember", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Swaps", "label": "Fixed To Floating [Member]", "documentation": "Fixed To Floating [Member]" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyCashFlowHedgeGainLossReclassifiedToEarningsNet", "crdr": "credit", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net", "label": "Foreign Currency Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net", "documentation": "The amount of net gains or losses on foreign currency cash flow hedges reclassified during the period to earnings from accumulated other comprehensive income upon the hedged transaction affecting earnings." } } }, "auth_ref": [ "r121" ] }, "bdx_ForeignCurrencyDenominatedDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "ForeignCurrencyDenominatedDebtMember", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesGainsLossesonNetInvestmentHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency-denominated debt", "label": "Foreign Currency-Denominated Debt [Member]", "documentation": "Foreign-Currency Denominated Debt [Member]" } } }, "auth_ref": [] }, "us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignExchangeContractMember", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesAdditionalInformationDetail", "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Exchange Contracts", "label": "Foreign Exchange Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates." } } }, "auth_ref": [ "r833", "r868", "r879", "r880" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r926", "r936", "r946", "r978" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r926", "r936", "r946", "r978" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r926", "r936", "r946", "r978" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r926", "r936", "r946", "r978" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r926", "r936", "r946", "r978" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r959" ] }, "stpr_GA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "GA", "presentation": [ "http://www.bd.com/role/ContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "GEORGIA", "label": "GEORGIA" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bd.com/role/AcquisitionDetails", "http://www.bd.com/role/CondensedConsolidatedBalanceSheets", "http://www.bd.com/role/IntangibleAssetsReconciliationofGoodwillbyBusinessSegmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Goodwill, beginning balance", "periodEndLabel": "Goodwill, ending balance", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r189", "r306", "r655", "r842", "r847", "r881", "r888", "r1037", "r1044" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.bd.com/role/IntangibleAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r1035", "r1047" ] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.bd.com/role/IntangibleAssetsReconciliationofGoodwillbyBusinessSegmentDetail" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Currency translation", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r313" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillLineItems", "presentation": [ "http://www.bd.com/role/IntangibleAssetsReconciliationofGoodwillbyBusinessSegmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r847" ] }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillPurchaseAccountingAdjustments", "crdr": "debit", "presentation": [ "http://www.bd.com/role/IntangibleAssetsReconciliationofGoodwillbyBusinessSegmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price allocation adjustments", "label": "Goodwill, Measurement Period Adjustment", "documentation": "Amount of increase (decrease) from measurement period adjustment of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r0", "r1043" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillRollForward", "presentation": [ "http://www.bd.com/role/IntangibleAssetsReconciliationofGoodwillbyBusinessSegmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingRelationshipDomain", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesAdditionalInformationDetail", "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r14" ] }, "bdx_HerniaProductClaimsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "HerniaProductClaimsMember", "presentation": [ "http://www.bd.com/role/ContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Hernia Product Claims", "label": "HerniaProductClaims [Member]", "documentation": "HerniaProductClaims [Member]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome", "http://www.bd.com/role/SegmentDataFinancialInformationforCompanysSegmentsDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Income Before Income Taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r90", "r129", "r133", "r660", "r672", "r836", "r841", "r1026", "r1028", "r1030", "r1031", "r1032" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "crdr": "credit", "presentation": [ "http://www.bd.com/role/SegmentDataFinancialInformationforCompanysSegmentsDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Total Segment Operating Income", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments." } } }, "auth_ref": [ "r133", "r678", "r836", "r1026", "r1028", "r1030", "r1031", "r1032" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.bd.com/role/ContingenciesDetail", "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r332", "r334", "r345", "r582", "r584", "r589", "r699", "r701", "r769", "r824", "r882", "r1107" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.bd.com/role/ContingenciesDetail", "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r334", "r345", "r582", "r584", "r589", "r699", "r701", "r769", "r824", "r882", "r1107" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.bd.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r224", "r531", "r533", "r534", "r535", "r536", "r537", "r538", "r541", "r543", "r544", "r545", "r719", "r878" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax provision", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r135", "r138", "r243", "r244", "r260", "r276", "r290", "r532", "r533", "r542", "r679", "r878" ] }, "us-gaap_IncreaseDecreaseInOperatingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapital", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in operating assets and liabilities", "label": "Increase (Decrease) in Operating Capital", "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.bd.com/role/ShareholdersEquityChangesinCertainComponentsofShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "bdx_IncreaseDecreaseinPensionBenefitObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bd.com/20241231", "localname": "IncreaseDecreaseinPensionBenefitObligation", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Pension obligation", "label": "Increase (Decrease) in Pension Benefit Obligation", "documentation": "Amount of increase (decrease) in obligation for pension benefits." } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.bd.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r318", "r323", "r327", "r848" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.bd.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Unamortized intangible assets", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r305", "r327", "r848" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.bd.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r318", "r323", "r327", "r848" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r926", "r936", "r946", "r970", "r978", "r982", "r990" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r988" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r918", "r994" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r918", "r994" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r918", "r994" ] }, "bdx_IntegrationAndRestructuringExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "IntegrationAndRestructuringExpenseMember", "presentation": [ "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Integration and Restructuring Expense", "label": "Integration and Restructuring Expense [Member]", "documentation": "Integration and Restructuring Expense" } } }, "auth_ref": [] }, "bdx_IntegrationRestructuringAndTransactionExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bd.com/20241231", "localname": "IntegrationRestructuringAndTransactionExpense", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome", "http://www.bd.com/role/SegmentDataFinancialInformationforCompanysSegmentsDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Integration, restructuring and transaction expense", "negatedLabel": "Integration, restructuring and transaction expense", "label": "Integration, Restructuring and Transaction Expense", "documentation": "Expenses associated with exit or disposal activities pursuant to an authorized plan. Also includes acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; business integration costs, systems integration and conversion costs, and severance and other employee-related costs; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [] }, "us-gaap_IntellectualPropertyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntellectualPropertyMember", "presentation": [ "http://www.bd.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Patents, trademarks and other", "label": "Intellectual Property [Member]", "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights." } } }, "auth_ref": [ "r19", "r1048", "r1049", "r1050", "r1051", "r1053", "r1054", "r1056", "r1057" ] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r272", "r1013" ] }, "us-gaap_InterestIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNet", "crdr": "credit", "presentation": [ "http://www.bd.com/role/SegmentDataFinancialInformationforCompanysSegmentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Net interest expense", "label": "Interest Income (Expense), Operating", "documentation": "Amount of interest income (expense) classified as operating." } } }, "auth_ref": [ "r656", "r1028" ] }, "bdx_InterventionalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "InterventionalMember", "presentation": [ "http://www.bd.com/role/IntangibleAssetsReconciliationofGoodwillbyBusinessSegmentDetail", "http://www.bd.com/role/SegmentDataFinancialInformationforCompanysSegmentsDetail", "http://www.bd.com/role/SegmentDataRevenuesbyGeographicAreasDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Interventional", "verboseLabel": "Interventional", "label": "Interventional [Member]", "documentation": "Interventional [Member]" } } }, "auth_ref": [] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Finished products", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r105", "r830" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r199", "r829", "r888" ] }, "us-gaap_InventoryNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNetAbstract", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories:", "label": "Inventory, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r105", "r832" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r105", "r831" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r260", "r271", "r290", "r841", "r1012" ] }, "bdx_ItalianMedicalDevicePaybackLegislationMatterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "ItalianMedicalDevicePaybackLegislationMatterMember", "presentation": [ "http://www.bd.com/role/ContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Italian Medical Device Payback Legislation Matter", "label": "Italian Medical Device Payback Legislation Matter [Member]", "documentation": "Italian Medical Device Payback Legislation Matter" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities and Shareholders\u2019 Equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r85", "r127", "r669", "r888", "r1019", "r1034", "r1092" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Shareholders\u2019 Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r76", "r185", "r223", "r300", "r362", "r363", "r365", "r366", "r367", "r368", "r369", "r371", "r372", "r560", "r562", "r563", "r595", "r888", "r1070", "r1097", "r1098" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current Liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "bdx_LifeSciencesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "LifeSciencesMember", "presentation": [ "http://www.bd.com/role/IntangibleAssetsReconciliationofGoodwillbyBusinessSegmentDetail", "http://www.bd.com/role/SegmentDataFinancialInformationforCompanysSegmentsDetail", "http://www.bd.com/role/SegmentDataRevenuesbyGeographicAreasDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Life Sciences", "verboseLabel": "Life\u00a0Sciences", "label": "Life Sciences [Member]", "documentation": "Life Sciences [Member]" } } }, "auth_ref": [] }, "us-gaap_LoansPayableFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansPayableFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "label": "Loans Payable, Fair Value Disclosure", "documentation": "Fair value portion of contractual obligation to pay money on demand or on fixed or determinable dates." } } }, "auth_ref": [ "r1081", "r1089" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Long-Term Debt", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r194" ] }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": [ "http://www.bd.com/role/ContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency Nature [Axis]", "label": "Loss Contingency Nature [Axis]", "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": [ "r355", "r356", "r357", "r361", "r529", "r710", "r854", "r1066", "r1067" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.bd.com/role/ContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r355", "r356", "r357", "r361", "r529", "r854", "r1066", "r1067" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": [ "http://www.bd.com/role/ContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": [ "r355", "r356", "r357", "r361", "r529", "r854", "r1066", "r1067" ] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": [ "http://www.bd.com/role/ContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency accrual", "label": "Loss Contingency Accrual", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": [ "r355", "r1001" ] }, "us-gaap_LossContingencyAccrualProductLiabilityNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualProductLiabilityNet", "crdr": "credit", "presentation": [ "http://www.bd.com/role/ContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency accrual, product liability, net", "label": "Loss Contingency Accrual, Product Liability, Net", "documentation": "Present value of the estimated aggregate accrual for damages arising from third-party use of the entity's product(s) or process(es) as of the balance sheet date (if the accrual qualifies for discounting)." } } }, "auth_ref": [ "r358", "r1065" ] }, "us-gaap_LossContingencyDamagesSoughtValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyDamagesSoughtValue", "crdr": "debit", "presentation": [ "http://www.bd.com/role/ContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, damages sought, value", "label": "Loss Contingency, Damages Sought, Value", "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter." } } }, "auth_ref": [ "r1065", "r1066", "r1067" ] }, "us-gaap_LossContingencyLossInPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyLossInPeriod", "crdr": "debit", "presentation": [ "http://www.bd.com/role/ContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, loss in period", "label": "Loss Contingency, Loss in Period", "documentation": "The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates." } } }, "auth_ref": [ "r1065" ] }, "us-gaap_LossContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyNatureDomain", "presentation": [ "http://www.bd.com/role/ContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Nature [Domain]", "label": "Loss Contingency, Nature [Domain]", "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability." } } }, "auth_ref": [ "r355", "r356", "r357", "r361", "r529", "r710", "r854", "r1066", "r1067" ] }, "us-gaap_LossContingencyNumberOfPlaintiffs": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyNumberOfPlaintiffs", "presentation": [ "http://www.bd.com/role/ContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, number of plaintiffs", "label": "Loss Contingency, Number of Plaintiffs", "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency." } } }, "auth_ref": [ "r1066", "r1067" ] }, "us-gaap_LossContingencyPendingClaimsNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyPendingClaimsNumber", "presentation": [ "http://www.bd.com/role/ContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Pending claims", "label": "Loss Contingency, Pending Claims, Number", "documentation": "Number of pending claims pertaining to a loss contingency." } } }, "auth_ref": [ "r1066", "r1067" ] }, "us-gaap_MaterialReconcilingItemsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MaterialReconcilingItemsMember", "presentation": [ "http://www.bd.com/role/SegmentDataFinancialInformationforCompanysSegmentsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reconciling Items", "label": "Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]", "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity." } } }, "auth_ref": [ "r285", "r288", "r291", "r841", "r842" ] }, "bdx_MaturityPeriodOfShortTermInvestment": { "xbrltype": "durationItemType", "nsuri": "http://www.bd.com/20241231", "localname": "MaturityPeriodOfShortTermInvestment", "presentation": [ "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity period of short-term investments at the time of purchase", "label": "Maturity Period Of Short Term Investment", "documentation": "The maturity period of time deposits classified as short-term investments in the consolidated balance sheet." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.bd.com/role/ContingenciesDetail", "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r143", "r145", "r147", "r148", "r150", "r178", "r179", "r356", "r357", "r359", "r360", "r500", "r529", "r581", "r617", "r698", "r700", "r710", "r736", "r737", "r789", "r791", "r793", "r794", "r800", "r822", "r823", "r846", "r860", "r877", "r883", "r884", "r885", "r886", "r898", "r1072", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r962" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r962" ] }, "bdx_MedicalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "MedicalMember", "presentation": [ "http://www.bd.com/role/IntangibleAssetsReconciliationofGoodwillbyBusinessSegmentDetail", "http://www.bd.com/role/SegmentDataFinancialInformationforCompanysSegmentsDetail", "http://www.bd.com/role/SegmentDataRevenuesbyGeographicAreasDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Medical", "label": "Medical [Member]", "documentation": "Medical." } } }, "auth_ref": [] }, "bdx_MedicationDeliverySolutionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "MedicationDeliverySolutionsMember", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesbyGeographicAreasDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Medication Delivery Solutions", "label": "Medication Delivery Solutions [Member]", "documentation": "Medication Delivery Solutions [Member]" } } }, "auth_ref": [] }, "bdx_MedicationManagementSolutionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "MedicationManagementSolutionsMember", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesbyGeographicAreasDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Medication Management Solutions", "label": "Medication Management Solutions [Member]", "documentation": "Medication Management Solutions [Member]" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r143", "r145", "r147", "r148", "r150", "r178", "r179", "r356", "r357", "r359", "r360", "r500", "r529", "r581", "r617", "r698", "r700", "r710", "r736", "r737", "r789", "r791", "r793", "r794", "r800", "r822", "r823", "r846", "r860", "r877", "r883", "r884", "r885", "r898", "r1072", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r981" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r989" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r963" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Used for Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r220" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Provided by (Used for) Investing Activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r220" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Investing Activities", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Provided by Continuing Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r100", "r101", "r102" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 2.0 }, "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.bd.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome", "http://www.bd.com/role/ShareholdersEquityChangesinCertainComponentsofShareholdersEquityDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net Income", "terseLabel": "Net Income", "netLabel": "Net income", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r93", "r102", "r130", "r183", "r208", "r211", "r215", "r223", "r232", "r236", "r237", "r238", "r239", "r240", "r243", "r244", "r252", "r300", "r362", "r363", "r365", "r366", "r367", "r368", "r369", "r371", "r372", "r551", "r558", "r578", "r595", "r673", "r765", "r782", "r783", "r912", "r1070" ] }, "us-gaap_NetInvestmentHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetInvestmentHedgingMember", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Net investment hedges", "label": "Net Investment Hedging [Member]", "documentation": "Hedges of a net investment in a foreign operation." } } }, "auth_ref": [ "r64" ] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "presentation": [ "http://www.bd.com/role/AccountingChanges" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Changes", "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle." } } }, "auth_ref": [ "r139", "r181", "r230", "r231", "r234", "r235", "r245", "r246", "r298", "r302", "r303", "r549", "r550", "r552", "r558", "r571", "r575", "r608", "r610", "r611", "r620", "r621", "r622", "r705", "r706", "r707", "r708", "r709" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.bd.com/role/AccountingChangesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "New Accounting Principle Adopted and New Accounting Principles Not Yet Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r962" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r926", "r936", "r946", "r970", "r978" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r953" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r952" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r970" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r989" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r989" ] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonUsMember", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesbyGeographicAreasDetail" ], "lang": { "en-us": { "role": { "terseLabel": "International", "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r1138", "r1139", "r1140", "r1141" ] }, "bdx_Notes0034DueAugust132025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "Notes0034DueAugust132025Member", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Notes 0.034% due August 13, 2025", "label": "Notes 0.034% due August 13, 2025 [Member]", "documentation": "Notes 0.034% due August 13, 2025" } } }, "auth_ref": [] }, "bdx_Notes1.208dueJune42026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "Notes1.208dueJune42026Member", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Notes 1.208% due June 4, 2026", "label": "Notes 1.208% due June 4, 2026 [Member]", "documentation": "Notes 1.208% due June 4, 2026 [Member]" } } }, "auth_ref": [] }, "bdx_Notes1.900dueDecember152026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "Notes1.900dueDecember152026Member", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Notes 1.900% due December 15, 2026", "label": "Notes 1.900% due December 15, 2026 [Member]", "documentation": "Notes 1.900% due December 15, 2026 [Member]" } } }, "auth_ref": [] }, "bdx_Notes1213NotesDueFebruary122036Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "Notes1213NotesDueFebruary122036Member", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Notes 1.213% Notes due February 12, 2036", "label": "Notes 1.213% Notes due February 12, 2036 [Member]", "documentation": "Notes 1.213% Notes due February 12, 2036" } } }, "auth_ref": [] }, "bdx_Notes3.020dueMay242025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "Notes3.020dueMay242025Member", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Notes 3.020% due May 24, 2025", "label": "Notes 3.020% due May 24, 2025 [Member]", "documentation": "Notes 3.020% due May 24, 2025 [Member]" } } }, "auth_ref": [] }, "bdx_Notes3.519DueFebruary82031Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "Notes3.519DueFebruary82031Member", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Notes 3.519% due February 8, 2031", "label": "Notes 3.519% due February 8, 2031 [Member]", "documentation": "Notes 3.519% due February 8, 2031" } } }, "auth_ref": [] }, "bdx_Notes3.828DueJune72032Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "Notes3.828DueJune72032Member", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Notes 3.828% due June 7, 2032", "label": "Notes 3.828% due June 7, 2032 [Member]", "documentation": "Notes 3.828% due June 7, 2032" } } }, "auth_ref": [] }, "bdx_NumberOfEtOSterilizationLawsuitsAllegeInjuryFromUnrelatedDefendants": { "xbrltype": "integerItemType", "nsuri": "http://www.bd.com/20241231", "localname": "NumberOfEtOSterilizationLawsuitsAllegeInjuryFromUnrelatedDefendants", "presentation": [ "http://www.bd.com/role/ContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of EtO sterilization lawsuits, allege injury from unrelated defendants", "label": "Number of EtO Sterilization Lawsuits, Allege Injury From Unrelated Defendants", "documentation": "Number of EtO Sterilization Lawsuits, Allege Injury From Unrelated Defendants" } } }, "auth_ref": [] }, "bdx_NumberOfEtOSterilizationLawsuitsFiled": { "xbrltype": "integerItemType", "nsuri": "http://www.bd.com/20241231", "localname": "NumberOfEtOSterilizationLawsuitsFiled", "presentation": [ "http://www.bd.com/role/ContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of EtO lawsuits filed", "label": "Number Of EtO Sterilization Lawsuits Filed", "documentation": "Number Of EtO Sterilization Lawsuits Filed" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.bd.com/role/SegmentDataAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of principal business segments (segment)", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r842", "r1027" ] }, "bdx_OfficerTradingArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "OfficerTradingArrangementMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Officer Trading Arrangement [Member]", "documentation": "Officer Trading Arrangement" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Operating Income", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r133", "r836", "r1026", "r1028", "r1030", "r1031", "r1032" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.bd.com/role/SegmentDataFinancialInformationforCompanysSegmentsDetail", "http://www.bd.com/role/SegmentDataRevenuesbyGeographicAreasDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r284", "r285", "r286", "r287", "r288", "r291", "r841", "r842" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.bd.com/role/BasisofPresentation" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r72", "r118", "r711", "r712" ] }, "bdx_OrganizationalUnitAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.bd.com/20241231", "localname": "OrganizationalUnitAxis", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesbyGeographicAreasDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Organizational Unit [Axis]", "label": "Organizational Unit [Axis]", "documentation": "Organizational Unit [Axis]" } } }, "auth_ref": [] }, "bdx_OrganizationalUnitDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "OrganizationalUnitDomain", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesbyGeographicAreasDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Organizational Unit [Domain]", "label": "Organizational Unit [Domain]", "documentation": "[Domain] for Organizational Unit [Axis]" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r200", "r888" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other Assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r191" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "crdr": "credit", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossComponentsandChangesofAccumulatedOtherComprehensiveIncomeLossDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income before reclassifications, net of taxes", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r18", "r22", "r214", "r597", "r600", "r603", "r674", "r1009" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r202", "r206", "r674" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flow hedges", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r206" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesGainsLossesonNetInvestmentHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments", "verboseLabel": "Net gains (losses) recorded to Accumulated other comprehensive income (loss), net of tax", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r4", "r674" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Other Comprehensive Income, Net of Tax", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r13", "r18", "r209", "r212", "r217", "r240", "r597", "r598", "r603", "r657", "r674", "r1009", "r1010" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income (Loss), Net of Tax", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "negatedLabel": "Defined benefit pension and postretirement plans", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan." } } }, "auth_ref": [ "r5", "r6", "r88", "r89", "r674" ] }, "bdx_OtherInitiativesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "OtherInitiativesMember", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Other Initiatives", "label": "Other Initiatives [Member]", "documentation": "Other Initiatives [Member]" } } }, "auth_ref": [] }, "us-gaap_OtherIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other Intangibles, Net", "label": "Other Intangible Assets, Net", "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Income Taxes and Other Liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r77" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Other expense, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r95" ] }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other, net", "label": "Other Operating Activities, Cash Flow Statement", "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)." } } }, "auth_ref": [] }, "us-gaap_OtherOperatingIncomeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingIncomeExpenseMember", "presentation": [ "http://www.bd.com/role/ContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Other Operating Income (Expense)", "label": "Other Operating Income (Expense) [Member]", "documentation": "Primary financial statement caption encompassing other operating income (expense)." } } }, "auth_ref": [] }, "us-gaap_OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other operating expense, net", "label": "Other Operating Income (Expense), Net", "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r962" ] }, "us-gaap_OtherRestructuringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherRestructuringMember", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Restructuring [Member]", "documentation": "Restructuring and related activities classified as other." } } }, "auth_ref": [ "r850", "r851", "r852", "r853" ] }, "us-gaap_OtherShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherShortTermInvestments", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Other Short-Term Investments", "documentation": "Amount of short-term investments classified as other." } } }, "auth_ref": [ "r128", "r662", "r663", "r1007" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r924", "r934", "r944", "r976" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r927", "r937", "r947", "r979" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r927", "r937", "r947", "r979" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r951" ] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other, net", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r1002", "r1014" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchases of common stock", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r98" ] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash payments", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r344", "r1016" ] }, "us-gaap_PaymentsOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividends", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Dividends paid", "label": "Payments of Dividends", "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests." } } }, "auth_ref": [ "r98" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisitions, net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r25" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Capital expenditures", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r97" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r961" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r961" ] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [ "http://www.bd.com/role/BenefitPlans" ], "lang": { "en-us": { "role": { "terseLabel": "Benefit Plans", "label": "Retirement Benefits [Text Block]", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r427", "r452", "r454", "r460", "r477", "r479", "r480", "r481", "r482", "r483", "r495", "r496", "r497", "r869" ] }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Employee Benefit Obligations", "label": "Liability, Defined Benefit Plan, Noncurrent", "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent." } } }, "auth_ref": [ "r77", "r428", "r429", "r451", "r869" ] }, "us-gaap_PensionPlansDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionPlansDefinedBenefitMember", "presentation": [ "http://www.bd.com/role/BenefitPlansDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Plans", "label": "Pension Plan [Member]", "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits." } } }, "auth_ref": [ "r428", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r478", "r481", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r497", "r498", "r501", "r869", "r870", "r874", "r875", "r876" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r953" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r970" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r963" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r952" ] }, "bdx_PeripheralInterventionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "PeripheralInterventionMember", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesbyGeographicAreasDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Peripheral Intervention", "label": "Peripheral Intervention [Member]", "documentation": "Peripheral Intervention [Member]" } } }, "auth_ref": [] }, "bdx_PharmaceuticalSystemsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "PharmaceuticalSystemsMember", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesbyGeographicAreasDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Pharmaceutical Systems", "label": "Pharmaceutical Systems [Member]", "documentation": "Pharmaceutical Systems [Member]" } } }, "auth_ref": [] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": [ "r954" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r998" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r953" ] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other, net", "label": "Proceeds from (Payments for) Other Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": [ "r1003", "r1015" ] }, "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRepaymentsOfShortTermDebt", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Change in short-term debt", "label": "Proceeds from (Repayments of) Short-Term Debt", "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Maturities and sales of investments", "label": "Proceeds from Sale, Maturity and Collection of Investments", "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period." } } }, "auth_ref": [ "r24" ] }, "us-gaap_ProductLiabilityAccrualPeriodExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductLiabilityAccrualPeriodExpense", "crdr": "debit", "presentation": [ "http://www.bd.com/role/ContingenciesDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Product liability accrual, pre-tax credit", "label": "Product Liability Accrual, Period Expense", "documentation": "The amount of loss reported during the period pertaining to product liability." } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.bd.com/role/ContingenciesDetail", "http://www.bd.com/role/RevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r152", "r153", "r154", "r155", "r156", "r157", "r177", "r293", "r618", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r826", "r861", "r897", "r898", "r899", "r902", "r903", "r1006", "r1068", "r1069", "r1075", "r1106", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.bd.com/role/ContingenciesDetail", "http://www.bd.com/role/RevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r152", "r153", "r154", "r155", "r156", "r157", "r177", "r293", "r618", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r826", "r861", "r897", "r898", "r899", "r902", "r903", "r1006", "r1068", "r1069", "r1075", "r1106", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135" ] }, "bdx_ProductsWithinMassTortLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "ProductsWithinMassTortLitigationMember", "presentation": [ "http://www.bd.com/role/ContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Products Within Mass Tort Litigation", "label": "Products Within Mass Tort Litigation [Member]", "documentation": "Products Within Mass Tort Litigation" } } }, "auth_ref": [] }, "bdx_ProductsandorServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "ProductsandorServicesMember", "presentation": [ "http://www.bd.com/role/RevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Products and/or Services", "label": "Products and/or Services [Member]", "documentation": "Products and/or Services [Member]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r106", "r187", "r671" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Property, Plant and Equipment, Net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r9", "r607", "r661", "r671", "r888" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r951" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r951" ] }, "bdx_PyxisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "PyxisMember", "presentation": [ "http://www.bd.com/role/ContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Pyxis", "label": "Pyxis [Member]", "documentation": "Pyxis" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.bd.com/role/ContingenciesDetail", "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r143", "r145", "r147", "r148", "r150", "r178", "r179", "r356", "r357", "r359", "r360", "r452", "r500", "r525", "r526", "r527", "r529", "r581", "r615", "r616", "r617", "r698", "r700", "r710", "r736", "r737", "r789", "r791", "r793", "r794", "r800", "r822", "r823", "r846", "r860", "r877", "r883", "r884", "r885", "r886", "r898", "r906", "r1062", "r1072", "r1082", "r1100", "r1101", "r1102", "r1103", "r1104" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.bd.com/role/ContingenciesDetail", "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r143", "r145", "r147", "r148", "r150", "r178", "r179", "r356", "r357", "r359", "r360", "r452", "r500", "r525", "r526", "r527", "r529", "r581", "r615", "r616", "r617", "r698", "r700", "r710", "r736", "r737", "r789", "r791", "r793", "r794", "r800", "r822", "r823", "r846", "r860", "r877", "r883", "r884", "r885", "r886", "r898", "r906", "r1062", "r1072", "r1082", "r1100", "r1101", "r1102", "r1103", "r1104" ] }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "crdr": "debit", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossComponentsandChangesofAccumulatedOtherComprehensiveIncomeLossDetail" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amounts reclassified into income, net of taxes", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r18", "r22", "r214", "r597", "r602", "r603", "r674", "r1009" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r919", "r929", "r939", "r971" ] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments of debt", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r99", "r717" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expense", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r530", "r824", "r841", "r1105" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r920", "r930", "r940", "r972" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r921", "r931", "r941", "r973" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r928", "r938", "r948", "r980" ] }, "us-gaap_RestrictedCashAndInvestmentsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndInvestmentsCurrent", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsCashandEquivalentsandRestrictedCashDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets", "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsCashandEquivalentsandRestrictedCashDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "verboseLabel": "Restricted cash", "label": "Restricted Cash and Investments, Current", "documentation": "The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal." } } }, "auth_ref": [ "r809", "r810", "r1008" ] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Activities [Abstract]", "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://www.bd.com/role/BusinessRestructuringCharges" ], "lang": { "en-us": { "role": { "terseLabel": "Business Restructuring Charges", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r341", "r342", "r344", "r347", "r352" ] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Charged to expense", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r8", "r348", "r349", "r1063" ] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Type [Axis]", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r343", "r344", "r349", "r350" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r343", "r344", "r345", "r346", "r349", "r350", "r351" ] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanAxis", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Axis]", "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanDomain", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r344", "r350" ] }, "us-gaap_RestructuringReserveAccrualAdjustment1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveAccrualAdjustment1", "crdr": "debit", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesDetail" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other adjustments", "label": "Restructuring Reserve, Accrual Adjustment", "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability." } } }, "auth_ref": [ "r344", "r350" ] }, "us-gaap_RestructuringReserveRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveRollForward", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve [Roll Forward]", "label": "Restructuring Reserve [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserveSettledWithoutCash2": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveSettledWithoutCash2", "crdr": "debit", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesDetail" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Non-cash settlements", "label": "Restructuring Reserve, Settled without Cash", "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash." } } }, "auth_ref": [ "r344", "r350" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r82", "r113", "r668", "r705", "r709", "r718", "r746", "r888" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.bd.com/role/ShareholdersEquityChangesinCertainComponentsofShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r180", "r227", "r228", "r229", "r233", "r240", "r242", "r244", "r301", "r304", "r331", "r539", "r540", "r546", "r547", "r548", "r552", "r557", "r558", "r566", "r568", "r569", "r572", "r576", "r605", "r606", "r702", "r704", "r720", "r1137" ] }, "us-gaap_RetirementPlanTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanTypeAxis", "presentation": [ "http://www.bd.com/role/BenefitPlansDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Axis]", "label": "Retirement Plan Type [Axis]", "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r428", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r478", "r481", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r497", "r498", "r499", "r501", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876" ] }, "us-gaap_RetirementPlanTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanTypeDomain", "presentation": [ "http://www.bd.com/role/BenefitPlansDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Domain]", "label": "Retirement Plan Type [Domain]", "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": [ "r428", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r478", "r481", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r497", "r498", "r499", "r501", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.bd.com/role/AccountingChangesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r140", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r825" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.bd.com/role/Revenues" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r140", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r426" ] }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": [ "http://www.bd.com/role/SegmentDataTables" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from External Customers by Geographic Area", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue." } } }, "auth_ref": [ "r103" ] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [ "http://www.bd.com/role/RevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, remaining performance obligation, amount", "label": "Revenue, Remaining Performance Obligation, Amount", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r136" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": [ "http://www.bd.com/role/RevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction (in years)", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r137" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": [ "http://www.bd.com/role/RevenuesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format." } } }, "auth_ref": [ "r137" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome", "http://www.bd.com/role/SegmentDataRevenuesbyGeographicAreasDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r131", "r132", "r216", "r223", "r260", "r269", "r270", "r284", "r290", "r293", "r295", "r297", "r300", "r362", "r363", "r365", "r366", "r367", "r368", "r369", "r371", "r372", "r595", "r660", "r841", "r1070" ] }, "bdx_RichardByrdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "RichardByrdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Richard Byrd [Member]", "documentation": "Richard Byrd" } } }, "auth_ref": [] }, "bdx_RichardByrdTradingArrangementCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "RichardByrdTradingArrangementCommonStockMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Richard Byrd, Trading Arrangement, Common Stock [Member]", "documentation": "Richard Byrd, Trading Arrangement, Common Stock" } } }, "auth_ref": [] }, "bdx_RichardByrdTradingArrangementCommonStockUponTheVestingOfPerformanceUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "RichardByrdTradingArrangementCommonStockUponTheVestingOfPerformanceUnitsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Richard Byrd, Trading Arrangement, Common Stock Upon The Vesting Of Performance Units [Member]", "documentation": "Richard Byrd, Trading Arrangement, Common Stock Upon The Vesting Of Performance Units" } } }, "auth_ref": [] }, "bdx_RichardByrdTradingArrangementCommonStockUponTheVestingOfTimeVestedUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "RichardByrdTradingArrangementCommonStockUponTheVestingOfTimeVestedUnitsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Richard Byrd, Trading Arrangement, Common Stock Upon The Vesting Of Time Vested Units [Member]", "documentation": "Richard Byrd, Trading Arrangement, Common Stock Upon The Vesting Of Time Vested Units" } } }, "auth_ref": [] }, "bdx_RichardByrdTradingArrangementStockAppreciationRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "RichardByrdTradingArrangementStockAppreciationRightsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Richard Byrd, Trading Arrangement, Stock Appreciation Rights [Member]", "documentation": "Richard Byrd, Trading Arrangement, Stock Appreciation Rights" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r989" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r989" ] }, "bdx_SECMatterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "SECMatterMember", "presentation": [ "http://www.bd.com/role/ContingenciesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Matter", "label": "SEC Matter [Member]", "documentation": "SEC Matter" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.bd.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r22", "r1093", "r1094" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.bd.com/role/EarningsperShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r29" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.bd.com/role/AcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": [ "r52", "r53", "r555" ] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash and Cash Equivalents", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": [ "http://www.bd.com/role/BenefitPlansDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]", "label": "Defined Benefit Plan [Table]", "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r10", "r45", "r46", "r47", "r48" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r1080", "r1081" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://www.bd.com/role/IntangibleAssetsReconciliationofGoodwillbyBusinessSegmentDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill [Table]", "label": "Goodwill [Table]", "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason." } } }, "auth_ref": [ "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r847" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.bd.com/role/IntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Goodwill by Business Segment", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r847", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046" ] }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "presentation": [ "http://www.bd.com/role/IntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Components of Intangible Assets", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class." } } }, "auth_ref": [ "r1035", "r1047" ] }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "presentation": [ "http://www.bd.com/role/BenefitPlansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Net Pension and Postretirement Cost", "label": "Schedule of Net Benefit Costs [Table Text Block]", "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments." } } }, "auth_ref": [ "r115" ] }, "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss)", "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period." } } }, "auth_ref": [ "r1078" ] }, "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Notional Amounts of Outstanding Derivative Positions", "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]", "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions." } } }, "auth_ref": [ "r61" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": [ "r343", "r344", "r345", "r346", "r349", "r350", "r351" ] }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Restructuring Accrual Activity", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } } }, "auth_ref": [ "r35", "r107" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.bd.com/role/SegmentDataFinancialInformationforCompanysSegmentsDetail", "http://www.bd.com/role/SegmentDataRevenuesbyGeographicAreasDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r30", "r31", "r32" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.bd.com/role/SegmentDataTables" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Information for Company's Segments", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r30", "r31", "r32" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r37", "r38", "r39", "r40", "r41", "r42", "r109", "r111", "r112", "r113", "r195", "r196", "r197", "r262", "r390", "r391", "r392", "r394", "r397", "r402", "r404", "r714", "r715", "r716", "r717", "r860", "r1000", "r1017" ] }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityTableTextBlock", "presentation": [ "http://www.bd.com/role/ShareholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Shareholders Equity", "label": "Schedule of Stockholders Equity [Table Text Block]", "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented." } } }, "auth_ref": [ "r13" ] }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "presentation": [ "http://www.bd.com/role/EarningsperShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Common Shares Used in Computations of Basic and Diluted Earnings Per Share", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)." } } }, "auth_ref": [ "r28" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r914" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r916" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [ "http://www.bd.com/role/IntangibleAssetsReconciliationofGoodwillbyBusinessSegmentDetail", "http://www.bd.com/role/SegmentDataFinancialInformationforCompanysSegmentsDetail", "http://www.bd.com/role/SegmentDataRevenuesbyGeographicAreasDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r131", "r132", "r133", "r134", "r260", "r265", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r290", "r291", "r292", "r297", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r330", "r346", "r351", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r838", "r841", "r842", "r847", "r901", "r1106", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.bd.com/role/ContingenciesDetail", "http://www.bd.com/role/SegmentDataRevenuesbyGeographicAreasDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": [ "r144", "r146", "r149", "r151", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r295", "r296", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r732", "r733", "r734", "r790", "r792", "r795", "r801", "r808", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r827", "r862", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r900", "r906", "r1075", "r1106", "r1108", "r1109", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.bd.com/role/SegmentData" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Data", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r134", "r260", "r264", "r265", "r266", "r267", "r268", "r280", "r282", "r283", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r297", "r837", "r839", "r840", "r841", "r843", "r844", "r845" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.bd.com/role/SegmentDataFinancialInformationforCompanysSegmentsDetail", "http://www.bd.com/role/SegmentDataRevenuesbyGeographicAreasDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Selling and administrative expense", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r94" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Award Types", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528" ] }, "bdx_ShareBasedCompensationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "ShareBasedCompensationMember", "presentation": [ "http://www.bd.com/role/EarningsperShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share Based Compensation", "label": "Share Based Compensation [Member]", "documentation": "Share Based Compensation [Member]" } } }, "auth_ref": [] }, "srt_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramAxis", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails", "http://www.bd.com/role/ShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Axis]", "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth_ref": [ "r1074" ] }, "srt_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramDomain", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails", "http://www.bd.com/role/ShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Domain]", "label": "Share Repurchase Program [Domain]", "documentation": "Name of share repurchase program." } } }, "auth_ref": [ "r1074" ] }, "us-gaap_ShareRepurchaseProgramExciseTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareRepurchaseProgramExciseTax", "crdr": "debit", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share repurchase program, excise tax", "label": "Share Repurchase Program, Excise Tax", "documentation": "Amount of excise tax on share purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [ "r1073" ] }, "bdx_SpecimenManagementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "SpecimenManagementMember", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesbyGeographicAreasDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Specimen Management", "label": "Specimen Management [Member]", "documentation": "Specimen Management" } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.bd.com/role/IntangibleAssetsReconciliationofGoodwillbyBusinessSegmentDetail", "http://www.bd.com/role/SegmentDataFinancialInformationforCompanysSegmentsDetail", "http://www.bd.com/role/SegmentDataRevenuesbyGeographicAreasDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r131", "r132", "r133", "r134", "r182", "r260", "r265", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r290", "r291", "r292", "r297", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r330", "r333", "r346", "r351", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r838", "r841", "r842", "r847", "r901", "r1106", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.bd.com/role/CoverPage", "http://www.bd.com/role/ShareholdersEquityChangesinCertainComponentsofShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r141", "r195", "r196", "r197", "r223", "r250", "r251", "r253", "r255", "r262", "r263", "r300", "r362", "r365", "r366", "r367", "r371", "r372", "r390", "r391", "r394", "r397", "r404", "r595", "r714", "r715", "r716", "r717", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r745", "r766", "r784", "r802", "r803", "r804", "r805", "r806", "r1000", "r1017", "r1024" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails", "http://www.bd.com/role/ShareholdersEquityAccumulatedOtherComprehensiveIncomeLossComponentsandChangesofAccumulatedOtherComprehensiveIncomeLossDetail", "http://www.bd.com/role/ShareholdersEquityChangesinCertainComponentsofShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r13", "r80", "r83", "r84", "r180", "r213", "r214", "r215", "r227", "r228", "r229", "r233", "r240", "r242", "r244", "r261", "r301", "r304", "r331", "r405", "r539", "r540", "r546", "r547", "r548", "r552", "r557", "r558", "r566", "r567", "r568", "r569", "r570", "r572", "r576", "r597", "r599", "r600", "r601", "r602", "r603", "r605", "r606", "r609", "r674", "r702", "r703", "r704", "r720", "r784" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.bd.com/role/ContingenciesDetail", "http://www.bd.com/role/SegmentDataRevenuesbyGeographicAreasDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r144", "r146", "r149", "r151", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r295", "r296", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r732", "r733", "r734", "r790", "r792", "r795", "r801", "r808", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r827", "r862", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r900", "r906", "r1075", "r1106", "r1108", "r1109", "r1111", "r1112", "r1113", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119", "r1120", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.bd.com/role/ShareholdersEquityChangesinCertainComponentsofShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r227", "r228", "r229", "r261", "r606", "r618", "r713", "r731", "r738", "r739", "r740", "r741", "r742", "r743", "r745", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r758", "r759", "r760", "r761", "r762", "r764", "r767", "r768", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r784", "r907" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.bd.com/role/ShareholdersEquityChangesinCertainComponentsofShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r227", "r228", "r229", "r261", "r299", "r606", "r618", "r713", "r731", "r738", "r739", "r740", "r741", "r742", "r743", "r745", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r758", "r759", "r760", "r761", "r762", "r764", "r767", "r768", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r784", "r907" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r923", "r933", "r943", "r975" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://www.bd.com/role/ShareholdersEquityChangesinCertainComponentsofShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock issued for share-based compensation and other plans, net (in shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r13", "r79", "r80", "r113" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.bd.com/role/ShareholdersEquityChangesinCertainComponentsofShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares under employee and other plans, net", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r49", "r79", "r80", "r113" ] }, "srt_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails", "http://www.bd.com/role/ShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, authorized amount", "label": "Share Repurchase Program, Authorized, Amount", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [ "r1074" ] }, "bdx_StockRepurchaseProgramExciseTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bd.com/20241231", "localname": "StockRepurchaseProgramExciseTax", "crdr": "debit", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Repurchase Program, Excise Tax", "label": "Stock Repurchase Program, Excise Tax", "documentation": "Stock Repurchase Program, Excise Tax" } } }, "auth_ref": [] }, "bdx_StockRepurchaseProgramExciseTaxPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.bd.com/20241231", "localname": "StockRepurchaseProgramExciseTaxPercentage", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails", "http://www.bd.com/role/ShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of excise tax excluded", "label": "Stock Repurchase Program, Excise Tax, Percentage", "documentation": "Stock Repurchase Program, Excise Tax, Percentage" } } }, "auth_ref": [] }, "bdx_StockRepurchaseProgramNumberOfAdditionalSharesAuthorizedToBeRepurchased": { "xbrltype": "sharesItemType", "nsuri": "http://www.bd.com/20241231", "localname": "StockRepurchaseProgramNumberOfAdditionalSharesAuthorizedToBeRepurchased", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of additional shares authorized to be repurchased (in shares)", "label": "Stock Repurchase Program, Number of Additional Shares Authorized to be Repurchased", "documentation": "Stock Repurchase Program, Number of Additional Shares Authorized to be Repurchased" } } }, "auth_ref": [] }, "srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program, Authorized, Number of Shares", "label": "Share Repurchase Program, Authorized, Number of Shares", "documentation": "Number of shares authorized to be purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [ "r1074" ] }, "us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program, Remaining Authorized, Number of Shares", "label": "Share Repurchase Program, Remaining Authorized, Number of Shares", "documentation": "Number of shares remaining authorized to be purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets", "http://www.bd.com/role/ShareholdersEquityChangesinCertainComponentsofShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Shareholders\u2019 Equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r80", "r83", "r84", "r104", "r747", "r763", "r785", "r786", "r888", "r913", "r1019", "r1034", "r1092", "r1137" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders\u2019 Equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity Note [Abstract]", "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.bd.com/role/ShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders' Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r110", "r222", "r389", "r391", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r403", "r405", "r574", "r787", "r788", "r807" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails", "http://www.bd.com/role/ShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r604", "r613" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails", "http://www.bd.com/role/ShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r604", "r613" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails", "http://www.bd.com/role/ShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r604", "r613" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events [Abstract]", "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.bd.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r612", "r614" ] }, "us-gaap_SupplierFinanceProgramObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierFinanceProgramObligation", "crdr": "credit", "presentation": [ "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier finance program, obligation", "label": "Supplier Finance Program, Obligation", "documentation": "Amount of obligation for supplier finance program." } } }, "auth_ref": [ "r336", "r337", "r338", "r339", "r340", "r849" ] }, "us-gaap_SupplierFinanceProgramPaymentTimingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierFinanceProgramPaymentTimingPeriod", "presentation": [ "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Payment terms of supplier finance programs (in days)", "label": "Supplier Finance Program, Payment Timing, Period", "documentation": "Period when payment is expected to be made to finance provider or intermediary in supplier finance program, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r335" ] }, "bdx_SurgeryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "SurgeryMember", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesbyGeographicAreasDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Surgery", "label": "Surgery [Member]", "documentation": "Surgery [Member]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r969" ] }, "bdx_TerminatedCurrencySwapMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "TerminatedCurrencySwapMember", "presentation": [ "http://www.bd.com/role/DerivativeInstrumentsandHedgingActivitiesGainsLossesonNetInvestmentHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Terminated Currency Swap", "label": "Terminated Currency Swap [Member]", "documentation": "Terminated Currency Swap" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r961" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r968" ] }, "bdx_TotalSharesToBeDeliveredUnderAcceleratedShareRepurchaseProgram": { "xbrltype": "sharesItemType", "nsuri": "http://www.bd.com/20241231", "localname": "TotalSharesToBeDeliveredUnderAcceleratedShareRepurchaseProgram", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total shares to be delivered under accelerated share repurchase program", "label": "Total Shares to be Delivered Under Accelerated Share Repurchase Program", "documentation": "Total Shares to be Delivered Under Accelerated Share Repurchase Program" } } }, "auth_ref": [] }, "us-gaap_TrademarksMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TrademarksMember", "presentation": [ "http://www.bd.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Trademarks", "label": "Trademarks [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style." } } }, "auth_ref": [ "r56", "r848", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r988" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r990" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized", "crdr": "credit", "presentation": [ "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsTransferofFinancialAssetsAccountedforasSalesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts yet to be collected and remitted to the third parties", "label": "Transfer of Financial Assets Accounted for as Sales, Amount Derecognized", "documentation": "Amount of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction, at the date of derecognition." } } }, "auth_ref": [ "r17" ] }, "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock", "presentation": [ "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Transfer of Financial Assets Accounted for as Sales", "label": "Transfer of Financial Assets Accounted for as Sales [Table Text Block]", "documentation": "Tabular disclosure of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction." } } }, "auth_ref": [ "r16" ] }, "bdx_TransfersOfFinancialAssetsDuringThePeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bd.com/20241231", "localname": "TransfersOfFinancialAssetsDuringThePeriod", "crdr": "debit", "presentation": [ "http://www.bd.com/role/FinancialInstrumentsandFairValueMeasurementsTransferofFinancialAssetsAccountedforasSalesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade receivables transferred to third parties under factoring arrangements", "label": "Transfers of financial assets during the period.", "documentation": "Transfers of financial assets during the period." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r991" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r992" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r992" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r990" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r990" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r993" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r991" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails", "http://www.bd.com/role/ShareholdersEquityChangesinCertainComponentsofShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r43" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.bd.com/role/ShareholdersEquityChangesinCertainComponentsofShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "negatedPeriodStartLabel": "Beginning balance (shares)", "negatedPeriodEndLabel": "Ending balance (shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r43" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails", "http://www.bd.com/role/ShareholdersEquityAdditionalInformationDetails", "http://www.bd.com/role/ShareholdersEquityChangesinCertainComponentsofShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchase of common stock (in shares)", "terseLabel": "Repurchase of common stock (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r13", "r80", "r113" ] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": { "http://www.bd.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.bd.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock", "label": "Treasury Stock, Value", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": [ "r43", "r44", "r80", "r83" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.bd.com/role/ShareholdersEquityAcceleratedShareRepurchasesDetails", "http://www.bd.com/role/ShareholdersEquityChangesinCertainComponentsofShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchase of common stock", "terseLabel": "Repurchase of common stock", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r13", "r43", "r113" ] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://www.bd.com/role/BusinessRestructuringChargesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Restructuring [Domain]", "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r343", "r344", "r349", "r350" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesbyGeographicAreasDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_UnclassifiedIndefinitelivedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnclassifiedIndefinitelivedIntangibleAssetsMember", "presentation": [ "http://www.bd.com/role/IntangibleAssetsComponentsofIntangibleAssetsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired in-process research and development", "label": "Unclassified Indefinite-Lived Intangible Assets [Member]", "documentation": "Costs of contractual or legal rights meeting the criteria for capitalization as intangible assets apart from goodwill, which have indefinite life and that are not otherwise specified in the taxonomy." } } }, "auth_ref": [ "r1048", "r1052", "r1055" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r987" ] }, "bdx_UrologyandCriticalCareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bd.com/20241231", "localname": "UrologyandCriticalCareMember", "presentation": [ "http://www.bd.com/role/SegmentDataRevenuesbyGeographicAreasDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Urology and Critical Care", "label": "Urology and Critical Care [Member]", "documentation": "Urology and Critical Care [Member]" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r957" ] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://www.bd.com/role/EarningsperShareDetail": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bd.com/role/EarningsperShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Dilutive share equivalents from share-based plans (shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r1025" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.bd.com/role/EarningsperShareDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bd.com/role/EarningsperShareDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Average common and common equivalent shares outstanding - assuming dilution (shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r249", "r255" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.bd.com/role/EarningsperShareDetail": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bd.com/role/EarningsperShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Average common shares outstanding (shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r248", "r255" ] }, "exch_XNYS": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/exch/2024", "localname": "XNYS", "presentation": [ "http://www.bd.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "NEW YORK STOCK EXCHANGE, INC.", "label": "NEW YORK STOCK EXCHANGE, INC. [Member]" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r955" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "16", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-16" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(j)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "44", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-44" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "460", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481138/505-30-25-5" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "SubTopic": "20", "Subparagraph": "(h)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/805/tableOfContent" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/815/tableOfContent" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/250/tableOfContent" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "a", "Publisher": "SEC" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column C", "Footnote": "5", "Publisher": "SEC" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column C", "Footnote": "4", "Publisher": "SEC" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column C", "Footnote": "2", "Publisher": "SEC" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column F", "Footnote": "7", "Publisher": "SEC" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column D", "Publisher": "SEC" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column A", "Footnote": "4", "Publisher": "SEC" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(C)", "Publisher": "SEC" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-6" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-3" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479468/405-50-50-4" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/420/tableOfContent" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715/tableOfContent" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3A" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(10)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(9)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(8)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-4" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478600/954-210-50-2" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477128/405-50-55-5" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r854": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r858": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r859": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r860": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r861": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r862": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r863": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r864": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r865": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r866": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r867": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r868": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r869": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r870": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18" }, "r871": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r872": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r873": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r874": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r875": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r876": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r877": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r878": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r879": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r880": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r881": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r882": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r883": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r884": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r885": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r886": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r887": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r888": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r889": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r890": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r891": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r892": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r893": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r894": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r895": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r896": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r897": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r898": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r899": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r900": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r901": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r902": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r903": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r904": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r905": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r906": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r907": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r908": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r909": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r910": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r911": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r912": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r913": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r914": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r915": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r925": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r926": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r927": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r928": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r929": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r930": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r931": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r932": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r933": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r934": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r935": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r936": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r937": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r938": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r939": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r940": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r941": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r942": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r943": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r944": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r945": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r946": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r947": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r948": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r949": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r950": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r951": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r952": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r953": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r954": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r955": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r956": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r957": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r958": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r959": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r960": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r961": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r962": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r963": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r964": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r965": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r966": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r967": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r968": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r969": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r970": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r971": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r972": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r973": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r974": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r975": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r976": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r977": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r978": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r979": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r980": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r981": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r982": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r983": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r984": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r985": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r986": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r987": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r988": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r989": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r990": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r991": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r992": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r993": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r994": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r995": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r996": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r997": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r998": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r999": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r1000": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r1001": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(ii)", "Publisher": "SEC" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)", "Publisher": "SEC" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1116": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1120": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1121": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1122": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1123": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1124": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1125": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1126": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1127": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1128": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1129": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1130": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1131": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1132": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1133": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1134": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1135": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1136": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1137": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1138": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1140": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1141": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" } } } ZIP 75 0000010795-25-000022-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000010795-25-000022-xbrl.zip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�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�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end XML 76 bdx-20241231_htm.xml IDEA: XBRL DOCUMENT 0000010795 2024-10-01 2024-12-31 0000010795 us-gaap:CommonStockMember exch:XNYS 2024-10-01 2024-12-31 0000010795 bdx:Notes1.900dueDecember152026Member exch:XNYS 2024-10-01 2024-12-31 0000010795 bdx:Notes3.020dueMay242025Member exch:XNYS 2024-10-01 2024-12-31 0000010795 bdx:Notes1.208dueJune42026Member exch:XNYS 2024-10-01 2024-12-31 0000010795 bdx:Notes1213NotesDueFebruary122036Member exch:XNYS 2024-10-01 2024-12-31 0000010795 bdx:Notes0034DueAugust132025Member exch:XNYS 2024-10-01 2024-12-31 0000010795 bdx:Notes3.519DueFebruary82031Member exch:XNYS 2024-10-01 2024-12-31 0000010795 bdx:Notes3.828DueJune72032Member exch:XNYS 2024-10-01 2024-12-31 0000010795 2024-12-31 0000010795 2023-10-01 2023-12-31 0000010795 2024-09-30 0000010795 2023-09-30 0000010795 2023-12-31 0000010795 us-gaap:CommonStockMember 2024-09-30 0000010795 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000010795 us-gaap:RetainedEarningsMember 2024-09-30 0000010795 us-gaap:DeferredCompensationShareBasedPaymentsMember 2024-09-30 0000010795 us-gaap:TreasuryStockCommonMember 2024-09-30 0000010795 us-gaap:RetainedEarningsMember 2024-10-01 2024-12-31 0000010795 us-gaap:AdditionalPaidInCapitalMember 2024-10-01 2024-12-31 0000010795 us-gaap:TreasuryStockCommonMember 2024-10-01 2024-12-31 0000010795 us-gaap:CommonStockMember 2024-12-31 0000010795 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000010795 us-gaap:RetainedEarningsMember 2024-12-31 0000010795 us-gaap:DeferredCompensationShareBasedPaymentsMember 2024-12-31 0000010795 us-gaap:TreasuryStockCommonMember 2024-12-31 0000010795 us-gaap:CommonStockMember 2023-09-30 0000010795 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000010795 us-gaap:RetainedEarningsMember 2023-09-30 0000010795 us-gaap:DeferredCompensationShareBasedPaymentsMember 2023-09-30 0000010795 us-gaap:TreasuryStockCommonMember 2023-09-30 0000010795 us-gaap:RetainedEarningsMember 2023-10-01 2023-12-31 0000010795 us-gaap:AdditionalPaidInCapitalMember 2023-10-01 2023-12-31 0000010795 us-gaap:TreasuryStockCommonMember 2023-10-01 2023-12-31 0000010795 us-gaap:CommonStockMember 2023-12-31 0000010795 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000010795 us-gaap:RetainedEarningsMember 2023-12-31 0000010795 us-gaap:DeferredCompensationShareBasedPaymentsMember 2023-12-31 0000010795 us-gaap:TreasuryStockCommonMember 2023-12-31 0000010795 bdx:AcceleratedShareRepurchaseProgramMember 2024-12-31 0000010795 bdx:AcceleratedShareRepurchaseProgramMember 2024-10-01 2024-12-31 0000010795 bdx:AcceleratedShareRepurchaseProgramMember us-gaap:SubsequentEventMember 2025-01-01 2025-01-31 0000010795 bdx:AcceleratedShareRepurchaseProgramMember us-gaap:TreasuryStockCommonMember us-gaap:SubsequentEventMember 2025-01-01 2025-01-31 0000010795 bdx:AcceleratedShareRepurchaseProgramMember us-gaap:AdditionalPaidInCapitalMember us-gaap:SubsequentEventMember 2025-01-01 2025-01-31 0000010795 bdx:AcceleratedShareRepurchaseProgramMember 2023-10-01 2023-12-31 0000010795 bdx:AcceleratedShareRepurchaseProgramMember 2023-12-31 0000010795 2021-11-03 0000010795 us-gaap:SubsequentEventMember 2025-01-28 0000010795 us-gaap:AccumulatedTranslationAdjustmentMember 2024-09-30 0000010795 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-09-30 0000010795 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-09-30 0000010795 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-09-30 0000010795 us-gaap:AccumulatedTranslationAdjustmentMember 2024-10-01 2024-12-31 0000010795 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-10-01 2024-12-31 0000010795 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-10-01 2024-12-31 0000010795 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-10-01 2024-12-31 0000010795 us-gaap:AccumulatedTranslationAdjustmentMember 2024-12-31 0000010795 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-12-31 0000010795 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-12-31 0000010795 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-12-31 0000010795 us-gaap:AccumulatedTranslationAdjustmentMember 2023-09-30 0000010795 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-09-30 0000010795 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-09-30 0000010795 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-09-30 0000010795 us-gaap:AccumulatedTranslationAdjustmentMember 2023-10-01 2023-12-31 0000010795 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-10-01 2023-12-31 0000010795 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-10-01 2023-12-31 0000010795 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-10-01 2023-12-31 0000010795 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0000010795 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-12-31 0000010795 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-12-31 0000010795 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-12-31 0000010795 bdx:ShareBasedCompensationMember 2024-10-01 2024-12-31 0000010795 bdx:ShareBasedCompensationMember 2023-10-01 2023-12-31 0000010795 bdx:HerniaProductClaimsMember 2024-12-31 0000010795 bdx:HerniaProductClaimsMember 2024-09-30 0000010795 bdx:SECMatterMember 2024-12-31 0000010795 srt:MaximumMember stpr:GA 2024-10-01 2024-12-31 0000010795 stpr:GA 2024-10-01 2024-12-31 0000010795 bdx:ItalianMedicalDevicePaybackLegislationMatterMember 2024-12-31 0000010795 bdx:PyxisMember 2024-12-31 0000010795 bdx:PyxisMember 2024-10-01 2024-12-31 0000010795 us-gaap:OtherOperatingIncomeExpenseMember 2023-10-01 2023-12-31 0000010795 bdx:ProductsWithinMassTortLitigationMember 2024-12-31 0000010795 bdx:ProductsWithinMassTortLitigationMember 2024-09-30 0000010795 bdx:ProductsandorServicesMember 2025-01-01 2024-12-31 0000010795 2025-01-01 2024-12-31 0000010795 bdx:ConsumablesMember 2025-01-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember bdx:MedicationDeliverySolutionsMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember bdx:MedicationDeliverySolutionsMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:MedicalMember bdx:MedicationDeliverySolutionsMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember bdx:MedicationDeliverySolutionsMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember bdx:MedicationDeliverySolutionsMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:MedicalMember bdx:MedicationDeliverySolutionsMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember bdx:MedicationManagementSolutionsMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember bdx:MedicationManagementSolutionsMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:MedicalMember bdx:MedicationManagementSolutionsMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember bdx:MedicationManagementSolutionsMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember bdx:MedicationManagementSolutionsMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:MedicalMember bdx:MedicationManagementSolutionsMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember bdx:PharmaceuticalSystemsMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember bdx:PharmaceuticalSystemsMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:MedicalMember bdx:PharmaceuticalSystemsMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember bdx:PharmaceuticalSystemsMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember bdx:PharmaceuticalSystemsMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:MedicalMember bdx:PharmaceuticalSystemsMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember bdx:AdvancedPatientMonitoringMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember bdx:AdvancedPatientMonitoringMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:MedicalMember bdx:AdvancedPatientMonitoringMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember bdx:AdvancedPatientMonitoringMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember bdx:AdvancedPatientMonitoringMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:MedicalMember bdx:AdvancedPatientMonitoringMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:MedicalMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:MedicalMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:MedicalMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:MedicalMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember bdx:SpecimenManagementMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember bdx:SpecimenManagementMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember bdx:SpecimenManagementMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember bdx:SpecimenManagementMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember bdx:SpecimenManagementMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember bdx:SpecimenManagementMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember bdx:DiagnosticSolutionsMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember bdx:DiagnosticSolutionsMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember bdx:DiagnosticSolutionsMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember bdx:DiagnosticSolutionsMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember bdx:DiagnosticSolutionsMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember bdx:DiagnosticSolutionsMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember bdx:BiosciencesMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember bdx:BiosciencesMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember bdx:BiosciencesMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember bdx:BiosciencesMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember bdx:BiosciencesMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember bdx:BiosciencesMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:LifeSciencesMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:LifeSciencesMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:LifeSciencesMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember bdx:SurgeryMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember bdx:SurgeryMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:InterventionalMember bdx:SurgeryMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember bdx:SurgeryMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember bdx:SurgeryMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:InterventionalMember bdx:SurgeryMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember bdx:PeripheralInterventionMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember bdx:PeripheralInterventionMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:InterventionalMember bdx:PeripheralInterventionMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember bdx:PeripheralInterventionMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember bdx:PeripheralInterventionMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:InterventionalMember bdx:PeripheralInterventionMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember bdx:UrologyandCriticalCareMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember bdx:UrologyandCriticalCareMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:InterventionalMember bdx:UrologyandCriticalCareMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember bdx:UrologyandCriticalCareMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember bdx:UrologyandCriticalCareMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:InterventionalMember bdx:UrologyandCriticalCareMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:InterventionalMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember country:US bdx:InterventionalMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember us-gaap:NonUsMember bdx:InterventionalMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember bdx:InterventionalMember 2023-10-01 2023-12-31 0000010795 country:US 2024-10-01 2024-12-31 0000010795 us-gaap:NonUsMember 2024-10-01 2024-12-31 0000010795 country:US 2023-10-01 2023-12-31 0000010795 us-gaap:NonUsMember 2023-10-01 2023-12-31 0000010795 us-gaap:OperatingSegmentsMember 2024-10-01 2024-12-31 0000010795 us-gaap:OperatingSegmentsMember 2023-10-01 2023-12-31 0000010795 us-gaap:MaterialReconcilingItemsMember 2024-10-01 2024-12-31 0000010795 us-gaap:MaterialReconcilingItemsMember 2023-10-01 2023-12-31 0000010795 us-gaap:CorporateNonSegmentMember 2024-10-01 2024-12-31 0000010795 us-gaap:CorporateNonSegmentMember 2023-10-01 2023-12-31 0000010795 us-gaap:PensionPlansDefinedBenefitMember 2024-10-01 2024-12-31 0000010795 us-gaap:PensionPlansDefinedBenefitMember 2023-10-01 2023-12-31 0000010795 bdx:AdvancedPatientMonitoringMember 2024-09-03 2024-09-03 0000010795 bdx:AdvancedPatientMonitoringMember us-gaap:DevelopedTechnologyRightsMember 2024-12-31 0000010795 bdx:AdvancedPatientMonitoringMember us-gaap:CustomerRelationshipsMember 2024-12-31 0000010795 bdx:AdvancedPatientMonitoringMember 2024-12-31 0000010795 bdx:AdvancedPatientMonitoringMember 2024-09-03 0000010795 bdx:AdvancedPatientMonitoringMember 2023-10-01 2023-12-31 0000010795 us-gaap:EmployeeSeveranceMember 2024-09-30 0000010795 us-gaap:OtherRestructuringMember 2024-09-30 0000010795 us-gaap:EmployeeSeveranceMember 2024-10-01 2024-12-31 0000010795 us-gaap:OtherRestructuringMember 2024-10-01 2024-12-31 0000010795 us-gaap:EmployeeSeveranceMember bdx:OtherInitiativesMember 2024-10-01 2024-12-31 0000010795 us-gaap:OtherRestructuringMember bdx:OtherInitiativesMember 2024-10-01 2024-12-31 0000010795 bdx:OtherInitiativesMember 2024-10-01 2024-12-31 0000010795 us-gaap:EmployeeSeveranceMember 2024-12-31 0000010795 us-gaap:OtherRestructuringMember 2024-12-31 0000010795 us-gaap:DevelopedTechnologyRightsMember 2024-12-31 0000010795 us-gaap:DevelopedTechnologyRightsMember 2024-09-30 0000010795 us-gaap:CustomerRelationshipsMember 2024-12-31 0000010795 us-gaap:CustomerRelationshipsMember 2024-09-30 0000010795 us-gaap:IntellectualPropertyMember 2024-12-31 0000010795 us-gaap:IntellectualPropertyMember 2024-09-30 0000010795 us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember 2024-12-31 0000010795 us-gaap:UnclassifiedIndefinitelivedIntangibleAssetsMember 2024-09-30 0000010795 us-gaap:TrademarksMember 2024-12-31 0000010795 us-gaap:TrademarksMember 2024-09-30 0000010795 bdx:MedicalMember 2024-09-30 0000010795 bdx:LifeSciencesMember 2024-09-30 0000010795 bdx:InterventionalMember 2024-09-30 0000010795 bdx:MedicalMember 2024-10-01 2024-12-31 0000010795 bdx:LifeSciencesMember 2024-10-01 2024-12-31 0000010795 bdx:InterventionalMember 2024-10-01 2024-12-31 0000010795 bdx:MedicalMember 2024-12-31 0000010795 bdx:LifeSciencesMember 2024-12-31 0000010795 bdx:InterventionalMember 2024-12-31 0000010795 us-gaap:ForeignExchangeContractMember 2024-12-31 0000010795 us-gaap:ForeignExchangeContractMember 2024-09-30 0000010795 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2024-12-31 0000010795 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2024-09-30 0000010795 us-gaap:DebtMember us-gaap:NetInvestmentHedgingMember 2024-12-31 0000010795 us-gaap:DebtMember us-gaap:NetInvestmentHedgingMember 2024-09-30 0000010795 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember 2024-12-31 0000010795 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember 2024-09-30 0000010795 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember 2023-10-01 2023-12-31 0000010795 bdx:ForeignCurrencyDenominatedDebtMember 2024-10-01 2024-12-31 0000010795 bdx:ForeignCurrencyDenominatedDebtMember 2023-10-01 2023-12-31 0000010795 us-gaap:CurrencySwapMember 2024-10-01 2024-12-31 0000010795 us-gaap:CurrencySwapMember 2023-10-01 2023-12-31 0000010795 bdx:TerminatedCurrencySwapMember 2024-10-01 2024-12-31 0000010795 bdx:FixedToFloatingMember us-gaap:FairValueHedgingMember 2024-12-31 0000010795 bdx:FixedToFloatingMember us-gaap:FairValueHedgingMember 2024-09-30 0000010795 srt:MinimumMember 2024-10-01 2024-12-31 0000010795 srt:MaximumMember 2024-10-01 2024-12-31 0000010795 bdx:IntegrationAndRestructuringExpenseMember 2024-10-01 2024-12-31 0000010795 srt:MinimumMember 2024-12-31 0000010795 srt:MaximumMember 2024-12-31 0000010795 bdx:RichardByrdMember 2024-10-01 2024-12-31 0000010795 bdx:RichardByrdMember bdx:RichardByrdTradingArrangementStockAppreciationRightsMember 2024-12-31 0000010795 bdx:RichardByrdMember bdx:RichardByrdTradingArrangementCommonStockMember 2024-12-31 0000010795 bdx:RichardByrdMember bdx:RichardByrdTradingArrangementCommonStockUponTheVestingOfTimeVestedUnitsMember 2024-12-31 0000010795 bdx:RichardByrdMember bdx:RichardByrdTradingArrangementCommonStockUponTheVestingOfPerformanceUnitsMember 2024-12-31 0000010795 bdx:AntoineEzellMember 2024-10-01 2024-12-31 0000010795 bdx:AntoineEzellMember bdx:AntoineEzellTradingArrangementCommonStockMember 2024-12-31 0000010795 bdx:RichardByrdMember bdx:OfficerTradingArrangementMember 2024-10-01 2024-12-31 0000010795 bdx:AntoineEzellMember bdx:OfficerTradingArrangementMember 2024-10-01 2024-12-31 shares iso4217:USD iso4217:USD shares pure bdx:claim bdx:lawsuit bdx:plaintiff bdx:segment 0000010795 --09-30 2025 Q1 false P459D P456D 10-Q true 2024-12-31 false 001-4802 Becton, Dickinson and Company NJ 22-0760120 1 Becton Drive, Franklin Lakes, NJ 07417-1880 (201) 847-6800 Common stock, par value $1.00 BDX NYSE 1.900% Notes due December 15, 2026 BDX26 NYSE 3.020% Notes due May 24, 2025 BDX25 NYSE 1.208% Notes due June 4, 2026 BDX/26A NYSE 1.213% Notes due February 12, 2036 BDX/36 NYSE 0.034% Notes due August 13, 2025 BDX25A NYSE 3.519% Notes due February 8, 2031 BDX31 NYSE 3.828% Notes due June 7, 2032 BDX32A NYSE Yes Yes Large Accelerated Filer false false false 287135421 5168000000 4706000000 2933000000 2679000000 1318000000 1213000000 343000000 290000000 92000000 75000000 -28000000 -11000000 4715000000 4267000000 453000000 439000000 155000000 111000000 23000000 34000000 -16000000 -4000000 306000000 359000000 3000000 77000000 303000000 281000000 1.05 0.97 1.04 0.96 1.04 0.95 303000000 281000000 46000000 40000000 -8000000 -12000000 2000000 -18000000 56000000 33000000 359000000 314000000 711000000 1717000000 102000000 139000000 17000000 445000000 2638000000 3033000000 904000000 803000000 453000000 443000000 2502000000 2597000000 3860000000 3843000000 1331000000 1292000000 8659000000 10468000000 14156000000 14378000000 7554000000 7557000000 6602000000 6821000000 26329000000 26465000000 7439000000 7733000000 2533000000 2635000000 517000000 549000000 2586000000 2615000000 54665000000 57286000000 1318000000 2170000000 6347000000 6786000000 7664000000 8956000000 17440000000 17940000000 939000000 942000000 3418000000 3558000000 1 1 640000000 640000000 370594401 370594401 371000000 371000000 19768000000 19893000000 16141000000 16139000000 25000000 25000000 9425000000 8807000000 -1676000000 -1732000000 25205000000 25890000000 54665000000 57286000000 303000000 281000000 607000000 561000000 90000000 83000000 -151000000 -91000000 370000000 -152000000 -2000000 -129000000 216000000 -2000000 693000000 855000000 105000000 116000000 411000000 0 8000000 0 94000000 116000000 204000000 -233000000 75000000 0 875000000 0 750000000 500000000 302000000 275000000 -76000000 -87000000 -1928000000 -862000000 0 -14000000 -12000000 7000000 -1043000000 -247000000 1856000000 1481000000 813000000 1234000000 Basis of Presentation<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and, in the opinion of the management of Becton, Dickinson and Company (the "Company" or "BD"), include all adjustments which are of a normal recurring nature, necessary for a fair presentation of the financial position and the results of operations and cash flows for the periods presented. However, the financial statements do not include all information and accompanying notes required for a presentation in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"). These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s 2024 Annual Report on Form 10-K. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the financial statements and tables presented, certain columns and rows may not add due to the use of rounded numbers for disclosure purposes. Percentages and earnings per share amounts presented are calculated from the underlying amounts. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year.</span></div> Accounting Changes<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Principles Not Yet Adopted</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the Financial Accounting Standards Board (“FASB”) issued an accounting standard update that requires the Company to disclose more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in each relevant income statement expense caption. The update is effective for the Company beginning with its fiscal year 2028 reporting and for interim reporting beginning with its fiscal year 2029. Early adoption is permitted. The Company is currently evaluating the impact that this update will have on its disclosures.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued an accounting standard update that requires more disaggregated information to be included in the income tax rate reconciliation and income taxes paid annual disclosures. This update is effective for the Company beginning in its fiscal year 2026 and the Company is currently evaluating the impact that this update will have on its disclosures.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued a new accounting standard update that requires more disaggregated expense information about a public entity’s reportable segments. This update is effective for the Company beginning with its fiscal year 2025 reporting and for interim reporting beginning with its fiscal year 2026. The Company is currently evaluating the impact that this update will have on its disclosures.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Principles Not Yet Adopted</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the Financial Accounting Standards Board (“FASB”) issued an accounting standard update that requires the Company to disclose more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in each relevant income statement expense caption. The update is effective for the Company beginning with its fiscal year 2028 reporting and for interim reporting beginning with its fiscal year 2029. Early adoption is permitted. The Company is currently evaluating the impact that this update will have on its disclosures.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued an accounting standard update that requires more disaggregated information to be included in the income tax rate reconciliation and income taxes paid annual disclosures. This update is effective for the Company beginning in its fiscal year 2026 and the Company is currently evaluating the impact that this update will have on its disclosures.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued a new accounting standard update that requires more disaggregated expense information about a public entity’s reportable segments. This update is effective for the Company beginning with its fiscal year 2025 reporting and for interim reporting beginning with its fiscal year 2026. The Company is currently evaluating the impact that this update will have on its disclosures.</span></div> Shareholders' Equity<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in certain components of shareholders' equity for the first quarters of fiscal years 2025 and 2024 were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"><tr><td style="width:1.0%"></td><td style="width:35.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.027%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common<br/>Stock  Issued<br/>at Par Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Capital in<br/>Excess of<br/>Par Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Deferred<br/>Compensation</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury Stock</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares (in<br/>thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,893 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,139 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81,493)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,807)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common dividends ($1.04 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares under employee and other plans, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock held in trusts, net (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,637)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(606)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,768 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,141 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,459)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,425)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"><tr><td style="width:1.0%"></td><td style="width:35.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.027%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common<br/>Stock  Issued<br/>at Par Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Capital in<br/>Excess of<br/>Par Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Deferred<br/>Compensation</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury Stock</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares (in<br/>thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,720 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,535 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,203)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,305)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common dividends ($0.95 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(275)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares under employee and other plans, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock held in trusts, net (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(503)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,741 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,540 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81,692)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,828)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Common stock held in trusts consists of the Company’s shares held in rabbi trusts in connection with deferred compensation under the Company’s employee salary and bonus deferral plan and directors’ deferral plan.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of fiscal year 2025, the Company executed an accelerated share repurchase (“ASR”) agreement and accounted for the agreement as two transactions upon prepayment: (1) the initial delivery of shares was recorded as an increase to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common stock in treasury</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to recognize the acquisition of common stock acquired in a treasury stock transaction, and (2) the remaining amount of shares was recorded as a decrease to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital in excess of par value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to recognize a net share-settled forward sale contract indexed to the Company's own common stock. The impacts of these accelerated share repurchase transactions were as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.397%"><tr><td style="width:1.0%"></td><td style="width:15.039%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.039%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.039%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.039%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.039%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.045%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Execution Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Settlement Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Common Stock Repurchased (millions of dollars) (a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Initial Shares Delivered (in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Shares Delivered at Settlement (in thousands) (b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Shares Delivered (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q1 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,637 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,256 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)    Excludes a 1% excise tax on share repurchases of $6 million.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)    Upon final settlement of the repurchase agreement and the forward sale contract, the Company’s receipt of additional shares was recorded as an increase to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common stock in treasury</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and an offsetting increase to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital in excess of par value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The final settlement for the first quarter transaction amounted to $150 million. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of fiscal year 2024, the Company executed and settled ASR agreements for the repurchase of 2.118 million shares of its common stock for total consideration of $500 million, excluding a 1% excise tax on share repurchases of $3 million. The share repurchases were recorded as an increase to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Treasury stock.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The share repurchases discussed above were made pursuant to the repurchase program authorized by the Board of Directors on November 3, 2021, for 10 million shares of BD common stock, for which there is no expiration date. As of December 31, 2024, 4 million shares remained unused under this program. On January 28, 2025, the Board of Directors authorized BD to repurchase up to an additional 10 million shares of BD common stock, for which there is no expiration date.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components and changes of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the first quarters of fiscal years 2025 and 2024 were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:41.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.837%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.721%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency<br/>Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Available-for-Sale Debt Securities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,732)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,244)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(557)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income before reclassifications, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified into income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,676)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,199)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(549)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:41.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency<br/>Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Available-for-Sale Debt Securities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,548)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,078)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(571)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified into income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,515)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,038)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(559)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts of foreign currency translation recognized in other comprehensive income during the three months ended December 31, 2024 and 2023 included net gains (losses) relating to net investment hedges. The amounts recognized in other comprehensive income relating to cash flow hedges primarily related to foreign exchange contracts during the three months ended December 31, 2024 and forward starting interest rate swaps during the three months ended December 31, 2023. Additional disclosures regarding the Company's derivatives are provided in Note 12. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax impacts for amounts recognized in other comprehensive income (loss) before reclassifications and for reclassifications out of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> relating to benefit plans and cash flow hedges during the three months ended December 31, 2024 and 2023 were immaterial to the Company's consolidated financial results.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in certain components of shareholders' equity for the first quarters of fiscal years 2025 and 2024 were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"><tr><td style="width:1.0%"></td><td style="width:35.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.027%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common<br/>Stock  Issued<br/>at Par Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Capital in<br/>Excess of<br/>Par Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Deferred<br/>Compensation</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury Stock</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares (in<br/>thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,893 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,139 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81,493)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,807)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common dividends ($1.04 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares under employee and other plans, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock held in trusts, net (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,637)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(606)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,768 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,141 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,459)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,425)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"><tr><td style="width:1.0%"></td><td style="width:35.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.183%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.027%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common<br/>Stock  Issued<br/>at Par Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Capital in<br/>Excess of<br/>Par Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Deferred<br/>Compensation</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury Stock</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares (in<br/>thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,720 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,535 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,203)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,305)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common dividends ($0.95 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(275)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares under employee and other plans, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock held in trusts, net (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,118)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(503)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,741 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,540 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81,692)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,828)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Common stock held in trusts consists of the Company’s shares held in rabbi trusts in connection with deferred compensation under the Company’s employee salary and bonus deferral plan and directors’ deferral plan.</span></div> 371000000 19893000000 16139000000 25000000 81493000 -8807000000 303000000 1.04 302000000 -65000000 679000 -12000000 90000000 -8000 150000000 2637000 606000000 371000000 19768000000 16141000000 25000000 83459000 -9425000000 371000000 19720000000 15535000000 24000000 80203000 -8305000000 281000000 0.95 275000000 -62000000 647000 -20000000 83000000 -19000 2118000 503000000 371000000 19741000000 15540000000 24000000 81692000 -8828000000 The impacts of these accelerated share repurchase transactions were as follows:<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.397%"><tr><td style="width:1.0%"></td><td style="width:15.039%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.039%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.039%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.039%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.039%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.045%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Execution Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Settlement Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Common Stock Repurchased (millions of dollars) (a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Initial Shares Delivered (in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Shares Delivered at Settlement (in thousands) (b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Shares Delivered (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q1 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Q2 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,637 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,256 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)    Excludes a 1% excise tax on share repurchases of $6 million.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)    Upon final settlement of the repurchase agreement and the forward sale contract, the Company’s receipt of additional shares was recorded as an increase to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common stock in treasury</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and an offsetting increase to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital in excess of par value</span>. The final settlement for the first quarter transaction amounted to $150 million. 750000000 2637000 619000 3256000 0.01 6000000 150000000 150000000 2118000 500000000 0.01 3000000 10000000 4000000 10000000 <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components and changes of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the first quarters of fiscal years 2025 and 2024 were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:41.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.837%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.721%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency<br/>Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Available-for-Sale Debt Securities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,732)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,244)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(557)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income before reclassifications, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified into income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,676)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,199)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(549)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:41.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency<br/>Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flow Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Available-for-Sale Debt Securities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,548)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,078)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(571)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified into income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,515)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,038)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(559)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> -1732000000 -1244000000 -557000000 70000000 -1000000 49000000 46000000 0 3000000 0 -6000000 0 -8000000 2000000 0 -1676000000 -1199000000 -549000000 72000000 -1000000 -1548000000 -1078000000 -571000000 103000000 0 21000000 40000000 0 -19000000 0 -12000000 0 -12000000 -1000000 0 -1515000000 -1038000000 -559000000 84000000 0 Earnings per Share<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average common shares used in the computations of basic and diluted earnings per share (shares in thousands) were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.391%"><tr><td style="width:1.0%"></td><td style="width:65.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.239%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,505 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,113 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive share equivalents from share-based plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common and common equivalent shares outstanding – assuming dilution</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,389 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,398 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share equivalents excluded from the diluted shares outstanding calculation:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based plans (a)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,758 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Excluded from the diluted earnings per share calculation as the exercise prices of these awards were greater than the average market price of the Company’s common shares.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average common shares used in the computations of basic and diluted earnings per share (shares in thousands) were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.391%"><tr><td style="width:1.0%"></td><td style="width:65.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.239%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,505 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,113 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive share equivalents from share-based plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common and common equivalent shares outstanding – assuming dilution</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290,389 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291,398 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share equivalents excluded from the diluted shares outstanding calculation:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based plans (a)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,758 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Excluded from the diluted earnings per share calculation as the exercise prices of these awards were greater than the average market price of the Company’s common shares.</span></div> 289505000 290113000 884000 1285000 290389000 291398000 2758000 552000 Contingencies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved, both as a plaintiff and a defendant, in various legal proceedings that arise in the ordinary course of business, including, without limitation, product liability and environmental matters in certain U.S. and international locations. Given the uncertain nature of litigation generally, the Company is not able, in all cases, to reasonably estimate the amount or range of loss that could result from an unfavorable outcome of litigation in which the Company is a party. Even if the Company believes it has meritorious defenses, from time to time the Company engages in settlement discussions and mediations and considers settlements taking into account various factors including, among other things, developments in such legal proceedings </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the resulting risks and uncertainties. These activities have resulted in settlements for certain matters and going forward could result in further settlements, which may be confidential and could be significant and result in charges in excess of accruals.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with U.S. GAAP, the Company establishes accruals to the extent future losses are probable and reasonably estimable. With respect to putative class action lawsuits and certain tort actions in the United States and certain of the Canadian lawsuits described below or in its other SEC filings, the Company may not be able to determine if a probable loss exists or estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; (ii) the Company has not received and reviewed complete information regarding all or certain of the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, there is uncertainty as to the likelihood of a class being certified or the ultimate size of any class. With respect to certain of the civil investigative demands (“CIDs”) served by the Department of Justice which are discussed below, the Company may not be able to determine if a probable loss exists, unless otherwise noted, for the following reasons: (i) all or certain of the proceedings are in early stages; and/or (ii) there are significant factual and legal issues to be resolved.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Liability Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, the Company is defending approximately 6,670 product liability claims involving the Company’s line of hernia repair devices (collectively, the “Hernia Product Claims”). The Company’s outstanding Hernia Product Claims as of September 30, 2024 were approximately 6,610, which reflected a settlement agreement that was consummated in the fourth quarter of fiscal year 2024 to resolve the vast majority of the Company’s existing hernia litigation. The majority of the claims are currently pending in a coordinated proceeding in Rhode Island State Court (“RI”) and in a federal multi-district litigation (“MDL”) established in the Southern District of Ohio, but claims are also pending in other state and/or federal court jurisdictions. In addition, outstanding claims include multiple putative class actions in Canada. Generally, the Hernia Product Claims seek damages for personal injury allegedly resulting from use of the products. The Company believes that it has meritorious defenses and is vigorously defending itself in these matters. There are no trials currently scheduled.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also continues to be a defendant in certain other mass tort litigation. As of December 31, 2024, the Company is defending product liability claims involving the Company’s line of pelvic mesh products, the majority of which are pending in a coordinated proceeding in New Jersey Superior Court and in various federal court jurisdictions, the Company’s line of inferior vena cava (“IVC”) filter products, which are pending in various jurisdictions, and the Company’s line of implantable ports, the majority of which are pending in an MDL in the United States District Court for the District of Arizona. The Company believes that it has meritorious defenses and is vigorously defending itself in these matters.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In most product liability litigations like those described above, plaintiffs allege a wide variety of claims, ranging from allegations of serious injury caused by the products to efforts to obtain compensation notwithstanding the absence of any injury. In many of these cases, the Company has not yet received and reviewed complete information regarding the plaintiffs and their medical conditions and, consequently, is unable to fully evaluate the claims. The Company expects that it will receive and review additional information regarding any remaining unsettled product liability matters.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 2, 2020, a putative shareholder derivative action captioned Jankowski v. Forlenza, et al., Civ. No. 2:20-cv-15474, was filed in the U.S. District Court for the District of New Jersey by a shareholder, derivatively on behalf of the Company, against certain of the Company’s directors and officers. The complaint asserts claims for breach of fiduciary duty; violations of sections 10(b), 14(a) and 21D of the Exchange Act, and insider trading. The complaint principally alleges, that the Company made misleading statements regarding Alaris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> infusion pumps in a proxy statement and other SEC filings. A second federal derivative action was filed on January 24, 2021, and the two actions were consolidated and stayed. In March 2021, the Company received letters from two additional shareholders which, in general, mirrored the allegations in the derivative actions, and demanded, among other things, that the Board of Directors pursue claims against members of management for claimed breaches of fiduciary duties. Consistent with New Jersey law, the Board appointed a special committee to review the allegations and demands in the derivative actions and demand letters. Following an investigation, the special committee determined that no action was warranted, and rejected the shareholders’ demands, communicating its determination to counsel for the shareholders. On January 10, 2023, one of the two shareholders referenced above filed a separate derivative action that: (i) is generally consistent with the shareholder letter and the two prior actions; and (ii) purports to challenge the reasonableness of the special committee’s process and determination. That action was also stayed. Following entry of a stipulated scheduling order for an amended complaint and motion to dismiss the consolidated federal action, the case schedule was adjourned without date pending mediation. Mediation proceedings have taken place. On September 10, 2024, the Company received an additional substantially identical shareholder demand letter and on September 26, 2024, that shareholder filed a second substantially identical state court derivative action. In November 2024, the Company entered into an agreement in principle to resolve this matter for an amount that is not expected to be material to the Company’s consolidated financial results.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in February 2021, the Company received subpoenas from the Enforcement Division of the Securities and Exchange Commission (“SEC”) requesting information from the Company relating to, among other things, certain reporting issues involving BD Alaris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> infusion pumps included in SEC disclosures prior to 2021. In December 2024, the Company reached an agreement to resolve the matter with the SEC for its previously accrued amount of $175 million. In accordance with the terms of the settlement, the Company has engaged and is working with an independent compliance consultant to review practices and procedures relating to the evaluation of product recalls and remediation under U.S. GAAP and its disclosure controls and procedures, including but not limited to controls and procedures relating to collection and assessment of information concerning potential risks, contingencies, operating events, trends, and uncertainties.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2017, C.R. Bard, which was acquired by the Company in December 2017, received a CID from the Department of Justice seeking documents and information relating to an investigation into possible violations of the False Claims Act in connection with the sales and marketing of FloChec® and QuantaFlo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> devices. The Company has responded to these requests and met with the Department of Justice in February and July 2024; discussions are ongoing.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, the Department of Justice served the Company and CareFusion with CIDs seeking information regarding certain of CareFusion’s contracts with the Department of Veteran’s Affairs, some dating back more than 10 years, for certain products, including Alaris</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Pyxis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> devices, in connection with a civil investigation of possible violations of the False Claims Act, and the government later expanded the investigation to include several additional contracts. The government has made several requests for documents and interviews or depositions of Company personnel and set forth a preliminary case assessment. The Company is cooperating with the government, responding to these requests and evaluating the assessment. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company received a CID related to an inquiry initiated by the Department of Justice in the Northern District of Georgia in 2018 concerning sales and marketing practices with respect to certain aspects of the Company’s urology business. After multiple document productions and interviews, the Company and the government mediated the case in an effort to resolve this dispute; an agreement was reached to resolve this matter for an adequately accrued amount that is not material to the Company’s consolidated financial results. This matter is now resolved.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, the Department of Justice served the Company with a CID seeking information regarding the Company’s Genesis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> container products in connection with an investigation of possible violations of the False Claims Act. The government has requested documents and set forth a preliminary case assessment, and the Company is cooperating with the government, responding to its requests and evaluating the assessment.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company was sued in state and federal courts in Georgia by plaintiffs who work or reside near Company facilities in Covington, GA, where ethylene oxide (“EtO”) sterilization activities take place. The federal cases have been dismissed and refiled in state court. The plaintiffs in the cases seek compensatory and punitive damages. Pursuant to Georgia statute, punitive damages in these cases are generally capped at $250,000 per claimant, unless the plaintiff can prove that the Company acted, or failed to act, with a specific intent to cause harm, which the court to date has cast as a jury issue, meaning that the jury could negate the cap. The cases allege a variety of injuries, including but not limited to multiple types of cancer, allegedly attributable to exposure to EtO. As of December 31, 2024, the Company has approximately 360 of such suits involving approximately 375 plaintiffs asserting individual personal injury claims; approximately 50 of the cases also allege injury caused by exposure to a chemical of another defendant entirely unrelated to the Company. No cases have yet been tried although a trial date has been set for one such case scheduled for April 2025. The Company believes that it has meritorious defenses and is vigorously defending itself in these matters. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, legislation was enacted in Italy which requires medical technology companies to make payments to the Italian government if Italy’s medical device expenditures exceed annual regional expenditure ceilings. The amount of these payments is based on the amount by which the regional ceilings for the given year were exceeded. Considerable uncertainty has existed regarding the enforceability and implementation of this payback legislation since it was enacted and the Company, as well as other medical device companies, have filed appeals which challenge the enforceability of this legislation. In July 2024, the Italian Constitutional Court issued two judgments which concluded that the medical device payback legislation is constitutional; however, litigation proceedings before Italian Courts are still pending. While the Company recorded $62 million during its fiscal year 2024 as a preliminary estimate of the liability related to this matter, substantially all of which relates to periods prior to fiscal year 2024, ultimate resolution is unknown at this time, and it is possible that the amount of the Company’s liability could differ from the currently accrued amount.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2024, CareFusion 303, Inc., the Company’s subsidiary that manufactures its BD Pyxis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> dispensing equipment, received a Form 483 Notice following an inspection from the U.S. Food and Drug Administration (“FDA”) that contained observations of non-conformance with the FDA’s Quality System and Medical Device Reporting (“MDR”) regulations. In November 2024, the Company received a Warning Letter following the inspection of its Dispensing quality management system at its facility located in San Diego, California, citing certain alleged violations of the quality system regulations, MDR regulation, the corrections and removals reporting regulation and law. The Company’s liability recorded for estimated future </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">costs associated with certain actions required to respond to the Warning Letter and to address the non-conformities was $50 million as of December 31, 2024, which reflected a $22 million adjustment recorded to increase the liability during the first quarter of fiscal year 2025. The Company submitted a comprehensive response to address FDA’s feedback in the Warning Letter, which committed to implementing additional corrective actions; however, no assurances can be given regarding further action by the FDA as a result of the Warning Letter, or that corrective actions proposed and taken by CareFusion 303, Inc. will be adequate to address the Warning Letter. Any failure to adequately address this Warning Letter may result in regulatory actions initiated by the FDA without further notice, which may include, but are not limited to, seizure, injunction and civil monetary penalties. As a result, the ultimate resolution of this Warning Letter and its impact on the Company’s operations is unknown at this time, and it is possible that the amount of the Company’s liability could exceed its currently accrued amount.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also involved both as a plaintiff and a defendant in other legal proceedings and claims that arise in the ordinary course of business. The Company believes that it has meritorious defenses and is vigorously defending itself in each of these matters.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise noted, the Company cannot predict the outcome of the other legal matters discussed above, nor can it predict whether any outcome will have a material adverse effect on the Company’s consolidated results of operations and/or consolidated cash flows. Further, the Company may not be able to determine if a probable loss exists for certain of the other legal matters discussed above, and accordingly, the Company has recorded no provisions for such matters in its consolidated results of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a potentially responsible party to a number of federal administrative proceedings in the United States brought under the Comprehensive Environment Response, Compensation and Liability Act, also known as “Superfund,” and similar state laws. The Company also is subject to administrative proceedings under environmental laws in jurisdictions outside the U.S. The affected sites are in varying stages of development. In some instances, the remedy has been completed, while in others, environmental studies are underway or commencing. For several sites, there are other potentially responsible parties that may be jointly or severally liable to pay all or part of cleanup costs. While it is not feasible to predict the outcome of these proceedings, based upon the Company’s experience, current information and applicable law, the Company does not expect these proceedings to have a material adverse effect on its consolidated results of operations and/or consolidated cash flows.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation Accruals</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly monitors and evaluates the status of product liability and other litigated matters, and may, from time-to-time, engage in settlement discussions and mediations taking into consideration, among other things, developments in the litigation and the risks and uncertainties associated therewith. These activities have resulted in confidential settlements and going forward could result in further settlements, the terms of which may be confidential and could be significant and result in charges in excess of accruals. A determination of the accrual amounts for these contingencies is made after analysis of each litigation matter. When appropriate, the accrual is developed with the consultation of outside counsel and, in the case of certain mass tort litigation, actuarial specialists regarding the nature, timing, and extent of each matter.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of fiscal year 2024, the Company recorded a pre-tax benefit to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other operating expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of approximately $36 million related to certain of the product liability matters discussed above under the heading “Product Liability Matters,” including the related legal defense costs. The benefit primarily reflected the favorable resolution of claims during the fiscal year.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers relevant information when estimating its product liability accruals, including, but not limited to: the nature, number, and quality of unfiled and filed claims; the rate of claims being filed; the status of settlement discussions with plaintiffs’ counsel; the allegations and documentation supporting or refuting such allegations; publicly available information regarding similar medical device mass tort settlements; historical information regarding other product liability settlements involving the Company; and the stage of litigation. Because currently available information regarding product liability matters is often limited, there is inherent uncertainty and volatility relating to the Company’s estimate of product liability. As additional information becomes available, the Company records adjustments to its product liability accruals as required. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals for the Company's product liability claims which are discussed above, as well as the related legal defense costs, amounted to approximately $1.6 billion and $1.7 billion at December 31, 2024 and September 30, 2024, respectively. These accruals are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payables, accrued expenses and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Income Taxes and Other Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the Company's condensed consolidated balance sheets. The decrease in the Company’s product liability accrual as of December 31, 2024, as compared with September 30, 2024, largely reflected reductions due to the payment of settlements and legal fees. The increase in the number of outstanding hernia repair device claims discussed above did not materially impact the Company’s product liability accrual because the underlying estimate of the Company’s liability includes and already accounts for unfiled claims. Moreover, the accrual reflects the determination that the quality of new hernia report device claims has generally diminished over time. Amounts payable pursuant to the settlement agreement that was consummated in the fourth </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">quarter of fiscal year 2024 to resolve the vast majority of the Company’s hernia litigation are included within the Company's current product liability accrual and will be paid out over a multi-year period. Claim activity during the first quarter of fiscal year 2025 relating to the pelvic mesh device and IVC filter matters did not materially impact the Company’s product liability accrual as of December 31, 2024.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The particular outcome in any one product liability trial is typically not representative of potential outcomes of all cases or claims. Because the accrual already contemplates a wide range of possible outcomes, including those with a de minimis value, individual outcomes generally do not impact the value of other cases in the total case inventory or the overall product liability accrual.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In view of the uncertainties discussed above, the Company could incur charges in excess of any currently established accruals and, to the extent available, liability insurance. In the opinion of management, any such future charges, individually or in the aggregate, could have a material adverse effect on the Company’s consolidated results of operations, financial condition, and/or consolidated cash flows.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved, both as a plaintiff and a defendant, in various legal proceedings that arise in the ordinary course of business, including, without limitation, product liability and environmental matters in certain U.S. and international locations. Given the uncertain nature of litigation generally, the Company is not able, in all cases, to reasonably estimate the amount or range of loss that could result from an unfavorable outcome of litigation in which the Company is a party. Even if the Company believes it has meritorious defenses, from time to time the Company engages in settlement discussions and mediations and considers settlements taking into account various factors including, among other things, developments in such legal proceedings </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the resulting risks and uncertainties. These activities have resulted in settlements for certain matters and going forward could result in further settlements, which may be confidential and could be significant and result in charges in excess of accruals.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with U.S. GAAP, the Company establishes accruals to the extent future losses are probable and reasonably estimable. With respect to putative class action lawsuits and certain tort actions in the United States and certain of the Canadian lawsuits described below or in its other SEC filings, the Company may not be able to determine if a probable loss exists or estimate a range of reasonably possible losses for the following reasons: (i) all or certain of the proceedings are in early stages; (ii) the Company has not received and reviewed complete information regarding all or certain of the plaintiffs and their medical conditions; and/or (iii) there are significant factual issues to be resolved. In addition, there is uncertainty as to the likelihood of a class being certified or the ultimate size of any class. With respect to certain of the civil investigative demands (“CIDs”) served by the Department of Justice which are discussed below, the Company may not be able to determine if a probable loss exists, unless otherwise noted, for the following reasons: (i) all or certain of the proceedings are in early stages; and/or (ii) there are significant factual and legal issues to be resolved.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In view of the uncertainties discussed above, the Company could incur charges in excess of any currently established accruals and, to the extent available, liability insurance. In the opinion of management, any such future charges, individually or in the aggregate, could have a material adverse effect on the Company’s consolidated results of operations, financial condition, and/or consolidated cash flows.</span></div> 6670 6610 175000000 250000 360 375 50 62000000 50000000 22000000 -36000000 1600000000 1700000000 Revenues<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s policies for recognizing sales have not changed from those described in the Company’s 2024 Annual Report on Form 10-K. The Company sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products which are distributed through independent distribution channels and directly by BD through sales representatives. End-users of the Company's products include healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. In the current and prior-year periods, the Company generated revenues attributable to licensing, which includes consideration received in exchange for the use of BD intellectual property by third parties.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Measurement of Revenues</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of its trade receivables. Such estimated credit losses are determined based on historical loss experiences, customer-specific credit risk, and reasonable and supportable forward-looking information, such as country or regional risks that are not captured in the historical loss information. The allowance for doubtful accounts for trade receivables is not material to the Company's consolidated financial results.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's gross revenues are subject to a variety of deductions which are recorded in the same period that the underlying revenues are recognized. Such variable consideration includes rebates, sales discounts and sales returns. The Company’s rebate liabilities are classified as an offset to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade receivables, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payables, accrued expenses and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, depending on the form of settlement and were </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$813 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $749 million at December 31, 2024 and September 30, 2024, respectively. The impact of other forms of variable consideration, including sales discounts and sales returns, is not material to the Company's revenues.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effects of Revenue Arrangements on Condensed Consolidated Balance Sheets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized contract costs associated with the costs to fulfill contracts for certain products in the Medication Management Solutions organizational unit are immaterial to the Company's condensed consolidated balance sheets. Commissions relating to revenues recognized over a period longer than one year are recorded as assets which are amortized over the period over which the revenues underlying the commissions are recognized. Capitalized contract costs related to such commissions are immaterial to the Company's condensed consolidated balance sheets.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities for unearned revenue that is allocable to performance obligations, such as extended warranty and software maintenance contracts, which are performed over time, were approximately $502 million and $482 million as of December 31, 2024 and September 30, 2024, respectively, and are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payables, accrued expenses and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the Company’s condensed consolidated balance sheets. The Company's liability for product warranties provided under its agreements with customers is not material to its condensed consolidated balance sheets. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Remaining Performance Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's obligations relative to service contracts and pending installations of equipment, primarily in the Company's Medication Management Solutions unit, represent unsatisfied performance obligations of the Company. The revenues under existing contracts with original expected durations of more than one year, which are attributable to products and/or services that have not yet been installed or provided are estimated to be approximately $2.3 billion at December 31, 2024. The Company expects to recognize the majority of this revenue over the next three years. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the Company's Medication Management Solutions, Medication Delivery Solutions, Diagnostic Solutions, and Biosciences units, some contracts also contain minimum purchase commitments of reagents or other consumables, and the future sales of these consumables represent additional unsatisfied performance obligations of the Company. The revenue attributable to the unsatisfied minimum purchase commitment-related performance obligations, for contracts with original expected durations of more than one year, is estimated to be approximately $2.0 billion at December 31, 2024. This revenue will be recognized over the customer relationship periods.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenues</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A disaggregation of the Company's revenues by segment, organizational unit and geographic region is provided in Note 7.</span></div> <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Measurement of Revenues</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s allowance for doubtful accounts reflects the current estimate of credit losses expected to be incurred over the life of its trade receivables. Such estimated credit losses are determined based on historical loss experiences, customer-specific credit risk, and reasonable and supportable forward-looking information, such as country or regional risks that are not captured in the historical loss information. The allowance for doubtful accounts for trade receivables is not material to the Company's consolidated financial results.</span></div>The Company's gross revenues are subject to a variety of deductions which are recorded in the same period that the underlying revenues are recognized. Such variable consideration includes rebates, sales discounts and sales returns. 813000000 749000000 502000000 482000000 2300000000 P3Y 2000000000.0 Segment Data<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's organizational structure is based upon three worldwide business segments: BD Medical (“Medical”), BD Life Sciences (“Life Sciences”) and BD Interventional (“Interventional”). The Company's segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services. Segment disclosures are on a performance basis consistent with internal management reporting. The Company evaluates performance of its business segments and allocates resources to them primarily based upon segment operating income, which represents revenues reduced by product costs and operating expenses. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by segment, organizational unit and geographical areas for the three-month periods are detailed below. The Company has no material intersegment revenues. </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.590%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Medical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medication Delivery Solutions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,052 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medication Management Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical Systems</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced Patient Monitoring</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,615 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,615 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,360 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,230 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Life Sciences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specimen Management (a)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostic Solutions (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biosciences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,297 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Interventional</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surgery</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peripheral Intervention</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Urology and Critical Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Company revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,080 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,089 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,168 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,749 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,957 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,706 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)    During the first quarter of fiscal year 2025, Life Sciences split its former Integrated Diagnostic Solutions organizational unit into two units to better align BD resources with the distinct needs of each business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment income for the three-month periods was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.099%"><tr><td style="width:1.0%"></td><td style="width:63.499%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.901%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Income Before Income Taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life Sciences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interventional</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Segment Operating Income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,198 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integration, restructuring and transaction expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net interest expense </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other unallocated items (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(733)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(688)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Income Before Income Taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense.</span></div> 3 <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by segment, organizational unit and geographical areas for the three-month periods are detailed below. The Company has no material intersegment revenues. </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.590%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Medical</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medication Delivery Solutions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,124 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,052 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medication Management Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical Systems</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced Patient Monitoring</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,615 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,615 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,360 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,230 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Life Sciences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specimen Management (a)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostic Solutions (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biosciences</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,297 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">587 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">701 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Interventional</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Surgery</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peripheral Intervention</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Urology and Critical Care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Company revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,080 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,089 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,168 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,749 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,957 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,706 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)    During the first quarter of fiscal year 2025, Life Sciences split its former Integrated Diagnostic Solutions organizational unit into two units to better align BD resources with the distinct needs of each business.</span></div> 694000000 430000000 1124000000 639000000 413000000 1052000000 659000000 142000000 801000000 594000000 153000000 747000000 104000000 314000000 418000000 127000000 304000000 431000000 159000000 113000000 271000000 0 0 0 1615000000 999000000 2615000000 1360000000 870000000 2230000000 238000000 223000000 462000000 234000000 213000000 447000000 212000000 262000000 474000000 210000000 256000000 467000000 153000000 208000000 361000000 143000000 232000000 375000000 603000000 694000000 1297000000 587000000 701000000 1288000000 303000000 92000000 395000000 280000000 88000000 369000000 253000000 220000000 473000000 234000000 220000000 454000000 306000000 83000000 389000000 287000000 78000000 365000000 861000000 396000000 1257000000 802000000 386000000 1188000000 3080000000 2089000000 5168000000 2749000000 1957000000 4706000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment income for the three-month periods was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.099%"><tr><td style="width:1.0%"></td><td style="width:63.499%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.300%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.901%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Income Before Income Taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life Sciences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interventional</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Segment Operating Income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,198 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integration, restructuring and transaction expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net interest expense </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other unallocated items (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(733)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(688)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Income Before Income Taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense.</span></div> 492000000 535000000 383000000 372000000 387000000 291000000 1263000000 1198000000 92000000 75000000 -132000000 -77000000 -733000000 -688000000 306000000 359000000 Benefit Plans<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has defined benefit pension plans covering certain employees in the United States and certain international locations. The measurement date used for these plans is September 30.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net pension cost included the following components for the three-month periods:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.052%"><tr><td style="width:1.0%"></td><td style="width:62.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.828%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.392%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net pension cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts provided above for amortization of prior service credit and amortization of loss represent the reclassifications of prior service credits and net actuarial losses that were recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in prior periods. All components of the Company’s net periodic pension and postretirement benefit costs, aside from service cost, are recorded to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other expense, net</span> on its condensed consolidated statements of income. <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net pension cost included the following components for the three-month periods:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.052%"><tr><td style="width:1.0%"></td><td style="width:62.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.828%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.392%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net pension cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 12000000 25000000 42000000 39000000 56000000 42000000 0 -1000000 -10000000 -16000000 8000000 37000000 Acquisition<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advanced Patient Monitoring</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 3, 2024, the Company completed its acquisition of Edwards Lifesciences’ Critical Care product group (“Critical Care”), which was renamed as BD Advanced Patient Monitoring (“Advanced Patient Monitoring”). Since the acquisition date, financial results for Advanced Patient Monitoring’s product offerings are being reported as a separate organizational unit within the Medical segment. Advanced Patient Monitoring is a global leader in advanced monitoring solutions that expands the Company’s portfolio of smart connected care solutions with its growing set of leading monitoring technologies, advanced AI-enabled clinical decision tools and robust innovation pipeline that complement the Company's existing technologies serving operating rooms and intensive care units. The Company funded the transaction with cash on hand, using net proceeds raised through debt issuances in the third quarter of fiscal year 2024 and borrowings under its commercial paper program. The acquisition was accounted for under the acquisition method of accounting for business combinations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is in the process of finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed, related to assessing certain assumptions underlying the valuation of intangible assets. The preliminary allocations of the purchase price provide a reasonable basis for estimating the fair values of assets acquired and liabilities assumed. These provisional estimates may be adjusted upon the availability of further information regarding events or circumstances that existed at the acquisition date. Such adjustments may be significant. The fair value of consideration transferred in connection with the acquisition was $3.906 billion. As of December 31, 2024, the assets acquired and the liabilities assumed in this acquisition included developed technology intangible assets of $717 million, customer relationships intangible assets of $653 million and $713 million of other net assets, which are primarily inventory. The goodwill recorded from the excess of the purchase price over the fair value of the acquired net assets was $1.823 billion, which related to synergies expected to be gained from combining operations of the acquiree and acquirer, as well as revenue and cash flow projections associated with future innovative technologies expected to occur. The preliminary estimate of the goodwill that is expected to be deductible for tax purposes is approximately $1.1 billion.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company included Advanced Patient Monitoring in its consolidated results of operations beginning on September 3, 2024. The Company’s unaudited pro forma </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three months ended December 31, 2023, giving effect as if Advanced Patient Monitoring had been acquired as of October 1, 2022, were $4.957 billion. The calculation of pro forma </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three months ended December 31, 2023 is not practicable because of complexities associated with its hypothetical calculation.</span></div> 3906000000 717000000 653000000 713000000 1823000000 1100000000 4957000000 Business Restructuring Charges<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred restructuring costs during the three months ended December 31, 2024, primarily in connection with the Company's simplification and other cost-saving initiatives, which were recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Integration, restructuring and transaction expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. These simplification and other cost-saving initiatives are focused on reducing complexity</span><span style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> optimizing the Company’s supply chain efficiency, streamlining its global manufacturing footprint, enhancing product quality, refining customer experience, and improving cost efficiency across all of the Company’s segments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring liability activity for the three months ended December 31, 2024 was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.163%"><tr><td style="width:1.0%"></td><td style="width:36.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.006%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.006%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee<br/>Termination</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)    Other non-employee-related expenses primarily relate to other costs associated with the execution of the Company’s cost efficiency and restructuring programs, such as incremental project management costs and facility exit costs.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring liability activity for the three months ended December 31, 2024 was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.163%"><tr><td style="width:1.0%"></td><td style="width:36.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.006%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.006%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee<br/>Termination</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other (a)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)    Other non-employee-related expenses primarily relate to other costs associated with the execution of the Company’s cost efficiency and restructuring programs, such as incremental project management costs and facility exit costs.</span></div> 58000000 2000000 60000000 20000000 46000000 66000000 29000000 36000000 65000000 0 6000000 6000000 2000000 0 2000000 47000000 6000000 53000000 Intangible Assets<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consisted of:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,788 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,439 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,827 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,094)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,733 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,511 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,978)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,533 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,513 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,878)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,635 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents, trademarks and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(688)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(682)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized intangible assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,486 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,014)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,472 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,525 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,654)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,871 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible amortization expense was $395 million and $365 million for the three months ended December 31, 2024 and 2023, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of goodwill by business segment:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.409%"><tr><td style="width:1.0%"></td><td style="width:40.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.254%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.254%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.254%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.177%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Life Sciences</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interventional</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill as of September 30, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,832 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,729 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,465 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase price allocation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill as of December 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,769 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,663 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,329 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consisted of:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed technology</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,788 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,439 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,827 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,094)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,733 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,511 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,978)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,533 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,513 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,878)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,635 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents, trademarks and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(688)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(682)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortized intangible assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,486 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,014)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,472 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,525 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,654)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,871 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div> 15788000000 8349000000 7439000000 15827000000 8094000000 7733000000 5511000000 2978000000 2533000000 5513000000 2878000000 2635000000 1188000000 688000000 500000000 1185000000 682000000 503000000 22486000000 12014000000 10472000000 22525000000 11654000000 10871000000 14000000 44000000 2000000 2000000 16000000 46000000 395000000 365000000 <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of goodwill by business segment:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.409%"><tr><td style="width:1.0%"></td><td style="width:40.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.254%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.254%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.254%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.177%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Life Sciences</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interventional</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill as of September 30, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,832 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,729 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,465 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase price allocation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill as of December 31, 2024</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,769 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,663 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,329 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 12832000000 904000000 12729000000 26465000000 -12000000 0 0 -12000000 51000000 8000000 66000000 125000000 12769000000 896000000 12663000000 26329000000 Derivative Instruments and Hedging Activities<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses derivative instruments to mitigate certain exposures. The Company does not enter into derivative financial instruments for trading or speculative purposes. The effects these derivative instruments and hedged items had on the Company’s balance sheets and the fair values of the derivatives outstanding at December 31, 2024 and September 30, 2024 were not material. The effects on the Company’s financial performance and cash flows are provided below.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Risks and Related Strategies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has foreign currency exposures throughout Europe, Greater Asia, Canada and Latin America. Transactional currency exposures that arise from entering into transactions, generally on an intercompany basis, in non-hyperinflationary countries that are denominated in currencies other than the functional currency are mitigated primarily through the use of forward contracts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to mitigate transactional foreign currency exposures resulting from anticipated intercompany purchases and sales denominated in a currency other than local functional currencies, the Company has hedged a portion of this currency risk with certain instruments such as foreign exchange forward and option contracts, which are designated as cash flow hedges. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to mitigate foreign currency exposure relating to its investments in certain foreign subsidiaries, the Company has hedged the currency risk associated with those investments with certain instruments, such as foreign currency-denominated debt and cross-currency swaps, which are designated as net investment hedges, as well as currency exchange contracts. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amounts of the Company’s foreign currency-related derivative instruments as of December 31, 2024 and September 30, 2024 were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.210%"><tr><td style="width:1.0%"></td><td style="width:36.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.089%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hedge Designation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts (a)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undesignated</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,366 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,521 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts (b)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt (c)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,874 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,065 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps (d)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Represents hedges of transactional foreign exchange exposures resulting primarily from intercompany payables and receivables. Gains and losses on these instruments are recognized immediately in income. These gains and losses are largely offset by gains and losses on the underlying hedged items, as well as the hedging costs associated with the derivative instruments. Net amounts recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, during the three months ended December 31, 2024 and 2023 were immaterial to the Company's consolidated financial results.</span></div><div style="margin-top:3pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Represents foreign exchange contracts related to anticipated intercompany purchases and sales, described above, which generally have durations of less than eighteen months. </span></div><div style="margin-top:3pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Represents foreign currency-denominated long-term notes outstanding which were effective as economic hedges of net investments in certain of the Company's foreign subsidiaries. </span></div><div style="margin-top:3pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Represents cross-currency swaps, which were effective as economic hedges of net investments in certain of the Company's foreign subsidiaries.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net gains or losses resulting from the change in fair value of the foreign exchange contracts designated as cash flow hedges are initially recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and reclassified into earnings upon the occurrence of the related underlying third-party transaction. If foreign exchange contracts designated as cash flow hedges are terminated prematurely as a result of the hedged transaction being probable of not occurring, the balance in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Accumulated other comprehensive income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> attributable to those derivatives is immediately reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Cost of products sold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (depending on whether the hedged item is an intercompany sale or purchase). Net after tax losses recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as amounts reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> into earnings relating to these cash flow hedges during the three months ended December 31, 2024 were immaterial. No amounts relating to foreign exchange contracts designated as cash flow hedges were recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during three months ended December 31, 2023. The amounts expected to be reclassified from accumulated other comprehensive income into earnings within the next 12 months, are not material to the Company's consolidated financial results.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net gains or losses relating to the net investment hedges, which are attributable to changes in the foreign currencies to U.S. dollar spot exchange rates, are recorded as foreign currency translation in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income (loss), net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon the termination of a net investment hedge, any net gain or loss included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> relative to the investment hedge remains until the foreign subsidiary investment is disposed of or is substantially liquidated. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net gains (losses) recorded to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> relating to the Company's net investment hedges for the three-month periods were as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.052%"><tr><td style="width:1.0%"></td><td style="width:62.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.828%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.392%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The amount for the three months ended December 31, 2024 includes a loss, net of tax, of $18 million recognized on terminated cross-currency swaps.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risks and Related Strategies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a mix of fixed and variable rate debt to manage its interest rate exposure, and periodically uses interest rate swaps to manage such exposures. Under these interest rate swaps, the Company exchanges, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. These swaps are designated as either cash flow or fair value hedges.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of the interest rate swaps designated as cash flow hedges (i.e., hedging the exposure to variability in expected future cash flows that is attributable to a particular risk) are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income (loss), net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If interest rate derivatives designated as cash flow hedges are terminated, the balance in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">attributable to those derivatives is reclassified into earnings, within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, over the remaining life of the hedged debt. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For interest rate swaps designated as fair value hedges (i.e., hedges against the exposure to changes in the fair value of an asset or a liability or an identified portion thereof that is attributable to a particular risk), changes in the fair value of the interest rate swaps offset changes in the fair value of the fixed rate debt due to changes in market interest rates. Amounts recorded during the three months ended December 31, 2024 and 2023 were immaterial to the Company's consolidated financial results. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amounts of the Company’s interest rate-related derivative instruments as of December 31, 2024 and September 30, 2024 were as follows: </span></div><div style="margin-top:3pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"></td><td style="width:39.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hedge Designation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps (a)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Represents fixed-to-floating interest rate swap agreements the Company entered into to convert the interest payments on certain long-term notes from the fixed rate to a floating interest rate based on secured overnight financing rates (“SOFR”). </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Risk Exposures</span></div>The Company purchases resins, which are oil-based components used in the manufacture of certain products. Significant increases in world oil prices that lead to increases in resin purchase costs could impact future operating results. From time to time, the Company has managed price risks associated with these commodity purchases through commodity derivative forward contracts. The Company's commodity derivative forward contracts at December 31, 2024 and September 30, 2024 were immaterial to the Company's consolidated financial results. The Company uses derivative instruments to mitigate certain exposures. The Company does not enter into derivative financial instruments for trading or speculative purposes.<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a mix of fixed and variable rate debt to manage its interest rate exposure, and periodically uses interest rate swaps to manage such exposures. Under these interest rate swaps, the Company exchanges, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. These swaps are designated as either cash flow or fair value hedges.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of the interest rate swaps designated as cash flow hedges (i.e., hedging the exposure to variability in expected future cash flows that is attributable to a particular risk) are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income (loss), net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If interest rate derivatives designated as cash flow hedges are terminated, the balance in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">attributable to those derivatives is reclassified into earnings, within</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, over the remaining life of the hedged debt. </span></div>For interest rate swaps designated as fair value hedges (i.e., hedges against the exposure to changes in the fair value of an asset or a liability or an identified portion thereof that is attributable to a particular risk), changes in the fair value of the interest rate swaps offset changes in the fair value of the fixed rate debt due to changes in market interest rates. <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amounts of the Company’s foreign currency-related derivative instruments as of December 31, 2024 and September 30, 2024 were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.210%"><tr><td style="width:1.0%"></td><td style="width:36.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.115%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.089%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hedge Designation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts (a)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undesignated</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,366 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,521 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange contracts (b)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flow hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt (c)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,874 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,065 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps (d)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net investment hedges</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,366 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Represents hedges of transactional foreign exchange exposures resulting primarily from intercompany payables and receivables. Gains and losses on these instruments are recognized immediately in income. These gains and losses are largely offset by gains and losses on the underlying hedged items, as well as the hedging costs associated with the derivative instruments. Net amounts recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, during the three months ended December 31, 2024 and 2023 were immaterial to the Company's consolidated financial results.</span></div><div style="margin-top:3pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Represents foreign exchange contracts related to anticipated intercompany purchases and sales, described above, which generally have durations of less than eighteen months. </span></div><div style="margin-top:3pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Represents foreign currency-denominated long-term notes outstanding which were effective as economic hedges of net investments in certain of the Company's foreign subsidiaries. </span></div><div style="margin-top:3pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Represents cross-currency swaps, which were effective as economic hedges of net investments in certain of the Company's foreign subsidiaries.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amounts of the Company’s interest rate-related derivative instruments as of December 31, 2024 and September 30, 2024 were as follows: </span></div><div style="margin-top:3pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"></td><td style="width:39.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hedge Designation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps (a)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value hedges</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span>Represents fixed-to-floating interest rate swap agreements the Company entered into to convert the interest payments on certain long-term notes from the fixed rate to a floating interest rate based on secured overnight financing rates (“SOFR”). 2366000000 4521000000 394000000 543000000 2874000000 3065000000 1022000000 1366000000 0 0 <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net gains (losses) recorded to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> relating to the Company's net investment hedges for the three-month periods were as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.052%"><tr><td style="width:1.0%"></td><td style="width:62.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.828%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.392%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency-denominated debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps (a)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The amount for the three months ended December 31, 2024 includes a loss, net of tax, of $18 million recognized on terminated cross-currency swaps.</span></div> 145000000 -29000000 67000000 -55000000 -18000000 700000000 700000000 Financial Instruments and Fair Value Measurements<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following reconciles cash and equivalents and restricted cash reported within the Company's condensed consolidated balance sheets at December 31, 2024 and September 30, 2024 to the total of these amounts shown on the Company's condensed consolidated statements of cash flows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:327.75pt"><tr><td style="width:1.0pt"></td><td style="width:166.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:75.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:75.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,717 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,856 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of all highly liquid investments with a maturity of three months or less at time of purchase. Restricted cash consists of cash restricted from withdrawal and usage except for certain product liability matters.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the Company’s financial instruments are as follows:</span></div><div style="margin-top:9pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.842%"><tr><td style="width:1.0%"></td><td style="width:40.482%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis of fair value measurement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Institutional money market accounts (a)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt (b)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt (b)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,199 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">These financial instruments are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated balance sheets. The institutional money market accounts permit daily redemption. The fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions. </span></div><div style="margin-top:3pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Long-term debt is recorded at amortized cost. The fair value of long-term debt is measured based upon quoted prices in active markets for similar instruments.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments are held to their maturities and are carried at cost, which approximates fair value. The short-term investments primarily consist of time deposits with maturities greater than three months and less than one year. All other </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">instruments measured by the Company at fair value, including derivatives, contingent consideration liabilities and available-for-sale debt securities, are immaterial to the Company's condensed consolidated balance sheets.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of fiscal year 2025, the Company recorded a non-cash asset impairment charge of $30 million to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to write down the carrying value of certain assets in the Life Sciences segment. The amount recognized was recorded to adjust the carrying amount of assets to the assets' fair values, which were estimated, based upon a market participant's perspective, using Level 3 measurements, including values estimated using the income approach.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transfers of Trade Receivables</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the normal course of its business activities, the Company transfers certain trade receivable assets to third parties under factoring agreements. Per the terms of these agreements, the Company surrenders control over its trade receivables upon transfer. Accordingly, the Company accounts for the transfers as sales of trade receivables by recognizing an increase to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and a decrease to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trade receivables, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when proceeds from the transactions are received. The costs incurred by the Company in connection with factoring activities were not material to its consolidated financial results. The amounts transferred and yet to be remitted under factoring arrangements are provided below.</span></div><div style="margin-top:6pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.029%"><tr><td style="width:1.0%"></td><td style="width:56.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.568%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.569%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables transferred to third parties under factoring arrangements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.614%"><tr><td style="width:1.0%"></td><td style="width:56.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.813%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts yet to be collected and remitted to the third parties</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supplier Finance Programs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements where participating suppliers are provided the ability to receive early payment of the Company’s obligations at a nominal discount through supplier finance programs entered into with third party financial institutions. The Company is not a party to these arrangements, and these programs do not impact the Company’s obligations or affect the Company’s payment terms, which generally range from 90 to 150 days. The agreements with the financial institutions do not require the Company to provide assets pledged as security or other forms of guarantees for the supplier finance programs. The Company had $118 million and $112 million of outstanding payables related to supplier finance programs as of December 31, 2024 and September 30, 2024, respectively, which were recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payables, accrued expenses and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the Company's condensed consolidated balance sheets.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following reconciles cash and equivalents and restricted cash reported within the Company's condensed consolidated balance sheets at December 31, 2024 and September 30, 2024 to the total of these amounts shown on the Company's condensed consolidated statements of cash flows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:327.75pt"><tr><td style="width:1.0pt"></td><td style="width:166.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:75.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:75.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,717 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,856 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 711000000 1717000000 102000000 139000000 813000000 1856000000 Cash equivalents consist of all highly liquid investments with a maturity of three months or less at time of purchase. Restricted cash consists of cash restricted from withdrawal and usage except for certain product liability matters. <div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the Company’s financial instruments are as follows:</span></div><div style="margin-top:9pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.842%"><tr><td style="width:1.0%"></td><td style="width:40.482%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Basis of fair value measurement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Institutional money market accounts (a)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt (b)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt (b)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,199 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">These financial instruments are recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the condensed consolidated balance sheets. The institutional money market accounts permit daily redemption. The fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions. </span></div><div style="margin-top:3pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Long-term debt is recorded at amortized cost. The fair value of long-term debt is measured based upon quoted prices in active markets for similar instruments.</span></div> 0 285000000 831000000 1748000000 16337000000 17199000000 The fair values of these investments are based upon the quoted prices in active markets provided by the holding financial institutions.<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Long-term debt is recorded at amortized cost. The fair value of long-term debt is measured based upon quoted prices in active markets for similar instruments.</span>Short-term investments are held to their maturities and are carried at cost, which approximates fair value. The short-term investments primarily consist of time deposits with maturities greater than three months and less than one year. P3M P1Y 30000000 The amounts transferred and yet to be remitted under factoring arrangements are provided below.<div style="margin-top:6pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.029%"><tr><td style="width:1.0%"></td><td style="width:56.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.568%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.569%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Millions of dollars)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables transferred to third parties under factoring arrangements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.614%"><tr><td style="width:1.0%"></td><td style="width:56.249%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.813%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts yet to be collected and remitted to the third parties</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 360000000 379000000 338000000 254000000 P90D P150D 118000000 112000000 Income Taxes<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s effective income tax rates for the three months ended December 31, 2024 and 2023 were 0.9% and 21.6%, respectively. The decrease in the Company’s effective tax rate for the three months ended December 31, 2024 was largely due to the partial release of the valuation allowance established for a non-U.S. tax credit.</span></div> 0.009 0.216 Subsequent Event<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BD’s Intention to Separate Biosciences and Diagnostic Solutions </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 5, 2025, the Company announced its intention to separate its Biosciences and Diagnostic Solutions business from the rest of the Company. The Company expects to announce more specifics on the separation plans by the end of fiscal year 2025 and intends to target completion of the transaction in fiscal year 2026. The completion of any separation transaction will be contingent upon various conditions and approvals, including approval of the Company’s board of directors, receipt of requisite regulatory clearances and compliance with applicable SEC requirements. No assurance can be given regarding the form that a separation transaction may take or the specific terms or timing, or that a separation will in fact occur.</span></div> <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 11, 2024, Richard Byrd, Executive Vice President and President, Interventional Segment of BD, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Byrd’s plan is for (i) the exercise of up to 15,061 stock appreciation rights (“SARs”) at various exercise prices, net of shares withheld to satisfy applicable taxes, (ii) the sale of up to 2,399 shares of BD’s common stock, (iii) the sale of up to 1,123 shares of BD’s common stock upon the vesting of time vested units (“TVUs”), net of shares withheld to satisfy applicable taxes, and (iv) the sale of up to 1,590 shares of BD’s common stock upon the vesting of performance units, subject to the final payout factor and net of shares withheld to satisfy applicable taxes. The foregoing exercises or sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and March 15, 2026.</span></div> December 11, 2024 Richard Byrd Executive Vice President and President, Interventional Segment of BD true 15061 2399 1123 1590 March 15, 2026 <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2024, Antoine Ezell, Executive Vice President, President of the Americas and Chief Marketing Officer of BD, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Ezell’s plan is for the sale of up to 3,900 shares of BD’s common stock. The sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and March 17, 2026.</span></div> December 16, 2024 Antoine Ezell Executive Vice President, President of the Americas and Chief Marketing Officer true 3900 March 17, 2026 false false false